All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/guidelines.

graphic  For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the guidelines see European Heart Journal online.

Table of Contents

  • 1 Preamble  4

  • 2 Introduction  6

  •  2.1 Why do we need new guidelines on valvular heart disease?  6

  •  2.2 Methodology  7

  •  2.3 Content of these guidelines  12

  •  2.4 New format of the guidelines  12

  •  2.5 How to use these guidelines  12

  • 3 General comments  13

  •  3.1 Concepts of Heart Team and Heart Valve Centre  13

  •  3.2 Patient evaluation  13

  •   3.2.1 Clinical evaluation  14

  •   3.2.2 Echocardiography  14

  •   3.2.3 Other non-invasive investigations  15

  •   3.2.4 Invasive investigations  15

  •   3.2.5 Assessment of comorbidity  15

  •  3.3 Risk stratification  15

  •   3.3.1 Risk scores  16

  •   3.3.2 Other factors  16

  •  3.4 Patient-related aspects  16

  •  3.5 Local resources  16

  •  3.6 Management of associated conditions  16

  •   3.6.1 Coronary artery disease  16

  •   3.6.2 Atrial fibrillation  17

  •  3.7 Endocarditis prophylaxis  17

  •  3.8 Prophylaxis for rheumatic fever  18

  • 4 Aortic regurgitation  18

  •  4.1 Evaluation  18

  •   4.1.1 Echocardiography  18

  •   4.1.2 Computed tomography and cardiac magnetic resonance  18

  •  4.2 Indications for intervention  18

  •  4.3 Medical therapy  20

  •  4.4 Serial testing  20

  •  4.5 Special patient populations  21

  • 5 Aortic stenosis  21

  •  5.1 Evaluation  21

  •   5.1.1 Echocardiography  21

  •   5.1.2 Additional diagnostic and prognostic parameters  21

  •   5.1.3 TAVI diagnostic workup  23

  •  5.2 Indications for intervention (SAVR or TAVI)  24

  •   5.2.1 Symptomatic aortic stenosis  24

  •   5.2.2 Asymptomatic aortic stenosis  25

  •   5.2.3 The mode of intervention  25

  •  5.3 Medical therapy  27

  •  5.4 Serial testing  27

  •  5.5 Special patient populations  27

  • 6 Mitral regurgitation  28

  •  6.1 Primary mitral regurgitation  28

  •   6.1.1 Evaluation  28

  •   6.1.2 Indications for intervention  28

  •   6.1.3 Medical therapy  30

  •   6.1.4 Serial testing  30

  •   6.1.5 Special populations  30

  •  6.2 Secondary mitral regurgitation  30

  •   6.2.1 Evaluation  30

  •   6.2.2 Medical therapy  31

  •   6.2.3 Indications for intervention  31

  • 7 Mitral stenosis  34

  •  7.1 Rheumatic mitral stenosis  34

  •   7.1.1 Evaluation  34

  •   7.1.2 Indications for intervention  34

  •   7.1.3 Medical therapy  35

  •   7.1.4 Serial testing  36

  •   7.1.5 Special patient populations  36

  •  7.2 Degenerative mitral stenosis with mitral annular calcification  36

  •   7.2.1 Evaluation  36

  •   7.2.2 Indications for intervention  36

  • 8 Tricuspid regurgitation  36

  •  8.1 Evaluation  36

  •  8.2 Indications for intervention  37

  •  8.3 Medical therapy  38

  • 9 Tricuspid stenosis  38

  •  9.1 Evaluation  39

  •  9.2 Indications for intervention  39

  •  9.3 Medical therapy  39

  • 10 Combined and multiple-valve diseases  39

  • 11 Prosthetic valves  40

  •  11.1 Choice of prosthetic valve  40

  •  11.2 Baseline assessment and follow-up  41

  •  11.3 Antithrombotic management  41

  •   11.3.1 Mechanical prostheses  41

  •   11.3.2 Bioprostheses  42

  •   11.3.3 Valve repair  44

  •  11.4 Management of prosthetic valve dysfunction and complications  44

  •   11.4.1 Structural valve deterioration  44

  •   11.4.2 Non-structural valve dysfunction  46

  •   11.4.3 Endocarditis  46

  •   11.4.4 Thrombosis  46

  •   11.4.5 Heart failure  46

  • 12 Management during non-cardiac surgery  47

  •  12.1 Preoperative evaluation  47

  •  12.2 Specific valve lesions  47

  •   12.2.1 Aortic stenosis  47

  •   12.2.2 Mitral stenosis  47

  •   12.2.3 Aortic andmitral regurgitation  47

  •  12.3 Perioperativemonitoring  47

  • 13 Management during pregnancy  47

  •  13.1 Management before pregnancy  48

  •  13.2 Management during pregnancy  48

  •   13.2.1 Patients with native valve disease  48

  •   13.2.2 Mechanical prosthesis  49

  • 14 Key messages  49

  • 15 Gaps in evidence  50

  • 16 To Do and Not To Do  51

  • 17 Supplementary data  54

  • 18 Author information  54

  • 19 Appendix  54

  • 20 References  55

List of Tables

  • Table 1 Classes of recommendations  5

  • Table 2 Levels of evidence  6

  • Table 3 What is new  7

  • Table 4 Requirements for a Heart Valve Centre  13

  • Table 5 Echocardiographic criteria for the definition of severe aortic valve regurgitation  18

  • Table 6 Clinical, anatomical and procedural factors that influence the choice of treatment modality for an individual patient  23

  • Table 7 Severe mitral regurgitation criteria based on 2D echocardiography  29

  • Table 8 Contraindications for percutaneous mitral commissurotomy in rheumatic mitral stenosisa  34

  • Table 9 Echocardiographic criteria for grading severity of tricuspid regurgitation  37

  • Table 10 Target international normalized ratio for mechanical prostheses  41

List of Figures

  • Figure 1 Central illustration: Patient-centred evaluation for intervention  14

  • Figure 2 Management of patients with aortic regurgitation  20

  • Figure 3 Integrated imaging assessment of aortic stenosis  22

  • Figure 4 Management of patients with severe aortic stenosis  24

  • Figure 5 Management of patients with severe chronic primary mitral regurgitation  31

  • Figure 6 Management of patients with chronic severe secondary mitral regurgitation  33

  • Figure 7 Management of clinically significant rheumatic mitral stenosis (MVA ≤1.5 cm2)  35

  • Figure 8 Management of tricuspid regurgitation (TR)  38

  • Figure 9 Antithrombotic therapy for valve prostheses  44

  • Figure 10 Management of left-sided obstructive and non-obstructive mechanical prosthetic thrombosis  45

  • Figure 11 Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis  48

Tables of Recommendations

  • Recommendations for management of CAD in patients with VHD  16

  • Recommendations on management of atrial fibrillation in patients with native VHD  17

  • Recommendations on indications for surgery in (A) severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)  19

  • Recommendations on indications for interventiona in symptomatic (A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C)  26

  • Recommendations on indications for intervention in severe primary mitral regurgitation  29

  • Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitation  32

  • Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically significant (moderate or severe) mitral stenosis (valve area ≤1.5 cm2)  34

  • Recommendations on indications for intervention in tricuspid valve disease  39

  • Recommendations for prosthetic valve selection  40

  • Recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods  42

  • Recommendations on management of prosthetic valve dysfunction  46

Abbreviations and acronyms

     
  • 2D

    Two-dimensional

  •  
  • 3D

    Three-dimensional

  •  
  • ACEI

    Angiotensin-converting enzyme inhibitor

  •  
  • ACS

    Acute coronary syndrome

  •  
  • AF

    Atrial fibrillation

  •  
  • ARB

    Angiotensin receptor blocker

  •  
  • ARC-HBR

    Academic Research Consortium – High Bleeding Risk

  •  
  • ASA

    Acetylsalicylic acid

  •  
  • AVA

    Aortic valve area

  •  
  • BAV

    Balloon aortic valvuloplasty

  •  
  • BHV

    Biological heart valve

  •  
  • BVF

    Bioprosthetic valve failure

  •  
  • BNP

    B-type natriuretic peptide

  •  
  • BP

    Blood pressure

  •  
  • BSA

    Body surface area

  •  
  • CABG

    Coronary artery bypass grafting

  •  
  • CAD

    Coronary artery disease

  •  
  • CCT

    Cardiac computed tomography

  •  
  • CI

    Confidence interval

  •  
  • CMR

    Cardiac magnetic resonance

  •  
  • CRT

    Cardiac resynchronization therapy

  •  
  • CT

    Computed tomography

  •  
  • DAPT

    Dual antiplatelet therapy

  •  
  • ΔPm

    Mean pressure gradient

  •  
  • DSE

    Dobutamine stress echocardiography

  •  
  • DVI

    Doppler velocity index/dimensionless index

  •  
  • EACTS

    European Association for Cardio-Thoracic Surgery

  •  
  • ECG

    Electrocardiogram

  •  
  • EDV

    End-diastolic velocity

  •  
  • EROA

    Effective regurgitant orifice area

  •  
  • ESC

    European Society of Cardiology

  •  
  • EuroSCORE

    European System for Cardiac Operative Risk Evaluation

  •  
  • FFP

    Fresh frozen plasma

  •  
  • GDMT

    Guideline-directed medical treatment therapy

  •  
  • HALT

    Hypo-attenuated leaflet thickening

  •  
  • HTx

    Heart transplantation

  •  
  • INR

    International normalized ratio

  •  
  • i.v.

    Intravenous

  •  
  • LA

    Left atrium/left atrial

  •  
  • LAA

    Left atrial appendage

  •  
  • LMWH

    Low-molecular-weight heparin

  •  
  • LV

    Left ventricle/left ventricular

  •  
  • LVAD

    Left ventricular assist devices

  •  
  • LVEDD

    Left ventricular end-diastolic diameter

  •  
  • LVEF

    Left ventricular ejection fraction

  •  
  • LVESD

    Left ventricular end-systolic diameter

  •  
  • LVOT

    Left ventricular outflow tract

  •  
  • MAC

    Mitral annular calcification

  •  
  • MHV

    Mechanical heart valve

  •  
  • MIDA

    Mitral Regurgitation International Database

  •  
  • MVA

    Mitral valve area

  •  
  • NCS

    Non-cardiac surgery

  •  
  • NOAC

    Non-vitamin K antagonist oral anticoagulant

  •  
  • NYHA

    New York Heart Association

  •  
  • OAC

    Oral anticoagulation

  •  
  • PCC

    Prothrombin complex concentration

  •  
  • PCI

    Percutaneous coronary intervention

  •  
  • PET

    Positron emission tomography

  •  
  • PISA

    Proximal isovelocity surface area

  •  
  • PMC

    Percutaneous mitral commissurotomy

  •  
  • PMR

    Primary mitral regurgitation

  •  
  • PPM

    Patient-prosthesis mismatch

  •  
  • PROM

    Predicted risk of mortality

  •  
  • RCT

    Randomized controlled trial

  •  
  • RV

    Right ventricle/right ventricular

  •  
  • SAPT

    Single antiplatelet therapy

  •  
  • SAVR

    Surgical aortic valve replacement

  •  
  • SMR

    Secondary mitral regurgitation

  •  
  • SVD

    Structural valve deterioration

  •  
  • SPAP

    Systolic pulmonary arterial pressure

  •  
  • STS

    Society of Thoracic Surgeons

  •  
  • SVi

    Stroke volume index

  •  
  • TAPSE

    Tricuspid annular pulmonary systolic excursion

  •  
  • TAVI

    Transcatheter aortic valve implantation

  •  
  • TE

    Thromboembolism

  •  
  • TEER

    Transcatheter edge-to-edge repair

  •  
  • TTVI

    Transcatheter tricuspid valve intervention

  •  
  • TOE

    Transoesophageal echocardiography

  •  
  • TTE

    Transthoracic echocardiography

  •  
  • TVI

    Time-velocity integral

  •  
  • TVR

    Tricuspid valve replacement or repair

  •  
  • UFH

    Unfractionated heparin

  •  
  • VHD

    Valvular heart disease

  •  
  • VKA

    Vitamin K antagonist

  •  
  • Vmax

    Peak transvalvular velocity

1 Preamble

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) and its partners such as the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

In addition to the publication of Clinical Practice Guidelines, the ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.

The Members of this Task Force were selected by the ESC and EACTS, including representation from relevant ESC and EACTS sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Clinical Practice Guidelines Committee (CPG). A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.

Table 1

Classes of recommendations

graphic
graphic
Table 1

Classes of recommendations

graphic
graphic
Table 2

Levels of evidence

graphic
graphic
Table 2

Levels of evidence

graphic
graphic

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.

This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC and EACTS without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publication in the European Heart Journal and the European Journal of Cardio-Thoracic Surgery. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC/EACTS Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ and EJCTS website. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC/EACTS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient or the patient's caregiver where appropriate and/or necessary. It is also the healthcare professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.

2 Introduction

2.1 Why do we need new guidelines on valvular heart disease?

Since the publication of the previous version of the guidelines on the management of valvular heart disease (VHD) in 2017, new evidence has accumulated, particularly on the following topics:

  • Epidemiology: the incidence of the degenerative aetiology has increased in industrialized countries while, unfortunately, rheumatic heart disease is still too frequently observed in many parts of the world.1–3

  • Current practices regarding interventions and medical management have been analysed in new surveys at the national and European level.

  • Non-invasive evaluation using three-dimensional (3D) echocardiography, cardiac computed tomography (CCT), cardiac magnetic resonance (CMR), and biomarkers plays a more and more central role.

  • New definitions of severity of secondary mitral regurgitation (SMR) based on the outcomes of studies on intervention.

  • New evidence on anti-thrombotic therapies leading to new recommendations in patients with surgical or transcatheter bioprostheses for bridging during perioperative periods and over the long term. The recommendation for non- vitamin K antagonist oral anticoagulants (NOACs) was reinforced in patients with native valvular disease, except for significant mitral stenosis, and in those with bioprostheses.

  • Risk stratification for the timing of intervention. This applies mostly to (i) the evaluation of progression in asymptomatic patients based on recent longitudinal studies mostly in aortic stenosis, and (ii) interventions in high-risk patients in whom futility should be avoided. Regarding this last aspect, the role of frailty is outlined.

  • Results and indication of intervention:

○ The choice of the mode of intervention: current evidence reinforces the critical role of the Heart Team, which should integrate clinical, anatomical, and procedural characteristics beyond conventional scores, and informed patient’s treatment choice.

○ Surgery: increasing experience and procedural safety led to expansion of indications toward earlier intervention in asymptomatic patients with aortic stenosis, aortic regurgitation or mitral regurgitation and stress the preference for valve repair when it is expected to be durable. A particular emphasis is put on the need for more comprehensive evaluation and earlier surgery in tricuspid regurgitation.

○ Transcatheter techniques: (i) Concerning transcatheter aortic valve implantation (TAVI), new information from randomized studies comparing TAVI vs. surgery in low-risk patients with a follow-up of 2 years has led to a need to clarify which types of patients should be considered for each mode of intervention. (ii) Transcatheter edge-to-edge repair (TEER) is increasingly used in SMR and has been evaluated against optimal medical therapy resulting in an upgrade of the recommendation. (iii) The larger number of studies on transcatheter valve-in-valve implantation after failure of surgical bioprostheses served as a basis to upgrade its indication. (iv) Finally, the encouraging preliminary experience with transcatheter tricuspid valve interventions (TTVI) suggests a potential role of this treatment in inoperable patients, although this needs to be confirmed by further evaluation.

The new evidence described above made a revision of the recommendations necessary.

Table 3

What is new

graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; ARC-HBR = Academic Research Consortium - high bleeding risk; BHV = biological heart valve; BNP = B-type natriuretic peptide; BSA = body surface area; CABG = Coronary artery bypass grafting; CCT = cardiac computed tomography; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guideline-directed medical therapy; INR = international normalized ratio; LA = left atrium/left atrial; LAA = left atrial appendage; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVESD = Left ventricular end-systolic diameter; MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; SPAP = systolic pulmonary arterial pressure; STS-PROM = Society of Thoracic Surgeons - predicted risk of mortality; TAVI = transcatheter aortic valve implantation; TEER = transcatheter edge-to-edge repair; UFH = unfractionated heparin; VHD = valvular heart disease; VKA = vitamin K antagonist; Vmax = peak transvalvular velocity.

Table 3

What is new

graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; ARC-HBR = Academic Research Consortium - high bleeding risk; BHV = biological heart valve; BNP = B-type natriuretic peptide; BSA = body surface area; CABG = Coronary artery bypass grafting; CCT = cardiac computed tomography; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guideline-directed medical therapy; INR = international normalized ratio; LA = left atrium/left atrial; LAA = left atrial appendage; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; LVESD = Left ventricular end-systolic diameter; MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; SPAP = systolic pulmonary arterial pressure; STS-PROM = Society of Thoracic Surgeons - predicted risk of mortality; TAVI = transcatheter aortic valve implantation; TEER = transcatheter edge-to-edge repair; UFH = unfractionated heparin; VHD = valvular heart disease; VKA = vitamin K antagonist; Vmax = peak transvalvular velocity.

2.2 Methodology

In preparation of the 2021 VHD Guidelines, a methodology group has been created for the first time, to assist the Task Force for the collection and interpretation of the evidence supporting specific recommendations. The group was constituted of two European Society of Cardiology (ESC) and two European Association for Cardio-Thoracic Surgery (EACTS) delegates who were also members of the Task Force. Although the principle activities of the group concerned the chapter on aortic stenosis and SMR, it was not limited to these two domains. The methodology group was at disposal, upon request of the Task Force members, to resolve specific methodological issues.

2.3 Content of these guidelines

Decision making in VHD involves accurate diagnosis, timing of intervention, risk assessment and, based on these, selection of the most suitable type of intervention. These guidelines focus on acquired VHD, are oriented towards management, and do not deal with endocarditis,4 congenital valve disease5 (including pulmonary valve disease), or recommendations concerning sports cardiology and exercise in patients with cardiovascular disease,6 as separate guidelines have been published by the ESC on these topics.

2.4 New format of the guidelines

The new guidelines have been adapted to facilitate their use in clinical practice and to meet readers' demands by focusing on condensed, clearly represented recommendations. At the end of the document, key points summarize the essentials. Gaps in evidence are listed to propose topics for future research. The guideline document will be harmonized with the chapter on VHD included in the ESC Textbook of Cardiovascular Medicine (ISBN: 9780198784906). The guidelines and the textbook are complementary. Background information and detailed discussion of the data that have provided the basis for the recommendations will be found in the relevant book chapter.

2.5 How to use these guidelines

The Committee emphasizes that many factors ultimately determine the most appropriate treatment in individual patients within a given community. These factors include the availability of diagnostic equipment, the expertise of cardiologists and surgeons, especially in the field of valve repair and percutaneous intervention, and, notably, the wishes of well-informed patients. Furthermore, owing to the lack of evidence-based data in the field of VHD, most recommendations are largely the result of expert consensus opinion. Therefore, deviations from these guidelines may be appropriate in certain clinical circumstances.

3 General comments

This section defines and discusses concepts common to all the types of VHD including the Heart Team and Heart Valve Centres, the main evaluation steps of patients presenting with VHD, as well as the most commonly associated cardiac diseases.

3.1 Concepts of Heart Team and Heart Valve Centre

The main purpose of Heart Valve Centres as centres of excellence in the treatment of VHD is to deliver optimal quality of care with a patient-centred approach. The main requirements of a Heart Valve Centre are presented in Table 4.

This is achieved through high procedural volume in conjunction with specialized training, continuous education, and focused clinical interest. Heart Valve Centres should promote timely referral of patients with VHD for comprehensive evaluation before irreversible damage occurs.

Decisions concerning treatment and intervention should be made by an active and collaborative Heart Team with expertise in VHD, comprising clinical and interventional cardiologists, cardiac surgeons, imaging specialists with expertise in interventional imaging,7,8 cardiovascular anaesthesiologists, and other specialists if necessary (e.g. heart failure specialists or electrophysiologists). Dedicated nursing personnel with expertise in the care of patients with VHD are also an important asset to the Heart Team. The Heart Team approach is particularly advisable for the management of high-risk and asymptomatic patients, as well as in case of uncertainty or lack of strong evidence.

Heart Valve Clinics are an important component of the Heart Valve Centres, aiming to provide standardized organization of care based on guidelines. Access to Heart Valve Clinics improves outcomes.9

Physicians experienced in the management of VHD and dedicated nurses organize outpatient visits, and referral to the Heart Team, if needed. Earlier referral should be encouraged if patient’s symptoms develop or worsen before the next planned visit.10,11

Beside the whole spectrum of valvular interventions, expertise in interventional and surgical management of coronary artery disease (CAD), vascular diseases, and complications must be available.

Techniques with a steep learning curve may be performed with better results at hospitals with high procedural volume and experience. The relationship between case volume and outcomes for surgery and transcatheter interventions is complex but should not be denied.12–14 However, the precise numbers of procedures per individual operator or hospital required to provide high-quality care remain controversial as inequalities exist between high- and middle-income countries.15 High-volume TAVI programmes are associated with lower mortality at 30 days, particularly at hospitals with a high surgical aortic valve replacement (SAVR) volume.16,17 The data available on transcatheter mitral valve repair14,18 and, even more so, transcatheter tricuspid procedures are more limited.

Since performance does not exclusively relate to intervention volume, internal quality assessment consisting of systematic recording of procedural data and patient outcomes at the level of a given Heart Valve Centre is essential, as well as participation in national or ESC/EACTS registries.

A Heart Valve Centre should have structured and possibly combined training programmes for interventionalists, cardiac surgeons, and imaging specialists13,19,20 (https://ebcts.org/syllabus/). New techniques should be taught by competent mentors to minimize the effects of the learning curve.

Finally, Heart Valve Centres should contribute to optimizing the management of patients with VHD, provide corresponding services at the community level, and promote networks that include other medical departments, referring cardiologists and primary care physicians.

Table 4

Requirements for a Heart Valve Centre

Requirements
  •  Centre performing heart valve procedures with institutional cardiology and cardiac surgery departments with 24 h/7-day services.

  • Heart Team: clinical cardiologist, interventional cardiologist, cardiac surgeon, imaging specialist with expertise in interventional imaging, cardiovascular anaesthesiologist.

  • Additional specialists if required: heart failure specialist, electrophysiologist, geriatrician and other specialists (intensive care, vascular surgery, infectious disease, neurology). Dedicated nursing personnel is an important asset to the Heart Team.

  •  The Heart Team must meet on a frequent basis and work with standard operating procedures and clinical governance arrangements defined locally.

  •  A hybrid catheterization laboratory is desirable.

  •  The entire spectrum of surgical and transcatheter valve procedures should be available.

  •  High volume for hospital and individual operators.

Multimodality imaging including echocardiography, CCT, CMR, and nuclear medicine, as well as expertise on guidance of surgical and interventional procedures.
Heart Valve Clinic for outpatient and follow-up management.
  •  Data review: continuous evaluation of outcomes with quality review and/or local/external audit.

  •  Education programmes targeting patient primary care, operator, diagnostic and interventional imager training and referring cardiologist.

Requirements
  •  Centre performing heart valve procedures with institutional cardiology and cardiac surgery departments with 24 h/7-day services.

  • Heart Team: clinical cardiologist, interventional cardiologist, cardiac surgeon, imaging specialist with expertise in interventional imaging, cardiovascular anaesthesiologist.

  • Additional specialists if required: heart failure specialist, electrophysiologist, geriatrician and other specialists (intensive care, vascular surgery, infectious disease, neurology). Dedicated nursing personnel is an important asset to the Heart Team.

  •  The Heart Team must meet on a frequent basis and work with standard operating procedures and clinical governance arrangements defined locally.

  •  A hybrid catheterization laboratory is desirable.

  •  The entire spectrum of surgical and transcatheter valve procedures should be available.

  •  High volume for hospital and individual operators.

Multimodality imaging including echocardiography, CCT, CMR, and nuclear medicine, as well as expertise on guidance of surgical and interventional procedures.
Heart Valve Clinic for outpatient and follow-up management.
  •  Data review: continuous evaluation of outcomes with quality review and/or local/external audit.

  •  Education programmes targeting patient primary care, operator, diagnostic and interventional imager training and referring cardiologist.

CCT = cardiac computed tomography; CMR = cardiac magnetic resonance.

Table 4

Requirements for a Heart Valve Centre

Requirements
  •  Centre performing heart valve procedures with institutional cardiology and cardiac surgery departments with 24 h/7-day services.

  • Heart Team: clinical cardiologist, interventional cardiologist, cardiac surgeon, imaging specialist with expertise in interventional imaging, cardiovascular anaesthesiologist.

  • Additional specialists if required: heart failure specialist, electrophysiologist, geriatrician and other specialists (intensive care, vascular surgery, infectious disease, neurology). Dedicated nursing personnel is an important asset to the Heart Team.

  •  The Heart Team must meet on a frequent basis and work with standard operating procedures and clinical governance arrangements defined locally.

  •  A hybrid catheterization laboratory is desirable.

  •  The entire spectrum of surgical and transcatheter valve procedures should be available.

  •  High volume for hospital and individual operators.

Multimodality imaging including echocardiography, CCT, CMR, and nuclear medicine, as well as expertise on guidance of surgical and interventional procedures.
Heart Valve Clinic for outpatient and follow-up management.
  •  Data review: continuous evaluation of outcomes with quality review and/or local/external audit.

  •  Education programmes targeting patient primary care, operator, diagnostic and interventional imager training and referring cardiologist.

Requirements
  •  Centre performing heart valve procedures with institutional cardiology and cardiac surgery departments with 24 h/7-day services.

  • Heart Team: clinical cardiologist, interventional cardiologist, cardiac surgeon, imaging specialist with expertise in interventional imaging, cardiovascular anaesthesiologist.

  • Additional specialists if required: heart failure specialist, electrophysiologist, geriatrician and other specialists (intensive care, vascular surgery, infectious disease, neurology). Dedicated nursing personnel is an important asset to the Heart Team.

  •  The Heart Team must meet on a frequent basis and work with standard operating procedures and clinical governance arrangements defined locally.

  •  A hybrid catheterization laboratory is desirable.

  •  The entire spectrum of surgical and transcatheter valve procedures should be available.

  •  High volume for hospital and individual operators.

Multimodality imaging including echocardiography, CCT, CMR, and nuclear medicine, as well as expertise on guidance of surgical and interventional procedures.
Heart Valve Clinic for outpatient and follow-up management.
  •  Data review: continuous evaluation of outcomes with quality review and/or local/external audit.

  •  Education programmes targeting patient primary care, operator, diagnostic and interventional imager training and referring cardiologist.

CCT = cardiac computed tomography; CMR = cardiac magnetic resonance.

3.2 Patient evaluation

The aims of the evaluation of patients with VHD are to diagnose, quantify, and assess the mechanism of VHD, as well as its consequences.

3.2.1 Clinical evaluation

Precise evaluation of the patient's history and symptomatic status, and proper physical examination, in particular auscultation21 and search for heart failure signs, are crucial. In addition, assessment of their comorbidities and general condition require particular attention. The essential questions in the evaluation of a patient for valvular intervention are summarized in Figure 1 (Central illustration).

Central illustration: Patient-centred evaluation for intervention. VHD = valvular heart disease; CCT = cardiac computed tomography; CMR = cardiac magnetic resonance; TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography.
Figure 1

Central illustration: Patient-centred evaluation for intervention. VHD = valvular heart disease; CCT = cardiac computed tomography; CMR = cardiac magnetic resonance; TOE = transoesophageal echocardiography; TTE = transthoracic echocardiography.

3.2.2 Echocardiography

Following adequate clinical evaluation, echocardiography is the key technique used to confirm the diagnosis of VHD, as well as to assess its aetiology, mechanisms, function, severity, and prognosis. It should be performed and interpreted by properly trained imagers.22,23

Echocardiographic criteria for the definition of severe valve stenosis and regurgitation are addressed in specific documents24,25 and summarized in the specific sections of these guidelines. Echocardiography is also key to evaluating the feasibility of a specific intervention.

Indices of left ventricular (LV) enlargement and function are strong prognostic factors. Recent studies suggest that global longitudinal strain has greater prognostic value than LV ejection fraction (LVEF), although cut-off values are not uniform.26,27 Transoesophageal echocardiography (TOE) should be considered when transthoracic echocardiography (TTE) is of suboptimal quality or when thrombosis, prosthetic valve dysfunction, or endocarditis is suspected. TOE is useful when detailed functional valve anatomy is required to assess repairability. Intraprocedural TOE, preferably 3D, is used to guide transcatheter mitral and tricuspid valve procedures and to assess the immediate result of surgical valve operations. Multimodality imaging may be required in specific conditions for evaluation and/or procedural guidance in TAVI and transcatheter mitral interventions.28,29

3.2.3 Other non-invasive investigations

3.2.3.1 Stress testing

The primary purpose of exercise testing is to unmask the objective occurrence of symptoms in patients who claim to be asymptomatic. It is especially useful for risk stratification in aortic stenosis.30 Exercise testing will also determine the level of recommended physical activity, including participation in sports. It should be emphasized that stress testing is safe and useful in asymptomatic patients with VHD. Unfortunately, the VHD II survey indicates that it is rarely performed in asymptomatic patients.1

Exercise echocardiography may identify the cardiac origin of dyspnoea. Prognostic impact has been shown mainly for aortic stenosis and mitral regurgitation.31,32

The use of stress tests to detect CAD associated with severe valvular disease is discouraged because of their low diagnostic value and potential risks in symptomatic patients with aortic stenosis.

3.2.3.2 Cardiac magnetic resonance

In patients with inadequate echocardiographic quality or discrepant results, CMR should be used to assess the severity of valvular lesions, particularly regurgitant lesions, and to assess ventricular volumes, systolic function, abnormalities of the ascending aorta, and myocardial fibrosis.33 CMR is the reference method for the evaluation of right ventricular (RV) volumes and function and is therefore particularly useful to evaluate the consequences of tricuspid regurgitation.34 It also has an incremental value for assessing the severity of aortic and mitral regurgitation.

3.2.3.3 Computed tomography

CCT may contribute to the evaluation of valve disease severity, particularly in aortic stenosis35,36 and possibly associated disease of the thoracic aorta (dilatation, calcification), as well as to evaluate the extent of MAC. CCT should be performed whenever the echocardiographic data indicate an aortic enlargement >40 mm, to clarify aortic diameter and to assess aortic morphology and configuration. CCT is essential in the pre-procedural planning of TAVI and can also be useful to assess patient-prosthesis mismatch (PPM).37 It is also a prerequisite for pre-procedural planning of mitral and tricuspid valve interventions.38 Positron emission tomography (PET)/CCT is useful in patients with a suspicion of endocarditis of a prosthetic valve.39,40

3.2.3.4 Cinefluoroscopy

Cinefluoroscopy is particularly useful for assessing the kinetics of the leaflet occluders of a mechanical prosthesis.

3.2.3.5 Biomarkers

B-type natriuretic peptide (BNP) serum levels, corrected for age and sex, are useful in asymptomatic patients and may assist selection of the appropriate time point for a given intervention,41 particularly if the level rises during follow-up. Other biomarkers have been tested, with evidence for fibrosis, inflammation, and adverse ventricular remodelling, which could improve decision making.42

3.2.3.6 Multimarkers and staging

In patients with at least moderate aortic stenosis and LVEF >50%, staging according to damage associated with aortic stenosis on LV/RV, left atrium (LA), mitral /tricuspid valve, and pulmonary circulation was predictive of excess mortality after TAVI and SAVR, and may help to identify patients who will benefit from an intervention.43,44

3.2.4 Invasive investigations

3.2.4.1 Coronary angiography

Coronary angiography is recommended for the assessment of CAD when surgery or an intervention is planned, to determine if concomitant coronary revascularization is recommended (see recommendations for management of CAD in patients with VHD).45,46 Alternatively, owing to its high negative predictive value, CCT may be used to rule out CAD in patients who are at low risk of atherosclerosis. The usefulness of fractional flow reserve or instantaneous wave-free ratio in patients with VHD is not well established, and caution is warranted in the interpretation of these measurements when VHD, and in particular aortic stenosis, is present.47,48

3.2.4.2 Cardiac catheterization

The measurement of pressures and cardiac output or the assessment of ventricular performance and valvular regurgitation by ventricular angiography or aortography is restricted to situations where non-invasive evaluation by multimodality imaging is inconclusive or discordant with clinical findings. When elevated, pulmonary pressure is the only criterion to support the indication for surgery, and confirmation of echo data by invasive measurement is recommended. Right heart catheterization is also indicated in patients with severe tricuspid regurgitation as Doppler gradient may be impossible or underestimate the severity of pulmonary hypertension.

3.2.5 Assessment of comorbidity

The choice of specific examinations to assess comorbidity is guided by the clinical evaluation.

3.3 Risk stratification

Risk stratification applies to any sort of intervention and is required for weighing the risk of intervention against the expected natural history of VHD and for choosing the type of intervention. Most experience relates to surgery and TAVI.

3.3.1 Risk scores

The Society of Thoracic Surgeons (STS) predicted risk of mortality (PROM) score (http://riskcalc.sts.org/stswebriskcalc/calculate) and the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II; http://www.euroscore.org/calc.html) accurately discriminate high- and low-risk surgical patients and show good calibration to predict postoperative outcome after valvular surgery in the majority of the patients,49,50 while risk estimation may be less accurate in high-risk patients.51 The STS-PROM score is dynamic and changes over time. Of note, the risk scores have not been validated for isolated tricuspid surgical interventions.

In isolation, surgical scores have major limitations for practical use in patients undergoing transcatheter intervention because they do not include major risk factors such as frailty, as well as anatomical factors with impact on the procedure, either surgical or transcatheter [porcelain aorta, previous chest radiation, mitral annular calcification (MAC)].

New scores have been developed to estimate the risk in patients undergoing TAVI, with better accuracy and discrimination than the surgical risk scores, despite numerous limitations52–54 (Supplementary Table 1).

Experience with risk stratification is currently limited for other interventional procedures, such as mitral or tricuspid interventions.

3.3.2 Other factors

Other factors should be taken into account:

  • Frailty, defined as a decrease of physiologic reserve and ability to maintain homeostasis leading to an increased vulnerability to stresses and conferring an increased risk of morbidity and mortality after both surgery and TAVI.55 The assessment of frailty should not rely on a subjective approach, such as the ‘eyeball test’, but rather on a combination of different objective estimates.55–59 Several tools are available for assessing frailty (Supplementary Table 2,59 and Supplementary Table 3).60

  • Malnutrition61 and cognitive dysfunction62 both predict poor prognosis.

  • Other major organ failures (Supplementary Table 4), in particular the combination of severe lung disease,63,64 postoperative pain from sternotomy or thoracotomy and prolonged time under anaesthesia in patients undergoing SAVR via full sternotomy, may contribute to pulmonary complications. There is a positive association between the impairment of renal function and increased mortality after valvular surgery and transcatheter procedures,65 especially when the glomerular filtration rate is <30 mL/min. Liver disease, is also an important prognostic factor.66

  • Anatomical aspects affecting procedural performance such as porcelain aorta or severe MAC67 (see Table 6 in section 5.1.3, and Supplementary Figure 1).

At the extreme of the risk spectrum, futility should be avoided. Therapeutic futility has been defined as a lack of medical efficacy, particularly when the physician judges that the therapy is unlikely to produce its intended clinical results, or lack of meaningful survival according to the personal values of the patient. Assessment of futility goes beyond survival and includes functional recovery. The futility of interventions has to be taken into consideration, particularly for transcatheter interventions.63

The high prevalence of comorbidity in the elderly makes assessment of the risk/benefit ratios of interventions more difficult, therefore the role of the Heart Team is essential in this specific population of patients (Supplementary Table 5).

3.4 Patient-related aspects

Patient-related life expectancy and expected quality of life should be considered. The patient and their family should be thoroughly informed and assisted in their decision on the best treatment option.13 A patient-centred approach would take patient-reported outcome measures and patient-reported experience measures into consideration and make these parameters part of the informed choice offered to patients.68,69

When benefit in symptom relief aligns with a patient’s goals, care is not futile. However, care is futile when no life prolongation or symptom relief is anticipated.70

3.5 Local resources

Even if it is desirable that Heart Valve Centres are able to perform a large spectrum of procedures, either surgical or catheter-based, specialization and thereby expertise in specific domains will vary and should be taken into account when deciding on the orientation of the patient in specific cases, such as complex surgical valve repair or transcatheter intervention.

In addition, penetration of transcatheter interventions is heterogeneous worldwide and highly dependent on socioeconomic inequalities.15,71 Appropriate stewardship of economic resources is a fundamental responsibility of the Heart Team.

3.6 Management of associated conditions

3.6.1 Coronary artery disease

Recommendations for the management of CAD associated with VHD are provided below and are detailed in specific sections (section 5 and section 6.2) of this guideline document, as well as in other dedicated guideline documents.45,46,72,73

Recommendations for management of CAD in patients with VHD.

graphic
graphic
graphic
graphic

CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; LV = left ventricle/left ventricular; PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; VHD = valvular heart disease.

a

Class of recommendation.

b

Level of evidence.

c

Chest pain, abnormal non-invasive testing.

d

Coronary CT angiography may also be used in patients requiring emergency surgery with acute infective endocarditis with large vegetations protruding in front of a coronary ostium.

e

Stenosis ≥50% can be considered for left main stenosis.

f

FFR ≤0.8 is a useful cut-off indicating the need for an intervention in patients with mitral or tricuspid diseases, but has not been validated in patients with aortic stenosis. Adapted from45,72

Recommendations for management of CAD in patients with VHD.

graphic
graphic
graphic
graphic

CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; LV = left ventricle/left ventricular; PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; VHD = valvular heart disease.

a

Class of recommendation.

b

Level of evidence.

c

Chest pain, abnormal non-invasive testing.

d

Coronary CT angiography may also be used in patients requiring emergency surgery with acute infective endocarditis with large vegetations protruding in front of a coronary ostium.

e

Stenosis ≥50% can be considered for left main stenosis.

f

FFR ≤0.8 is a useful cut-off indicating the need for an intervention in patients with mitral or tricuspid diseases, but has not been validated in patients with aortic stenosis. Adapted from45,72

3.6.2 Atrial fibrillation

Detailed recommendations on the management of patients with atrial fibrillation (AF) including management of anticoagulation are provided in specific guidelines.74 NOACs are recommended in patients with aortic stenosis, aortic regurgitation or mitral regurgitation presenting with AF75–78 as subgroup analyses of randomized controlled trials (RCTs) support the use of apixaban, dabigatran, edoxaban, and rivaroxaban. The use of NOACs is not recommended in patients who have AF associated with clinically significant mitral stenosis or those with mechanical prostheses.

Surgical ablation of AF combined with mitral valve surgery effectively reduces the incidence of AF but has no impact on adjusted short-term survival. An increased rate of pacemaker implantation has been observed after surgical ablation (9.5%, vs. 7.6% in the group with AF and no surgical ablation).79 Concomitant AF ablation should be considered in patients undergoing cardiac surgery, balancing the benefits of freedom from atrial arrhythmias with the risk factors for recurrence, such as age, LA dilatation, years in AF, renal dysfunction, and other cardiovascular risk factors. In addition, left atrial appendage (LAA) occlusion should be considered in combination with valve surgery in patients with AF and a CHA2DS2VASc score ≥2 to reduce the thromboembolic risk.80–82 The selected surgical technique should ensure complete occlusion of the LAA. For patients with AF and risk factors for stroke, long-term oral anticoagulation (OAC) is currently recommended, irrespective of the use of surgical ablation of AF and/or surgical LAA occlusion.

Recommendations for the management of AF in native VHD are summarized in the following table. The recommendations concerning patients with valve prostheses, and the combination of anticoagulants and antiplatelet agents in patients undergoing PCI, are described in section 11 (section 11.3.2.2 and related table of recommendations for perioperative and postoperative antithrombotic management of valve replacement or repair).

Recommendations on management of atrial fibrillation in patients with native VHD

graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

Recommendations on management of atrial fibrillation in patients with native VHD

graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

3.7 Endocarditis prophylaxis

Antibiotic prophylaxis should be considered for high-risk procedures in patients with prosthetic valves, including transcatheter valves, or with repairs using prosthetic material, and in patients with previous episode(s) of infective endocarditis.4 Particular attention to dental and cutaneous hygiene and strict aseptic measures during any invasive procedure are advised in this population. Antibiotic prophylaxis should be considered in dental procedures involving manipulation of the gingival or periapical region of the teeth or manipulation of the oral mucosa.4

3.8 Prophylaxis for rheumatic fever

Prevention of rheumatic heart disease should preferably target the first attack of acute rheumatic fever. Antibiotic treatment of group A Streptococcus infection throat is key in primary prevention. Echocardiographic screening in combination with secondary antibiotic prophylaxis in children with evidence of latent rheumatic heart disease is currently investigated to reduce its prevalence in endemic regions.91 In patients with established rheumatic heart disease, secondary long-term prophylaxis against rheumatic fever is recommended: benzathine benzyl penicillin 1.2 MUI every 3 to 4 weeks over 10 years. Lifelong prophylaxis should be considered in high-risk patients according to the severity of VHD and exposure to group A Streptococcus.92–95

4 Aortic regurgitation

Aortic regurgitation can be caused by primary disease of the aortic valve cusps and/or abnormalities of the aortic root and ascending aortic geometry. Degenerative tricuspid and bicuspid aortic regurgitation are the most common aetiologies in high-income countries, accounting for approximately two-thirds of the underlying aetiology of aortic regurgitation in the EURObservational Registry Programme Valvular Heart Disease II registry.1 Other causes include infective and rheumatic endocarditis. Acute severe aortic regurgitation is mostly caused by infective endocarditis, and less frequently by aortic dissection.

4.1 Evaluation

4.1.1 Echocardiography

Echocardiography is the key examination used to describe valve anatomy, quantify aortic regurgitation, evaluate its mechanisms, define the morphology of the aorta, and determine the feasibility of valve-sparing aortic surgery or valve repair.96,97 Identification of the mechanism follows the same principle such as for mitral regurgitation: normal cusps but insufficient coaptation due to dilatation of the aortic root with central jet (type 1), cusp prolapse with eccentric jet (type 2), or retraction with poor cusp tissue quality and large central or eccentric jet (type 3).96 Quantification of aortic regurgitation follows an integrated approach considering qualitative, semi-quantitative, and quantitative parameters24,98 (Table 5). New parameters obtained by 3D echocardiography and two-dimensional (2D) strain imaging as LV global longitudinal strain may be useful, particularly in patients with borderline LVEF where they may help in the decision for surgery.99 Measurement of the aortic root and ascending aorta in 2D is performed at four levels: annulus, sinuses of Valsalva, sinotubular junction, and tubular ascending aorta.100,101 Measurements are performed in the parasternal long-axis view from leading edge to leading edge at end diastole, except for the aortic annulus, which is measured in mid systole. As it will have surgical consequences, it is important to differentiate three phenotypes of the ascending aorta: aortic root aneurysms (sinuses of Valsalva >45 mm), tubular ascending aneurysm (sinuses of Valsalva <40–45 mm), and isolated aortic regurgitation (all aortic diameters <40 mm). The calculation of indexed values to account for body size has been suggested,102 in particular in patients with small stature. Anatomy of the aortic valve cusps and its suitability for valve repair should be provided by preoperative TOE if aortic valve repair or a valve-sparing surgery of the aortic root is considered. Intraoperative evaluation of the surgical result by TOE is mandatory in patients undergoing aortic valve preservation or repair.

Table 5

Echocardiographic criteria for the definition of severe aortic valve regurgitation

Qualitative
Valve morphologyAbnormal/flail/large coaptation defect
Colour flow regurgitant jet areaaLarge in central jets, variable in eccentric jets
CW signal of regurgitant jetDense
OtherHolodiastolic flow reversal in descending aorta (EDV >20 cm/s)
Semiquantitative
Vena contracta width (mm)>6
Pressure half-timeb (ms)<200
Quantitative
EROA (mm2)≥30
Regurgitant volume (mL/beat)≥60
Enlargement of cardiac chambersLV dilatation
Qualitative
Valve morphologyAbnormal/flail/large coaptation defect
Colour flow regurgitant jet areaaLarge in central jets, variable in eccentric jets
CW signal of regurgitant jetDense
OtherHolodiastolic flow reversal in descending aorta (EDV >20 cm/s)
Semiquantitative
Vena contracta width (mm)>6
Pressure half-timeb (ms)<200
Quantitative
EROA (mm2)≥30
Regurgitant volume (mL/beat)≥60
Enlargement of cardiac chambersLV dilatation

CW = continuous wave; EDV = end-diastolic velocity; EROA = effective regurgitant orifice area; LV = left ventricle/left ventricular.

a

At a Nyquist limit of 50–60 cm/s.

b

Pressure half-time is shortened with increasing LV diastolic pressure, vasodilator therapy, and in patients with a dilated compliant aorta, or lengthened in chronic aortic regurgitation.

Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611–644. Copyright (2013) by permission of Oxford University Press on behalf of the European Society of Cardiology.

Table 5

Echocardiographic criteria for the definition of severe aortic valve regurgitation

Qualitative
Valve morphologyAbnormal/flail/large coaptation defect
Colour flow regurgitant jet areaaLarge in central jets, variable in eccentric jets
CW signal of regurgitant jetDense
OtherHolodiastolic flow reversal in descending aorta (EDV >20 cm/s)
Semiquantitative
Vena contracta width (mm)>6
Pressure half-timeb (ms)<200
Quantitative
EROA (mm2)≥30
Regurgitant volume (mL/beat)≥60
Enlargement of cardiac chambersLV dilatation
Qualitative
Valve morphologyAbnormal/flail/large coaptation defect
Colour flow regurgitant jet areaaLarge in central jets, variable in eccentric jets
CW signal of regurgitant jetDense
OtherHolodiastolic flow reversal in descending aorta (EDV >20 cm/s)
Semiquantitative
Vena contracta width (mm)>6
Pressure half-timeb (ms)<200
Quantitative
EROA (mm2)≥30
Regurgitant volume (mL/beat)≥60
Enlargement of cardiac chambersLV dilatation

CW = continuous wave; EDV = end-diastolic velocity; EROA = effective regurgitant orifice area; LV = left ventricle/left ventricular.

a

At a Nyquist limit of 50–60 cm/s.

b

Pressure half-time is shortened with increasing LV diastolic pressure, vasodilator therapy, and in patients with a dilated compliant aorta, or lengthened in chronic aortic regurgitation.

Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611–644. Copyright (2013) by permission of Oxford University Press on behalf of the European Society of Cardiology.

4.1.2 Computed tomography and cardiac magnetic resonance

CMR should be used to quantify the regurgitant fraction when echocardiographic measurements are equivocal or discordant with clinical findings. In patients with aortic dilatation, CCT is recommended to assess the maximum diameter at four levels, as in echocardiography. CMR can be used for follow-up, but indication for surgery should preferably be based on CCT measurements. Different methods of aortic measurements have been reported. To improve reproducibility, it is recommended to measure diameters using the inner-inner-edge technique at end diastole on the strictly transverse plane by double oblique reconstruction perpendicular to the axis of blood flow of the corresponding segment. Maximum root diameter should be taken from sinus-to-sinus diameter rather than sinus-to-commissure diameter, as it correlates more closely to long-axis leading-edge-to-leading-edge echo maximum diameters.103,104

4.2 Indications for intervention

Acute aortic regurgitation may require urgent surgery. It is mainly caused by infective endocarditis and aortic dissection but may also occur after blunt chest trauma and iatrogenic complications during catheter-based cardiac interventions. Specific guidelines deal with these entities.4,101 The recommendations on indications for surgery in severe aortic regurgitation and aortic root disease may be related to symptoms, status of the LV, or dilatation of the aorta [see table of recommendations on indications for surgery in severe aortic regurgitation and aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation), and Figure 2].

Management of patients with aortic regurgitation. BSA = body surface area; LV = left ventricle/left ventricular; LVESD = left ventricle end-systolic diameter; LVEF = left ventricular ejection fraction. aSee recommendations on indications for surgery in severe aortic regurgitation and aortic root disease for definition. bSurgery should also be considered if significant changes in LV or aortic size occur during follow-up.
Figure 2

Management of patients with aortic regurgitation. BSA = body surface area; LV = left ventricle/left ventricular; LVESD = left ventricle end-systolic diameter; LVEF = left ventricular ejection fraction. aSee recommendations on indications for surgery in severe aortic regurgitation and aortic root disease for definition. bSurgery should also be considered if significant changes in LV or aortic size occur during follow-up.

In symptomatic patients, surgery is recommended irrespective of the LVEF as long as aortic regurgitation is severe and the operative risk is not prohibitive.105–109 Surgery is recommended in symptomatic and asymptomatic patients with severe aortic regurgitation undergoing coronary artery bypass grafting (CABG), or surgery of the ascending aorta or another valve.110,111 In asymptomatic patients with severe aortic regurgitation, impairment of LV function [LVEF ≤50% or left ventricular end-systolic diameter (LVESD) >50 mm] are associated with worse outcomes and surgery should therefore be pursued when these cut-offs are reached.107,108,112–114 LVESD should be related to body surface area (BSA) and a cut-off of 25 mm/m2 BSA appeared to be more appropriate, especially in patients with small body size (BSA <1.68 m2) or with large BSA who are not overweight.108,115 Some recent retrospective, non-randomized studies emphasized the role of indexed LVESD and proposed a lower cut-off value of 20 or 22 mm/m² BSA for the indexed LVESD.116–118 One of these studies also suggests a higher cut-off value of 55% for LVEF.118 Based on these data, low-risk surgery may be discussed in some selected asymptomatic patients with LVESD >20 mm/m2 or resting LVEF between 50% and 55%. In patients not reaching the thresholds for surgery, close follow-up is needed, and exercise testing should be liberally performed to identify borderline symptomatic patients. Progressive enlargement of the LV, or a progressive decrease in its function in asymptomatic patients not reaching the thresholds for surgery but with significant LV dilatation [left ventricular end-diastolic diameter (LVEDD) >65 mm], may also be an appropriate indicator for timing operations in asymptomatic patients.

TAVI may be considered in experienced centres for selected patients with aortic regurgitation and ineligible for SAVR.119,120

In patients with a dilated aorta, the rationale for surgery has been best defined in patients with Marfan syndrome and root dilation.121,122 Root aneurysms require root replacement, with or without preservation of the native aortic valve. In contrast, tubular ascending aortic aneurysms in the presence of normal aortic valves require only a supracommissural tube graft replacement. In patients with aortic diameters borderline indicated for aortic surgery, the family history, age, and anticipated risk of the procedure should be taken into consideration. Irrespective of the degree of aortic regurgitation and type of valve pathology, in patients with an aortic diameter ≥55 mm with tricuspid or bicuspid aortic valves, ascending aortic surgery is recommended (see recommendations on indications for surgery in severe aortic regurgitation and aortic root disease) when the operative risk is not prohibitive.123–125 In individuals with bicuspid aortic valve, when additional risk factors or coarctation126 are present, surgery should be considered when aortic diameter is ≥50 mm.127–129 In all patients with Marfan syndrome, aortic surgery is recommended for a maximal aortic diameter ≥50 mm.5,121,122 When additional risk factors are present in patients with Marfan syndrome and in patients with a TGFBR1 or TGFBR2 mutation (including Loeys–Dietz syndrome), surgery should be considered at a maximal aortic diameter ≥45 mm121,130 and even earlier (aortic diameter of 40 mm or more) in women with low BSA, TGFBR2 mutation, and severe extra-aortic features130. For patients who have an indication for aortic valve surgery, an aortic diameter ≥45 mm is considered to indicate concomitant surgery of the aortic root or tubular ascending aorta. The patient's stature, the aetiology of the valvular disease (bicuspid valve), and the intraoperative shape and wall thickness of the ascending aorta should be considered for individual decisions.

The choice of the surgical procedure should be adapted according to the experience of the team, the presence of an aortic root aneurysm, characteristics of the cusps, life expectancy, and desired anticoagulation status.

Valve replacement is the standard procedure in the majority of patients with aortic regurgitation. Aortic valve-sparing root replacement and valve repair yield good long-term results in selected patients, with low rates of valve-related events as well as good quality of life131–140 when performed in experienced centres. Aortic valve-sparing root replacement is recommended in younger patients who have an enlargement of the aortic root with normal cusp motion, when performed by experienced surgeons.133–136,140 In selected patients, aortic valve repair132,132,137 or the Ross procedure138,139 may be an alternative to valve replacement, when performed by experienced surgeons.

Recommendations on indications for surgery in (A) severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)

graphic
graphic
graphic
graphic

BSA = body surface area; CABG = coronary artery bypass grafting; CCT = cardiac computed tomography; CMR = cardiac magnetic resonance; ECG = electrocardiogram; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter.

a

Class of recommendation.

b

Level of evidence.

c

For clinical decision making, dimensions of the aorta should be confirmed by ECG-gated CCT.

d

Family history of aortic dissection (or personal history of spontaneous vascular dissection), severe aortic or mitral regurgitation, desire for pregnancy, uncontrolled systemic arterial hypertension and/or aortic size increase >3 mm/year (using serial echocardiography or CMR measurements at the same level of the aorta confirmed by ECG-gated CCT).

e

A lower threshold of 40 mm may be considered in women with low BSA, TGFBR2 mutation and severe extra-aortic features.130

f

Considering age, BSA, aetiology of the valvular disease, presence of a bicuspid aortic valve, and intraoperative shape and thickness of the ascending aorta.

Recommendations on indications for surgery in (A) severe aortic regurgitation and (B) aortic root or tubular ascending aortic aneurysm (irrespective of the severity of aortic regurgitation)

graphic
graphic
graphic
graphic

BSA = body surface area; CABG = coronary artery bypass grafting; CCT = cardiac computed tomography; CMR = cardiac magnetic resonance; ECG = electrocardiogram; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter.

a

Class of recommendation.

b

Level of evidence.

c

For clinical decision making, dimensions of the aorta should be confirmed by ECG-gated CCT.

d

Family history of aortic dissection (or personal history of spontaneous vascular dissection), severe aortic or mitral regurgitation, desire for pregnancy, uncontrolled systemic arterial hypertension and/or aortic size increase >3 mm/year (using serial echocardiography or CMR measurements at the same level of the aorta confirmed by ECG-gated CCT).

e

A lower threshold of 40 mm may be considered in women with low BSA, TGFBR2 mutation and severe extra-aortic features.130

f

Considering age, BSA, aetiology of the valvular disease, presence of a bicuspid aortic valve, and intraoperative shape and thickness of the ascending aorta.

4.3 Medical therapy

Medical therapy, especially angiotensin-converting enzyme inhibitors (ACEI) or dihydropiridines, may provide symptomatic improvement in individuals with chronic severe aortic regurgitation in whom surgery is not feasible. The value of ACEI or dihydropiridine in delaying surgery in the presence of moderate or severe aortic regurgitation in asymptomatic patients has not been established and their use is not recommended for this indication.

In patients who undergo surgery but continue to suffer from heart failure or hypertension, ACEI, angiotensin receptor blockers (ARBs), and beta-blockers are useful.141,142

In patients with Marfan syndrome, beta-blockers remain the mainstay for medical treatment and reducing shear stress and aortic growth rate and should be considered before and after surgery.143–145 While ARBs did not prove to have a superior effect when compared to beta-blockers, they may be considered as an alternative in patients intolerant to beta-blockers.146–148 By analogy, while there are no studies that provide supporting evidence, it is common clinical practice to advise beta-blocker or ARBs in patients with bicuspid aortic valve if the aortic root and/or ascending aorta is dilated. Management of aortic regurgitation during pregnancy is discussed in section 13.

4.4 Serial testing

All asymptomatic patients with severe aortic regurgitation and normal LV function should be followed up at least every year. In patients with either a first diagnosis or with LV diameter and/or ejection fraction showing significant changes or approaching thresholds for surgery, follow-up should be continued at 3–6-month intervals. Surgery may be considered in asymptomatic patients with significant LV dilatation (LVEDD >65 mm), and with progressive enlargement in the size of LV or progressive decrease of LVEF during follow-up. Patient’s BNP levels could be of potential interest as a predictor of outcomes (particularly symptom onset and deterioration of LV function) and may be helpful in the follow-up of asymptomatic patients.149 Patients with mild-to-moderate aortic regurgitation can be seen on a yearly basis and echocardiography performed every 2 years.

If the ascending aorta is dilated (>40 mm), it is recommended to systematically perform CCT or CMR. Follow-up assessment of the aortic dimension should be performed using echocardiography and/or CMR. Any increase >3 mm should be validated by CCT angiography/CMR and compared with baseline data. After repair of the ascending aorta, Marfan patients remain at risk for dissection of the residual aorta and lifelong regular multidisciplinary follow-up at an expert centre is required.

4.5 Special patient populations

If aortic regurgitation requiring surgery is associated with severe primary and secondary mitral regurgitation, both should be treated during the same operation.

In patients with moderate aortic regurgitation who undergo CABG or mitral valve surgery, the decision to treat the aortic valve is controversial, as data show that progression of moderate aortic regurgitation is very slow in patients without aortic dilation.150 The Heart Team should decide based on the aetiology of aortic regurgitation, other clinical factors, the life expectancy of the patient, and the patient's operative risk.

The level of physical and sports activity in the presence of a dilated aorta remains a matter of clinical judgment in the absence of evidence. Current guidelines are very restrictive, particularly regarding isometric exercise, to avoid a catastrophic event.151 This approach is justified in the presence of connective tissue disease, but a more liberal approach is likely to be appropriate in other patients.

Given the familial risk of thoracic aortic aneurysms, screening and referral for genetic testing of the patient's first-degree relatives with appropriate imaging studies is indicated in patients with connective tissue disease. For patients with bicuspid valves, it is appropriate to have an echocardiographic screening of first-degree relatives.

5 Aortic stenosis

Aortic stenosis is the most common primary valve lesion requiring surgery or transcatheter intervention in Europe1 and North America. Its prevalence is rising rapidly as a consequence of the ageing population.2,152

5.1 Evaluation

5.1.1 Echocardiography

Echocardiography is key to confirming the diagnosis and severity of aortic stenosis, assessing valve calcification, LV function and wall thickness, detecting other valve disease or aortic pathology, and providing prognostic information.43,153,154 Assessment should be undertaken when blood pressure (BP) is well controlled to avoid the confounding flow effects of increased afterload. New echocardiographic parameters, stress imaging and CCT provide important adjunctive information when severity is uncertain (Figure 3).

Integrated imaging assessment of aortic stenosis. AS = aortic stenosis; AV = aortic valve; AVA = aortic valve area; CT = computed tomography; ΔPm = mean pressure gradient; DSE = dobutamine stress echocardiography; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; SVi = stroke volume index; Vmax = peak transvalvular velocity. aHigh flow may be reversible in patients with anaemia, hyperthyroidism or arterio-venous fistulae, and may also be present in patients with hypertrophic obstructive cardiomyopathy. Upper limit of normal flow using pulsed Doppler echocardiography: cardiac index 4.1 L/min/m² in men and women, SVi 54 mL/m² in men, 51 mL/m² in women).155bConsider also: typical symptoms (with no other explanation), LV hypertrophy (in the absence of coexistent hypertension) or reduced LV longitudinal function (with no other cause). cDSE flow reserve = >20% increase in stroke volume in response to low-dose dobutamine. dPseudo-severe aortic stenosis = AVA >1.0 cm2 with increased flow. eThresholds for severe aortic stenosis assessed by means of CT measurement of aortic valve calcification (Agatston units): men >3000, women >1600 = highly likely; men >2000, women >1200 = likely; men <1600, women <800 = unlikely.
Figure 3

Integrated imaging assessment of aortic stenosis. AS = aortic stenosis; AV = aortic valve; AVA = aortic valve area; CT = computed tomography; ΔPm = mean pressure gradient; DSE = dobutamine stress echocardiography; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; SVi = stroke volume index; Vmax = peak transvalvular velocity. aHigh flow may be reversible in patients with anaemia, hyperthyroidism or arterio-venous fistulae, and may also be present in patients with hypertrophic obstructive cardiomyopathy. Upper limit of normal flow using pulsed Doppler echocardiography: cardiac index 4.1 L/min/m² in men and women, SVi 54 mL/m² in men, 51 mL/m² in women).155bConsider also: typical symptoms (with no other explanation), LV hypertrophy (in the absence of coexistent hypertension) or reduced LV longitudinal function (with no other cause). cDSE flow reserve = >20% increase in stroke volume in response to low-dose dobutamine. dPseudo-severe aortic stenosis = AVA >1.0 cm2 with increased flow. eThresholds for severe aortic stenosis assessed by means of CT measurement of aortic valve calcification (Agatston units): men >3000, women >1600 = highly likely; men >2000, women >1200 = likely; men <1600, women <800 = unlikely.

Current international recommendations for the echocardiographic evaluation of patients with aortic stenosis25 depend upon measurement of mean pressure gradient (the most robust parameter), peak transvalvular velocity (Vmax), and valve area. Although valve area is the theoretically ideal measurement for assessing severity, there are numerous technical limitations. Clinical decision making in discordant cases should therefore take account of additional parameters: functional status, stroke volume, Doppler velocity index,156 degree of valve calcification, LV function, the presence or absence of LV hypertrophy, flow conditions, and the adequacy of BP control.25 Low flow is arbitrarily defined by a stroke volume index (SVi) ≤35 mL/m²—a threshold that is under current debate.155,157,158 The use of sex -specific thresholds has been recently proposed.159 Four broad categories can be defined:

  • High-gradient aortic stenosis [mean gradient ≥40 mmHg, peak velocity ≥4.0 m/s, valve area ≤1 cm2 (or ≤0.6 cm²/m²)]. Severe aortic stenosis can be assumed irrespective of LV function and flow conditions.

  • Low-flow, low-gradient aortic stenosis with reduced ejection fraction (mean gradient <40 mmHg, valve area ≤1 cm2, LVEF <50%, SVi ≤35 mL/m2). Low-dose dobutamine stress echocardiography (DSE) is recommended to distinguish between true severe and pseudo-severe aortic stenosis (increase in valve area to >1.0 cm2 with increased flow) and identify patients with no flow (or contractile) reserve.160 However, utility in elderly patients has only been evaluated in small registries.161

  • Low-flow, low-gradient aortic stenosis with preserved ejection fraction (mean gradient <40 mmHg, valve area ≤1 cm2, LVEF ≥50%, SVi ≤35 mL/m2). Typically encountered in hypertensive elderly subjects with small LV size and marked hypertrophy.157,162 This scenario may also result from conditions associated with low stroke volume (e.g. moderate/severe mitral regurgitation, severe tricuspid regurgitation, severe mitral stenosis, and large ventricular septal defect and severe RV dysfunction). Diagnosis of severe aortic stenosis is challenging and requires careful exclusion of measurement errors and other explanations for the echocardiographic findings,25 as well as the presence or absence of typical symptoms (with no other explanation), LV hypertrophy (in the absence of coexistent hypertension) or reduced LV longitudinal strain (with no other cause). CCT assessment of the degree of valve calcification provides important additional information [thresholds (Agatston units) for severe aortic stenosis: men >3000, women >1600 = highly likely; men >2000, women >1200 = likely; men <1600, women <800 = unlikely].35,36,163,164

  • Normal-flow, low-gradient aortic stenosis with preserved ejection fraction (mean gradient <40 mmHg, valve area ≤1 cm2, LVEF≥50%, SVi >35 mL/m2). These patients usually have only moderate aortic stenosis.36,165–167

5.1.2 Additional diagnostic and prognostic parameters

The resting Doppler velocity index (DVI, also termed ‘dimensionless index’)—the ratio of the left ventricular outflow tract (LVOT) time-velocity integral (TVI) to that of the aortic valve jet—does not require calculation of LVOT area and may assist evaluation when other parameters are equivocal (a value <0.25 suggests that severe aortic stenosis is highly likely).156 Assessment of global longitudinal strain provides additional information concerning LV function and a threshold of 15% may help to identify patients with severe asymptomatic aortic stenosis who are at higher risk of clinical deterioration or premature mortality.26,168 TOE allows evaluation of concomitant mitral valve disease and may be of value for periprocedural imaging during TAVI and SAVR.169

Natriuretic peptides predict symptom-free survival and outcome in normal and low-flow severe aortic stenosis.170,171 They can be used to arbitrate the source of symptoms in patients with multiple potential causes and identify those with high-risk asymptomatic aortic stenosis who may benefit from early intervention (section 5.2.2, Table 6 and Figure 3).

Exercise testing may unmask symptoms and is recommended for risk stratification of asymptomatic patients with severe aortic stenosis.172 Exercise echocardiography provides additional prognostic information by assessing the increase in mean pressure gradient and change in LV function.173

CCT provides information concerning the anatomy of the aortic root and ascending aorta, and the extent and distribution of valve and vascular calcification, and feasibility of vascular access.174 Quantification of valve calcification predicts disease progression and clinical events164 and may be useful when combined with geometric assessment of valve area in assessing the severity of aortic stenosis in patients with low valve gradient.35,36,163,164

Myocardial fibrosis is a major driver of LV decompensation in aortic stenosis (regardless of the presence or absence of CAD), which can be detected and quantified using CMR. Amyloidosis is also frequently associated with aortic stenosis in elderly patients (incidence 9–15%).175 When cardiac amyloidosis is clinically suspected, based on symptoms (neuropathy and hematologic data), diphosphonate scintigraphy and/or CMR should be considered. Both entities persist following valve intervention and are associated with poor long-term prognosis.176–179

Coronary angiography is essential prior to TAVI and SAVR to determine the potential need for concomitant revascularization (see section 3.2.4.1 and section 5.5). Retrograde LV catheterization is not recommended unless there are symptoms and signs of severe aortic stenosis and non-invasive investigations are inconclusive.

5.1.3 TAVI diagnostic workup

Prior to TAVI, CCT is the preferred imaging tool to assess: (i) aortic valve anatomy, (ii) annular size and shape, (iii) extent and distribution of valve and vascular calcification, (iv) risk of coronary ostial obstruction, (v) aortic root dimensions, (vi) optimal fluoroscopic projections for valve deployment, and (vii) feasibility of vascular access (femoral, subclavian, axillary, carotid, transcaval or transapical). Adverse anatomical findings may suggest that SAVR is a better treatment option (Table 6). TOE is more operator-dependent but may be considered when CCT is difficult to interpret or relatively contraindicated (e.g. chronic renal failure).

Table 6

Clinical, anatomical and procedural factors that influence the choice of treatment modality for an individual patient

FavoursFavours
TAVISAVR
Clinical characteristics
Lower surgical risk+
Higher surgical risk+
Younger agea+
Older agea+
Previous cardiac surgery (particularly intact coronary artery bypass grafts at risk of injury during repeat sternotomy)+
Severe frailtyb+
Active or suspected endocarditis+
Anatomical and procedural factors
TAVI feasible via transfemoral approach+
Transfemoral access challenging or impossible and SAVR feasible Transfemoral access challenging or impossible and SAVR inadvisable  +  c+  
Sequelae of chest radiation+
Porcelain aorta+
High likelihood of severe patient–prosthesis mismatch (AVA <0.65 cm2/m2 BSA)+
Severe chest deformation or scoliosis+
Aortic annular dimensions unsuitable for available TAVI devices+
Bicuspid aortic valve+
Valve morphology unfavourable for TAVI (e.g. high risk of coronary obstruction due to low coronary ostia or heavy leaflet/LVOT calcification)+
Thrombus in aorta or LV+
Concomitant cardiac conditions requiring intervention
Significant multi-vessel CAD requiring surgical revascularizationd+
Severe primary mitral valve disease+
Severe tricuspid valve disease+
Significant dilatation/aneurysm of the aortic root and/or ascending aorta+
Septal hypertrophy requiring myectomy+
FavoursFavours
TAVISAVR
Clinical characteristics
Lower surgical risk+
Higher surgical risk+
Younger agea+
Older agea+
Previous cardiac surgery (particularly intact coronary artery bypass grafts at risk of injury during repeat sternotomy)+
Severe frailtyb+
Active or suspected endocarditis+
Anatomical and procedural factors
TAVI feasible via transfemoral approach+
Transfemoral access challenging or impossible and SAVR feasible Transfemoral access challenging or impossible and SAVR inadvisable  +  c+  
Sequelae of chest radiation+
Porcelain aorta+
High likelihood of severe patient–prosthesis mismatch (AVA <0.65 cm2/m2 BSA)+
Severe chest deformation or scoliosis+
Aortic annular dimensions unsuitable for available TAVI devices+
Bicuspid aortic valve+
Valve morphology unfavourable for TAVI (e.g. high risk of coronary obstruction due to low coronary ostia or heavy leaflet/LVOT calcification)+
Thrombus in aorta or LV+
Concomitant cardiac conditions requiring intervention
Significant multi-vessel CAD requiring surgical revascularizationd+
Severe primary mitral valve disease+
Severe tricuspid valve disease+
Significant dilatation/aneurysm of the aortic root and/or ascending aorta+
Septal hypertrophy requiring myectomy+

AVA = aortic valve area, BSA = body surface area, CAD = coronary artery disease; ESC = European Society of Cardiology; LV = left ventricle/left ventricular; LVOT = left ventricular outflow tract; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation.

Integration of these factors provides guidance for the Heart Team decision (indications for intervention are provided in the table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention).

a

Life expectancy is highly dependent on absolute age and frailty, differs between men and women, and may be a better guide than age alone. There is wide variation across Europe and elsewhere in the world (http://ghdx.healthdata.org/record/ihme-data/gbd-2017-life-tables-1950-2017).

b

Severe frailty = >2 factors according to Katz index59 (see section 3.3 for further discussion).

c

Via non-transfemoral approach.

d

According to the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

Table 6

Clinical, anatomical and procedural factors that influence the choice of treatment modality for an individual patient

FavoursFavours
TAVISAVR
Clinical characteristics
Lower surgical risk+
Higher surgical risk+
Younger agea+
Older agea+
Previous cardiac surgery (particularly intact coronary artery bypass grafts at risk of injury during repeat sternotomy)+
Severe frailtyb+
Active or suspected endocarditis+
Anatomical and procedural factors
TAVI feasible via transfemoral approach+
Transfemoral access challenging or impossible and SAVR feasible Transfemoral access challenging or impossible and SAVR inadvisable  +  c+  
Sequelae of chest radiation+
Porcelain aorta+
High likelihood of severe patient–prosthesis mismatch (AVA <0.65 cm2/m2 BSA)+
Severe chest deformation or scoliosis+
Aortic annular dimensions unsuitable for available TAVI devices+
Bicuspid aortic valve+
Valve morphology unfavourable for TAVI (e.g. high risk of coronary obstruction due to low coronary ostia or heavy leaflet/LVOT calcification)+
Thrombus in aorta or LV+
Concomitant cardiac conditions requiring intervention
Significant multi-vessel CAD requiring surgical revascularizationd+
Severe primary mitral valve disease+
Severe tricuspid valve disease+
Significant dilatation/aneurysm of the aortic root and/or ascending aorta+
Septal hypertrophy requiring myectomy+
FavoursFavours
TAVISAVR
Clinical characteristics
Lower surgical risk+
Higher surgical risk+
Younger agea+
Older agea+
Previous cardiac surgery (particularly intact coronary artery bypass grafts at risk of injury during repeat sternotomy)+
Severe frailtyb+
Active or suspected endocarditis+
Anatomical and procedural factors
TAVI feasible via transfemoral approach+
Transfemoral access challenging or impossible and SAVR feasible Transfemoral access challenging or impossible and SAVR inadvisable  +  c+  
Sequelae of chest radiation+
Porcelain aorta+
High likelihood of severe patient–prosthesis mismatch (AVA <0.65 cm2/m2 BSA)+
Severe chest deformation or scoliosis+
Aortic annular dimensions unsuitable for available TAVI devices+
Bicuspid aortic valve+
Valve morphology unfavourable for TAVI (e.g. high risk of coronary obstruction due to low coronary ostia or heavy leaflet/LVOT calcification)+
Thrombus in aorta or LV+
Concomitant cardiac conditions requiring intervention
Significant multi-vessel CAD requiring surgical revascularizationd+
Severe primary mitral valve disease+
Severe tricuspid valve disease+
Significant dilatation/aneurysm of the aortic root and/or ascending aorta+
Septal hypertrophy requiring myectomy+

AVA = aortic valve area, BSA = body surface area, CAD = coronary artery disease; ESC = European Society of Cardiology; LV = left ventricle/left ventricular; LVOT = left ventricular outflow tract; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation.

Integration of these factors provides guidance for the Heart Team decision (indications for intervention are provided in the table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention).

a

Life expectancy is highly dependent on absolute age and frailty, differs between men and women, and may be a better guide than age alone. There is wide variation across Europe and elsewhere in the world (http://ghdx.healthdata.org/record/ihme-data/gbd-2017-life-tables-1950-2017).

b

Severe frailty = >2 factors according to Katz index59 (see section 3.3 for further discussion).

c

Via non-transfemoral approach.

d

According to the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

5.2 Indications for intervention (SAVR or TAVI)

Indications for aortic valve intervention are summarized in the table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention and in Figure 4.

Management of patients with severe aortic stenosis. BP = blood pressure;
EuroSCORE = European System for Cardiac Operative Risk Evaluation; LVEF = left
ventricular ejection fraction; SAVR = surgical aortic valve replacement;
STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality;
TAVI = transcatheter aortic valve implantation; TF = transfemoral. aSee Figure 3: Integrated
imaging assessment of aortic stenosis. bProhibitive risk is defined in Supplementary Table
5. cHeart Team assessment based upon careful evaluation
of clinical, anatomical, and procedural factors (see Table 6 and table on Recommendations
on indications for intervention in symptomatic and asymptomatic aortic stenosis and
recommended mode of intervention). The Heart Team recommendation should be discussed
with the patient who can then make an informed treatment choice. dAdverse
features according to clinical, imaging (echocardiography/CT), and/or biomarker
assessment. eSTS-PROM: http://riskcalc.sts.org/stswebriskcalc/#/calculate,
EuroSCORE II: http://www.euroscore.org/calc.html. fIf suitable for
procedure according to clinical, anatomical, and procedural factors
(Table 6).
Figure 4

Management of patients with severe aortic stenosis. BP = blood pressure; EuroSCORE = European System for Cardiac Operative Risk Evaluation; LVEF = left ventricular ejection fraction; SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality; TAVI = transcatheter aortic valve implantation; TF = transfemoral. aSee Figure 3: Integrated imaging assessment of aortic stenosis. bProhibitive risk is defined in Supplementary Table 5. cHeart Team assessment based upon careful evaluation of clinical, anatomical, and procedural factors (see Table 6 and table on Recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention). The Heart Team recommendation should be discussed with the patient who can then make an informed treatment choice. dAdverse features according to clinical, imaging (echocardiography/CT), and/or biomarker assessment. eSTS-PROM: http://riskcalc.sts.org/stswebriskcalc/#/calculate, EuroSCORE II: http://www.euroscore.org/calc.html. fIf suitable for procedure according to clinical, anatomical, and procedural factors (Table 6).

5.2.1 Symptomatic aortic stenosis

Symptomatic severe aortic stenosis has dismal prognosis and early intervention is strongly recommended in all patients. The only exceptions are for those in whom intervention is unlikely to improve quality of life or survival (due to severe comorbidities) or for those with concomitant conditions associated with survival <1 year (e.g. malignancy) (section 3).

Intervention is recommended in symptomatic patients with high-gradient aortic stenosis, regardless of LVEF. However, management of patients with low-gradient aortic stenosis is more challenging:

  • LV function usually improves after intervention in patients with low-flow, low-gradient aortic stenosis, when reduced ejection fraction is predominantly caused by excessive afterload.32,180 Conversely, improvement is uncertain if the primary cause of reduced ejection fraction is scarring due to myocardial infarction or cardiomyopathy. Intervention is recommended when severe aortic stenosis is confirmed by stress echocardiography (true severe aortic stenosis; Figure 3),32 while patients with pseudo-severe aortic stenosis should receive conventional heart failure treatment.142,181 The presence or absence of flow reserve (increase in stroke volume ≥20%) does not appear to influence prognosis in contemporary series of patients undergoing TAVI or SAVR,182–184 and although those with no flow reserve show increased procedural mortality, both modes of intervention improve ejection fraction and clinical outcomes.32,180,182 Decision making for such patients should take account of comorbidities, degree of valve calcification, extent of CAD, and feasibility of revascularization.

  • Data concerning the natural history of low-flow, low-gradient aortic stenosis and preserved ejection fraction, and outcomes after SAVR and TAVI remain controversial.162,165,167 Intervention should only be considered in those with symptoms and significant valve obstruction (see table of recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention and Figure 4).

  • The prognosis of patients with normal-flow, low-gradient aortic stenosis and preserved ejection fraction is similar to that of moderate aortic stenosis—regular clinical and echocardiographic surveillance is recommended.165,166,185

5.2.2 Asymptomatic aortic stenosis

Intervention is recommended in asymptomatic patients with severe aortic stenosis and impaired LV function of no other cause,9 and those who are asymptomatic during normal activities but develop symptoms during exercise testing.172,186 Management of asymptomatic severe aortic stenosis is otherwise controversial and the decision to intervene requires careful assessment of the benefits and risks in an individual patient.

In the absence of adverse prognostic features, watchful waiting has generally been recommended with prompt intervention at symptom onset.187 Data from a single RCT have shown significant reduction in the primary endpoint (death during or within 30 days of surgery or cardiovascular death during the entire follow-up period) following early SAVR compared with conservative management [1% vs. 15%; hazard ratio 0.09; 95% confidence interval (CI), 0.01–0.67; P = 0.003].188 However, subjects were selected per inclusion criteria (median age 64 years, minimal comorbidities, low operative risk) and follow-up in the conservative group was limited. Further randomized trials [EARLY TAVR (NCT03042104), AVATAR (NCT02436655), EASY-AS (NCT04204915), EVOLVED (NCT03094143)] will help determine future recommendations.

Predictors of symptom development and adverse outcomes in asymptomatic patients include clinical characteristics (older age, atherosclerotic risk factors), echocardiographic parameters (valve calcification, peak jet velocity189,190), LVEF, rate of haemodynamic progression,189 increase in mean gradient >20 mmHg with exercise,172 severe LV hypertrophy,191 indexed stroke volume,158 LA volume,192 LV global longitudinal strain,26,168,193 and abnormal biomarker levels (natriuretic peptides, troponin, and fetuin-A).170,171,194,195 Early intervention may be considered in asymptomatic patients with severe aortic stenosis and one or more of these predictors if procedural risk is low (although application of TAVI in this setting has yet to be formally evaluated) (Table 6 and Figure 4). Otherwise, watchful waiting is a safer and more appropriate strategy.

5.2.3 The mode of intervention

Use of SAVR and TAVI as complementary treatment options has allowed a substantial increase in the overall number of patients with aortic stenosis undergoing surgical or transcatheter intervention in the past decade.196 RCTs have assessed the two modes of intervention across the spectrum of surgical risk in predominantly elderly patients and a detailed appraisal of the evidence base is provided in Supplementary Section 5. In brief, these trials used surgical risk scores to govern patient selection and demonstrate that TAVI is superior to medical therapy in extreme-risk patients,197 and non-inferior to SAVR in high-198201 and intermediate-risk patients at follow-up extending to 5 years.202–208 The more recent PARTNER 3 and Evolut Low Risk trials demonstrate that TAVI is non-inferior to SAVR in low-risk patients at 2-year follow-up.209–212 Importantly, patients in the low-risk trials were predominantly male and relatively elderly (e.g. PARTNER 3: mean age 73.4 years, <70 years 24%, 70–75 years 36%, >75 years 40%, >80 years 13%) whilst those with low-flow aortic stenosis or adverse anatomical characteristics for either procedure (including bicuspid aortic valves or complex coronary disease) were excluded.

Rates of vascular complications, pacemaker implantation, and paravalvular regurgitation are consistently higher after TAVI, whereas severe bleeding, acute kidney injury, and new-onset AF are more frequent after SAVR. Although the likelihood of paravalvular regurgitation has been reduced with newer transcatheter heart valve designs, pacemaker implantation (and new-onset left bundle branch block) may have long-term consequences213–215 and further refinements are required. Most patients undergoing TAVI have a swift recovery, short hospital stay, and rapidly return to normal activities.216,217 Despite these benefits, there is wide variation in worldwide access to the procedure as a result of high device costs and differing levels of healthcare resources.71,218,219

The Task Force has attempted to address the gaps in evidence and provide recommendations concerning the indications for intervention and mode of treatment (Recommendations on indications for intervention in symptomatic and asymptomatic aortic stenosis and recommended mode of intervention, Figure 4) that are guided by the RCT findings and compatible with real-world Heart Team decision making for individual patients (many of whom fall outside the RCT inclusion criteria). Aortic stenosis is a heterogeneous condition and selection of the most appropriate mode of intervention should be carefully considered by the Heart Team for all patients, accounting for individual age and estimated life expectancy, comorbidities (including frailty and overall quality of life, section 3), anatomical and procedural characteristics (Table 6), the relative risks of SAVR and TAVI and their long-term outcomes, prosthetic heart valve durability, feasibility of transfemoral TAVI, and local experience and outcome data. These factors should be discussed with the patient and their family to allow informed treatment choice.

The interplay between estimated life expectancy and prosthetic heart valve durability is a key consideration in these discussions. Age is a surrogate for life expectancy but had no impact on the outcomes of the low-risk RCTs at 1–2 year follow-up. Life expectancy varies widely across the world and is highly dependent on absolute age, sex, frailty, and the presence of comorbidities (http://ghdx.healthdata.org/record/ihme-data/gbd-2017-life-tables-1950-2017); it may be a better guide than age alone but is difficult to determine in individual patients. Although some (now abandoned) surgical bioprosthetic designs have failed early, the durability of contemporary surgical bioprosthetic valves beyond 10 years is well established.220 Conversely, registry data provide some reassurance concerning the long-term durability of TAVI devices up to 8 years but largely relate to older high-/intermediate-risk patients,221–224 whereas information concerning durability in low-risk patients is currently limited to 2-year follow-up. Data comparing the durability of transcatheter heart valves and surgical bioprostheses directly remain limited. Rates of aortic valve re-intervention were higher after TAVI using a balloon-expandable valve compared to SAVR at 5-year follow-up in the PARTNER 2A trial (3.2% vs. 0.8%; hazard ratio, 3.3; 95% CI, 1.3–8.1),206 whereas rates of structural valve deterioration (SVD) were not statistically different following SAVR and TAVI using the third generation SAPIEN 3 device in a parallel observational registry over the same time frame.225

Recommendations on indications for interventiona in symptomatic (A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C)

graphic
graphic
graphic
graphic
graphic
graphic

BNP = B-type natriuretic peptide; BP = blood pressure; CABG = coronary artery bypass grafting; CCT = cardiac computed tomography; EuroSCORE = European System for Cardiac Operative Risk Evaluation; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; NCS = non-cardiac surgery; SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality; SVi = stroke volume index; TAVI = transcatheter aortic valve implantation; Vmax = peak transvalvular velocity.

a

SAVR or TAVI.

b

Class of recommendation.

c

Level of evidence.

d

Explanations other than severe aortic stenosis for a small valve area but low gradient despite preserved LVEF are frequent and must be carefully excluded (Figure 3).

f

If suitable for surgery (see Table 6).

g

If suitable for transfemoral TAVI (see Table 6).

h

Moderate aortic stenosis is defined as a valve area of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal flow conditions—clinical assessment is essential to determine whether SAVR is appropriate for an individual patient.

Recommendations on indications for interventiona in symptomatic (A) and asymptomatic (B) aortic stenosis and recommended mode of intervention (C)

graphic
graphic
graphic
graphic
graphic
graphic

BNP = B-type natriuretic peptide; BP = blood pressure; CABG = coronary artery bypass grafting; CCT = cardiac computed tomography; EuroSCORE = European System for Cardiac Operative Risk Evaluation; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; NCS = non-cardiac surgery; SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality; SVi = stroke volume index; TAVI = transcatheter aortic valve implantation; Vmax = peak transvalvular velocity.

a

SAVR or TAVI.

b

Class of recommendation.

c

Level of evidence.

d

Explanations other than severe aortic stenosis for a small valve area but low gradient despite preserved LVEF are frequent and must be carefully excluded (Figure 3).

f

If suitable for surgery (see Table 6).

g

If suitable for transfemoral TAVI (see Table 6).

h

Moderate aortic stenosis is defined as a valve area of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal flow conditions—clinical assessment is essential to determine whether SAVR is appropriate for an individual patient.

Valve-in-valve TAVI is an established treatment option for surgical bioprosthetic valve deterioration but may not be appropriate or feasible in all patients due to the increased likelihood of PPM in patients with a small aortic root (or undersized original prosthesis), incompatible surgical valve designs associated with increased risk of coronary occlusion, or difficult vascular access; re-do SAVR should also be considered in these settings.226–228 Favourable short-term outcomes of redo-TAVI have been demonstrated in selected older patients with transcatheter heart valve deterioration,229 despite theoretical concerns relating to maintained coronary access.230

A bicuspid aortic valve is more frequent in younger patients with aortic stenosis. While several registries have reported excellent outcomes of TAVI in patients with a bicuspid valve who were unsuitable for surgery,231–233 SAVR remains more appropriate in patients with aortic stenosis affecting a bicuspid valve and in those with associated disease (e.g. aortic root dilatation, complex coronary disease, or severe mitral regurgitation) requiring a surgical approach.

In summary, prosthetic heart valve durability is a key consideration in younger patients (<75 years) at low surgical risk and SAVR (if feasible) is therefore the preferred treatment option. Conversely, durability is a lower priority in older patients (≥75 years), or those who are inoperable or high risk for surgery, and TAVI is preferred in these groups (particularly if feasible via transfemoral approach). The Heart Team should make tailored recommendations for remaining patients based upon their individual characteristics (Table 6). This guidance should be re-addressed when further data concerning the long-term durability of TAVI become available.

Balloon aortic valvuloplasty (BAV) may be considered as a bridge to TAVI or SAVR in patients with decompensated aortic stenosis and (when feasible) in those with severe aortic stenosis who require urgent high-risk non-cardiac surgery (NCS) (section 12). The procedure carries significant risk of complications234 and should only be undertaken after Heart Team discussion.

5.3 Medical therapy

No medical therapies influence the natural history of aortic stenosis. Statins (which demonstrated favourable effects in pre-clinical studies) do not affect disease progression246 and clinical trials targeting calcium metabolic pathways are ongoing. Patients with heart failure who are unsuitable (or waiting) for SAVR or TAVI should be medically treated according to ESC heart failure Guidelines.247 ACEI are safe in aortic stenosis (provided that BP is monitored carefully) and may have beneficial myocardial effects before the onset of symptoms, and after TAVI and SAVR.248–250 Coexisting hypertension should be treated to avoid additional afterload, although medication (particularly vasodilators) should be titrated to avoid symptomatic hypotension.

Antithrombotic therapy after TAVI is discussed in section 11.

5.4 Serial testing

Rate of progression of aortic stenosis varies widely. Asymptomatic patients, their family and medical carers need careful education, with emphasis on the importance of regular follow-up (ideally in a Heart Valve Clinic9) and prompt reporting of symptoms. Those with severe aortic stenosis should be followed up every 6 months (at least) to allow earliest symptom detection (using exercise testing if symptoms are doubtful) and any change in echocardiographic parameters (particularly LVEF). Measurement of natriuretic peptides may be considered.

Several studies suggest that the prognosis of moderate degenerative aortic stenosis is worse than previously considered251–254 (particularly if there is significant valve calcification) and these patients should be re-evaluated at least annually. Younger patients with mild aortic stenosis and no significant calcification may be followed up every 2–3 years.

5.5 Special patient populations

Women with aortic stenosis have higher mortality than men, resulting from late diagnosis and initial specialist assessment followed by less frequent and delayed referral for intervention.255–257 Measures are needed to improve this situation and ensure that both sexes receive equivalent care.

CAD and aortic stenosis frequently coexist and the combination confers higher risk of clinical events, therefore the need to consider revascularization in conjunction with aortic valve intervention is common. The impact of coronary revascularization in patients with silent CAD accompanying aortic stenosis is unclear and further studies are warranted in this context (section 3). Both simultaneous SAVR and CABG, and SAVR late after CABG, carry a higher procedural risk than isolated SAVR. Nevertheless, retrospective data indicate that patients with moderate aortic stenosis, in whom CABG is indicated, benefit from concomitant SAVR. Patients aged <70 years with mean gradient progression ≥5 mmHg/year benefit from SAVR at the time of CABG once baseline peak gradient exceeds 30 mmHg.258 Decisions for individual patients should take into account haemodynamic data, rate of progression, extent of leaflet calcification, life expectancy, and associated comorbidities, as well as the individual risk of concomitant SAVR or deferred TAVI.244

Percutaneous coronary intervention (PCI) and TAVI may be undertaken as combined or staged procedures according to the clinical situation, pattern of CAD, and extent of myocardium at risk.259 In the SURTAVI trial, there was no significant difference in the primary endpoint (all-cause mortality or stroke at 2-year follow-up) in intermediate-risk patients with severe aortic stenosis and non-complex CAD (SYNTAX score <22) undergoing either TAVI and PCI or SAVR and CABG [16.0% (95% CI, 11.1–22.9) vs. 14% (95% CI, 9.2–21.1); P = 0.62].260 Assessing the clinical value of systematic PCI in TAVI patients with significant associated CAD is the objective of ongoing RCTs. Patients with severe symptomatic aortic stenosis and diffuse CAD unsuitable for revascularization should receive optimal medical therapy and undergo SAVR or TAVI according to individual characteristics.

Severity of mitral regurgitation accompanying severe aortic stenosis may be overestimated as a result of elevated LV pressures and careful quantification is required. In patients with severe primary mitral regurgitation (PMR), mitral valve surgery is required at the time of SAVR. In patients with severe SMR, surgery may also be considered in the presence of significant annular dilatation and marked LV enlargement. In high-risk or inoperable patients with severe aortic stenosis and severe mitral regurgitation, combined (or more often sequential) TAVI and TEER may be feasible, but there is insufficient experience to allow robust recommendations.261–263 In patients with severe PMR, TEER should be considered early if the patient remains symptomatic and mitral regurgitation is still severe after TAVI. In patients with severe SMR, TAVI should be followed by careful clinical and echocardiographic reassessment to determine whether further mitral intervention is required.264

Section 4 provides recommendations for the management of aneurysm/dilatation of the ascending aorta accompanying aortic stenosis. Assessment and management of congenital aortic stenosis is addressed in ESC Guidelines on adult congenital heart disease.265

6 Mitral regurgitation

Mitral regurgitation is the second-most frequent VHD in Europe.1,3 The underlying mechanism (primary or secondary) determines the therapeutic approach.

6.1 Primary mitral regurgitation

Primary lesion of one or more components of the mitral valve apparatus characterizes PMR. Degenerative aetiology (fibroelastic deficiency and Barlow disease) is most frequent in Western countries.1,2,266 In low-income countries, rheumatic aetiology is the most frequent cause of mitral regurgitation.267 Endocarditis can cause PMR and is addressed in the corresponding ESC Guidelines.4

6.1.1 Evaluation

Echocardiography is the first choice of imaging technique to grade PMR (Table 7). An integrative approach including qualitative, semi-quantitative, and quantitative measures of mitral regurgitation (besides quantification of LV and LA dimensions) is recommended.24,268 Routinely measured effective regurgitant orifice area (EROA) is strongly associated with all-cause mortality, and compared with the general population an excess mortality appears for an EROA ≥20 mm2 and steadily increases beyond 40 mm2.269 Evaluation of the specific lesion leading to mitral regurgitation has prognostic implications266,270 and is fundamental to determine the feasibility of surgical and transcatheter valve repair271–273 (Supplementary Figure 1). Three-dimensional TOE provides an ‘en face’ view of the mitral leaflets resembling the surgical inspection of the valve, thereby facilitating Heart Team discussion.24,268 In addition, 3D echocardiography has shown better agreement with CMR in quantifying the regurgitant volume than 2D echocardiography, particularly in eccentric, multiple and late-systolic regurgitant jets.274–277 When various echocardiographic parameters used to grade mitral regurgitation are inconsistent, CMR is a valid alternative to quantify the regurgitant volume and is the reference standard to quantify LV and LA volumes.278 In addition, quantification of mitral regurgitation with CMR has shown prognostic implications.277 Finally, preliminary data show that myocardial fibrosis assessed with CMR is frequent in PMR and has been associated with sudden cardiac death and ventricular arrhythmias.279

Exercise echocardiography permits evaluation of changes in mitral regurgitant volume and pulmonary pressures during peak exercise and is particularly helpful in patients with discordant symptoms and regurgitation grade at rest.280,281 In asymptomatic patients with severe PMR and non-dilated LV and LA, low BNP values are associated with low mortality and can be useful during follow-up.41,282

LV dimensions and ejection fraction are considered to guide the management of patients with severe PMR. However, there is cumulative evidence showing that LV global longitudinal strain has incremental prognostic value in patients treated with surgical repair.283,284 Recently, the Mitral Regurgitation International Database (MIDA) score has been proposed to estimate the risk of all-cause mortality in patients with severe PMR due to flail leaflet, who are under medical treatment or surgically treated.285 Among the variables included in the score, LA diameter ≥55 mm and LVESD ≥40 mm are new thresholds that have been included in the current recommendations.

Right heart catheterization is systematically used to confirm pulmonary hypertension diagnosed by echocardiography when this is the only criterion to refer the patient for surgery.

Table 7

Severe mitral regurgitation criteria based on 2D echocardiography

Primary mitral regurgitationSecondary mitral regurgitation
Qualitative
Mitral valve morphologyFlail leaflet, ruptured papillary muscle, severe retraction, large perforationNormal leaflets but with severe tenting, poor leaflet coaptation
Colour flow jet areaLarge central jet (>50% of LA) or eccentric wall impinging jet of variable sizeLarge central jet (>50% of LA) or eccentric wall impinging jet of variable size
Flow convergenceLarge throughout systoleLarge throughout systole
Continuous wave Doppler jetHolosystolic/dense/triangularHolosystolic/dense/triangular
Semiquantitative
Vena contracta width (mm)≥7 (≥8 mm for biplane)≥7 (≥8 mm for biplane)
Pulmonary vein flowSystolic flow reversalSystolic flow reversal
Mitral inflowE-wave dominant (>1.2 m/s)E-wave dominant (>1.2 m/s)
TVI mitral/TVI aortic>1.4>1.4
Quantitative
EROA (2D PISA, mm2)≥40 mm2≥40 mm2 (may be ≥30 mm2 if elliptical regurgitant orifice area)
Regurgitant volume (mL/beat)≥60 mL≥60 mL (may be ≥45 mL if low flow conditions)
Regurgitant fraction (%)≥50%≥50%
Structural
Left ventricleDilated (ESD ≥40 mm)Dilated
Left atriumDilated (diameter ≥55 mm or volume ≥60 mL/m2)Dilated
Primary mitral regurgitationSecondary mitral regurgitation
Qualitative
Mitral valve morphologyFlail leaflet, ruptured papillary muscle, severe retraction, large perforationNormal leaflets but with severe tenting, poor leaflet coaptation
Colour flow jet areaLarge central jet (>50% of LA) or eccentric wall impinging jet of variable sizeLarge central jet (>50% of LA) or eccentric wall impinging jet of variable size
Flow convergenceLarge throughout systoleLarge throughout systole
Continuous wave Doppler jetHolosystolic/dense/triangularHolosystolic/dense/triangular
Semiquantitative
Vena contracta width (mm)≥7 (≥8 mm for biplane)≥7 (≥8 mm for biplane)
Pulmonary vein flowSystolic flow reversalSystolic flow reversal
Mitral inflowE-wave dominant (>1.2 m/s)E-wave dominant (>1.2 m/s)
TVI mitral/TVI aortic>1.4>1.4
Quantitative
EROA (2D PISA, mm2)≥40 mm2≥40 mm2 (may be ≥30 mm2 if elliptical regurgitant orifice area)
Regurgitant volume (mL/beat)≥60 mL≥60 mL (may be ≥45 mL if low flow conditions)
Regurgitant fraction (%)≥50%≥50%
Structural
Left ventricleDilated (ESD ≥40 mm)Dilated
Left atriumDilated (diameter ≥55 mm or volume ≥60 mL/m2)Dilated

2D = two-dimensional; ESD = endsystolic diameter; EROA = effective regurgitant orifice area; LA = left atrium; PMR = primary mitral regurgitation; SMR = secondary mitral regurgitation; PISA = proximal isovelocity surface area; TVI = time-velocity integral.

Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611–644. Copyright (2013) by permission of Oxford University Press on behalf of the European Society of Cardiology.

Reproduced from Zoghbi WA et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303–371. Copyright (2017), with permission from the American Society of Echocardiography.

Table 7

Severe mitral regurgitation criteria based on 2D echocardiography

Primary mitral regurgitationSecondary mitral regurgitation
Qualitative
Mitral valve morphologyFlail leaflet, ruptured papillary muscle, severe retraction, large perforationNormal leaflets but with severe tenting, poor leaflet coaptation
Colour flow jet areaLarge central jet (>50% of LA) or eccentric wall impinging jet of variable sizeLarge central jet (>50% of LA) or eccentric wall impinging jet of variable size
Flow convergenceLarge throughout systoleLarge throughout systole
Continuous wave Doppler jetHolosystolic/dense/triangularHolosystolic/dense/triangular
Semiquantitative
Vena contracta width (mm)≥7 (≥8 mm for biplane)≥7 (≥8 mm for biplane)
Pulmonary vein flowSystolic flow reversalSystolic flow reversal
Mitral inflowE-wave dominant (>1.2 m/s)E-wave dominant (>1.2 m/s)
TVI mitral/TVI aortic>1.4>1.4
Quantitative
EROA (2D PISA, mm2)≥40 mm2≥40 mm2 (may be ≥30 mm2 if elliptical regurgitant orifice area)
Regurgitant volume (mL/beat)≥60 mL≥60 mL (may be ≥45 mL if low flow conditions)
Regurgitant fraction (%)≥50%≥50%
Structural
Left ventricleDilated (ESD ≥40 mm)Dilated
Left atriumDilated (diameter ≥55 mm or volume ≥60 mL/m2)Dilated
Primary mitral regurgitationSecondary mitral regurgitation
Qualitative
Mitral valve morphologyFlail leaflet, ruptured papillary muscle, severe retraction, large perforationNormal leaflets but with severe tenting, poor leaflet coaptation
Colour flow jet areaLarge central jet (>50% of LA) or eccentric wall impinging jet of variable sizeLarge central jet (>50% of LA) or eccentric wall impinging jet of variable size
Flow convergenceLarge throughout systoleLarge throughout systole
Continuous wave Doppler jetHolosystolic/dense/triangularHolosystolic/dense/triangular
Semiquantitative
Vena contracta width (mm)≥7 (≥8 mm for biplane)≥7 (≥8 mm for biplane)
Pulmonary vein flowSystolic flow reversalSystolic flow reversal
Mitral inflowE-wave dominant (>1.2 m/s)E-wave dominant (>1.2 m/s)
TVI mitral/TVI aortic>1.4>1.4
Quantitative
EROA (2D PISA, mm2)≥40 mm2≥40 mm2 (may be ≥30 mm2 if elliptical regurgitant orifice area)
Regurgitant volume (mL/beat)≥60 mL≥60 mL (may be ≥45 mL if low flow conditions)
Regurgitant fraction (%)≥50%≥50%
Structural
Left ventricleDilated (ESD ≥40 mm)Dilated
Left atriumDilated (diameter ≥55 mm or volume ≥60 mL/m2)Dilated

2D = two-dimensional; ESD = endsystolic diameter; EROA = effective regurgitant orifice area; LA = left atrium; PMR = primary mitral regurgitation; SMR = secondary mitral regurgitation; PISA = proximal isovelocity surface area; TVI = time-velocity integral.

Adapted from Lancellotti P et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611–644. Copyright (2013) by permission of Oxford University Press on behalf of the European Society of Cardiology.

Reproduced from Zoghbi WA et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303–371. Copyright (2017), with permission from the American Society of Echocardiography.

6.1.2 Indications for intervention

Urgent surgery is indicated in patients with acute severe mitral regurgitation. In the case of papillary muscle rupture as the underlying disease, valve replacement is generally required.

Indications for surgery in severe chronic PMR are shown in the following table of recommendations and in Figure 5. Surgery is recommended in patients with symptomatic severe PMR and acceptable surgical risk according to the Heart Team decision. The presence of LVEF ≤60%, LVESD ≥40 mm,285,286 LA volume ≥60 mL/m2 or diameter ≥55 mm,287,288 systolic pulmonary arterial pressure (SPAP) >50 mmHg,289 and AF290,291 have been associated with worse outcomes and are considered triggers for intervention regardless of symptomatic status.292 In the absence of these criteria, watchful waiting is a safe strategy in asymptomatic patients with severe PMR and ideally should be performed in a Heart Valve Clinic.

Management of patients with severe chronic primary mitral regurgitation.
AF = atrial fibrillation; HF = heart failure; LA = left atrium/left atrial;
LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic
diameter; SPAP = systolic pulmonary arterial pressure; TEER: transcatheter
edge-to-edge repair. aLA dilatation: volume index ≥60 mL/m2 or
diameter ≥55 mm at sinus rhythm. bExtended heart failure treatment
includes the following: CRT; ventricular assist devices; heart
transplantation.247
Figure 5

Management of patients with severe chronic primary mitral regurgitation. AF = atrial fibrillation; HF = heart failure; LA = left atrium/left atrial; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP = systolic pulmonary arterial pressure; TEER: transcatheter edge-to-edge repair. aLA dilatation: volume index ≥60 mL/m2 or diameter ≥55 mm at sinus rhythm. bExtended heart failure treatment includes the following: CRT; ventricular assist devices; heart transplantation.247

When surgery is considered, mitral valve repair is the surgical intervention of first choice when the results are expected to be durable according to the Heart Team evaluation since it is associated with better survival compared to mitral valve replacement.293,294 PMR due to segmental valve prolapse can be repaired with a low risk of recurrence and reoperation.294–296 The reparability of rheumatic lesions, extensive valve prolapse and to a greater extent leaflet calcification or extensive annular calcification is more challenging.297,298 Patients requiring a predictably complex repair should undergo surgery in experienced repair centres with high repair rates, low operative mortality, and a record of durable results. When repair is not feasible, mitral valve replacement with preservation of the subvalvular apparatus is favoured.

Transcatheter mitral valve implantation for severe PMR is a safe alternative in patients with contraindications for surgery or high operative risk.299–302 TEER is the most evidenced, while the safety and efficacy of other techniques have been demonstrated in smaller series.303–306 The efficacy of more recent TEER system iterations307 will be investigated in high-risk (MITRA-HR study NCT03271762)308 and intermediate-risk patients (REPAIR-MR study NCT04198870).

Recommendations on indications for intervention in severe primary mitral regurgitation

graphic
graphic
graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP = systolic pulmonary arterial pressure; TEER = transcatheter edge-to-edge repair.

a

Class of recommendations.

b

Level of evidence.

c

If an elevated SPAP is the only indication for surgery, the value should be confirmed by invasive measurement.

d

Cut-offs refer to average-size adults and may require adaptations in patients with unusually small or large stature.

Recommendations on indications for intervention in severe primary mitral regurgitation

graphic
graphic
graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP = systolic pulmonary arterial pressure; TEER = transcatheter edge-to-edge repair.

a

Class of recommendations.

b

Level of evidence.

c

If an elevated SPAP is the only indication for surgery, the value should be confirmed by invasive measurement.

d

Cut-offs refer to average-size adults and may require adaptations in patients with unusually small or large stature.

6.1.3 Medical therapy

In acute mitral regurgitation, nitrates and diuretics are used to reduce filling pressures. Sodium nitroprusside reduces afterload and regurgitant fraction. Inotropic agents and an intra-aortic balloon pump are of use in hypotension and haemodynamic instability.

In chronic PMR with preserved LVEF, there is no evidence to support the prophylactic use of vasodilators. In patients with overt heart failure, medical treatment as per current heart failure guidelines applies.247

6.1.4 Serial testing

Asymptomatic patients with severe mitral regurgitation and LVEF >60% should be followed clinically and by echocardiography every 6 months, ideally in the setting of a Heart Valve Centre.309 Measurement of BNP levels, exercise echocardiography, electrocardiogram-Holter monitoring and CMR are useful complementary diagnostic and risk stratification tools.268 The association between PMR, sudden cardiac death and ventricular arrhythmias remains controversial.310–312 The presence of mitral annulus disjunction (abnormal atrial displacement of the hinge point of the mitral valve away from the ventricular myocardium) has been also associated with increased risk of ventricular arrhythmias.310,311,313 Interestingly, the majority of these patients did not have severe mitral regurgitation. In asymptomatic patients with severe PMR and progressive increase of LV size (LVESD approaching 40 mm) or decrease of LVEF on serial studies, surgical mitral valve repair should be discussed. Asymptomatic patients with moderate mitral regurgitation and preserved LV function can be followed on a yearly basis and echocardiography should be performed every 1–2 years. After intervention, serial follow-up focuses on evaluation of symptomatic status, presence of arrhythmic events, assessment of valve function,314 and recurrence of mitral regurgitation. After surgical mitral valve repair, high-volume centres have reported good durability with a recurrence rate of moderate or severe mitral regurgitation of 12.5% at 20 years of follow-up.296 After transcatheter mitral valve repair, the currently reported rates of residual moderate and severe mitral regurgitation (23–30%) would suggest that yearly echocardiogram is appropriate.14,300,301

6.1.5 Special populations

Sex differences in terms of prevalence of underlying aetiology of PMR and management have been reported.298,315,316 Despite the reduction in the prevalence of rheumatic disease in Western countries, women still have higher rates of rheumatic mitral regurgitation than men and emerging aetiologies such as radiation heart disease are also more frequent in women.297 These aetiologies are often characterized by severe calcification of the mitral valve apparatus and associated with mitral stenosis precluding durable repair. Women with PMR referred for surgical treatment received mitral valve repair at a similar rate to men.316 However, women more frequently present with post-operative heart failure, probably related to a later referral and more advanced disease as compared to men.

6.2 Secondary mitral regurgitation

In SMR, the valve leaflets and chordae are structurally normal and mitral regurgitation results from an imbalance between closing and tethering forces secondary to alterations in LV and LA geometry.317,318 It is most commonly seen in dilated or ischaemic cardiomyopathies, both in severely dilated LV with markedly depressed LV function or after an isolated infero-basal myocardial infarction leading to posterior leaflet tethering, despite almost normal LV size and ejection fraction. SMR may also arise as a consequence of LA enlargement and mitral annular dilatation in patients with longstanding AF, in whom LVEF is usually normal and LV dilatation less pronounced (so called ‘atrial functional mitral regurgitation’).319

6.2.1 Evaluation

The echocardiographic criteria to define severe SMR do not differ from those used in PMR and an integrative approach should be used (Table 7).24,268 However, it should be acknowledged that when quantifying EROA and regurgitant volume in SMR, lower thresholds may be applied to define severe SMR. In heart failure patients, the total forward LV stroke volume is lower and that may lead to lower estimated regurgitant volume (<60 mL/beat). Calculation of regurgitant fraction in those circumstances could account for lower flows and has shown prognostic implications.320 In addition, the crescent shape of the regurgitant orifice, characteristic of SMR, may lead to underestimation of the vena contracta width and of the EROA. An EROA ≥30 mm2 by 2D proximal isovelocity surface area (PISA) likely corresponds to severe SMR. In contrast, whether an EROA ≥20 mm2 defines severe SMR remains controversial. In heart failure patients, even mild mitral regurgitation is associated with poor prognosis321 and evidence that surgical or transcatheter treatment of moderate SMR does not seem to improve patient outcomes322,323 supports the change in definition of severe SMR. Caution is required, therefore, when labelling severe SMR based solely on prognostic implications. Other factors such as the extent of myocardial scar, as assessed with CMR, have been associated with poor prognosis.324 In addition, LVEF has been shown to be misleading in patients with severe SMR, while LV global longitudinal strain has been shown to have incremental prognostic value.325,326 The use of 3D echocardiography, CMR and exercise echocardiography may help to identify patients with severe mitral regurgitation when 2D echocardiography at rest is inconclusive.24,268

6.2.2 Medical therapy

Optimal medical therapy in line with the guidelines for the management of heart failure247 should be the first and essential step in the management of all patients with SMR and should include replacement of ACEI or ARB with sacubitril/valsartan, sodium-glucose co-transporter 2 inhibitors and/or ivabradine, whenever indicated.247,327 Indications for cardiac resynchronization therapy (CRT) should be evaluated in accordance with related guidelines.247 If symptoms persist after optimization of conventional heart failure therapy, options for mitral valve intervention should be promptly evaluated before further deterioration of LV systolic function or cardiac remodelling occur.

6.2.3 Indications for intervention

Chronic SMR is associated with impaired prognosis321,328 and its interventional management is complex (see recommendations on indications for mitral valve intervention in chronic severe SMR, and Figure 6). The detailed analysis of the available level of evidence made by the methodology group of the task force is available in Supplementary Section 5. The importance of decision making by a multidisciplinary Heart Team needs to be emphasized in this setting. The Heart Team, including a heart failure specialist, should optimize guideline-directed medical therapy (GDMT) and consider the indications of electrophysiological, transcatheter and surgical interventions, their priority and order of implementation.

Management of patients with chronic severe secondary mitral regurgitation.
CAD = coronary artery disease; CABG = coronary artery bypass grafting; CRT = cardiac
resynchronization therapy; ESC = European Society of Cardiology;
GDMT = guideline-directed medical therapy; HF = heart failure; HTx = heart
transplantation; LVAD = left ventricular assist devices; LV = left ventricle/left
ventricular; LVEF = left ventricular ejection fraction; MV = mitral valve;
PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular;
SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve
implantation; TEER: transcatheter edge-to-edge repair. aLVEF, predicted
surgical risk, amount of myocardial viability, coronary anatomy/target vessels, type
of concomitant procedure needed, TEER eligibility, likelihood of durable surgical
repair, need of surgical mitral replacement, local expertise. bParticularly when concomitant tricuspid valve surgery is needed. cCOAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients With Functional Mitral
Regurgitation): see Supplementary Table 7.
Figure 6

Management of patients with chronic severe secondary mitral regurgitation. CAD = coronary artery disease; CABG = coronary artery bypass grafting; CRT = cardiac resynchronization therapy; ESC = European Society of Cardiology; GDMT = guideline-directed medical therapy; HF = heart failure; HTx = heart transplantation; LVAD = left ventricular assist devices; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; MV = mitral valve; PCI = percutaneous coronary intervention; RV = right ventricle/right ventricular; SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; TEER: transcatheter edge-to-edge repair. aLVEF, predicted surgical risk, amount of myocardial viability, coronary anatomy/target vessels, type of concomitant procedure needed, TEER eligibility, likelihood of durable surgical repair, need of surgical mitral replacement, local expertise. bParticularly when concomitant tricuspid valve surgery is needed. cCOAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation): see Supplementary Table 7.

The evidence supporting surgical intervention remains limited. Mitral valve surgery is recommended in patients with severe SMR undergoing CABG or other cardiac surgery.329,330 The surgical approach has to be tailored to the individual patient.247,331 In selected patients without advanced LV remodelling, mitral valve repair with an undersized complete rigid ring restores valve competence, improves symptoms, and results in reverse LV remodelling.331 Additional valvular/subvalvular techniques or chordal sparing valve replacement may be considered in patients with echocardiographic predictors of repair failure.332 Valve replacement avoids recurrence of mitral regurgitation, although this does not translate into better LV reverse remodelling or survival.333 Indications for isolated mitral valve surgery in SMR are particularly restrictive, owing to significant procedural risk, high rates of recurrent mitral regurgitation, and the absence of proven survival benefit.333–335 In patients with atrial functional mitral regurgitation, LVEF is usually normal, LV dilatation less pronounced and mitral annular dilatation represents the main mechanism of mitral regurgitation. This subgroup may be more effectively treated by ring annuloplasty often associated with ablation of AF but evidence is still limited.319

TEER with the MitraClip system is a minimal-invasive treatment option for SMR. Two RCTs (COAPT and MITRA-FR)323,336,337 have evaluated its safety and efficacy in patients with symptomatic heart failure and severe SMR persisting despite medical therapy, who were considered either ineligible or not appropriate for surgery by the Heart Team (Supplementary Table 7). The results indicate that the procedure is safe and effectively reduces SMR up to 3 years.338 However, in the MITRA-FR trial,323,336 MitraClip implantation had no impact on the primary endpoint of all-cause mortality or heart failure hospitalization at 12 months and 2 years compared to GDMT alone. In the COAPT trial,337 MitraClip implantation substantially reduced the primary endpoint of cumulative hospitalizations for heart failure, as well as several pre-specified secondary endpoints, including all-cause mortality at 2 years.

Subanalyses of the COAPT trial confirm the positive response to TEER in several patient subgroups;339–343 conversely, the effect of the interventional treatment was neutral throughout all subgroups in an echocardiographic subanalyses of the MITRA-FR trial.344

The conflicting results of these two trials have generated considerable discussion. These diverging results might be partially explained by effect size of the trials, differences in trial design, patient selection, echocardiographic assessment of SMR severity, use of medical therapy, and technical factors. Patients in COAPT demonstrated greater severity of SMR (EROA 41±15 mm2 vs. 31±10 mm2) and less LV dilatation (mean indexed LV end-diastolic volume 101±34 mL/m2 vs. 135±35 mL/m2) than those enrolled in MITRA-FR. Perhaps reflecting greater severity of SMR in relation to LV dimensions (‘disproportionate’ mitral regurgitation), patients in COAPT were overall more likely to benefit from TEER in terms of reduced mortality and heart failure hospitalization.345

Additional studies are needed to identify patients who will benefit the most from TEER.

Therefore, TEER should be considered in selected patients with severe SMR fulfilling the COAPT inclusion criteria,346–348 who receive optimal medical therapy supervised by a heart failure specialist and are as close as possible to the patients actually enrolled in the study. Optimization of the procedural result should also be pursued. In addition, TEER may be considered only in selected cases when the COAPT criteria are not fulfilled with the aim of improving symptoms and quality of life.349–353 In patients with less severe SMR (EROA <30 mm2) and advanced LV dilatation/dysfunction, the prognostic benefit of MitraClip remains unproven.323,354,355 Patients with end-stage LV and/or RV failure and no option for revascularization may be better served by cardiac transplantation or LV assist device implantation. Valve intervention is generally not an option when LVEF is <15%.247

The management of moderate ischaemic SMR in patients undergoing CABG remains an object of debate.322,330 Surgery is more likely to be considered if myocardial viability is present and if comorbidity is low. Exercise-induced dyspnoea and a large increase in mitral regurgitation severity and SPAP favour combined surgery.

Transcatheter mitral valve repair systems other than TEER, as well as transcatheter mitral valve replacement devices, are currently the subject of intense investigation but clinical data are still limited.

Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitationa

graphic
graphic

2D = two-dimensional; CABG = coronary artery bypass grafting; CRT = cardiac resynchronization therapy; EROA = effective regurgitation orifice area; GDMT = guideline-directed medical therapy; LVEF = left ventricular ejection fraction; SMR = secondary mitral regurgitation; PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; TEER: transcatheter edge-to-edge repair.

a

See Table 7 for SMR quantification (an EROA ≥30 mm2 by 2D proximal isovelocity surface area corresponds likely to severe SMR). Quantification of SMR must always be performed under optimal guidelines-directed medical treatment.

b

Class of recommendation.

c

Level of evidence.

d

LVEF, predicted surgical risk, amount of myocardial viability, coronary anatomy/target vessels, type of concomitant procedure needed, TEER eligibility, likelihood of durable surgical repair, need of surgical mitral replacement, local expertise.

e

COAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation): see Supplementary Table 7.

Recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitationa

graphic
graphic

2D = two-dimensional; CABG = coronary artery bypass grafting; CRT = cardiac resynchronization therapy; EROA = effective regurgitation orifice area; GDMT = guideline-directed medical therapy; LVEF = left ventricular ejection fraction; SMR = secondary mitral regurgitation; PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation; TAVI = transcatheter aortic valve implantation; TEER: transcatheter edge-to-edge repair.

a

See Table 7 for SMR quantification (an EROA ≥30 mm2 by 2D proximal isovelocity surface area corresponds likely to severe SMR). Quantification of SMR must always be performed under optimal guidelines-directed medical treatment.

b

Class of recommendation.

c

Level of evidence.

d

LVEF, predicted surgical risk, amount of myocardial viability, coronary anatomy/target vessels, type of concomitant procedure needed, TEER eligibility, likelihood of durable surgical repair, need of surgical mitral replacement, local expertise.

e

COAPT criteria (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation): see Supplementary Table 7.

7 Mitral stenosis

Aetiology of mitral stenosis is mostly rheumatic or degenerative. Rheumatic fever is the most common cause of mitral stenosis worldwide. Its prevalence has greatly decreased in industrialized countries, but it remains a significant healthcare problem in developing countries and affects young patients.2,267,358 Degenerative mitral stenosis related to MAC is a distinct pathology and its prevalence significantly increases with age.359,360 Both types of mitral stenosis are more frequent in females.361 In rare cases, mitral stenosis due to valve rigidity but without commissural fusion, may be related to chest radiation, carcinoid heart disease, or inherited metabolic diseases.

7.1 Rheumatic mitral stenosis

7.1.1 Evaluation

Clinically significant mitral stenosis is defined by a mitral valve area (MVA) ≤1.5 cm2. Commissural fusion with thickening of the posterior leaflet is the most important mechanism of stenosis. Echocardiography is the preferred method for diagnosis, assessment of severity, and haemodynamic consequences of mitral stenosis. Valve area using 2D planimetry is the reference measurement of mitral stenosis severity, whereas mean transvalvular gradient and pulmonary pressures reflect its consequences and have a prognostic role.362 3D-TTE planimetry may have an additional diagnostic value. TTE usually provides sufficient information for routine management. Scoring systems have been developed to help assess suitability for percutaneous mitral commissurotomy (PMC; Supplementary Table 8),363–365 TOE should be performed to exclude LA thrombus before PMC or after an embolic episode, and to obtain detailed information on mitral anatomy (commissural zones and subvalvular apparatus) before intervention when TTE is suboptimal. Stress testing is indicated in patients with no symptoms or symptoms equivocal or discordant with the severity of mitral stenosis. Exercise echocardiography may provide objective information by assessing changes in mitral gradient and pulmonary artery pressure and is superior to DSE. Echocardiography plays an important role in the periprocedural monitoring of PMC and follow-up.

7.1.2 Indications for intervention

The type of treatment (PMC or surgery), as well as its timing, should be decided based on clinical characteristics, anatomy of valve and subvalvular apparatus, and local expertise.366–369 In general, indication for intervention should be limited to patients with clinically significant (moderate-to-severe) rheumatic mitral stenosis (valve area ≤1.5 cm2) in whom PMC has had a significant impact on its management. In Western countries where incidence of rheumatic fever and number of PMC is low, this treatment should be restricted to expert operators in specialized centres to improve safety and procedural success rate.366 Efforts should be made to increase availability of PMC in developing countries where access to treatment is limited due to economic reasons.267 PMC should be considered as an initial treatment for selected patients with mild to moderate calcification or impaired subvalvular apparatus, but who have otherwise favourable clinical characteristics.360

The management of clinically significant rheumatic mitral stenosis is summarized in Figure 7 and the indications and contraindications for PMC are provided in the table of recommendations below, and Table 8.

Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically significant (moderate or severe) mitral stenosis (valve area ≤1.5 cm2)

graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; MVA = mitral valve area; NCS = non-cardiac surgery; PMC = percutaneous mitral commissurotomy.

a

Class of recommendation.

b

Level of evidence.

c

Unfavourable characteristics for PMC can be defined by the presence of several of the following characteristics. Clinical characteristics: old age, history of commissurotomy, New York Heart Association class IV, permanent AF, severe pulmonary hypertension. Anatomical characteristics: echocardiographic score >8, Cormier score 3 (calcification of mitral valve of any extent as assessed by fluoroscopy), very small MVA, severe tricuspid regurgitation. For the definition of scores, see Supplementary Table 8.

Recommendations on indications for percutaneous mitral commissurotomy and mitral valve surgery in clinically significant (moderate or severe) mitral stenosis (valve area ≤1.5 cm2)

graphic
graphic

AF = atrial fibrillation; LA = left atrium/left atrial; MVA = mitral valve area; NCS = non-cardiac surgery; PMC = percutaneous mitral commissurotomy.

a

Class of recommendation.

b

Level of evidence.

c

Unfavourable characteristics for PMC can be defined by the presence of several of the following characteristics. Clinical characteristics: old age, history of commissurotomy, New York Heart Association class IV, permanent AF, severe pulmonary hypertension. Anatomical characteristics: echocardiographic score >8, Cormier score 3 (calcification of mitral valve of any extent as assessed by fluoroscopy), very small MVA, severe tricuspid regurgitation. For the definition of scores, see Supplementary Table 8.

Management of clinically significant rheumatic mitral stenosis (MVA ≤1.5
cm2). AF = atrial fibrillation; LA = left atrium/left atrial;
MVA = mitral valve area; NCS = non-cardiac surgery; PMC = percutaneous mitral
commissurotomy. aHigh thromboembolic risk: history of systemic embolism,
dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic
decompensation: systolic pulmonary pressure >50 mmHg at rest, need for major NCS,
desire for pregnancy. bSurgical commissurotomy may be considered by
experienced surgical teams in patients with contraindications to PMC. cSee recommendations on indications for PMC and mitral valve surgery in
clinically significant mitral stenosis in section 7.2. dSurgery if symptoms occur for a low
level of exercise and operative risk is low.
Figure 7

Management of clinically significant rheumatic mitral stenosis (MVA ≤1.5 cm2). AF = atrial fibrillation; LA = left atrium/left atrial; MVA = mitral valve area; NCS = non-cardiac surgery; PMC = percutaneous mitral commissurotomy. aHigh thromboembolic risk: history of systemic embolism, dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic decompensation: systolic pulmonary pressure >50 mmHg at rest, need for major NCS, desire for pregnancy. bSurgical commissurotomy may be considered by experienced surgical teams in patients with contraindications to PMC. cSee recommendations on indications for PMC and mitral valve surgery in clinically significant mitral stenosis in section 7.2. dSurgery if symptoms occur for a low level of exercise and operative risk is low.

Management of tricuspid regurgitation. LV = left ventricle/left ventricular;
RV = right ventricle/right ventricular; TA = tricuspid annulus; TR = tricuspid
regurgitation; TV = tricuspid valve. aThe Heart Team with expertise in
the treatment of tricuspid valve disease evaluates anatomical eligibility for
transcatheter therapy including jet location, coaptation gap, leaflet tethering,
potential interference with pacing lead. bReplacement when repair is not
feasible.
Figure 8

Management of tricuspid regurgitation. LV = left ventricle/left ventricular; RV = right ventricle/right ventricular; TA = tricuspid annulus; TR = tricuspid regurgitation; TV = tricuspid valve. aThe Heart Team with expertise in the treatment of tricuspid valve disease evaluates anatomical eligibility for transcatheter therapy including jet location, coaptation gap, leaflet tethering, potential interference with pacing lead. bReplacement when repair is not feasible.

Table 8

Contraindications for percutaneous mitral commissurotomy in rheumatic mitral stenosisa

Contraindications
MVA >1.5 cm2a
LA thrombus
More than mild mitral regurgitation
Severe or bi-commissural calcification
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery
Concomitant CAD requiring bypass surgery
Contraindications
MVA >1.5 cm2a
LA thrombus
More than mild mitral regurgitation
Severe or bi-commissural calcification
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery
Concomitant CAD requiring bypass surgery

CAD = coronary artery disease; LA = left atrium/left atrial; MVA = mitral valve area; PMC = percutaneous mitral commissurotomy.

a

PMC may be considered in patients with valve area >1.5 cm2 with symptoms that cannot be explained by another cause and if the anatomy is favourable.

Table 8

Contraindications for percutaneous mitral commissurotomy in rheumatic mitral stenosisa

Contraindications
MVA >1.5 cm2a
LA thrombus
More than mild mitral regurgitation
Severe or bi-commissural calcification
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery
Concomitant CAD requiring bypass surgery
Contraindications
MVA >1.5 cm2a
LA thrombus
More than mild mitral regurgitation
Severe or bi-commissural calcification
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery
Concomitant CAD requiring bypass surgery

CAD = coronary artery disease; LA = left atrium/left atrial; MVA = mitral valve area; PMC = percutaneous mitral commissurotomy.

a

PMC may be considered in patients with valve area >1.5 cm2 with symptoms that cannot be explained by another cause and if the anatomy is favourable.

7.1.3 Medical therapy

Diuretics, beta-blockers, digoxin, non-dihydropyridine calcium channel blockers and ivabradine can improve symptoms. Anticoagulation with vitamin K antagonist (VKA) with a target international normalized ratio (INR) between 2 and 3 is indicated in patients with AF. Patients with moderate-to-severe mitral stenosis and AF should be kept on VKA and not receive NOACs. Currently there is no solid evidence to support the use of NOACs in this setting370 and a randomized clinical trial is underway (INVICTUS VKA NCT 02832544). Neither cardioversion nor catheter pulmonary vein isolation are indicated before intervention in patients with significant mitral stenosis, as they do not durably restore sinus rhythm. If AF is of recent onset and the LA is only moderately enlarged, cardioversion should be performed soon after successful intervention, it should also be considered in patients with less than severe mitral stenosis. Amiodarone is most effective in maintaining the sinus rhythm after cardioversion. In patients in sinus rhythm, OAC is recommended when there has been a history of systemic embolism or a thrombus is present in the LA and should also be considered when TOE shows dense spontaneous echocardiographic contrast or an enlarged LA (M-mode diameter >50 mm or LA volume >60 mL/m2).

7.1.4 Serial testing

Asymptomatic patients with clinically significant mitral stenosis should be followed up yearly by clinical and echocardiographic examinations; and at longer intervals (2–3 years) in case of moderate stenosis. Follow-up of patients after successful PMC is similar to that of asymptomatic patients and should be more frequent if asymptomatic restenosis occurs.

7.1.5 Special patient populations

When symptomatic restenosis occurs after surgical commissurotomy or PMC, re-intervention in most cases requires valve replacement, but PMC can be proposed in selected candidates with favourable characteristics if the predominant mechanism is commissural refusion.369

In patients with severe rheumatic mitral stenosis combined with severe aortic valve disease, surgery is preferable when it is not contraindicated. The management of patients in whom surgery is contraindicated is difficult and requires a comprehensive and individualized evaluation by the Heart Team. In cases with severe mitral stenosis associated with moderate aortic valve disease, PMC can be performed to postpone the surgical treatment of both valves. In patients with severe tricuspid regurgitation, PMC may be considered in selected patients with sinus rhythm, moderate atrial enlargement, and severe functional tricuspid regurgitation secondary to pulmonary hypertension. In other cases, surgery on both valves is preferred.371

In the elderly population with rheumatic mitral stenosis when surgery is high risk, PMC is a useful option, even if as palliative care.364,367,368 Treatment of patients with low-gradient severe mitral stenosis (MVA ≤1.5 cm2, mean gradient <10 mmHg) is difficult, as these patients are older and have less optimal anatomy.372

7.2 Degenerative mitral stenosis with mitral annular calcification

MAC is a distinct entity that differs from rheumatic mitral stenosis. Usually, these patients are elderly and may have significant comorbidities including disease of other valves. Overall, the prognosis is poor due to high-risk profile and technical anatomic challenges resulting from the presence of annular calcification.373 Between 9% and 15% of the general population may have MAC, with higher frequency in elderly patients (40%).67,374–376 Furthermore, almost half of patients with aortic stenosis undergoing TAVI have MAC, and the disease is severe in 9.5% of cases.359,377 Severe MAC may result in mitral stenosis (more frequently) or mitral regurgitation, or both.

7.2.1 Evaluation

In patients with degenerative mitral stenosis and MAC, the echocardiographic evaluation of the disease severity is difficult and the usual parameters lack validation. Planimetry is less reliable due to diffuse calcium and irregular orifice. The mean transmitral gradient has been shown to have prognostic value.378 For the evaluation of severity, it is necessary to take into account the abnormalities of LA and LV compliance before indicating an intervention. If an intervention is planned, echocardiography is used for initial evaluation and CCT is necessary to assess the degree and location of calcification and to evaluate the feasibility of an intervention.379

7.2.2 Indications for intervention

Treatment options, including transcatheter and surgical approaches, are high-risk procedures and evidence from randomized trials is lacking. Even if the procedure is done successfully and the transvalvular gradient is reduced, due to low compliance of the LA and LV the mean atrial pressure may remain elevated.

In elderly patients with degenerative mitral stenosis and MAC, surgery is technically challenging and high risk.380 As there is no commissural fusion, degenerative mitral stenosis is not amenable to PMC.359 In symptomatic inoperable patients with suitable anatomy, preliminary experience showed that transcatheter mitral valve implantation (in mitral position, using an inverted balloon-expandable TAVI prosthesis), is feasible in selected patients with severe mitral stenosis, when performed by experienced operators after careful pre-planning using multimodality imaging.379 The largest case series reported to date included only 116 patients.381 However, operative mortality is high, in particular due to the risk of LVOT obstruction and mid-term results are less favourable compared to mitral valve-in-valve procedures.382,383 The most recent case series show that results are improving owing to better patient selection and the use of different accesses, as well as concomitant or preventive measures such as alcohol septal ablation384 or laceration/resection of the anterior leaflet.385–387

Recently, a preliminary case series suggested that transcatheter mitral valve replacement using a dedicated prosthesis is feasible and can result in symptom improvement.388

8 Tricuspid regurgitation

Moderate or severe tricuspid regurgitation is observed in 0.55% of the general population and its prevalence increases with age, affecting about 4% of the patients aged 75 years or more.389 Aetiology is secondary in ≥90% of cases, due to pressure and/or volume overload mediated RV dilatation or enlarged right atrium and tricuspid annulus due to chronic AF. Secondary tricuspid regurgitation is associated with left-sided valvular or myocardial dysfunction in most cases, whereas it is isolated in 8.1% of subjects and independently related to mortality.389 Secondary tricuspid regurgitation may also develop late after left-sided valve surgery.390,391

Causes of primary tricuspid regurgitation include infective endocarditis [especially in intravenous (i.v.) drug addicts], rheumatic heart disease, carcinoid syndrome, myxomatous disease, endomyocardial fibrosis, congenital valve dysplasia (e.g. Ebstein’s anomaly), thoracic trauma, and iatrogenic valve damage.

Atrial fibrillation induces annular remodelling even in the absence of left-heart disease.392 Cardiac implantable electronic device-lead implantation leads to progressive tricuspid regurgitation in 20–30% of the patients393–395 and predicts its progression over time.396

In patients with heart failure and reduced LVEF, secondary tricuspid regurgitation is a very frequent finding and is an independent predictor of clinical outcomes.397

8.1 Evaluation

Tricuspid regurgitation should be evaluated first by echocardiography. In primary tricuspid regurgitation, specific abnormalities of the valve can be identified. In secondary tricuspid regurgitation, annular dilatation, along with RV and right atrium dimensions, as well as RV function should be measured, owing to their prognostic relevance.398 In experienced laboratories, RV strain27 and/or 3D measurements of RV volumes399,400 may be considered to overcome the existing limitations of conventional RV function indices.102 When available, CMR is the preferred method to assess the RV400 due to its high accuracy and reproducibility.401

Echocardiographic evaluation of tricuspid regurgitation severity is based on an integrative approach considering multiple qualitative and quantitative parameters (Table 9). Due to the non-circular and non-planar shape of the regurgitant orifice, biplane vena contracta width should be considered in addition to the conventional 2D measurement.402 Similarly, underestimation of tricuspid regurgitation severity by the PISA method may occur.403 In case of inconsistent findings, the 3D vena contracta area may be evaluated, although diverging cut-offs have been reported.402,404–406 Recently, a new grading scheme including two additional grades (‘massive’ and ‘torrential’) has been proposed407 and used in clinical studies on transcatheter interventions.408,409 Studies showed an incremental prognostic value of the two additional grades (massive and torrential) in terms of mortality and rehospitalization for heart failure in patients with advanced disease.410–412

Alternatively, calculation of the tricuspid regurgitant volume by CMR using RV volumetry may be helpful.

Importantly, estimation of pulmonary pressures using Doppler gradient may be impossible or might underestimate the severity of pulmonary hypertension in the presence of severe tricuspid regurgitation, justifying cardiac catheterization to evaluate pulmonary vascular resistances.413

Table 9

Echocardiographic criteria for grading severity of tricuspid regurgitation

Qualitative
Tricuspid valve morphologyAbnormal/flail
Colour flow regurgitant jetVery large central jet or eccentric wall impinging jeta
CW signal of regurgitant jetDense/triangular with early peaking
Semiquantitative
Vena contracta width (mm)>7a,b
PISA radius (mm)>9c
Hepatic vein flowcSystolic flow reversal
Tricuspid inflowE-wave dominant ≥1m/sd
Quantitative
EROA (mm2)≥40
Regurgitant volume (mL/beat)≥45
Enlargement of cardiac chambers/vesselsRV, RA, inferior vena cava
Qualitative
Tricuspid valve morphologyAbnormal/flail
Colour flow regurgitant jetVery large central jet or eccentric wall impinging jeta
CW signal of regurgitant jetDense/triangular with early peaking
Semiquantitative
Vena contracta width (mm)>7a,b
PISA radius (mm)>9c
Hepatic vein flowcSystolic flow reversal
Tricuspid inflowE-wave dominant ≥1m/sd
Quantitative
EROA (mm2)≥40
Regurgitant volume (mL/beat)≥45
Enlargement of cardiac chambers/vesselsRV, RA, inferior vena cava

CW = continuous wave; EROA = effective regurgitant orifice area; PISA = proximal isovelocity surface area; RA = right atrium/right atrial; RV = right ventricle/right ventricular; TR = tricuspid regurgitation.

a

At a Nyquist limit of 50–60 cm/s.

b

Preferably biplane.

c

Baseline Nyquist limit shift of 28 cm/s.

d

In the absence of other causes of elevated RA pressure.

Table 9

Echocardiographic criteria for grading severity of tricuspid regurgitation

Qualitative
Tricuspid valve morphologyAbnormal/flail
Colour flow regurgitant jetVery large central jet or eccentric wall impinging jeta
CW signal of regurgitant jetDense/triangular with early peaking
Semiquantitative
Vena contracta width (mm)>7a,b
PISA radius (mm)>9c
Hepatic vein flowcSystolic flow reversal
Tricuspid inflowE-wave dominant ≥1m/sd
Quantitative
EROA (mm2)≥40
Regurgitant volume (mL/beat)≥45
Enlargement of cardiac chambers/vesselsRV, RA, inferior vena cava
Qualitative
Tricuspid valve morphologyAbnormal/flail
Colour flow regurgitant jetVery large central jet or eccentric wall impinging jeta
CW signal of regurgitant jetDense/triangular with early peaking
Semiquantitative
Vena contracta width (mm)>7a,b
PISA radius (mm)>9c
Hepatic vein flowcSystolic flow reversal
Tricuspid inflowE-wave dominant ≥1m/sd
Quantitative
EROA (mm2)≥40
Regurgitant volume (mL/beat)≥45
Enlargement of cardiac chambers/vesselsRV, RA, inferior vena cava

CW = continuous wave; EROA = effective regurgitant orifice area; PISA = proximal isovelocity surface area; RA = right atrium/right atrial; RV = right ventricle/right ventricular; TR = tricuspid regurgitation.

a

At a Nyquist limit of 50–60 cm/s.

b

Preferably biplane.

c

Baseline Nyquist limit shift of 28 cm/s.

d

In the absence of other causes of elevated RA pressure.

8.2 Indications for intervention

Severe tricuspid regurgitation is associated with impaired survival389,414–416 and worsening heart failure.397,417 In clinical practice, tricuspid valve interventions are underused and often initiated too late.418–420 Appropriate timing of intervention is crucial to avoid irreversible RV damage and organ failure with subsequent increased surgical risk421,422 (see table of recommendations on indications for intervention in tricuspid valve disease in section 9 and Figure 8).

Surgery is recommended in symptomatic patients with severe primary tricuspid regurgitation. In selected asymptomatic or mildly symptomatic patients who are appropriate for surgery, an intervention should also be considered when RV dilatation or declining RV function is observed. However, exact thresholds have not yet been defined.

According to observational data, tricuspid valve repair should be performed liberally during left-sided surgery in patients with secondary tricuspid regurgitation. Indeed, it does not increase operative risk, but promotes reverse remodelling of the RV and improves functional status when annular dilatation is present, even in the absence of severe tricuspid regurgitation.423–427

The benefit of surgical correction of isolated secondary tricuspid regurgitation compared to medical treatment is not well established428 and the procedure has a non-negligible risk of periprocedural mortality and morbidity when patients present late.429–432 However, in carefully selected candidates, surgery can be performed safely with good long-term survival.418,433 It should therefore be considered early in selected symptomatic patients appropriate for surgery, as well as in those with no or mild symptoms, RV dilatation and severe tricuspid regurgitation. Although a tricuspid annular pulmonary systolic excursion (TAPSE) <17 mm has been associated with worse prognosis in patients with secondary tricuspid regurgitation,398,434 thresholds for severe RV dysfunction making intervention futile have not yet been defined.

Reoperation on the tricuspid valve in new-onset or worsening secondary tricuspid regurgitation after left-sided surgery carries a high procedural risk, possibly due to late referral and subsequent poor clinical condition.435 To improve prognosis, treatment of severe tricuspid regurgitation in this challenging scenario should be considered even in asymptomatic patients if there are signs of RV dilatation or decline in RV function (after exclusion of left-sided valve dysfunction, severe RV or LV dysfunction and severe pulmonary vascular disease/hypertension).

Whenever possible, annuloplasty with prosthetic rings is preferable to valve replacement,423,430,436 which should only be considered when the tricuspid valve leaflets are tethered and the annulus severely dilated. In presence of a cardiac implantable electronic device lead, the technique used should be adapted to the patient’s condition and the surgeon’s experience.437

TTVI are under clinical development. Early registry and study data demonstrated the feasibility to reduce tricuspid regurgitation using various systems, enabling either leaflet approximation,408,438–440 direct annuloplasty,409,441 or valve replacement,442–444 with subsequent symptomatic and haemodynamic improvement.445,446 In a propensity-score-matched study comparing medical treatment to TTVI, all-cause mortality and rehospitalizations at 1 year were lower among the patients who received the interventional treatment.447 Several RCTs will investigate the efficacy of TTVI against medical treatment.

Therefore, TTVI may be considered by the Heart Team at experienced Heart Valve Centres in symptomatic, inoperable, anatomically eligible patients in whom symptomatic or prognostic improvement can be expected. For detailed anatomical evaluation, TOE and CCT may be preferred owing to higher spatial resolution.448,449

8.3 Medical therapy

Diuretics are useful in the presence of right heart failure. To counterbalance the activation of the renin-angiotensin-aldosterone system associated with hepatic congestion, the addition of an aldosterone antagonist may be considered.247 Dedicated treatment of pulmonary hypertension is indicated in specific cases. Although data are limited, rhythm control may help to decrease tricuspid regurgitation and contain annular dilatation in patients with chronic AF.450 Importantly, in the absence of advanced RV dysfunction or severe pulmonary hypertension, none of the above-mentioned therapies should delay referral for surgery or transcatheter therapy.

9 Tricuspid stenosis

Tricuspid stenosis is often combined with tricuspid regurgitation and most frequently of rheumatic origin. It is therefore usually associated with left-sided valve lesions, particularly mitral stenosis. Other causes are rare, including congenital, carcinoid and drug-induced valve diseases, Whipple’s disease, endocarditis, and large right atrial tumour.

9.1 Evaluation

Echocardiography provides the most useful information. Tricuspid stenosis is often overlooked and requires careful evaluation. Echocardiographic evaluation of valve anatomy and subvalvular apparatus is important to assess valve reparability. No generally accepted grading of tricuspid stenosis severity exists, but a mean echocardiographic transvalvular gradient ≥5 mmHg at normal heart rate is considered indicative of significant tricuspid stenosis.362

9.2 Indications for intervention

Intervention on the tricuspid valve is usually performed concomitantly during procedures for left-sided valve disease in patients who are symptomatic despite medical therapy. Although the lack of pliable leaflet tissue is a main limitation for valve repair, the choice between repair and replacement depends on anatomy and surgical expertise. Owing to satisfactory long-term durability, biological prostheses are usually preferred over mechanical valves, which have a high risk of thrombosis.451

Percutaneous tricuspid balloon valvuloplasty has been performed in a limited number of cases, either alone or in combination with PMC. It frequently induces significant regurgitation and long-term results are lacking.452 It can be considered in rare cases with anatomically suitable valves, when tricuspid stenosis is isolated or additional mitral stenosis can also be treated interventionally (see recommendations on indications for PMC and mitral valve surgery in clinically significant mitral stenosis in section 7).

9.3 Medical therapy

Diuretics are useful in the presence of heart failure symptoms but are of limited long-term efficacy.

10 Combined and multiple-valve diseases

Significant stenosis and regurgitation can be found on the same valve. Disease of multiple valves may be encountered in several conditions, particularly in rheumatic and congenital heart disease, but also less frequently in degenerative valve disease. There is a lack of data on combined or multiple-valve disease.453–460 This does not allow for evidence-based recommendations. The general principles for the management of combined or multiple-valve disease are as follows:

  • When either stenosis or regurgitation is predominant, management follows the recommendations concerning the predominant VHD. When the severity of both stenosis and regurgitation is balanced, indications for interventions should be based on symptoms and objective consequences rather than on the indices of severity of stenosis or regurgitation.453–456 In this setting, Doppler pressure gradient reflects the global haemodynamic burden (stenosis and regurgitation) of the valve lesion.453

  • Besides the separate assessment of each valve lesion, it is necessary to consider the interaction between the different valve lesions. As an illustration, associated mitral regurgitation may lead to underestimation of the severity of aortic stenosis, as decreased stroke volume due to mitral regurgitation lowers the flow across the aortic valve and hence the aortic gradient.453 This underlines the need to combine different measurements, including assessment of valve areas, if possible using methods that are less dependent on loading conditions, such as planimetry.457

  • Indications for intervention are based on global assessment of the consequences of the different valve lesions (i.e. symptoms or presence of LV dilatation or dysfunction). Intervention can be considered for non-severe multiple lesions associated with symptoms or leading to LV impairment.453

  • The decision to intervene on multiple valves should take into account the age, comorbidities, and risk of combined procedures, and should be made by the Heart Team after precise and comprehensive evaluation of valve lesions and their interactions with each other.453,461 The risk of combined intervention should be weighed against the evolution of untreated valve disease and the inherent risk of subsequent intervention.

  • The choice of surgical technique/interventional procedure should take into account the presence of the other VHD.453,458,459,461

  • When interventional procedures are considered, staged procedures may be preferable in cases with aortic stenosis and mitral regurgitation (see section 5.5). Improved 1-year survival after combined transcatheter treatment of mitral and tricuspid regurgitation has been reported compared to mitral regurgitation alone.263 PMC may delay surgery, in situations such as severe mitral stenosis associated with moderate aortic regurgitation.

The management of specific associations of VHD is detailed in the individual sections of this document.

Recommendations on indications for intervention in tricuspid valve disease

graphic
graphic

2D = two-dimensional; LV = left ventricle/left ventricular; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular.

a

Class of recommendation.

b

Level of evidence.

c

Percutaneous balloon valvuloplasty can be attempted as a first approach if tricuspid stenosis is isolated.

d

Percutaneous balloon valvuloplasty can be attempted if PMC can be performed on the mitral valve.

e

In patients with previous surgery recurrent left-sided valve dysfunction needs to be excluded.

f

Transcatheter treatment can be performed according to Heart Team at experienced valve centres in anatomically eligible patients in whom improvement of quality of life or survival can be expected.

Recommendations on indications for intervention in tricuspid valve disease

graphic
graphic

2D = two-dimensional; LV = left ventricle/left ventricular; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular.

a

Class of recommendation.

b

Level of evidence.

c

Percutaneous balloon valvuloplasty can be attempted as a first approach if tricuspid stenosis is isolated.

d

Percutaneous balloon valvuloplasty can be attempted if PMC can be performed on the mitral valve.

e

In patients with previous surgery recurrent left-sided valve dysfunction needs to be excluded.

f

Transcatheter treatment can be performed according to Heart Team at experienced valve centres in anatomically eligible patients in whom improvement of quality of life or survival can be expected.

11 Prosthetic valves

11.1 Choice of prosthetic valve

Factors for valve selection are the patient’s life expectancy, lifestyle, and environmental factors, bleeding and thromboembolic risks related to anticoagulation, potential for surgical or transcatheter re-intervention, and, importantly, informed patient preference. Generally, biological heart valves (BHVs) should be preferred in patients with shorter anticipated survival or comorbidities that may lead to further surgical procedures, and those who are at increased risk for bleeding complications. Thromboembolic complications are less frequent in pregnant women with BHVs.

Recommendations for prosthetic valve selection

graphic
graphic
graphic
graphic

AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; SVD = structural valve deterioration; TAVI = transcatheter aortic valve implantation.

a

Class of recommendation.

b

Level of evidence.

c

Increased bleeding risk because of comorbidities, adherence concerns or geographic, lifestyle or occupational conditions.

d

Young age (<40 years), hyperparathyroidism, haemodialysis.

e

In patients 60–65 years of age who should receive an aortic prosthesis and those between 65 and 70 years of age in the case of mitral prosthesis, both valves are acceptable and the choice requires careful analysis of factors other than age.

f

Risk factors for thromboembolism are AF, previous unprovoked proximal deep venous thromboembolism and/or symptomatic pulmonary embolism, hypercoagulable state, antiphospholipid antibody.

g

Life expectancy should be estimated at >10 years according to age, sex, comorbidities, and country-specific life expectancy.

Recommendations for prosthetic valve selection

graphic
graphic
graphic
graphic

AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; SVD = structural valve deterioration; TAVI = transcatheter aortic valve implantation.

a

Class of recommendation.

b

Level of evidence.

c

Increased bleeding risk because of comorbidities, adherence concerns or geographic, lifestyle or occupational conditions.

d

Young age (<40 years), hyperparathyroidism, haemodialysis.

e

In patients 60–65 years of age who should receive an aortic prosthesis and those between 65 and 70 years of age in the case of mitral prosthesis, both valves are acceptable and the choice requires careful analysis of factors other than age.

f

Risk factors for thromboembolism are AF, previous unprovoked proximal deep venous thromboembolism and/or symptomatic pulmonary embolism, hypercoagulable state, antiphospholipid antibody.

g

Life expectancy should be estimated at >10 years according to age, sex, comorbidities, and country-specific life expectancy.

In a nationwide observational study, patients aged 45 to 54 with surgical aortic BHV implantation and those aged 40 to 70 years with surgical mitral BHV implantation had a significantly higher 15-year mortality than those with a mechanical heart valve (MHV). An analysis of patients 55 to 64 years of age showed no difference in mortality between aortic BHV and MHV prosthesis.462 However, an earlier systematic review463 and a recent meta-analysis464 of studies comparing aortic MHVs and BHVs showed a significant mortality reduction with MHVs in patients ≤60 and in those 50–70 years of age, respectively. All these studies are limited by their predominantly observational nature and missing information on the type of prostheses implanted. There is no new high-quality evidence supporting a decrease in the established age cut-off for prosthesis selection.

The best aortic valve substitute for younger adults remains unclear. In appropriately selected patients, replacement of the aortic valve using an autograft may be performed, with long-term survival rates and valve-related reoperation that are comparable to those achieved with a MHV, but high expertise in aortic root surgery is required.465 Strategies for patients with small aortic annulus include root enlargement and use of stentless valves. Although the use of sutureless and rapid-deployment aortic valves may reduce invasiveness, cross-clamp and cardiopulmonary bypass times, and potentially lower perioperative complications of SAVR, there is a lack of a large-scale randomized comparison on both short- and long-term safety, efficacy, and haemodynamic performance of this approach against conventional aortic valve replacement, which remains the gold standard of procedure.

11.2 Baseline assessment and follow-up

All patients with prosthetic valves require lifelong follow-up to detect early deterioration in prosthetic function or ventricular function, or progressive disease of another heart valve.314 Clinical assessment should be performed yearly or as soon as possible if new cardiac symptoms occur. TTE should be performed if any new symptoms occur or if complications are suspected. After transcatheter, as well as surgical implantation of a BHV, echocardiography, including measurement of transprosthetic gradients, should be performed within 30 days after valve implantation (i.e. baseline), at 1 year, and annually thereafter.470 TOE should be considered if TTE is of poor quality and in all cases of suspected prosthetic dysfunction (especially if the prosthesis is in the mitral position) or endocarditis.314,471 Cinefluoroscopy for MHVs and CCT scanning provide useful additional information if valve thrombus or pannus are suspected to impair valve function.314

11.3 Antithrombotic management

11.3.1 Mechanical prostheses

11.3.1.1 Postoperative anticoagulation management

MHVs require lifelong treatment with VKA guided by the INR.472,473 NOACs currently have no role in patients with MHVs.474 Treatment with VKA should be started on the first postoperative day in combination with bridging therapy [with therapeutic doses of either unfractionated heparin (UFH) or off-label use of low-molecular-weight heparin (LMWH)] until therapeutic INR is achieved.475 Similar safety and efficacy outcomes have been reported following bridging with either UFH or LMWH.476 Once a stable therapeutic INR is reached for ≥24 h, bridging can be discontinued. The postoperative risk of thromboembolism peaks about 1 month after implantation, but risks are substantially increased up to 6 months.477,478 Long-term prevention of valve thrombosis and thromboembolism after MHV implantation involves effective antithrombotic medication and risk factor modification for thromboembolism.479

11.3.1.2 Target international normalized ratio

Target INR should be based upon prosthesis thrombogenicity and patient-related risk factors (Table 10).479 It is recommended to target a median INR value rather than a range to avoid considering extreme values in the target range as a valid target INR. High INR variability is a strong independent predictor of adverse events after valve replacement. Although some studies have supported lowering a target INR for aortic MHVs,480,481 further evaluation in larger cohorts is warranted before updating current recommendations. The use of self-monitoring INR is associated with a lower rate of VKA-related complications in all ages.482 In a trial of lower intensity warfarin plus aspirin (INR 1.5–2.0) or standard warfarin plus aspirin (INR 2.0–3.0) after implantation of the On-X MHV in the aortic position, the similar safety of the two approaches was partly attributed to use of home INR monitoring and high degree of adherence among patients.481 Patient’s education plays an important role for achieving stable anticoagulation in the therapeutic range. Effective management of patients with unstable INR requires frequent in-clinic testing and dose titration. Because of the lack of good-quality evidence, pharmacogenetic testing cannot be recommended to guide the dosing of VKAs.

Table 10

Target international normalized ratio for mechanical prostheses

Prosthesis thrombogenicityPatient-related risk factorsa
None≥1 risk factor
Lowb2.53.0
Mediumc3.03.5
Highd3.54.0
Prosthesis thrombogenicityPatient-related risk factorsa
None≥1 risk factor
Lowb2.53.0
Mediumc3.03.5
Highd3.54.0

AF = atrial fibrillation; LVEF = left ventricular ejection fraction.

a

Mitral or tricuspid valve replacement; previous thromboembolism; AF; mitral stenosis of any degree; LVEF <35%.

b

Carbomedics, Medtronic Hall, ATS, Medtronic Open-Pivot, St Jude Medical, Sorin Bicarbon.

c

Other bileaflet valves with insufficient data.

d

Lillehei-Kaster, Omniscience, Starr-Edwards (ball-cage), Bjork-Shiley and other tilting-disc valves.

Table 10

Target international normalized ratio for mechanical prostheses

Prosthesis thrombogenicityPatient-related risk factorsa
None≥1 risk factor
Lowb2.53.0
Mediumc3.03.5
Highd3.54.0
Prosthesis thrombogenicityPatient-related risk factorsa
None≥1 risk factor
Lowb2.53.0
Mediumc3.03.5
Highd3.54.0

AF = atrial fibrillation; LVEF = left ventricular ejection fraction.

a

Mitral or tricuspid valve replacement; previous thromboembolism; AF; mitral stenosis of any degree; LVEF <35%.

b

Carbomedics, Medtronic Hall, ATS, Medtronic Open-Pivot, St Jude Medical, Sorin Bicarbon.

c

Other bileaflet valves with insufficient data.

d

Lillehei-Kaster, Omniscience, Starr-Edwards (ball-cage), Bjork-Shiley and other tilting-disc valves.

11.3.1.3 Management of vitamin K antagonist (VKA) overdose and bleeding

Bleeding increases exponentially with INR >4.5.483 In case of major and/or life-threatening bleeding and in patients who need to undergo urgent surgery, the VKA should be discontinued and 10 mg vitamin K should be administrated by slow i.v. infusion and repeated every 12 h if needed. Until the anticoagulation effect is reversed, administration of prothrombin complex concentration (PCC) and/or fresh frozen plasma (FFP) therapy should be initiated according to body weight and pre-treatment INR. The efficacy should be monitored by re-check of INR at 30 min and every 4–6 h until normalization. The optimal time to restart anticoagulation should be discussed in relation to location of the bleeding event and interventions performed to stop bleeding and/or to treat an underlying cause.484

In the absence of bleeding, the use of PCC and/or FFP therapy is not recommended and the decision to start vitamin K should be individualized. In asymptomatic patients with INR >10, the VKA must be stopped and oral vitamin K (2.5–5 mg) prescribed, while the INR must be monitored on a daily base for 2 weeks. Multiple RCTs in patients with INR between 4.5 and 10 suggest no difference in bleeding events with vitamin K vs. placebo.483,485 Therefore, in such patients, warfarin should be stopped temporarily, and a small dose of oral vitamin K (1–2 mg) can be considered on an individual basis balancing between the risks. Finally, asymptomatic patients with INR <4.5 require careful down-titration and/or skipping one or more doses. In all patients with MHVs, VKAs must be resumed once the INR achieves the therapeutic range or is slightly elevated.

11.3.1.4 Combination of oral anticoagulation (OAC) with antiplatelet drugs

The addition of low-dose (75–100 mg) acetylsalicylic acid (ASA) to VKA may reduce the incidence of thromboembolism at the cost of bleeding.477 Therefore, addition of antiplatelets to VKAs should be reserved for patients at very high risk of thromboembolism where advantages clearly outweigh the risks.486,487 In patients with thromboembolism despite adequate INR, low dose (75–100 mg) ASA should be added to VKAs. Management of oral antithrombotic therapy in patients with CAD is summarized in Supplementary Figure 2.

11.3.1.5 Interruption of anticoagulant therapy for planned invasive procedures

In patients with MHVs, preoperative bridging with UFH or LMWH before surgery imposes a risk of perioperative bleeding while interrupting anticoagulation results in an increased risk of thromboembolism.488 Therefore, anticoagulation in patients with MHVs undergoing elective NCS requires careful management by multidisciplinary consensus.478,489 For minor surgical procedures (e.g. dental, cataract, skin incision) in which blood loss is usually small and easily controlled, it is recommended that OAC is not interrupted. Major surgeries require temporary interruption and therapeutic bridging with either UFH or LMWH, aiming for an INR <1.5 (Supplementary Figure 3). Fondaparinux should not be routinely used for bridging, but may have a role in patients with history of heparin-induced thrombocytopenia.490

11.3.2 Bioprostheses

11.3.2.1 Patients with no baseline indication to oral anticoagulation (OAC)

Surgical bioprostheses: The optimal antithrombotic strategy early after surgical implantation of an aortic BHV remains controversial due to lack of high-quality evidence. Multiple observational studies support the use of VKAs to reduce the risk of thromboembolism.491–493 A small randomized trial found that VKA for 3 months significantly increased major bleeding compared with ASA, without reducing the rate of deaths or thromboembolic events, but the statistical power was low for demonstrating a thrombotic benefit.494 VKA for 3 months should be considered in all patients with a mitral or tricuspid BHV and ASA or VKA should be considered for 3 months after surgical implantation of an aortic bioprosthesis.

Transcatheter bioprostheses: A meta-analysis of three small RCTs showed a significant increase in major or life-threatening bleeding with dual antiplatelet therapy (DAPT) over ASA at 30 days, with no difference in ischaemic outcomes.495 Consistently, the more recent POPular TAVI trial (cohort A) found reduced bleeding and the composite of bleeding or thromboembolic events with ASA compared with DAPT.496 A randomized trial was halted prematurely due to safety concerns with a rivaroxaban-based regimen as compared with DAPT, including a higher risk of death or thromboembolic complications and a higher risk of bleeding.497 There is a lack of data on the management of antithrombotic therapy after implantation of transcatheter mitral BHVs (e.g. valve-in-valve or valve-in-ring) for which 3 months of VKA is commonly prescribed.498

11.3.2.2 Patients with baseline indication to oral anticoagulation (OAC)

Surgical bioprostheses: OAC is recommended lifelong for patients with surgical BHVs who have other indications for anticoagulation. The evidence supporting the use of NOACs in preference to VKA has increased since the publication of the 2017 VHD Guidelines. In the RIVER trial, including patients with AF and a BHV in the mitral position, the NOAC rivaroxaban was non-inferior to warfarin with respect to a net benefit endpoint at 12 months.499 The benefit of NOAC was consistent among subgroups. However, only 20% of patients were enrolled in the trial before the third postoperative month, which raises a note of caution and calls for additional data in this particular subgroup. In the small ENAVLE trial (N = 220), including patients with and without AF, edoxaban was non-inferior to warfarin for preventing thromboembolism and the occurrence of major bleeding in the first 3 months after aortic or mitral surgical bioprosthetic valve implantation or repair, which warrants confirmation in larger investigations.500

Recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods

graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; ARC-HBR = Academic Research Consortium – high bleeding risk; ASA = acetylsalicylic acid; BHV = biological heart valve; DAPT = dual antiplatelet therapy; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; PCI = percutaneous coronary intervention; MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; SAPT = single antiplatelet therapy; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

c

≤5 days for warfarin and ≤3 days for acenocoumarol.

d

CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (2 points), diabetes, prior stroke (2 points) – vascular disease, age 65–74, sex category (female).

e

LV apex thrombus, antithrombin 3 deficit and proteins C and/or S deficit.

f

AF, venous thromboembolism, hypercoagulable state or, with a lesser degree of evidence, severely impaired LV dysfunction (ejection fraction <35%).

Recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair in the perioperative and postoperative periods

graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; ARC-HBR = Academic Research Consortium – high bleeding risk; ASA = acetylsalicylic acid; BHV = biological heart valve; DAPT = dual antiplatelet therapy; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; PCI = percutaneous coronary intervention; MHV = mechanical heart valve; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; SAPT = single antiplatelet therapy; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

c

≤5 days for warfarin and ≤3 days for acenocoumarol.

d

CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (2 points), diabetes, prior stroke (2 points) – vascular disease, age 65–74, sex category (female).

e

LV apex thrombus, antithrombin 3 deficit and proteins C and/or S deficit.

f

AF, venous thromboembolism, hypercoagulable state or, with a lesser degree of evidence, severely impaired LV dysfunction (ejection fraction <35%).

Transcatheter bioprostheses: In the POPular TAVI trial (cohort B), the incidence of bleeding over a period of 1 month or 1 year was lower with OAC than with OAC plus clopidogrel.501 OAC alone was non-inferior to OAC plus clopidogrel with respect to ischaemic events, but the non-inferiority margin was large. An observational study suggested that there is a higher risk of ischaemic events at 1 year with NOACs compared with VKAs, after adjustment for potential confounders.502 Randomized trials comparing NOACs vs. VKAs are ongoing (NCT02943785, NCT02664649). Data on the management of antithrombotic therapy after transcatheter mitral or tricuspid valve implantation are scant.498

11.3.3 Valve repair

Observational data suggest comparable risk of thromboembolism with ASA or VKAs following mitral valve repair,503 but randomized data are lacking. The high incidence of new-onset AF and its recurrence, the thrombogenic tendency of the non-endothelialized repair components, and a relatively high rate of patients who are resistant to ASA establish VKAs as a preferable option for the initial period (e.g. 3 months). However, the potential for bleeding complications in the postoperative phase dictates careful patient selection.

The management of antithrombotic treatment after prosthetic valve implantation or valve repair is summarized in the table of recommendations for management of antithrombotic therapy after prosthetic valve implantation or valve repair and in Figure 9.

Antithrombotic therapy for valve prostheses. AF = atrial fibrillation;
ASA = acetylsalicylic acid; CAD = coronary artery disease; DAPT = dual antiplatelet
therapy; INR = international normalized ratio; LMWH = low-molecular-weight heparin;
LV = left ventricle/left ventricular; MHV = mechanical heart valve; MVR = mitral
valve replacement or repair; OAC = oral anticoagulation; SAPT = single antiplatelet
therapy; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve
implantation; TVR = tricuspid valve replacement or repair; UFH = unfractionated
heparin; VKA = vitamin K antagonist. Colour coding corresponds to class of
recommendation.
Figure 9

Antithrombotic therapy for valve prostheses. AF = atrial fibrillation; ASA = acetylsalicylic acid; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; MHV = mechanical heart valve; MVR = mitral valve replacement or repair; OAC = oral anticoagulation; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation; TVR = tricuspid valve replacement or repair; UFH = unfractionated heparin; VKA = vitamin K antagonist. Colour coding corresponds to class of recommendation.

11.4 Management of prosthetic valve dysfunction and complications

11.4.1 Structural valve deterioration

Definitions of SVD and bioprosthetic valve failure (BVF) were standardized by recent consensus.470,522 The comparative durability of TAVI and SAVR BHVs must be ascertained at longer term. Reversible causes of BVF (e.g. endocarditis, thrombosis) should be excluded, and considerations on timing of dysfunction (e.g. for BHV obstruction, mismatch in early phases, thrombosis in later phases) and location of malfunction (e.g. endocarditis or SVD in case of central regurgitation, endocarditis or anatomical/technical factors in case of paravalvular regurgitation) may reveal the most plausible underlying cause and guide clinical decision making.

Percutaneous balloon interventions should be avoided in the treatment of stenotic left-sided bioprostheses. Transcatheter valve-in-valve implantation is an option for treating degenerated BHVs in patients with increased surgical risk.227,523–525 Redo-TAVI is a safe and feasible option in selected patients, but the risk of PPM in small valves and that of coronary occlusion, as well the possibility for future access to the coronary arteries need to be considered.229,526–528 Experience is mostly in aortic BHVs and remains limited for BHVs in the mitral position and even more so in the tricuspid position529–532 for which valve-in-valve procedures may be reasonable in patients at increased surgical risk.531,533 Valve-in-ring mitral procedures are also acceptable in selected candidates, while the role of valve-in-ring tricuspid procedures remains uncertain. It is necessary for the Heart Team to discuss every patient and choose the best individualized approach. Careful pre-procedural planning is needed to minimize the risk of coronary artery obstruction and enable future coronary re-access in aortic BHV re-interventions if necessary. For mitral re-interventions the risk of LVOT obstruction should be carefully evaluated.534

11.4.2 Non-structural valve dysfunction

11.4.2.1 Patient-prosthesis mismatch

Patient-prosthesis mismatch (PPM) significantly decreases long-term survival, correlates with SVD and increases readmission rates for both heart failure and reoperation.535–537 Efforts to prevent PPM should receive more emphasis to improve long-term survival after either SAVR or TAVI.538

11.4.2.2 Paravalvular leak and haemolysis

Blood tests for haemolysis should be part of routine follow-up after valve replacement. Diagnosis of haemolytic anaemia requires TOE to detect paravalvular leaks for prostheses in the mitral position if TTE is not contributory. Reoperation is recommended if the paravalvular leak is related to endocarditis or causes haemolysis requiring repeated blood transfusions or leading to severe symptoms. Transcatheter closure of a paravalvular leak is feasible, but experience is limited and there is presently no conclusive evidence to show consistent efficacy.539 Transcatheter closure of paravalvular leaks should be considered for anatomically suitable paravalvular leaks in candidates selected by the Heart Team.540 Medical therapy (including iron supplementation, beta-blockers, and erythropoietin) is indicated in patients with severe haemolytic anaemia when contraindications to surgical or transcatheter closure are present.540

11.4.3 Endocarditis

The management of patients with endocarditis should follow the relevant guidelines.4

11.4.4 Thrombosis

11.4.4.1 General comments

Obstructive valve thrombosis should be suspected promptly in any patient with any type of prosthetic valve who presents with recent dyspnoea or an embolic event. The diagnosis should be confirmed by TTE and TOE, cinefluoroscopy, or CCT if promptly available.268,314 Valve thrombosis occurs mainly in MHVs. However, cases of thrombosis of BHVs have also been reported after surgery or transcatheter valve implantation.541 Thrombus on BHVs can present as hypo-attenuated leaflet thickening (HALT) with relatively normal leaflet motion, HALT with reduced leaflet motion but normal gradients, and clinical valve thrombosis with elevated gradients. Distinguishing between thrombus and pannus by means of CCT is important to guide decision making.

11.4.4.2 Valve thrombosis

The management of MHVs thrombosis is high risk, whatever the option taken. Fibrinolysis carries risks of bleeding, systemic embolism, and recurrent thrombosis.542 Emergency valve replacement is recommended for obstructive prosthetic valve thrombosis in critically ill patients without a contraindication to surgery. Management of non-obstructive thrombosis of an MHV depends mainly on the occurrence of a thromboembolic event and the size of the thrombus. Surgery should be considered for a large (>10 mm) non-obstructive prosthetic valve thrombus that is complicated by embolism or persists despite optimal anticoagulation.543 Fibrinolysis may be considered if surgery is not an option or is very high risk for the treatment of thrombosis of right-sided prostheses, but carries a risk of bleeding and thromboembolism. Anticoagulation using a VKA and/or UFH is the first-line treatment of BHV thrombosis. Because BHV thrombosis is associated with recurrence and early prosthetic degeneration, indefinite anticoagulation should be considered after a confirmed episode, but this strategy must be balanced against an increased risk of bleeding544,545 (Figure 10).

Management of left-sided obstructive and non-obstructive mechanical prosthetic
thrombosis. ASA = acetylsalicylic acid; CCT = cardiac computed tomography;
i.v. = intravenous; TOE = transoesophageal echocardiography; TE = thromboembolism;
TTE = transthoracic echocardiography; UFH = unfractionated heparin. Risk and
benefits of both treatments should be individualized. The presence of a
first-generation prosthesis is an incentive to surgery. aRefer to
recommendations for the imaging assessment of prosthetic heart valves. Evaluation
generally includes TTE plus TOE or CCT and occasionally fluoroscopy.
Figure 10

Management of left-sided obstructive and non-obstructive mechanical prosthetic thrombosis. ASA = acetylsalicylic acid; CCT = cardiac computed tomography; i.v. = intravenous; TOE = transoesophageal echocardiography; TE = thromboembolism; TTE = transthoracic echocardiography; UFH = unfractionated heparin. Risk and benefits of both treatments should be individualized. The presence of a first-generation prosthesis is an incentive to surgery. aRefer to recommendations for the imaging assessment of prosthetic heart valves. Evaluation generally includes TTE plus TOE or CCT and occasionally fluoroscopy.

11.4.4.3 Subclinical leaflet thrombosis

HALT is detected by CCT in 12.4% and 32.4% of TAVI patients on OAC or DAPT at 3 months, respectively.546 The clinical significance of these findings is uncertain. Selective use of oral anticoagulants in patients with confirmed HALT and restricted leaflet motion with elevated gradients should be considered.

11.4.5 Heart failure

Heart failure after valve surgery should lead to a quick search for SVD or PPM, deterioration of repair, LV dysfunction, or progression of another valve disease. Non-valvular-related causes such as CAD, hypertension, or sustained arrhythmias should also be considered. The management of patients with heart failure should follow the relevant guidelines and consensus documents.142,247

Recommendations on management of prosthetic valve dysfunction

graphic
graphic
graphic
graphic

UFH = unfractionated heparin; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

Recommendations on management of prosthetic valve dysfunction

graphic
graphic
graphic
graphic

UFH = unfractionated heparin; VKA = vitamin K antagonist.

a

Class of recommendation.

b

Level of evidence.

12 Management during non-cardiac surgery

Cardiovascular morbidity and mortality are increased in patients with VHD who undergo NCS. Symptomatic severe aortic stenosis or mitral stenosis may require valve replacement or percutaneous intervention before NCS. A detailed description of recommendations in the setting is available in specific ESC Guidelines.489

12.1 Preoperative evaluation

Patient and surgical specific factors dictate the strategy.489,548,549 The cardiologist provides recommendations on pre- and perioperative management, surveillance, and continuation of chronic cardiovascular medical treatment. Echocardiography should be performed in any patient with VHD requiring NCS. Determination of functional capacity is a pivotal step in preoperative risk assessment, measured either by ability to perform activities in daily life or by exercise test. The decision for management should be taken after multidisciplinary discussion involving cardiologists, surgeons, and cardiac anaesthesiologists, as well as the team who will be in charge of NCS.

Patients receiving anticoagulation treatment should be managed as discussed in section 11.

12.2 Specific valve lesions

12.2.1 Aortic stenosis

In patients with severe aortic stenosis, urgent NCS should be performed under careful haemodynamic monitoring. In case of high risk of NCS, balloon valvuloplasty may be considered before NCS.549 Management related to elective NCS depends on the presence of symptoms and the type of surgery.489,549–553 In symptomatic patients, aortic valve procedure should be considered before NCS. The type of procedure, TAVI or SAVR, is decided by the Heart Team. In asymptomatic patients, elective NCS, if at low to moderate risk, can be performed safely, albeit with a risk of worsening heart failure.489,552,553 If NCS implies large volume shifts, aortic valve procedure (TAVI or SAVR) should be considered first according to the Heart Team’s decision (Figure 11).

Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis.
AV = aortic valve; BAV = balloon aortic valvuloplasty; NCS = non cardiac surgery;
SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve
implantation.
Figure 11

Management of non-cardiac surgery (NCS) in patients with severe aortic stenosis. AV = aortic valve; BAV = balloon aortic valvuloplasty; NCS = non cardiac surgery; SAVR = surgical aortic valve replacement; TAVI = transcatheter aortic valve implantation.

12.2.2 Mitral stenosis

NCS can be performed safely in patients with non-significant mitral stenosis (valve area >1.5 cm2) and in asymptomatic patients with significant mitral stenosis and an SPAP <50 mmHg. In symptomatic patients or in patients with SPAP >50 mmHg, correction of mitral stenosis, by means of PMC whenever possible, should be attempted before NCS if it is high risk.

12.2.3 Aortic and mitral regurgitation

NCS can be performed safely in asymptomatic patients with severe mitral regurgitation or aortic regurgitation and preserved LV function. The presence of symptoms or LV dysfunction should lead to consideration of valvular surgery, but this is seldom needed before NCS. If LV dysfunction is severe (ejection fraction <30%) and/or SPAP is >50/60 mmHg, NCS should be performed only if strictly necessary and after optimization of medical therapy for heart failure.

12.3 Perioperative monitoring

Heart rate control (particularly in mitral stenosis) and careful fluid management (particularly in aortic stenosis) are needed. TOE monitoring may be considered.

13 Management during pregnancy

Detailed guidelines on the management of cardiovascular disease during pregnancy are available in another document.554 The decision for management before and during pregnancy should be taken after multidisciplinary discussion in the pregnancy Heart Team involving cardiologists, cardiac surgeons, obstetricians, neonatologists, and anaesthesiologists.

13.1 Management before pregnancy

Valve disease should be evaluated before pregnancy and treated if necessary.554,555

Pregnancy should be discouraged, and intervention should be recommended before pregnancy in the following cases:

  • Patients with mitral stenosis and a valve area <1.5 cm² (especially if <1.0 cm²).554,556

  • All symptomatic patients with severe AS or asymptomatic patients with impaired LV function (LVEF <50%) or an abnormal exercise test should be counselled against pregnancy, and surgery should be performed pre-pregnancy.554,557

  • Women with Marfan syndrome and an aortic diameter >45 mm should be strongly discouraged from becoming pregnant without prior aortic repair because of the high risk of aortic dissection. Although an aortic diameter <40 mm is rarely associated with aortic dissection, a completely safe diameter does not exist. With an aortic diameter between 40 and 45 mm, previous aortic growth and family history are important for advising pregnancy with or without aortic repair.558 Although the actual risk of dissection is not well documented in the setting of bicuspid valves, counselling against pregnancy is recommended in the setting of aortic diameters >50 mm (>27 mm² BSA).559 Finally, an aortic diameter >25 mm/m² BSA in Turner syndrome and all patients with vascular Ehlers-Danlos syndrome are also contraindications for pregnancy.

In women considering pregnancy and requiring heart valve replacement, it is recommended to choose the prosthesis in consultation with a pregnancy Heart Team.554,560

Pregnancy in women with a mechanical valve, especially in the mitral position, is associated with a high risk of maternal and foetal complications,554,561 which should be carefully discussed with the patient and family.

13.2 Management during pregnancy

13.2.1 Patients with native valve disease

Moderate or severe mitral stenosis with a valve area <1.5 cm² in pregnant women is usually poorly tolerated. PMC should be considered in severely symptomatic patients [New York Heart Association (NYHA) class III–IV] and/or those with SPAP >50 mmHg despite optimal therapy. PMC should preferably be performed after the 20th week of pregnancy in experienced centres.554

In patients who are severely symptomatic despite medical therapy, BAV for severe aortic stenosis can be undertaken by an experienced operator.557 TAVI is a promising alternative, but experience during pregnancy is very limited.554

Surgery under cardiopulmonary bypass is associated with a foetal mortality rate of 15–56%562 and should be restricted to the rare conditions that threaten the mother’s life if transcatheter intervention is not possible or has failed. Valve replacement should be considered after early delivery by caesarean section.

Caesarean section is recommended for patients with severe mitral or aortic stenosis, ascending aortic diameter >45 mm, severe pulmonary hypertension, or if delivery starts while treated with a VKA or <2 weeks after discontinuation of a VKA.

13.2.2 Mechanical prosthesis

It is recommended to manage pregnancy in patients with MHV in a centre with a pregnancy Heart Team.554

Therapeutic anticoagulation during pregnancy is of utmost importance to avoid complications in these patients, keeping in mind that no anticoagulation regimen is ideal and management will require a careful balance between maternal and foetal risks.

In patients requiring <5 mg/day warfarin, oral anticoagulants throughout pregnancy and a change to UFH before delivery is favoured. In patients requiring higher doses, switching to LMWH during the first trimester with strict anti-Xa monitoring (therapeutic range 0.8–1.2 IU/mL, aortic valve prosthesis; and 1.0–1.2 IU/mL, mitral and right sided valve prosthesis) and the use of oral anticoagulants afterwards is favoured with a change to UFH before delivery.554

14 Key messages

General comments

1. Precise evaluation of the patient’s history and symptomatic status, as well as proper physical examination, are crucial for the diagnosis and management of VHD.

2. Echocardiography is the key technique to diagnose VHD and assess its severity and prognosis. Other non-invasive investigations such as CMR, CCT, fluoroscopy, and biomarkers provide important additional information in selected patients. Stress testing should be widely used in asymptomatic patients. Invasive investigation, beyond preoperative coronary angiography, is restricted to situations where non-invasive evaluation is inconclusive.

3. Decision making in elderly patients requires the integration of multiple parameters, including estimation of life expectancy and anticipated quality of life, evaluation of comorbidities, and general condition (including frailty).

4. Decision making in asymptomatic patients weighs the risk of intervention against the expected natural history of VHD. Stress testing should be liberally performed.

5. Informed patient’s expectations and values are an important part of the decision-making process.

6. Interventions (surgery or transcatheter) are indicated in symptomatic patients (spontaneous or exercise induced) in the absence of futility. In selected asymptomatic patients, presence of predictors of rapid symptom progression justifies early intervention when procedural risk is low.

7. Heart Valve Centres with multidisciplinary Heart Teams, Heart Valve Clinics, comprehensive equipment, and sufficient volumes of procedures are required to deliver high-quality care and provide adequate training.

8. Careful follow-up of symptomatic status, LV/RV size, and function is mandatory in asymptomatic patients with severe VHD if an intervention is not yet indicated.

9. In patients with AF, NOACs are contraindicated in patients with clinically significant mitral stenosis or mechanical valves. For stroke prevention in patients who are eligible for OAC, NOACs are recommended in preference to VKAs in patients with aortic stenosis, aortic and mitral regurgitation, or aortic bioprostheses >3 months after implantation.

Aortic regurgitation

10. The evaluation of aortic regurgitation requires careful assessment of potentially associated aortic dilatation to guide the timing and type of surgery.

Aortic stenosis

11. Diagnosis of severe aortic stenosis requires integrative evaluation of pressure gradients (the most robust measurements), AVA, extent of valve calcification, flow conditions, and LV function.

12. Selection of the most appropriate mode of intervention by the Heart Team should take into account clinical characteristics (age and estimated life expectancy, general condition), anatomical characteristics, the relative risks of SAVR and TAVI, the feasibility of transfemoral TAVI, local experience and outcome data, as well as informed patient preference.

Mitral regurgitation

13. Regarding imaging, routine quantification of EROA is an important part of the integrative evaluation for quantification and risk stratification in patients with PMR. 3D transoesophageal echocardiography is more accurate than 2D echocardiography for defining the underlying mechanism of PMR. CMR is useful when echocardiographic evaluation of severe PMR grade is inconclusive.

14. Surgical mitral valve repair is the preferred method of treatment in PMR if a durable repair can be achieved. TEER is a safe but less efficacious alternative that may be considered in patients with contraindications for surgery or high operative risk.

15. In patients with severe SMR, GDMT (including CRT if indicated) should be the first step. If the patient remains symptomatic: mitral surgery is recommended concomitantly in patients with an indication for CABG or other cardiac surgery. Isolated valve surgery may be considered in selected patients. TEER should be considered in patients not eligible for surgery and fulfilling criteria indicating an increased chance of responding to the treatment. Circulatory support devices, cardiac transplantation, or palliative care should be considered as an alternative in patients with end-stage LV and/or RV failure.

Mitral stenosis

16. PMC is currently the standard of care in patients with severe rheumatic mitral stenosis and favourable valve anatomy.

17. Decision making as to the type of intervention used in patients with unfavourable anatomy is still a matter of debate and must take into account the multifactorial nature of predicting the results of PMC.

Tricuspid regurgitation

18. Relevant tricuspid regurgitation requires early intervention to avoid secondary damage of the RV.

19. Tricuspid regurgitation should be liberally treated at the time of left-sided valve surgery. Isolated surgery of severe secondary tricuspid regurgitation (with or without previous left-sided valve surgery) requires comprehensive assessment of the underlying disease, pulmonary haemodynamics, and RV function.

Prosthetic valves

20. The choice between a mechanical prosthesis and a bioprosthesis should be patient-centred and multifactorial based on patient characteristics, the indication for lifelong anticoagulation, the potential and risks of a re-intervention, and the informed patient preference.

21. Clinical assessment of prosthetic valves should be performed yearly and as soon as possible if new cardiac symptoms occur.

15 Gaps in evidence

Important gaps in evidence exist in the following aspects of VHD:

General comments

1. Prognostic value of CMR-derived indices in patients with aortic regurgitation, aortic stenosis, and mitral regurgitation.

2. Tools for risk stratification for the decision for intervention (including the avoidance of futile interventions) and the choice of the type of intervention (TAVI vs. SAVR for aortic stenosis, repair vs. replacement for mitral and aortic regurgitation).

3. In asymptomatic patients with aortic regurgitation, aortic stenosis, and mitral regurgitation, identification and evaluation of earlier markers of LV dysfunction (biomarkers, imaging, multimodality) as well as longitudinal and translational studies on progression.

4. Gender issues regarding pathophysiology, indications, and timing of treatment.

5. Minimum volumes of procedures that are required to achieve optimal results of intervention.

6. Safety and efficacy of NOACs in patients with surgical or transcatheter bioprostheses in the first 3 months after implantation.

7. Patient education for shared decision making and timely evaluation.

8. Systematic epidemiological data addressing the burden of rheumatic heart disease.

9. Advocacy of VHD.

Aortic regurgitation

10. Potential differences in the risk of aortic complications depending on subtypes of aortic aneurysms (site and morphology), as well as in patients with bicuspid aortic valves.

11. Further evaluation of surgical aortic valve repair.

Aortic stenosis

12. Pathophysiology of progression and novel therapeutic targets for medical treatment.

13. Further research to evaluate the role of intervention:

  •  a. Long-term durability of transcatheter heart valves in comparison with surgical bioprostheses.

  •  b. Role of intervention (SAVR or TAVI) in asymptomatic patients.

  •  c. Role of TAVI in younger low-risk patients, patients with aortic stenosis affecting bicuspid valves, and patients with moderate aortic stenosis and LV impairment.

  •  d. Results of re-intervention (valve or coronary) after TAVI or SAVR.

  •  e. The role of revascularization in patients with severe aortic stenosis and asymptomatic concomitant CAD.

Mitral regurgitation

14. Association between PMR and sudden cardiac death and ventricular arrhythmias.

15. Role of genetic testing to mitral valve prolapse.

16. Further evaluation of the role of intervention:

  •  a. Long-term results of transcatheter intervention.

  • b. Indications of transcatheter intervention in patients with severe PMR at lower surgical risk.

  •  c. Potential impact of mitral valve intervention (surgery and catheter intervention) on survival in patients with SMR.

  •  d. Selection of criteria to identify responders to TEER for SMR (severity criteria, concept of ‘disproportionate mitral regurgitation’).

  •  e. The role of newer transcatheter treatment options (annuloplasty, combined repair techniques, valve replacement).

Mitral stenosis

17. Scores predicting the results and complications of PMC, particularly that of severe mitral regurgitation.

18. Role of transcatheter mitral valve implantation in high-risk patients, particularly in patients with severe degenerative mitral stenosis and MAC.

Tricuspid regurgitation

19. Quantification of tricuspid regurgitation severity and evaluation of RV function.

20. Further research to evaluate the role of intervention:

  •  a. Criteria for optimal timing of surgery in primary tricuspid regurgitation.

  •  b. Evidence on the clinical impact, timing, and treatment modality of isolated severe secondary tricuspid regurgitation.

  • c. Criteria for concomitant tricuspid valve surgery at the time of left-sided surgery in patients without severe tricuspid regurgitation.

  •  d. Results and indications of transcatheter tricuspid valve treatment.

Combined and multi-valve diseases

21. Further evaluation of the impact on outcomes and modalities of transcatheter intervention to better define the indications for intervention.

Pregnancy

22. Optimal management of pregnant women with MHVs regarding antithrombotic regimens.

Non-cardiac surgery

23. Evaluation of the role of ‘urgent TAVI’ in the management of patients with severe aortic stenosis undergoing NCS.

16 To Do and Not To Do

graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; BHV = biological heart valve; BSA = body surface area; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guideline-directed medical therapy; h = hours; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; MHV = mechanical heart valve; MR = mitral regurgitation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality; SVD = structural valve deterioration; SVi = stroke volume index; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VHD = valvular heart disease; VKA = vitamin K antagonist.

graphic
graphic
graphic
graphic
graphic
graphic

ACS = acute coronary syndrome; AF = atrial fibrillation; BHV = biological heart valve; BSA = body surface area; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CRT = cardiac resynchronization therapy; DAPT = dual antiplatelet therapy; EuroSCORE = European System for Cardiac Operative Risk Evaluation; GDMT = guideline-directed medical therapy; h = hours; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricle/left ventricular; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; MHV = mechanical heart valve; MR = mitral regurgitation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCI = percutaneous coronary intervention; PMC = percutaneous mitral commissurotomy; RV = right ventricle/right ventricular; SAPT = single antiplatelet therapy; SAVR = surgical aortic valve replacement; SMR = secondary mitral regurgitation; STS-PROM = Society of Thoracic Surgeons – predicted risk of mortality; SVD = structural valve deterioration; SVi = stroke volume index; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VHD = valvular heart disease; VKA = vitamin K antagonist.

17 Supplementary data

Supplementary Data with additional Supplementary figures, tables, and text complementing the full text are available on the European Heart Journal website and via the ESC website at https://www.escardio.org/guidelines.

18 Author information

Author/Task Force Member Affiliations: Fabien Praz, Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland; Milan Milojevic1, Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia and Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands; Stephan Baldus, Heart Centre, Department of Cardiology, University Hospital Cologne, Cologne, Germany; Johann Bauersachs, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; Davide Capodanno, Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico ‘Gaspare Rodolico – San Marco’, Catania, Italy; Lenard Conradi1, Department of Cardiovascular Surgery, University Heart and Vascular Centre Hamburg, Hamburg, Germany; Michele De Bonis1, Department of Cardiac Surgery, IRCCS San Raffaele Hospital, ‘Vita-Salute’ San Raffaele University, Milan, Italy; Ruggero De Paulis1, Cardiac Surgery Department, European Hospital, Unicamillus International Medical University, Rome, Italy; Victoria Delgado, Cardiology, Leiden University Medical Centre, Leiden, Netherlands; Nick Freemantle1, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom; Martine Gilard, Cardiology, Brest University Hospital, Brest, France; Kristina H. Haugaa, Department of Cardiology, Oslo University Hospital and University of Oslo, Oslo, Norway; Anders Jeppsson1, Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Peter Jüni, Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Canada; Luc Pierard, Cardiology, University of Liège, Liège, Belgium; Bernard D. Prendergast, Department of Cardiology, St Thomas' Hospital and Cleveland Clinic London, London, United Kingdom; J. Rafael Sádaba1, Department of Cardiac Surgery, Complejo Hospitalario de Navarra, Pamplona, Spain; Christophe Tribouilloy, Department of Cardiology, Amiens University Hospital, Amiens, France; Wojtek Wojakowski, Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Author/Task Force Member affiliations: listed in Author information.

ESC Clinical Practice Guidelines Committee (CPG): listed in the Appendix.

EACTS Council: listed in the Appendix.

Representing the European Association for Cardio-Thoracic Surgery (EACTS)

ESC subspecialty communities having participated in the development of this document:

Associations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Council on Valvular Heart Disease.

Working Groups: Cardiovascular Surgery, Thrombosis.

Patient Forum The content of these European Society of Cardiology (ESC) / European Association for Cardio-Thoracic Surgery (EACTS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS Guidelines may be translated or reproduced in any form without written permission from the ESC and the EACTS. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC ([email protected]).

Disclaimer: The ESC/EACTS Guidelines represent the views of the ESC and the EACTS and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

19 Appendix

ESC/EACTS Scientific Document Group

Includes Document Reviewers and ESC National Cardiac Societies.

Document Reviewers: Franz-Josef Neumann (ESC Review Coordinator) (Germany), Patrick Myers1 (EACTS Review Coordinator) (Switzerland), Magdy Abdelhamid (Egypt), Stephan Achenbach (Germany), Riccardo Asteggiano (Italy), Fabio Barili1 (Italy), Michael A. Borger (Germany), Thierry Carrel1 (Switzerland), Jean-Philippe Collet (France), Dan Foldager (Denmark), Gilbert Habib (France), Christian Hassager (Denmark), Alar Irs1 (Estonia), Bernard Iung (France), Marjan Jahangiri1 (United Kingdom), Hugo A. Katus (Germany), Konstantinos C. Koskinas (Switzerland), Steffen Massberg (Germany), Christian E. Mueller (Switzerland), Jens Cosedis Nielsen (Denmark), Philippe Pibarot (Canada), Amina Rakisheva (Kazakhstan), Marco Roffi (Switzerland), Andrea Rubboli (Italy), Evgeny Shlyakhto (Russia), Matthias Siepe1 (Germany), Marta Sitges (Spain), Lars Sondergaard (Denmark), Miguel Sousa-Uva1 (Portugal), Guiseppe Tarantini (Italy), Jose Luis Zamorano (Spain).

ESC National Cardiac Societies actively involved in the review process of the 2021 ESC/EACTS Guidelines for the management of valvular heart disease.

Algeria: Algerian Society of Cardiology, Yasmina Benchabi; Armenia: Armenian Cardiologists Association, Aram Chilingaryan; Austria: Austrian Society of Cardiology, Bernhard Metzler; Azerbaijan: Azerbaijan Society of Cardiology, Yasmin Rustamova; Belarus: Belorussian Scientific Society of Cardiologists, Vadim Shumavets; Belgium: Belgian Society of Cardiology, Patrizio Lancellotti; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Elnur Smajic; Bulgaria: Bulgarian Society of Cardiology, Diana Trendafilova-Lazarova; Croatia: Croatian Cardiac Society, Jure Samardzic; Cyprus: Cyprus Society of Cardiology, Maria Karakyriou; Czech Republic: Czech Society of Cardiology, Tomáš Paleček; Denmark: Danish Society of Cardiology, Jordi Sanchez Dahl; Egypt: Egyptian Society of Cardiology, Marwa Sayed Meshaal; Estonia: Estonian Society of Cardiology, Kairit Palm; Finland: Finnish Cardiac Society, Marko Virtanen; France: French Society of Cardiology, Claire Bouleti; Georgia: Georgian Society of Cardiology, Zviad Bakhutashvili; Germany: German Cardiac Society, Stephan Achenbach; Greece: Hellenic Society of Cardiology, Maria Boutsikou; Hungary: Hungarian Society of Cardiology, Attila Béla Kertész; Iceland: Icelandic Society of Cardiology, Ragnar Danielsen; Israel: Israel Heart Society, Yan Topilsky; Italy: Italian Federation of Cardiology, Paolo Golino; Kazakhstan: Association of Cardiologists of Kazakhstan, Rustem Tuleutayev; Kosovo (Republic of): Kosovo Society of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina Kerimkulova; Latvia: Latvian Society of Cardiology, Ainars Rudzitis; Lithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; Luxembourg: Luxembourg Society of Cardiology, Rouguiatou Sow; Malta: Maltese Cardiac Society, Daniela Cassar Demarco; Montenegro: Montenegro Society of Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of Cardiology, Aicha Aouad; Netherlands: Netherlands Society of Cardiology, Renée van den Brink; North Macedonia: North Macedonian Society of Cardiology, Emilija Antova; Norway: Norwegian Society of Cardiology, Jan Otto Beitnes; Poland: Polish Cardiac Society, Andrzej Ochala; Portugal: Portuguese Society of Cardiology, Regina Ribeiras; Romania: Romanian Society of Cardiology, Dragos Vinereanu; Russian Federation: Russian Society of Cardiology, Olga Irtyuga; Serbia: Cardiology Society of Serbia, Branislava Ivanovic; Slovakia: Slovak Society of Cardiology, Iveta Simkova; Spain: Spanish Society of Cardiology, Ariana González Gómez; Sweden: Swedish Society of Cardiology, Giovanna Sarno; Switzerland: Swiss Society of Cardiology, Giovanni B. Pedrazzini; Syrian Arab Republic: Syrian Cardiovascular Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Lilia Zakhama; Turkey: Turkish Society of Cardiology, Levent Korkmaz; Ukraine: Ukrainian Association of Cardiology, Sergii Cherniuk; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Mohammed Y. Khanji; Uzbekistan: Association of Cardiologists of Uzbekistan, Islamjan Sharipov.

ESC Clinical Practice Guidelines Committee (CPG): Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United Kingdom).

EACTS Council: Friedhelm Beyersdorf (Germany), Lorenzo Galletti (Italy), Mark Hazekamp (Netherlands), Peter Licht (Denmark), Patrick Myers (Switzerland), Patrick Perier (Germany), Richard Prager (United States of America), Eric Roessner (Germany), J. Rafael Sádaba (Spain), Matthias Siepe (Germany), Konstantinos Tsagakis (Germany), Alicja Zientara (United Kingdom).

References

1

Iung
 
B
,
Delgado
V
,
Rosenhek
R
,
Price
S
,
Prendergast
B
,
Wendler
O
,
De Bonis
M
,
Tribouilloy
C
,
Evangelista
A
,
Bogachev-Prokophiev
A
,
Apor
A
,
Ince
H
,
Laroche
C
,
Popescu
BA
,
Pierard
L
,
Haude
M
,
Hindricks
G
,
Ruschitzka
F
,
Windecker
S
,
Bax
JJ
,
Maggioni
A
,
Vahanian
A
,
EORP VHD II Investigators
.
Contemporary presentation and management of valvular heart disease: The EURObservational Research Programme Valvular Heart Disease II Survey
.
Circulation
2019
;
140
:
1156
1169
.

2

Yadgir
 
S
,
Johnson
CO
,
Aboyans
V
,
Adebayo
OM
,
Adedoyin
RA
,
Afarideh
M
,
Alahdab
F
,
Alashi
A
,
Alipour
V
,
Arabloo
J
,
Azari
S
,
Barthelemy
CM
,
Benziger
CP
,
Berman
AE
,
Bijani
A
,
Carrero
JJ
,
Carvalho
F
,
Daryani
A
,
Duraes
AR
,
Esteghamati
A
,
Farid
TA
,
Farzadfar
F
,
Fernandes
E
,
Filip
I
,
Gad
MM
,
Hamidi
S
,
Hay
SI
,
Ilesanmi
OS
,
Naghibi Irvani
SS
,
Jurisson
M
,
Kasaeian
A
,
Kengne
AP
,
Khan
AR
,
Kisa
A
,
Kisa
S
,
Kolte
D
,
Manafi
N
,
Manafi
A
,
Mensah
GA
,
Mirrakhimov
EM
,
Mohammad
Y
,
Mokdad
AH
,
Negoi
RI
,
Thi Nguyen
HL
,
Nguyen
TH
,
Nixon
MR
,
Otto
CM
,
Patel
S
,
Pilgrim
T
,
Radfar
A
,
Rawaf
DL
,
Rawaf
S
,
Rawasia
WF
,
Rezapour
A
,
Roever
L
,
Saad
AM
,
Saadatagah
S
,
Senthilkumaran
S
,
Sliwa
K
,
Tesfay
BE
,
Tran
BX
,
Ullah
I
,
Vaduganathan
M
,
Vasankari
TJ
,
Wolfe
CDA
,
Yonemoto
N
,
Roth
GA
,
Global Burden of Disease Study Nonrheumatic Valve Disease Collaborators
.
Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017
.
Circulation
2020
;
141
:
1670
1680
.

3

Cahill
 
TJ
,
Prothero
A
,
Wilson
J
,
Kennedy
A
,
Brubert
J
,
Masters
M
,
Newton
JD
,
Dawkins
S
,
Enriquez-Sarano
M
,
Prendergast
BD
,
Myerson
SG.
 
Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation
.
Heart
2021
doi: 10.1136/heartjnl-2020-318482.

4

Habib
 
G
,
Lancellotti
P
,
Antunes
MJ
,
Bongiorni
MG
,
Casalta
JP
,
Del Zotti
F
,
Dulgheru
R
,
El Khoury
G
,
Erba
PA
,
Iung
B
,
Miro
JM
,
Mulder
BJ
,
Plonska-Gosciniak
E
,
Price
S
,
Roos-Hesselink
J
,
Snygg-Martin
U
,
Thuny
F
,
Tornos Mas
P
,
Vilacosta
I
,
Zamorano
JL
,
ESC Scientific Document Group
.
2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)
.
Eur Heart J
2015
;
36
:
3075
3128
.

5

Baumgartner
 
H
,
De Backer
J
,
Babu-Narayan
SV
,
Budts
W
,
Chessa
M
,
Diller
GP
,
Lung
B
,
Kluin
J
,
Lang
IM
,
Meijboom
F
,
Moons
P
,
Mulder
BJM
,
Oechslin
E
,
Roos-Hesselink
JW
,
Schwerzmann
M
,
Sondergaard
L
,
Zeppenfeld
K
,
ESC Scientific Document Group
.
2020 ESC Guidelines for the management of adult congenital heart disease
.
Eur Heart J
2021
;
42
:
563
645
.

6

Pelliccia
 
A
,
Sharma
S
,
Gati
S
,
Back
M
,
Borjesson
M
,
Caselli
S
,
Collet
JP
,
Corrado
D
,
Drezner
JA
,
Halle
M
,
Hansen
D
,
Heidbuchel
H
,
Myers
J
,
Niebauer
J
,
Papadakis
M
,
Piepoli
MF
,
Prescott
E
,
Roos-Hesselink
JW
,
Graham Stuart
A
,
Taylor
RS
,
Thompson
PD
,
Tiberi
M
,
Vanhees
L
,
Wilhelm
M
,
ESC Scientific Document Group
.
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
.
Eur Heart J
2021
;
42
:
17
96
.

7

Agricola
 
E
,
Ancona
F
,
Brochet
E
,
Donal
E
,
Dweck
M
,
Faletra
F
,
Lancellotti
P
,
Mahmoud-Elsayed
H
,
Marsan
NA
,
Maurovich-Hovart
P
,
Monaghan
M
,
Ribeiro
J
,
Sade
LE
,
Swaans
M
,
Von Bardeleben
RS
,
Wunderlich
N
,
Zamorano
JL
,
Popescu
BA
,
Cosyns
B
,
Edvardsen
T.
 
The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
2021
;
22
:
471
479
.

8

Hahn
 
RT
,
Mahmood
F
,
Kodali
S
,
Lang
R
,
Monaghan
M
,
Gillam
LD
,
Swaminathan
M
,
Bonow
RO
,
von Bardeleben
RS
,
Bax
JJ
,
Grayburn
P
,
Zoghbi
WA
,
Sengupta
PP
,
Chandrashekhar
Y
,
Little
SH.
 
Core competencies in echocardiography for imaging structural heart disease interventions: an expert consensus statement
.
JACC Cardiovasc Imaging
2019
;
12
:
2560
2570
.

9

Lancellotti
 
P
,
Magne
J
,
Dulgheru
R
,
Clavel
MA
,
Donal
E
,
Vannan
MA
,
Chambers
J
,
Rosenhek
R
,
Habib
G
,
Lloyd
G
,
Nistri
S
,
Garbi
M
,
Marchetta
S
,
Fattouch
K
,
Coisne
A
,
Montaigne
D
,
Modine
T
,
Davin
L
,
Gach
O
,
Radermecker
M
,
Liu
S
,
Gillam
L
,
Rossi
A
,
Galli
E
,
Ilardi
F
,
Tastet
L
,
Capoulade
R
,
Zilberszac
R
,
Vollema
EM
,
Delgado
V
,
Cosyns
B
,
Lafitte
S
,
Bernard
A
,
Pierard
LA
,
Bax
JJ
,
Pibarot
P
,
Oury
C.
 
Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics
.
JAMA Cardiol
2018
;
3
:
1060
1068
.

10

Lancellotti
 
P
,
Rosenhek
R
,
Pibarot
P
,
Iung
B
,
Otto
CM
,
Tornos
P
,
Donal
E
,
Prendergast
B
,
Magne
J
,
La Canna
G
,
Pierard
LA
,
Maurer
G.
 
ESC Working Group on Valvular Heart Disease position paper–heart valve clinics: organization, structure, and experiences
.
Eur Heart J
2013
;
34
:
1597
1606
.

11

Chambers
 
JB
,
Prendergast
B
,
Iung
B
,
Rosenhek
R
,
Zamorano
JL
,
Pierard
LA
,
Modine
T
,
Falk
V
,
Kappetein
AP
,
Pibarot
P
,
Sundt
T
,
Baumgartner
H
,
Bax
JJ
,
Lancellotti
P.
 
Standards defining a ‘Heart Valve Centre’: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint
.
Eur Heart J
2017
;
38
:
2177
2183
.

12

Badheka
 
AO
,
Patel
NJ
,
Panaich
SS
,
Patel
SV
,
Jhamnani
S
,
Singh
V
,
Pant
S
,
Patel
N
,
Patel
N
,
Arora
S
,
Thakkar
B
,
Manvar
S
,
Dhoble
A
,
Patel
A
,
Savani
C
,
Patel
J
,
Chothani
A
,
Savani
GT
,
Deshmukh
A
,
Grines
CL
,
Curtis
J
,
Mangi
AA
,
Cleman
M
,
Forrest
JK.
 
Effect of hospital volume on outcomes of transcatheter aortic valve implantation
.
Am J Cardiol
2015
;
116
:
587
594
.

13

Nishimura
 
RA
,
O’Gara
PT
,
Bavaria
JE
,
Brindis
RG
,
Carroll
JD
,
Kavinsky
CJ
,
Lindman
BR
,
Linderbaum
JA
,
Little
SH
,
Mack
MJ
,
Mauri
L
,
Miranda
WR
,
Shahian
DM
,
Sundt
TM
3rd.
 
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: a proposal to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
.
J Am Coll Cardiol
2019
;
73
:
2609
2635
.

14

Chhatriwalla
 
AK
,
Vemulapalli
S
,
Szerlip
M
,
Kodali
S
,
Hahn
RT
,
Saxon
JT
,
Mack
MJ
,
Ailawadi
G
,
Rymer
J
,
Manandhar
P
,
Kosinski
AS
,
Sorajja
P.
 
Operator experience and outcomes of transcatheter mitral valve repair in the United States
.
J Am Coll Cardiol
2019
;
74
:
2955
2965
.

15

Timmis
 
A
,
Townsend
N
,
Gale
CP
,
Torbica
A
,
Lettino
M
,
Petersen
SE
,
Mossialos
EA
,
Maggioni
AP
,
Kazakiewicz
D
,
May
HT
,
De Smedt
D
,
Flather
M
,
Zuhlke
L
,
Beltrame
JF
,
Huculeci
R
,
Tavazzi
L
,
Hindricks
G
,
Bax
J
,
Casadei
B
,
Achenbach
S
,
Wright
L
,
Vardas
P
,
European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2019
.
Eur Heart J
2020
;
41
:
12
85
.

16

Vemulapalli
 
S
,
Carroll
JD
,
Mack
MJ
,
Li
Z
,
Dai
D
,
Kosinski
AS
,
Kumbhani
DJ
,
Ruiz
CE
,
Thourani
VH
,
Hanzel
G
,
Gleason
TG
,
Herrmann
HC
,
Brindis
RG
,
Bavaria
JE.
 
Procedural volume and outcomes for transcatheter aortic-valve replacement
.
N Engl J Med
2019
;
380
:
2541
2550
.

17

Mao
 
J
,
Redberg
RF
,
Carroll
JD
,
Marinac-Dabic
D
,
Laschinger
J
,
Thourani
V
,
Mack
M
,
Sedrakyan
A.
 
Association between hospital surgical aortic valve replacement volume and transcatheter aortic valve replacement outcomes
.
JAMA Cardiol
2018
;
3
:
1070
1078
.

18

Bonow
 
RO
,
O’Gara
PT
,
Adams
DH
,
Badhwar
V
,
Bavaria
JE
,
Elmariah
S
,
Hung
JW
,
Lindenfeld
J
,
Morris
A
,
Satpathy
R
,
Whisenant
B
,
Woo
YJ.
 
2019 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: operator and institutional recommendations and requirements for transcatheter mitral valve intervention: a joint report of the American Association for Thoracic Surgery, the American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons
.
J Am Coll Cardiol
2020
;
76
:
96
117
.

19

Garbi
 
M
,
Chambers
J
,
Pierard
L
,
Maisano
F
,
Lancellotti
P.
Heart Valve Specialist Core Syllabus: a learning framework for continuous medical education on valvular heart disease. European Society of Cardiology, 1 June 2021. https://www.escardio.org/Councils/Council-on-Valvular-Heart-Disease/heart-valve-specialist-core-syllabus. Accessed on 20 July 2021.

20

Dreyfus
 
G
,
Windecker
S.
 
How to shape the future of cardiology and cardiac surgery?
 
Eur Heart J
 
2020
;
41
:
3693
3701
.

21

Iung
 
B
,
Delgado
V
,
Lazure
P
,
Murray
S
,
Sirnes
PA
,
Rosenhek
R
,
Price
S
,
Metra
M
,
Carrera
C
,
De Bonis
M
,
Haude
M
,
Hindricks
G
,
Bax
J
,
Vahanian
A.
 
Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study
.
Eur Heart J
2018
;
39
:
1295
1303
.

22

Popescu
 
BA
,
Andrade
MJ
,
Badano
LP
,
Fox
KF
,
Flachskampf
FA
,
Lancellotti
P
,
Varga
A
,
Sicari
R
,
Evangelista
A
,
Nihoyannopoulos
P
,
Zamorano
JL
European Association of E, Document R
Derumeaux
G
,
Kasprzak
JD
,
Roelandt
JR.
 
European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography
.
Eur J Echocardiogr
2009
;
10
:
893
905
.

23

Chambers
 
JB
,
Garbi
M
,
Nieman
K
,
Myerson
S
,
Pierard
LA
,
Habib
G
,
Zamorano
JL
,
Edvardsen
T
,
Lancellotti
P
This document was reviewed by members of the ESDC
Delgado
V
,
Cosyns
B
,
Donal
E
,
Dulgheru
R
,
Galderisi
M
,
Lombardi
M
,
Muraru
D
,
Kauffmann
P
,
Cardim
N
,
Haugaa
K
,
Rosenhek
R.
 
Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a European Association of Cardiovascular Imaging report of literature review and current practice
.
Eur Heart J Cardiovasc Imaging
2017
;
18
:
489
498
.

24

Lancellotti
 
P
,
Tribouilloy
C
,
Hagendorff
A
,
Popescu
BA
,
Edvardsen
T
,
Pierard
LA
,
Badano
L
,
Zamorano
JL
,
Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
2013
;
14
:
611
644
.

25

Baumgartner
 
HC
,
Hung
JC-C
,
Bermejo
J
,
Chambers
JB
,
Edvardsen
T
,
Goldstein
S
,
Lancellotti
P
,
LeFevre
M
,
Miller
F
Jr.
,
Otto
CM.
 
Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography
.
Eur Heart J Cardiovasc Imaging
2017
;
18
:
254
275
.

26

Magne
 
J
,
Cosyns
B
,
Popescu
BA
,
Carstensen
HG
,
Dahl
J
,
Desai
MY
,
Kearney
L
,
Lancellotti
P
,
Marwick
TH
,
Sato
K
,
Takeuchi
M
,
Zito
C
,
Casalta
AC
,
Mohty
D
,
Pierard
L
,
Habib
G
,
Donal
E.
 
Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis: an individual participant data meta-analysis
.
JACC Cardiovasc Imaging
2019
;
12
:
84
92
.

27

Prihadi
 
EA
,
van der Bijl
P
,
Dietz
M
,
Abou
R
,
Vollema
EM
,
Marsan
NA
,
Delgado
V
,
Bax
JJ.
 
Prognostic implications of right ventricular free wall longitudinal strain in patients with significant functional tricuspid regurgitation
.
Circ Cardiovasc Imaging
2019
;
12
:
e008666
.

28

van Rosendael
 
PJ
,
van Wijngaarden
SE
,
Kamperidis
V
,
Kong
WKF
,
Leung
M
,
Ajmone Marsan
N
,
Delgado
V
,
Bax
JJ.
 
Integrated imaging of echocardiography and computed tomography to grade mitral regurgitation severity in patients undergoing transcatheter aortic valve implantation
.
Eur Heart J
2017
;
38
:
2221
2226
.

29

Schulz
 
E
,
Tamm
A
,
Kasper-Konig
W
,
Beiras-Fernandez
A
,
Vahl
CF
,
Munzel
T
,
von Bardeleben
RS.
 
Transapical implantation of a transcatheter aortic valve prosthesis into a mitral annuloplasty ring guided by real-time three-dimensional cardiac computed tomography-fluoroscopy fusion imaging
.
Eur Heart J
2018
;
39
:
327
328
.

30

Henri
 
C
,
Pierard
LA
,
Lancellotti
P
,
Mongeon
FP
,
Pibarot
P
,
Basmadjian
AJ.
 
Exercise testing and stress imaging in valvular heart disease
.
Can J Cardiol
2014
;
30
:
1012
1026
.

31

Picano
 
E
,
Pibarot
P
,
Lancellotti
P
,
Monin
JL
,
Bonow
RO.
 
The emerging role of exercise testing and stress echocardiography in valvular heart disease
.
J Am Coll Cardiol
2009
;
54
:
2251
2260
.

32

Monin
 
JL
,
Quere
JP
,
Monchi
M
,
Petit
H
,
Baleynaud
S
,
Chauvel
C
,
Pop
C
,
Ohlmann
P
,
Lelguen
C
,
Dehant
P
,
Tribouilloy
C
,
Gueret
P.
 
Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics
.
Circulation
2003
;
108
:
319
324
.

33

Bing
 
R
,
Cavalcante
JL
,
Everett
RJ
,
Clavel
MA
,
Newby
DE
,
Dweck
MR.
 
Imaging and impact of myocardial fibrosis in aortic stenosis
.
JACC Cardiovasc Imaging
2019
;
12
:
283
296
.

34

American College of Cardiology Foundation Task Force on Expert Consensus D, Hundley
 
WG
,
Bluemke
DA
,
Finn
JP
,
Flamm
SD
,
Fogel
MA
,
Friedrich
MG
,
Ho
VB
,
Jerosch-Herold
M
,
Kramer
CM
,
Manning
WJ
,
Patel
M
,
Pohost
GM
,
Stillman
AE
,
White
RD
,
Woodard
PK.
,
ACCF/ACR/AHA/NASCI/SCMR
2010
expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol
2010
;
55
:
2614
2662
.

35

Cueff
 
C
,
Serfaty
JM
,
Cimadevilla
C
,
Laissy
JP
,
Himbert
D
,
Tubach
F
,
Duval
X
,
Iung
B
,
Enriquez-Sarano
M
,
Vahanian
A
,
Messika-Zeitoun
D.
 
Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction
.
Heart
2011
;
97
:
721
726
.

36

Clavel
 
MA
,
Messika-Zeitoun
D
,
Pibarot
P
,
Aggarwal
SR
,
Malouf
J
,
Araoz
PA
,
Michelena
HI
,
Cueff
C
,
Larose
E
,
Capoulade
R
,
Vahanian
A
,
Enriquez-Sarano
M.
 
The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study
.
J Am Coll Cardiol
2013
;
62
:
2329
2338
.

37

Pibarot
 
P
,
Magne
J
,
Leipsic
J
,
Cote
N
,
Blanke
P
,
Thourani
VH
,
Hahn
R.
 
Imaging for predicting and assessing prosthesis-patient mismatch after aortic valve replacement
.
JACC Cardiovasc Imaging
2019
;
12
:
149
162
.

38

Pulerwitz
 
TC
,
Khalique
OK
,
Leb
J
,
Hahn
RT
,
Nazif
TM
,
Leon
MB
,
George
I
,
Vahl
TP
,
D’Souza
B
,
Bapat
VN
,
Dumeer
S
,
Kodali
SK
,
Einstein
AJ.
 
Optimizing cardiac CT protocols for comprehensive acquisition prior to percutaneous MV and TV repair/replacement
.
JACC Cardiovasc Imaging
2020
;
13
:
836
850
.

39

San
 
S
,
Ravis
E
,
Tessonier
L
,
Philip
M
,
Cammilleri
S
,
Lavagna
F
,
Norscini
G
,
Arregle
F
,
Martel
H
,
Oliver
L
,
Torras
O
,
Renard
S
,
Ambrosi
P
,
Camoin
L
,
Casalta
AC
,
Hubert
S
,
Casalta
JP
,
Gouriet
F
,
Riberi
A
,
Avierinos
JF
,
Lepidi
H
,
Collart
F
,
Raoult
D
,
Drancourt
M
,
Habib
G.
 
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in infective endocarditis
.
J Am Coll Cardiol
2019
;
74
:
1031
1040
.

40

Habib
 
G
,
Erba
PA
,
Iung
B
,
Donal
E
,
Cosyns
B
,
Laroche
C
,
Popescu
BA
,
Prendergast
B
,
Tornos
P
,
Sadeghpour
A
,
Oliver
L
,
Vaskelyte
JJ
,
Sow
R
,
Axler
O
,
Maggioni
AP
,
Lancellotti
P
,
EURO-ENDO Investigators
.
Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study
.
Eur Heart J
2019
;
40
:
3222
3232
.

41

Clavel
 
MA
,
Tribouilloy
C
,
Vanoverschelde
JL
,
Pizarro
R
,
Suri
RM
,
Szymanski
C
,
Lazam
S
,
Oberti
P
,
Michelena
HI
,
Jaffe
A
,
Enriquez-Sarano
M.
 
Association of B-type natriuretic peptide with survival in patients with degenerative mitral regurgitation
.
J Am Coll Cardiol
2016
;
68
:
1297
1307
.

42

Lindman
 
BR
,
Clavel
MA
,
Abu-Alhayja’a
R
,
Cote
N
,
Dagenais
F
,
Novak
E
,
Voisine
P
,
Poulin
A
,
Arsenault
BJ
,
Desmeules
P
,
Dahou
A
,
Taster
L
,
Aldahoun
K
,
Bosse
Y
,
Mathieu
P
,
Pibarot
P.
 
Multimarker approach to identify patients with higher mortality and rehospitalization rate after surgical aortic valve replacement for aortic stenosis
.
JACC Cardiovasc Interv
2018
;
11
:
2172
2181
.

43

Tastet
 
L
,
Tribouilloy
C
,
Marechaux
S
,
Vollema
EM
,
Delgado
V
,
Salaun
E
,
Shen
M
,
Capoulade
R
,
Clavel
MA
,
Arsenault
M
,
Bedard
E
,
Bernier
M
,
Beaudoin
J
,
Narula
J
,
Lancellotti
P
,
Bax
JJ
,
Genereux
P
,
Pibarot
P.
 
Staging cardiac damage in patients with asymptomatic aortic valve stenosis
.
J Am Coll Cardiol
2019
;
74
:
550
563
.

44

Genereux
 
P
,
Pibarot
P
,
Redfors
B
,
Mack
MJ
,
Makkar
RR
,
Jaber
WA
,
Svensson
LG
,
Kapadia
S
,
Tuzcu
EM
,
Thourani
VH
,
Babaliaros
V
,
Herrmann
HC
,
Szeto
WY
,
Cohen
DJ
,
Lindman
BR
,
McAndrew
T
,
Alu
MC
,
Douglas
PS
,
Hahn
RT
,
Kodali
SK
,
Smith
CR
,
Miller
DC
,
Webb
JG
,
Leon
MB.
 
Staging classification of aortic stenosis based on the extent of cardiac damage
.
Eur Heart J
2017
;
38
:
3351
3358
.

45

Authors/Task Force m
 
Windecker
 
S
,
Kolh
P
,
Alfonso
F
,
Collet
JP
,
Cremer
J
,
Falk
V
,
Filippatos
G
,
Hamm
C
,
Head
SJ
,
Juni
P
,
Kappetein
AP
,
Kastrati
A
,
Knuuti
J
,
Landmesser
U
,
Laufer
G
,
Neumann
FJ
,
Richter
DJ
,
Schauerte
P
,
Sousa Uva
M
,
Stefanini
GG
,
Taggart
DP
,
Torracca
L
,
Valgimigli
M
,
Wijns
W
,
Witkowski
A.
 
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
.
Eur Heart J
2014
;
35
:
2541
2619
.

46

Knuuti
 
J
,
Wijns
W
,
Saraste
A
,
Capodanno
D
,
Barbato
E
,
Funck-Brentano
C
,
Prescott
E
,
Storey
RF
,
Deaton
C
,
Cuisset
T
,
Agewall
S
,
Dickstein
K
,
Edvardsen
T
,
Escaned
J
,
Gersh
BJ
,
Svitil
P
,
Gilard
M
,
Hasdai
D
,
Hatala
R
,
Mahfoud
F
,
Masip
J
,
Muneretto
C
,
Valgimigli
M
,
Achenbach
S
,
Bax
JJ
,
ESC Scientific Document Group
.
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
.
Eur Heart J
2020
;
41
:
407
477
.

47

Scarsini
 
R
,
Pesarini
G
,
Zivelonghi
C
,
Piccoli
A
,
Ferrero
V
,
Lunardi
M
,
Gottin
L
,
Zanetti
C
,
Faggian
G
,
Ribichini
F.
 
Physiologic evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation
.
EuroIntervention
2018
;
13
:
1512
1519
.

48

Scarsini
 
R
,
Pesarini
G
,
Zivelonghi
C
,
Piccoli
A
,
Ferrero
V
,
Lunardi
M
,
Barbierato
M
,
Caprioglio
F
,
Vassanelli
C
,
Ribichini
F.
 
Coronary physiology in patients with severe aortic stenosis: comparison between fractional flow reserve and instantaneous wave-free ratio
.
Int J Cardiol
2017
;
243
:
40
46
.

49

Osnabrugge
 
RL
,
Speir
AM
,
Head
SJ
,
Fonner
CE
,
Fonner
E
,
Kappetein
AP
,
Rich
JB.
 
Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation
.
Eur J Cardiothorac Surg
2014
;
46
:
400
408
; discussion 408.

50

Barili
 
F
,
Pacini
D
,
Capo
A
,
Rasovic
O
,
Grossi
C
,
Alamanni
F
,
Di Bartolomeo
R
,
Parolari
A.
 
Does EuroSCORE II perform better than its original versions? A multicentre validation study
.
Eur Heart J
2013
;
34
:
22
29
.

51

Provenchere
 
S
,
Chevalier
A
,
Ghodbane
W
,
Bouleti
C
,
Montravers
P
,
Longrois
D
,
Iung
B.
 
Is the EuroSCORE II reliable to estimate operative mortality among octogenarians?
 
PLoS One
 
2017
;
12
:
e0187056
.

52

Iung
 
B
,
Laouenan
C
,
Himbert
D
,
Eltchaninoff
H
,
Chevreul
K
,
Donzeau-Gouge
P
,
Fajadet
J
,
Leprince
P
,
Leguerrier
A
,
Lievre
M
,
Prat
A
,
Teiger
E
,
Laskar
M
,
Vahanian
A
,
Gilard
M
,
FRANCE 2 Investigators
.
Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score
.
Heart
2014
;
100
:
1016
1023
.

53

Edwards
 
FH
,
Cohen
DJ
,
O’Brien
SM
,
Peterson
ED
,
Mack
MJ
,
Shahian
DM
,
Grover
FL
,
Tuzcu
EM
,
Thourani
VH
,
Carroll
J
,
Brennan
JM
,
Brindis
RG
,
Rumsfeld
J
,
Holmes
DR
Jr.
,
Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy R. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement
.
JAMA Cardiol
2016
;
1
:
46
52
.

54

Arnold
 
SV
,
Reynolds
MR
,
Lei
Y
,
Magnuson
EA
,
Kirtane
AJ
,
Kodali
SK
,
Zajarias
A
,
Thourani
VH
,
Green
P
,
Rodes-Cabau
J
,
Beohar
N
,
Mack
MJ
,
Leon
MB
,
Cohen
DJ
,
PARTNER Investigators
.
Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial
.
Circulation
2014
;
129
:
2682
2690
.

55

Afilalo
 
J.
 
The Clinical Frailty Scale: Upgrade your eyeball test
.
Circulation
2017
;
135
:
2025
2027
.

56

Kundi
 
H
,
Popma
JJ
,
Reynolds
MR
,
Strom
JB
,
Pinto
DS
,
Valsdottir
LR
,
Shen
C
,
Choi
E
,
Yeh
RW.
 
Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort
.
Eur Heart J
2019
;
40
:
2231
2239
.

57

Hosler
 
QP
,
Maltagliati
AJ
,
Shi
SM
,
Afilalo
J
,
Popma
JJ
,
Khabbaz
KR
,
Laham
RJ
,
Guibone
K
,
Kim
DH.
 
A practical two-stage frailty assessment for older adults undergoing aortic valve replacement
.
J Am Geriatr Soc
2019
;
67
:
2031
2037
.

58

Dent
 
E
,
Martin
FC
,
Bergman
H
,
Woo
J
,
Romero-Ortuno
R
,
Walston
JD.
 
Management of frailty: opportunities, challenges, and future directions
.
Lancet
2019
;
394
:
1376
1386
.

59

Katz
 
S.
 
Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living
.
J Am Geriatr Soc
1983
;
31
:
721
727
.

60

Afilalo
 
J
,
Lauck
S
,
Kim
DH
,
Lefevre
T
,
Piazza
N
,
Lachapelle
K
,
Martucci
G
,
Lamy
A
,
Labinaz
M
,
Peterson
MD
,
Arora
RC
,
Noiseux
N
,
Rassi
A
,
Palacios
IF
,
Genereux
P
,
Lindman
BR
,
Asgar
AW
,
Kim
CA
,
Trnkus
A
,
Morais
JA
,
Langlois
Y
,
Rudski
LG
,
Morin
JF
,
Popma
JJ
,
Webb
JG
,
Perrault
LP.
 
Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study
.
J Am Coll Cardiol
2017
;
70
:
689
700
.

61

Goldfarb
 
M
,
Lauck
S
,
Webb
JG
,
Asgar
AW
,
Perrault
LP
,
Piazza
N
,
Martucci
G
,
Lachapelle
K
,
Noiseux
N
,
Kim
DH
,
Popma
JJ
,
Lefevre
T
,
Labinaz
M
,
Lamy
A
,
Peterson
MD
,
Arora
RC
,
Morais
JA
,
Morin
JF
,
Rudski
LG
,
Afilalo
J.
 
Malnutrition and mortality in frail and non-frail older adults undergoing aortic valve replacement
.
Circulation
2018
;
138
:
2202
2211
.

62

Yanagisawa
 
R
,
Tanaka
M
,
Yashima
F
,
Arai
T
,
Kohno
T
,
Shimizu
H
,
Fukuda
K
,
Naganuma
T
,
Mizutani
K
,
Araki
M
,
Tada
N
,
Yamanaka
F
,
Shirai
S
,
Tabata
M
,
Ueno
H
,
Takagi
K
,
Higashimori
A
,
Watanabe
Y
,
Yamamoto
M
,
Hayashida
K.
 
Frequency and consequences of cognitive impairment in patients underwent transcatheter aortic valve implantation
.
Am J Cardiol
2018
;
122
:
844
850
.

63

Puri
 
R
,
Iung
B
,
Cohen
DJ
,
Rodes-Cabau
J.
 
TAVI or no TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation
.
Eur Heart J
2016
;
37
:
2217
2225
.

64

Gunter
 
RL
,
Kilgo
P
,
Guyton
RA
,
Chen
EP
,
Puskas
JD
,
Cooper
WA
,
Halkos
ME
,
Lattouf
OM
,
Babaliaros
V
,
Myung
R
,
Leshnower
B
,
Thourani
VH.
 
Impact of preoperative chronic lung disease on survival after surgical aortic valve replacement
.
Ann Thorac Surg
2013
;
96
:
1322
1328
.

65

Allende
 
R
,
Webb
JG
,
Munoz-Garcia
AJ
,
de Jaegere
P
,
Tamburino
C
,
Dager
AE
,
Cheema
A
,
Serra
V
,
Amat-Santos
I
,
Velianou
JL
,
Barbanti
M
,
Dvir
D
,
Alonso-Briales
JH
,
Nuis
RJ
,
Faqiri
E
,
Imme
S
,
Benitez
LM
,
Cucalon
AM
,
Al Lawati
H
,
Garcia del Blanco
B
,
Lopez
J
,
Natarajan
MK
,
DeLarochelliere
R
,
Urena
M
,
Ribeiro
HB
,
Dumont
E
,
Nombela-Franco
L
,
Rodes-Cabau
J.
 
Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients
.
Eur Heart J
2014
;
35
:
2685
2696
.

66

Tirado-Conte
 
G
,
Rodes-Cabau
J
,
Rodriguez-Olivares
R
,
Barbanti
M
,
Lhermusier
T
,
Amat-Santos
I
,
Toggweiler
S
,
Cheema
AN
,
Munoz-Garcia
AJ
,
Serra
V
,
Giordana
F
,
Veiga
G
,
Jimenez-Quevedo
P
,
Campelo-Parada
F
,
Loretz
L
,
Todaro
D
,
Del Trigo
M
,
Hernandez-Garcia
JM
,
Garcia Del Blanco
B
,
Bruno
F
,
de la Torre Hernandez
JM
,
Stella
P
,
Tamburino
C
,
Macaya
C
,
Nombela-Franco
L.
 
Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis
.
Circ Cardiovasc Interv
2018
;
11
:
e005727
.

67

Abramowitz
 
Y
,
Kazuno
Y
,
Chakravarty
T
,
Kawamori
H
,
Maeno
Y
,
Anderson
D
,
Allison
Z
,
Mangat
G
,
Cheng
W
,
Gopal
A
,
Jilaihawi
H
,
Mack
MJ
,
Makkar
RR.
 
Concomitant mitral annular calcification and severe aortic stenosis: prevalence, characteristics and outcome following transcatheter aortic valve replacement
.
Eur Heart J
2017
;
38
:
1194
1203
.

68

Lindman
 
BR
,
Arnold
SV
,
Bagur
R
,
Clarke
L
,
Coylewright
M
,
Evans
F
,
Hung
J
,
Lauck
SB
,
Peschin
S
,
Sachdev
V
,
Tate
LM
,
Wasfy
JH
,
Otto
CM.
 
Priorities for patient-centered research in valvular heart disease: a report from the National Heart, Lung, and Blood Institute Working Group
.
J Am Heart Assoc
2020
;
9
:
e015975
.

69

Hejjaji
 
V
,
Cohen
DJ
,
Carroll
JD
,
Li
Z
,
Manandhar
P
,
Vemulapalli
S
,
Nelson
AJ
,
Malik
AO
,
Mack
MJ
,
Spertus
JA
,
Arnold
SV.
 
Practical application of patient-reported health status measures for transcatheter valve therapies: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry
.
Circ Cardiovasc Qual Outcomes
2021
;
14
:
e007187
.

70

Steiner
 
JM
,
Cooper
S
,
Kirkpatrick
JN.
 
Palliative care in end-stage valvular heart disease
.
Heart
2017
;
103
:
1233
1237
.

71

Timmis
 
A
,
Gale
CP
,
Flather
M
,
Maniadakis
N
,
Vardas
P.
 
Cardiovascular disease statistics from the European atlas: inequalities between high- and middle-income member countries of the ESC
.
Eur Heart J Qual Care Clin Outcomes
2018
;
4
:
1
3
.

72

Neumann
 
FJ
,
Sousa-Uva
M
,
Ahlsson
A
,
Alfonso
F
,
Banning
AP
,
Benedetto
U
,
Byrne
RA
,
Collet
JP
,
Falk
V
,
Head
SJ
,
Juni
P
,
Kastrati
A
,
Koller
A
,
Kristensen
SD
,
Niebauer
J
,
Richter
DJ
,
Seferovic
PM
,
Sibbing
D
,
Stefanini
GG
,
Windecker
S
,
Yadav
R
,
Zembala
MO
,
ESC Scientific Document Group
.
2018 ESC/EACTS Guidelines on myocardial revascularization
.
Eur Heart J
2019
;
40
:
87
165
.

73

Mach
 
F
,
Baigent
C
,
Catapano
AL
,
Koskinas
KC
,
Casula
M
,
Badimon
L
,
Chapman
MJ
,
De Backer
GG
,
Delgado
V
,
Ference
BA
,
Graham
IM
,
Halliday
A
,
Landmesser
U
,
Mihaylova
B
,
Pedersen
TR
,
Riccardi
G
,
Richter
DJ
,
Sabatine
MS
,
Taskinen
MR
,
Tokgozoglu
L
,
Wiklund
O
,
ESC Scientific Document Group
.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
.
Eur Heart J
2020
;
41
:
111
188
.

74

Hindricks
 
G
,
Potpara
T
,
Dagres
N
,
Arbelo
E
,
Bax
JJ
,
Blomstrom-Lundqvist
C
,
Boriani
G
,
Castella
M
,
Dan
GA
,
Dilaveris
PE
,
Fauchier
L
,
Filippatos
G
,
Kalman
JM
,
La Meir
M
,
Lane
DA
,
Lebeau
JP
,
Lettino
M
,
Lip
GYH
,
Pinto
FJ
,
Thomas
GN
,
Valgimigli
M
,
Van Gelder
IC
,
Van Putte
BP
,
Watkins
CL
,
ESC Scientific Document Group
.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
.
Eur Heart J
2021
;
42
:
373
498
.

75

Breithardt
 
G
,
Baumgartner
H
,
Berkowitz
SD
,
Hellkamp
AS
,
Piccini
JP
,
Stevens
SR
,
Lokhnygina
Y
,
Patel
MR
,
Halperin
JL
,
Singer
DE
,
Hankey
GJ
,
Hacke
W
,
Becker
RC
,
Nessel
CC
,
Mahaffey
KW
,
Fox
KA
,
Califf
RM
,
Committee RAS, Investigators
.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
.
Eur Heart J
2014
;
35
:
3377
3385
.

76

Avezum
 
A
,
Lopes
RD
,
Schulte
PJ
,
Lanas
F
,
Gersh
BJ
,
Hanna
M
,
Pais
P
,
Erol
C
,
Diaz
R
,
Bahit
MC
,
Bartunek
J
,
De Caterina
R
,
Goto
S
,
Ruzyllo
W
,
Zhu
J
,
Granger
CB
,
Alexander
JH.
 
Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
.
Circulation
2015
;
132
:
624
632
.

77

Ezekowitz
 
MD
,
Nagarakanti
R
,
Noack
H
,
Brueckmann
M
,
Litherland
C
,
Jacobs
M
,
Clemens
A
,
Reilly
PA
,
Connolly
SJ
,
Yusuf
S
,
Wallentin
L.
 
Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)
.
Circulation
2016
;
134
:
589
598
.

78

De Caterina
 
R
,
Renda
G
,
Carnicelli
AP
,
Nordio
F
,
Trevisan
M
,
Mercuri
MF
,
Ruff
CT
,
Antman
EM
,
Braunwald
E
,
Giugliano
RP.
 
Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
.
J Am Coll Cardiol
2017
;
69
:
1372
1382
.

79

Rankin
 
JS
,
Grau-Sepulveda
MV
,
Ad
N
,
Damiano
RJ
Jr.
,
Gillinov
AM
,
Brennan
JM
,
McCarthy
PM
,
Thourani
VH
,
Jacobs
JP
,
Shahian
DM
,
Badhwar
V.
 
Associations between surgical ablation and operative mortality after mitral valve procedures
.
Ann Thorac Surg
2018
;
105
:
1790
1796
.

80

Tsai
 
YC
,
Phan
K
,
Munkholm-Larsen
S
,
Tian
DH
,
La Meir
M
,
Yan
TD
.
Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis
.
Eur J Cardiothorac Surg
2015
;
47
:
847
854
.

81

Martin Gutierrez
 
E
,
Castano
M
,
Gualis
J
,
Martinez-Comendador
JM
,
Maiorano
P
,
Castillo
L
,
Laguna
G.
 
Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients
.
Eur J Cardiothorac Surg
2020
;
57
:
252
262
.

82

Whitlock
 
RP
,
Belley-Cote
EP
,
Paparella
D
,
Healey
JS
,
Brady
K
,
Sharma
M
,
Reents
W
,
Budera
P
,
Baddour
AJ
,
Fila
P
,
Devereaux
PJ
,
Bogachev-Prokophiev
A
,
Boening
A
,
Teoh
KHT
,
Tagarakis
GI
,
Slaughter
MS
,
Royse
AG
,
McGuinness
S
,
Alings
M
,
Punjabi
PP
,
Mazer
CD
,
Folkeringa
RJ
,
Colli
A
,
Avezum
A
,
Nakamya
J
,
Balasubramanian
K
,
Vincent
J
,
Voisine
P
,
Lamy
A
,
Yusuf
S
,
Connolly
SJ
,
LAAOS III Investigators
.
Left atrial appendage occlusion during cardiac surgery to prevent stroke
.
N Engl J Med
2021
;
384
:
2081
2091
.

83

Ruff
 
CT
,
Giugliano
RP
,
Braunwald
E
,
Hoffman
EB
,
Deenadayalu
N
,
Ezekowitz
MD
,
Camm
AJ
,
Weitz
JI
,
Lewis
BS
,
Parkhomenko
A
,
Yamashita
T
,
Antman
EM.
 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
.
Lancet
2014
;
383
:
955
962
.

84

Wang
 
KL
,
Lip
GY
,
Lin
SJ
,
Chiang
CE.
 
Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis
.
Stroke
2015
;
46
:
2555
2561
.

85

Badhwar
 
V
,
Rankin
JS
,
Ad
N
,
Grau-Sepulveda
M
,
Damiano
RJ
,
Gillinov
AM
,
McCarthy
PM
,
Thourani
VH
,
Suri
RM
,
Jacobs
JP
,
Cox
JL.
 
Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes
.
Ann Thorac Surg
2017
;
104
:
493
500
.

86

Gillinov
 
AM
,
Gelijns
AC
,
Parides
MK
,
DeRose
JJ
Jr.
,
Moskowitz
AJ
,
Voisine
P
,
Ailawadi
G
,
Bouchard
D
,
Smith
PK
,
Mack
MJ
,
Acker
MA
,
Mullen
JC
,
Rose
EA
,
Chang
HL
,
Puskas
JD
,
Couderc
JP
,
Gardner
TJ
,
Varghese
R
,
Horvath
KA
,
Bolling
SF
,
Michler
RE
,
Geller
NL
,
Ascheim
DD
,
Miller
MA
,
Bagiella
E
,
Moquete
EG
,
Williams
P
,
Taddei-Peters
WC
,
O’Gara
PT
,
Blackstone
EH
,
Argenziano
M
,
Investigators C
.
Surgical ablation of atrial fibrillation during mitral-valve surgery
.
N Engl J Med
2015
;
372
:
1399
1409
.

87

Huffman
 
MD
,
Karmali
KN
,
Berendsen
MA
,
Andrei
AC
,
Kruse
J
,
McCarthy
PM
,
Malaisrie
SC.
 
Concomitant atrial fibrillation surgery for people undergoing cardiac surgery
.
Cochrane Database Syst Rev
2016
:
CD011814
.

88

Wang
 
H
,
Han
J
,
Wang
Z
,
Yin
Z
,
Liu
Z
,
Jin
Y
,
Han
H.
 
A prospective randomized trial of the cut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve disease
.
J Thorac Cardiovasc Surg
2018
;
155
:
608
617
.

89

Lawrance
 
CP
,
Henn
MC
,
Miller
JR
,
Sinn
LA
,
Schuessler
RB
,
Maniar
HS
,
Damiano
RJ
,
Jr. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay
.
J Thorac Cardiovasc Surg
2014
;
148
:
955
961
.

90

Weimar
 
T
,
Schena
S
,
Bailey
MS
,
Maniar
HS
,
Schuessler
RB
,
Cox
JL
,
Damiano
RJ
,
Jr. The Cox-Maze procedure for lone atrial fibrillation: a single-center experience over 2 decades
.
Circ Arrhythm Electrophysiol
2012
;
5
:
8
14
.

91

Karki
 
P
,
Uranw
S
,
Bastola
S
,
Mahato
R
,
Shrestha
NR
,
Sherpa
K
,
Dhungana
S
,
Odutayo
A
,
Gurung
K
,
Pandey
N
,
Agrawal
K
,
Shah
P
,
Rothenbuhler
M
,
Juni
P
,
Pilgrim
T.
 
Effectiveness of systematic echocardiographic screening for rheumatic heart disease in Nepalese schoolchildren: a cluster randomized clinical trial
.
JAMA Cardiol
2021
;
6
:
420
426
.

92

Gerber
 
MA
,
Baltimore
RS
,
Eaton
CB
,
Gewitz
M
,
Rowley
AH
,
Shulman
ST
,
Taubert
KA.
 
Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics
.
Circulation
2009
;
119
:
1541
1551
.

93

Remenyi
 
B
,
Carapetis
J
,
Wyber
R
,
Taubert
K
,
Mayosi
BM
,
World Heart Federation. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease
.
Nat Rev Cardiol
2013
;
10
:
284
292
.

94

Watkins
 
DA
,
Beaton
AZ
,
Carapetis
JR
,
Karthikeyan
G
,
Mayosi
BM
,
Wyber
R
,
Yacoub
MH
,
Zuhlke
LJ.
 
Rheumatic heart disease worldwide: JACC Scientific Expert Panel
.
J Am Coll Cardiol
2018
;
72
:
1397
1416
.

95

Kumar
 
RK
,
Antunes
MJ
,
Beaton
A
,
Mirabel
M
,
Nkomo
VT
,
Okello
E
,
Regmi
PR
,
Remenyi
B
,
Sliwa-Hahnle
K
,
Zuhlke
LJ
,
Sable
C
,
American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association
.
Circulation
2020
;
142
:
e337
e357
.

96

le Polain de Waroux
 
JB
,
Pouleur
AC
,
Goffinet
C
,
Vancraeynest
D
,
Van Dyck
M
,
Robert
A
,
Gerber
BL
,
Pasquet
A
,
El Khoury
G
,
Vanoverschelde
JL.
 
Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography
.
Circulation
2007
;
116
:
I264
269
.

97

Lansac
 
E
,
Di Centa
I
,
Raoux
F
,
Al Attar
N
,
Acar
C
,
Joudinaud
T
,
Raffoul
R.
 
A lesional classification to standardize surgical management of aortic insufficiency towards valve repair
.
Eur J Cardiothorac Surg
2008
;
33
:
872
878
; discussion 878-880.

98

Lancellotti
 
P
,
Tribouilloy
C
,
Hagendorff
A
,
Moura
L
,
Popescu
BA
,
Agricola
E
,
Monin
JL
,
Pierard
LA
,
Badano
L
,
Zamorano
JL
,
European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease)
.
Eur J Echocardiogr
2010
;
11
:
223
244
.

99

Alashi
 
A
,
Khullar
T
,
Mentias
A
,
Gillinov
AM
,
Roselli
EE
,
Svensson
LG
,
Popovic
ZB
,
Griffin
BP
,
Desai
MY.
 
Long-term outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal strain
.
JACC Cardiovasc Imaging
2020
;
13
:
12
21
.

100

Goldstein
 
SA
,
Evangelista
A
,
Abbara
S
,
Arai
A
,
Asch
FM
,
Badano
LP
,
Bolen
MA
,
Connolly
HM
,
Cuellar-Calabria
H
,
Czerny
M
,
Devereux
RB
,
Erbel
RA
,
Fattori
R
,
Isselbacher
EM
,
Lindsay
JM
,
McCulloch
M
,
Michelena
HI
,
Nienaber
CA
,
Oh
JK
,
Pepi
M
,
Taylor
AJ
,
Weinsaft
JW
,
Zamorano
JL
,
Dietz
H
,
Eagle
K
,
Elefteriades
J
,
Jondeau
G
,
Rousseau
H
,
Schepens
M.
 
Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance
.
J Am Soc Echocardiogr
2015
;
28
:
119
182
.

101

Erbel
 
R
,
Aboyans
V
,
Boileau
C
,
Bossone
E
,
Bartolomeo
RD
,
Eggebrecht
H
,
Evangelista
A
,
Falk
V
,
Frank
H
,
Gaemperli
O
,
Grabenwoger
M
,
Haverich
A
,
Iung
B
,
Manolis
AJ
,
Meijboom
F
,
Nienaber
CA
,
Roffi
M
,
Rousseau
H
,
Sechtem
U
,
Sirnes
PA
,
Allmen
RS
,
Vrints
CJ
,
ESC Committee for Practice Guidelines
.
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC
).
Eur Heart J
2014
;
35
:
2873
2926
.

102

Lang
 
RM
,
Badano
LP
,
Mor-Avi
V
,
Afilalo
J
,
Armstrong
A
,
Ernande
L
,
Flachskampf
FA
,
Foster
E
,
Goldstein
SA
,
Kuznetsova
T
,
Lancellotti
P
,
Muraru
D
,
Picard
MH
,
Rietzschel
ER
,
Rudski
L
,
Spencer
KT
,
Tsang
W
,
Voigt
JU.
 
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
2015
;
16
:
233
270
.

103

Freeman
 
LA
,
Young
PM
,
Foley
TA
,
Williamson
EE
,
Bruce
CJ
,
Greason
KL.
 
CT and MRI assessment of the aortic root and ascending aorta
.
AJR Am J Roentgenol
2013
;
200
:
W581
592
.

104

Amsallem
 
M
,
Ou
P
,
Milleron
O
,
Henry-Feugeas
MC
,
Detaint
D
,
Arnoult
F
,
Vahanian
A
,
Jondeau
G.
 
Comparative assessment of ascending aortic aneurysms in Marfan patients using ECG-gated computerized tomographic angiography versus trans-thoracic echocardiography
.
Int J Cardiol
2015
;
184
:
22
27
.

105

Chaliki
 
HP
,
Mohty
D
,
Avierinos
JF
,
Scott
CG
,
Schaff
HV
,
Tajik
AJ
,
Enriquez-Sarano
M.
 
Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function
.
Circulation
2002
;
106
:
2687
2693
.

106

Kaneko
 
T
,
Ejiofor
JI
,
Neely
RC
,
McGurk
S
,
Ivkovic
V
,
Stevenson
LW
,
Leacche
M
,
Cohn
LH.
 
Aortic regurgitation with markedly reduced left ventricular function is not a contraindication for aortic valve replacement
.
Ann Thorac Surg
2016
;
102
:
41
47
.

107

Tornos
 
P
,
Sambola
A
,
Permanyer-Miralda
G
,
Evangelista
A
,
Gomez
Z
,
Soler-Soler
J.
 
Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery
.
J Am Coll Cardiol
2006
;
47
:
1012
1017
.

108

Dujardin
 
KS
,
Enriquez-Sarano
M
,
Schaff
HV
,
Bailey
KR
,
Seward
JB
,
Tajik
AJ.
 
Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study
.
Circulation
1999
;
99
:
1851
1857
.

109

Klodas
 
E
,
Enriquez-Sarano
M
,
Tajik
AJ
,
Mullany
CJ
,
Bailey
KR
,
Seward
JB.
 
Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms
.
J Am Coll Cardiol
1997
;
30
:
746
752
.

110

Tribouilloy
 
CM
,
Enriquez-Sarano
M
,
Schaff
HV
,
Orszulak
TA
,
Fett
SL
,
Bailey
KR
,
Tajik
AJ
,
Frye
RL.
 
Excess mortality due to coronary artery disease after valve surgery. Secular trends in valvular regurgitation and effect of internal mammary artery bypass
.
Circulation
1998
;
98
:
II108
115
.

111

Fiedler
 
AG
,
Bhambhani
V
,
Laikhter
E
,
Picard
MH
,
Wasfy
MM
,
Tolis
G
,
Melnitchouk
S
,
Sundt
TM
,
Wasfy
JH.
 
Aortic valve replacement associated with survival in severe regurgitation and low ejection fraction
.
Heart
2018
;
104
:
835
840
.

112

Forman
 
R
,
Firth
BG
,
Barnard
MS.
 
Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement
.
Am J Cardiol
1980
;
45
:
1120
1125
.

113

Bonow
 
RO
,
Lakatos
E
,
Maron
BJ
,
Epstein
SE.
 
Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function
.
Circulation
1991
;
84
:
1625
1635
.

114

Bhudia
 
SK
,
McCarthy
PM
,
Kumpati
GS
,
Helou
J
,
Hoercher
KJ
,
Rajeswaran
J
,
Blackstone
EH.
 
Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction
.
J Am Coll Cardiol
2007
;
49
:
1465
1471
.

115

Sambola
 
A
,
Tornos
P
,
Ferreira-Gonzalez
I
,
Evangelista
A.
 
Prognostic value of preoperative indexed end-systolic left ventricle diameter in the outcome after surgery in patients with chronic aortic regurgitation
.
Am Heart J
2008
;
155
:
1114
1120
.

116

Yang
 
LT
,
Michelena
HI
,
Scott
CG
,
Enriquez-Sarano
M
,
Pislaru
SV
,
Schaff
HV
,
Pellikka
PA.
 
Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines
.
J Am Coll Cardiol
2019
;
73
:
1741
1752
.

117

Mentias
 
A
,
Feng
K
,
Alashi
A
,
Rodriguez
LL
,
Gillinov
AM
,
Johnston
DR
,
Sabik
JF
,
Svensson
LG
,
Grimm
RA
,
Griffin
BP
,
Desai
MY.
 
Long-term outcomes in patients with aortic regurgitation and preserved left ventricular ejection fraction
.
J Am Coll Cardiol
2016
;
68
:
2144
2153
.

118

de Meester
 
C
,
Gerber
BL
,
Vancraeynest
D
,
Pouleur
AC
,
Noirhomme
P
,
Pasquet
A
,
de Kerchove
L
,
El Khoury
G
,
Vanoverschelde
JL.
 
Do guideline-based indications result in an outcome penalty for patients with severe aortic regurgitation?
 
JACC Cardiovasc Imaging
 
2019
;
12
:
2126
2138
.

119

Sawaya
 
FJ
,
Deutsch
MA
,
Seiffert
M
,
Yoon
SH
,
Codner
P
,
Wickramarachchi
U
,
Latib
A
,
Petronio
AS
,
Rodes-Cabau
J
,
Taramasso
M
,
Spaziano
M
,
Bosmans
J
,
Biasco
L
,
Mylotte
D
,
Savontaus
M
,
Gheeraert
P
,
Chan
J
,
Jorgensen
TH
,
Sievert
H
,
Mocetti
M
,
Lefevre
T
,
Maisano
F
,
Mangieri
A
,
Hildick-Smith
D
,
Kornowski
R
,
Makkar
R
,
Bleiziffer
S
,
Sondergaard
L
,
De Backer
O.
 
Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an International Registry Study
.
JACC Cardiovasc Interv
2017
;
10
:
1048
1056
.

120

Yoon
 
SH
,
Schmidt
T
,
Bleiziffer
S
,
Schofer
N
,
Fiorina
C
,
Munoz-Garcia
AJ
,
Yzeiraj
E
,
Amat-Santos
IJ
,
Tchetche
D
,
Jung
C
,
Fujita
B
,
Mangieri
A
,
Deutsch
MA
,
Ubben
T
,
Deuschl
F
,
Kuwata
S
,
De Biase
C
,
Williams
T
,
Dhoble
A
,
Kim
WK
,
Ferrari
E
,
Barbanti
M
,
Vollema
EM
,
Miceli
A
,
Giannini
C
,
Attizzani
GF
,
Kong
WKF
,
Gutierrez-Ibanes
E
,
Jimenez Diaz
VA
,
Wijeysundera
HC
,
Kaneko
H
,
Chakravarty
T
,
Makar
M
,
Sievert
H
,
Hengstenberg
C
,
Prendergast
BD
,
Vincent
F
,
Abdel-Wahab
M
,
Nombela-Franco
L
,
Silaschi
M
,
Tarantini
G
,
Butter
C
,
Ensminger
SM
,
Hildick-Smith
D
,
Petronio
AS
,
Yin
WH
,
De Marco
F
,
Testa
L
,
Van Mieghem
NM
,
Whisenant
BK
,
Kuck
KH
,
Colombo
A
,
Kar
S
,
Moris
C
,
Delgado
V
,
Maisano
F
,
Nietlispach
F
,
Mack
MJ
,
Schofer
J
,
Schaefer
U
,
Bax
JJ
,
Frerker
C
,
Latib
A
,
Makkar
RR.
 
Transcatheter aortic valve replacement in pure native aortic valve regurgitation
.
J Am Coll Cardiol
2017
;
70
:
2752
2763
.

121

Jondeau
 
G
,
Detaint
D
,
Tubach
F
,
Arnoult
F
,
Milleron
O
,
Raoux
F
,
Delorme
G
,
Mimoun
L
,
Krapf
L
,
Hamroun
D
,
Beroud
C
,
Roy
C
,
Vahanian
A
,
Boileau
C.
 
Aortic event rate in the Marfan population: a cohort study
.
Circulation
2012
;
125
:
226
232
.

122

Desai
 
MY
,
Kalahasti
V
,
Hutt Centeno
E
,
Chen
K
,
Alashi
A
,
Rivas
CG
,
Roselli
EE
,
Johnston
DR
,
Griffin
BP
,
Svensson
LG.
 
Adult patients with Marfan syndrome and ascending aortic surgery
.
J Am Coll Cardiol
2019
;
73
:
733
734
.

123

Borger
 
MA
,
Preston
M
,
Ivanov
J
,
Fedak
PW
,
Davierwala
P
,
Armstrong
S
,
David
TE.
 
Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease?
 
J Thorac Cardiovasc Surg
 
2004
;
128
:
677
683
.

124

Coady
 
MA
,
Rizzo
JA
,
Hammond
GL
,
Mandapati
D
,
Darr
U
,
Kopf
GS
,
Elefteriades
JA.
 
What is the appropriate size criterion for resection of thoracic aortic aneurysms?
 
J Thorac Cardiovasc Surg
 
1997
;
113
:
476
491
.

125

Davies
 
RR
,
Goldstein
LJ
,
Coady
MA
,
Tittle
SL
,
Rizzo
JA
,
Kopf
GS
,
Elefteriades
JA.
 
Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size
.
Ann Thorac Surg
2002
;
73
:
17
27
.

126

Oliver
 
JM
,
Alonso-Gonzalez
R
,
Gonzalez
AE
,
Gallego
P
,
Sanchez-Recalde
A
,
Cuesta
E
,
Aroca
A
,
Lopez-Sendon
JL.
 
Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta
.
Am J Cardiol
2009
;
104
:
1001
1006
.

127

Michelena
 
HI
,
Khanna
AD
,
Mahoney
D
,
Margaryan
E
,
Topilsky
Y
,
Suri
RM
,
Eidem
B
,
Edwards
WD
,
Sundt
TM
3rd
,
Enriquez-Sarano
M.
 
Incidence of aortic complications in patients with bicuspid aortic valves
.
JAMA
2011
;
306
:
1104
1112
.

128

Tzemos
 
N
,
Therrien
J
,
Yip
J
,
Thanassoulis
G
,
Tremblay
S
,
Jamorski
MT
,
Webb
GD
,
Siu
SC.
 
Outcomes in adults with bicuspid aortic valves
.
JAMA
2008
;
300
:
1317
1325
.

129

Elefteriades
 
JA.
 
Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks
.
Ann Thorac Surg
2002
;
74
:
S1877
1880
.

130

Jondeau
 
G
,
Ropers
J
,
Regalado
E
,
Braverman
A
,
Evangelista
A
,
Teixedo
G
,
De Backer
J
,
Muino-Mosquera
L
,
Naudion
S
,
Zordan
C
,
Morisaki
T
,
Morisaki
H
,
Von Kodolitsch
Y
,
Dupuis-Girod
S
,
Morris
SA
,
Jeremy
R
,
Odent
S
,
Ades
LC
,
Bakshi
M
,
Holman
K
,
LeMaire
S
,
Milleron
O
,
Langeois
M
,
Spentchian
M
,
Aubart
M
,
Boileau
C
,
Pyeritz
R
,
Milewicz
DM
,
Montalcino Aortic Consortium. International Registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium
).
Circ Cardiovasc Genet
2016
;
9
:
548
558
.

131

Aicher
 
D
,
Fries
R
,
Rodionycheva
S
,
Schmidt
K
,
Langer
F
,
Schafers
HJ.
 
Aortic valve repair leads to a low incidence of valve-related complications
.
Eur J Cardiothorac Surg
2010
;
37
:
127
132
.

132

de Meester
 
C
,
Pasquet
A
,
Gerber
BL
,
Vancraeynest
D
,
Noirhomme
P
,
El Khoury
G
,
Vanoverschelde
JL.
 
Valve repair improves the outcome of surgery for chronic severe aortic regurgitation: a propensity score analysis
.
J Thorac Cardiovasc Surg
2014
;
148
:
1913
1920
.

133

Klotz
 
S
,
Stock
S
,
Sievers
HH
,
Diwoky
M
,
Petersen
M
,
Stierle
U
,
Richardt
D.
 
Survival and reoperation pattern after 20 years of experience with aortic valve-sparing root replacement in patients with tricuspid and bicuspid valves
.
J Thorac Cardiovasc Surg
2018
;
155
:
1403
1411 e1401
.

134

Elbatarny
 
M
,
Tam
DY
,
Edelman
JJ
,
Rocha
RV
,
Chu
MWA
,
Peterson
MD
,
El-Hamamsy
I
,
Appoo
JJ
,
Friedrich
JO
,
Boodhwani
M
,
Yanagawa
B
,
Ouzounian
M
,
Canadian Thoracic Aortic Collaborative Investigators
.
Valve-sparing root replacement versus composite valve grafting in aortic root dilation: a meta-analysis
.
Ann Thorac Surg
2020
;
110
:
296
306
.

135

Leontyev
 
S
,
Schamberger
L
,
Davierwala
PM
,
Von Aspern
K
,
Etz
C
,
Lehmann
S
,
Misfeld
M
,
Borger
MA.
 
Early and late results after David vs Bentall procedure: a propensity matched analysis
.
Ann Thorac Surg
2020
;
110
:
120
126
.

136

Mastrobuoni
 
S
,
de Kerchove
L
,
Navarra
E
,
Watremez
C
,
Vancraeynest
D
,
Rubay
J
,
Noirhomme
P
,
El Khoury
G.
 
Long-term experience with valve-sparing reimplantation technique for the treatment of aortic aneurysm and aortic regurgitation
.
J Thorac Cardiovasc Surg
2019
;
158
:
14
23
.

137

Lansac
 
E
,
Di Centa
I
,
Sleilaty
G
,
Lejeune
S
,
Khelil
N
,
Berrebi
A
,
Diakov
C
,
Mankoubi
L
,
Malergue
MC
,
Noghin
M
,
Zannis
K
,
Salvi
S
,
Dervanian
P
,
Debauchez
M.
 
Long-term results of external aortic ring annuloplasty for aortic valve repair
.
Eur J Cardiothorac Surg
2016
;
50
:
350
360
.

138

Mazine
 
A
,
Rocha
RV
,
El-Hamamsy
I
,
Ouzounian
M
,
Yanagawa
B
,
Bhatt
DL
,
Verma
S
,
Friedrich
JO.
 
Ross procedure vs mechanical aortic valve replacement in adults: a systematic review and meta-analysis
.
JAMA Cardiol
2018
;
3
:
978
987
.

139

Takkenberg
 
JJ
,
Klieverik
LM
,
Schoof
PH
,
van Suylen
RJ
,
van Herwerden
LA
,
Zondervan
PE
,
Roos-Hesselink
JW
,
Eijkemans
MJ
,
Yacoub
MH
,
Bogers
AJ.
 
The Ross procedure: a systematic review and meta-analysis
.
Circulation
2009
;
119
:
222
228
.

140

Lee
 
H
,
Cho
YH
,
Sung
K
,
Kim
WS
,
Park
KH
,
Jeong
DS
,
Park
PW
,
Lee
YT.
 
Clinical outcomes of root reimplantation and Bentall procedure: propensity score matching analysis
.
Ann Thorac Surg
2018
;
106
:
539
547
.

141

Elder
 
DH
,
Wei
L
,
Szwejkowski
BR
,
Libianto
R
,
Nadir
A
,
Pauriah
M
,
Rekhraj
S
,
Lim
TK
,
George
J
,
Doney
A
,
Pringle
SD
,
Choy
AM
,
Struthers
AD
,
Lang
CC.
 
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study
.
J Am Coll Cardiol
2011
;
58
:
2084
2091
.

142

Seferovic
 
PM
,
Ponikowski
P
,
Anker
SD
,
Bauersachs
J
,
Chioncel
O
,
Cleland
JGF
,
de Boer
RA
,
Drexel
H
,
Ben Gal
T
,
Hill
L
,
Jaarsma
T
,
Jankowska
EA
,
Anker
MS
,
Lainscak
M
,
Lewis
BS
,
McDonagh
T
,
Metra
M
,
Milicic
D
,
Mullens
W
,
Piepoli
MF
,
Rosano
G
,
Ruschitzka
F
,
Volterrani
M
,
Voors
AA
,
Filippatos
G
,
Coats
AJS.
 
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
.
Eur J Heart Fail
2019
;
21
:
1169
1186
.

143

Lacro
 
RV
,
Dietz
HC
,
Sleeper
LA
,
Yetman
AT
,
Bradley
TJ
,
Colan
SD
,
Pearson
GD
,
Selamet Tierney
ES
,
Levine
JC
,
Atz
AM
,
Benson
DW
,
Braverman
AC
,
Chen
S
,
De Backer
J
,
Gelb
BD
,
Grossfeld
PD
,
Klein
GL
,
Lai
WW
,
Liou
A
,
Loeys
BL
,
Markham
LW
,
Olson
AK
,
Paridon
SM
,
Pemberton
VL
,
Pierpont
ME
,
Pyeritz
RE
,
Radojewski
E
,
Roman
MJ
,
Sharkey
AM
,
Stylianou
MP
,
Wechsler
SB
,
Young
LT
,
Mahony
L
,
Pediatric Heart Network Investigators
.
Atenolol versus losartan in children and young adults with Marfan’s syndrome
.
N Engl J Med
2014
;
371
:
2061
2071
.

144

Forteza
 
A
,
Evangelista
A
,
Sanchez
V
,
Teixido-Tura
G
,
Sanz
P
,
Gutierrez
L
,
Gracia
T
,
Centeno
J
,
Rodriguez-Palomares
J
,
Rufilanchas
JJ
,
Cortina
J
,
Ferreira-Gonzalez
I
,
Garcia-Dorado
D.
 
Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial
.
Eur Heart J
2016
;
37
:
978
985
.

145

Brooke
 
BS
,
Habashi
JP
,
Judge
DP
,
Patel
N
,
Loeys
B
,
Dietz
HC
3rd.
 
Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome
.
N Engl J Med
2008
;
358
:
2787
2795
.

146

Milleron
 
O
,
Arnoult
F
,
Ropers
J
,
Aegerter
P
,
Detaint
D
,
Delorme
G
,
Attias
D
,
Tubach
F
,
Dupuis-Girod
S
,
Plauchu
H
,
Barthelet
M
,
Sassolas
F
,
Pangaud
N
,
Naudion
S
,
Thomas-Chabaneix
J
,
Dulac
Y
,
Edouard
T
,
Wolf
JE
,
Faivre
L
,
Odent
S
,
Basquin
A
,
Habib
G
,
Collignon
P
,
Boileau
C
,
Jondeau
G
 
Marfan Sartan: a randomized, double-blind, placebo-controlled trial
.
Eur Heart J
2015
;
36
:
2160
2166
.

147

Groenink
 
M
,
den Hartog
AW
,
Franken
R
,
Radonic
T
,
de Waard
V
,
Timmermans
J
,
Scholte
AJ
,
van den Berg
MP
,
Spijkerboer
AM
,
Marquering
HA
,
Zwinderman
AH
,
Mulder
BJ.
 
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial
.
Eur Heart J
2013
;
34
:
3491
3500
.

148

Mullen
 
M
,
Jin
XY
,
Child
A
,
Stuart
AG
,
Dodd
M
,
Aragon-Martin
JA
,
Gaze
D
,
Kiotsekoglou
A
,
Yuan
L
,
Hu
J
,
Foley
C
,
Van Dyck
L
,
Knight
R
,
Clayton
T
,
Swan
L
,
Thomson
JDR
,
Erdem
G
,
Crossman
D
,
Flather
M
,
AIMS Investigators
.
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
.
Lancet
2020
;
394
:
2263
2270
.

149

Pizarro
 
R
,
Bazzino
OO
,
Oberti
PF
,
Falconi
ML
,
Arias
AM
,
Krauss
JG
,
Cagide
AM.
 
Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation
.
J Am Coll Cardiol
2011
;
58
:
1705
1714
.

150

Weisenberg
 
D
,
Omelchenko
A
,
Shapira
Y
,
Vaturi
M
,
Monakier
D
,
Bental
T
,
Sagie
A.
 
Mid-term echocardiographic progression of patients with moderate aortic regurgitation: implications for aortic valve surgery
.
J Heart Valve Dis
2013
;
22
:
192
194
.

151

Budts
 
W
,
Pieles
GE
,
Roos-Hesselink
JW
,
Sanz de la Garza
M
,
D’Ascenzi
F
,
Giannakoulas
G
,
Muller
J
,
Oberhoffer
R
,
Ehringer-Schetitska
D
,
Herceg-Cavrak
V
,
Gabriel
H
,
Corrado
D
,
van Buuren
F
,
Niebauer
J
,
Borjesson
M
,
Caselli
S
,
Fritsch
P
,
Pelliccia
A
,
Heidbuchel
H
,
Sharma
S
,
Stuart
AG
,
Papadakis
M.
 
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and Prevention Working Group of the Association for European Paediatric and Congenital Cardiology (AEPC
).
Eur Heart J
2020
;
41
:
4191
4199
.

152

d’Arcy
 
JL
,
Coffey
S
,
Loudon
MA
,
Kennedy
A
,
Pearson-Stuttard
J
,
Birks
J
,
Frangou
E
,
Farmer
AJ
,
Mant
D
,
Wilson
J
,
Myerson
SG
,
Prendergast
BD.
 
Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study
.
Eur Heart J
2016
;
37
:
3515
3522
.

153

Prihadi
 
EA
,
Vollema
EM
,
Ng
ACT
,
Ajmone Marsan
N
,
Bax
JJ
,
Delgado
V.
 
Determinants and prognostic implications of left ventricular mechanical dispersion in aortic stenosis
.
Eur Heart J Cardiovasc Imaging
2019
;
20
:
740
748
.

154

Ilardi
 
F
,
Marchetta
S
,
Martinez
C
,
Sprynger
M
,
Ancion
A
,
Manganaro
R
,
Sugimoto
T
,
Tsugu
T
,
Postolache
A
,
Piette
C
,
Cicenia
M
,
Esposito
G
,
Galderisi
M
,
Oury
C
,
Dulgheru
R
,
Lancellotti
P.
 
Impact of aortic stenosis on layer-specific longitudinal strain: relationship with symptoms and outcome
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
408
416
.

155

Rusinaru
 
D
,
Bohbot
Y
,
Djelaili
F
,
Delpierre
Q
,
Altes
A
,
Serbout
S
,
Kubala
M
,
Marechaux
S
,
Tribouilloy
C.
 
Normative reference values of cardiac output by pulsed-wave Doppler echocardiography in adults
.
Am J Cardiol
2021
;
140
:
128
133
.

156

Rusinaru
 
D
,
Malaquin
D
,
Marechaux
S
,
Debry
N
,
Tribouilloy
C.
 
Relation of dimensionless index to long-term outcome in aortic stenosis with preserved LVEF
.
JACC Cardiovasc Imaging
2015
;
8
:
766
775
.

157

Hachicha
 
Z
,
Dumesnil
JG
,
Bogaty
P
,
Pibarot
P.
 
Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival
.
Circulation
2007
;
115
:
2856
2864
.

158

Rusinaru
 
D
,
Bohbot
Y
,
Ringle
A
,
Marechaux
S
,
Diouf
M
,
Tribouilloy
C.
 
Impact of low stroke volume on mortality in patients with severe aortic stenosis and preserved left ventricular ejection fraction
.
Eur Heart J
2018
;
39
:
1992
1999
.

159

Guzzetti
 
E
,
Poulin
A
,
Annabi
MS
,
Zhang
B
,
Kalavrouziotis
D
,
Couture
C
,
Dagenais
F
,
Pibarot
P
,
Clavel
MA.
 
Transvalvular flow, sex, and survival after valve replacement surgery in patients with severe aortic stenosis
.
J Am Coll Cardiol
2020
;
75
:
1897
1909
.

160

Annabi
 
MS
,
Touboul
E
,
Dahou
A
,
Burwash
IG
,
Bergler-Klein
J
,
Enriquez-Sarano
M
,
Orwat
S
,
Baumgartner
H
,
Mascherbauer
J
,
Mundigler
G
,
Cavalcante
JL
,
Larose
E
,
Pibarot
P
,
Clavel
MA.
 
Dobutamine stress echocardiography for management of low-flow, low-gradient aortic stenosis
.
J Am Coll Cardiol
2018
;
71
:
475
485
.

161

Ribeiro
 
HB
,
Lerakis
S
,
Gilard
M
,
Cavalcante
JL
,
Makkar
R
,
Herrmann
HC
,
Windecker
S
,
Enriquez-Sarano
M
,
Cheema
AN
,
Nombela-Franco
L
,
Amat-Santos
I
,
Munoz-Garcia
AJ
,
Garcia Del Blanco
B
,
Zajarias
A
,
Lisko
JC
,
Hayek
S
,
Babaliaros
V
,
Le Ven
F
,
Gleason
TG
,
Chakravarty
T
,
Szeto
WY
,
Clavel
MA
,
de Agustin
A
,
Serra
V
,
Schindler
JT
,
Dahou
A
,
Puri
R
,
Pelletier-Beaumont
E
,
Cote
M
,
Pibarot
P
,
Rodes-Cabau
J.
 
Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: the TOPAS-TAVI Registry
.
J Am Coll Cardiol
2018
;
71
:
1297
1308
.

162

Clavel
 
MA
,
Dumesnil
JG
,
Capoulade
R
,
Mathieu
P
,
Senechal
M
,
Pibarot
P.
 
Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction
.
J Am Coll Cardiol
2012
;
60
:
1259
1267
.

163

Clavel
 
MA
,
Pibarot
P
,
Messika-Zeitoun
D
,
Capoulade
R
,
Malouf
J
,
Aggarval
S
,
Araoz
PA
,
Michelena
HI
,
Cueff
C
,
Larose
E
,
Miller
JD
,
Vahanian
A
,
Enriquez-Sarano
M.
 
Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study
.
J Am Coll Cardiol
2014
;
64
:
1202
1213
.

164

Pawade
 
T
,
Clavel
MA
,
Tribouilloy
C
,
Dreyfus
J
,
Mathieu
T
,
Tastet
L
,
Renard
C
,
Gun
M
,
Jenkins
WSA
,
Macron
L
,
Sechrist
JW
,
Lacomis
JM
,
Nguyen
V
,
Galian Gay
L
,
Cuellar Calabria
H
,
Ntalas
I
,
Cartlidge
TRG
,
Prendergast
B
,
Rajani
R
,
Evangelista
A
,
Cavalcante
JL
,
Newby
DE
,
Pibarot
P
,
Messika Zeitoun
D
,
Dweck
MR.
 
Computed tomography aortic valve calcium scoring in patients with aortic stenosis
.
Circ Cardiovasc Imaging
2018
;
11
:
e007146
.

165

Mehrotra
 
P
,
Jansen
K
,
Flynn
AW
,
Tan
TC
,
Elmariah
S
,
Picard
MH
,
Hung
J.
 
Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis
.
Eur Heart J
2013
;
34
:
1906
1914
.

166

Tribouilloy
 
C
,
Rusinaru
D
,
Marechaux
S
,
Castel
AL
,
Debry
N
,
Maizel
J
,
Mentaverri
R
,
Kamel
S
,
Slama
M
,
Levy
F.
 
Low-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection fraction: characteristics, outcome, and implications for surgery
.
J Am Coll Cardiol
2015
;
65
:
55
66
.

167

Jander
 
N
,
Minners
J
,
Holme
I
,
Gerdts
E
,
Boman
K
,
Brudi
P
,
Chambers
JB
,
Egstrup
K
,
Kesaniemi
YA
,
Malbecq
W
,
Nienaber
CA
,
Ray
S
,
Rossebo
A
,
Pedersen
TR
,
Skjaerpe
T
,
Willenheimer
R
,
Wachtell
K
,
Neumann
FJ
,
Gohlke-Barwolf C. Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction
.
Circulation
2011
;
123
:
887
895
.

168

Vollema
 
EM
,
Sugimoto
T
,
Shen
M
,
Tastet
L
,
Ng
ACT
,
Abou
R
,
Marsan
NA
,
Mertens
B
,
Dulgheru
R
,
Lancellotti
P
,
Clavel
MA
,
Pibarot
P
,
Genereux
P
,
Leon
MB
,
Delgado
V
,
Bax
JJ.
 
Association of left ventricular global longitudinal strain with asymptomatic severe aortic stenosis: natural course and prognostic value
.
JAMA Cardiol
2018
;
3
:
839
847
.

169

Zamorano
 
JL
,
Badano
LP
,
Bruce
C
,
Chan
KL
,
Goncalves
A
,
Hahn
RT
,
Keane
MG
,
La Canna
G
,
Monaghan
MJ
,
Nihoyannopoulos
P
,
Silvestry
FE
,
Vanoverschelde
JL
,
Gillam
LD.
 
EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease
.
Eur Heart J
2011
;
32
:
2189
2214
.

170

Bergler-Klein
 
J
,
Klaar
U
,
Heger
M
,
Rosenhek
R
,
Mundigler
G
,
Gabriel
H
,
Binder
T
,
Pacher
R
,
Maurer
G
,
Baumgartner
H.
 
Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis
.
Circulation
2004
;
109
:
2302
2308
.

171

Clavel
 
MA
,
Malouf
J
,
Michelena
HI
,
Suri
RM
,
Jaffe
AS
,
Mahoney
DW
,
Enriquez-Sarano
M.
 
B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival
.
J Am Coll Cardiol
2014
;
63
:
2016
2025
.

172

Rafique
 
AM
,
Biner
S
,
Ray
I
,
Forrester
JS
,
Tolstrup
K
,
Siegel
RJ.
 
Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis
.
Am J Cardiol
2009
;
104
:
972
977
.

173

Marechaux
 
S
,
Hachicha
Z
,
Bellouin
A
,
Dumesnil
JG
,
Meimoun
P
,
Pasquet
A
,
Bergeron
S
,
Arsenault
M
,
Le Tourneau
T
,
Ennezat
PV
,
Pibarot
P.
 
Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis
.
Eur Heart J
2010
;
31
:
1390
1397
.

174

Pawade
 
T
,
Sheth
T
,
Guzzetti
E
,
Dweck
MR
,
Clavel
MA.
 
Why and how to measure aortic valve calcification in patients with aortic stenosis
.
JACC Cardiovasc Imaging
2019
;
12
:
1835
1848
.

175

Nitsche
 
C
,
Scully
PR
,
Patel
KP
,
Kammerlander
AA
,
Koschutnik
M
,
Dona
C
,
Wollenweber
T
,
Ahmed
N
,
Thornton
GD
,
Kelion
AD
,
Sabharwal
N
,
Newton
JD
,
Ozkor
M
,
Kennon
S
,
Mullen
M
,
Lloyd
G
,
Fontana
M
,
Hawkins
PN
,
Pugliese
F
,
Menezes
LJ
,
Moon
JC
,
Mascherbauer
J
,
Treibel
TA.
 
Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis
.
J Am Coll Cardiol
2021
;
77
:
128
139
.

176

Treibel
 
TA
,
Lopez
B
,
Gonzalez
A
,
Menacho
K
,
Schofield
RS
,
Ravassa
S
,
Fontana
M
,
White
SK
,
DiSalvo
C
,
Roberts
N
,
Ashworth
MT
,
Diez
J
,
Moon
JC.
 
Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients
.
Eur Heart J
2018
;
39
:
699
709
.

177

Everett
 
RJ
,
Tastet
L
,
Clavel
MA
,
Chin
CWL
,
Capoulade
R
,
Vassiliou
VS
,
Kwiecinski
J
,
Gomez
M
,
van Beek
EJR
,
White
AC
,
Prasad
SK
,
Larose
E
,
Tuck
C
,
Semple
S
,
Newby
DE
,
Pibarot
P
,
Dweck
MR.
 
Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study
.
Circ Cardiovasc Imaging
2018
;
11
:
e007451
.

178

Musa
 
TA
,
Treibel
TA
,
Vassiliou
VS
,
Captur
G
,
Singh
A
,
Chin
C
,
Dobson
LE
,
Pica
S
,
Loudon
M
,
Malley
T
,
Rigolli
M
,
Foley
JRJ
,
Bijsterveld
P
,
Law
GR
,
Dweck
MR
,
Myerson
SG
,
McCann
GP
,
Prasad
SK
,
Moon
JC
,
Greenwood
JP.
 
Myocardial scar and mortality in severe aortic stenosis
.
Circulation
2018
;
138
:
1935
1947
.

179

Ternacle
 
J
,
Krapf
L
,
Mohty
D
,
Magne
J
,
Nguyen
A
,
Galat
A
,
Gallet
R
,
Teiger
E
,
Cote
N
,
Clavel
MA
,
Tournoux
F
,
Pibarot
P
,
Damy
T.
 
Aortic stenosis and cardiac amyloidosis: JACC Review Topic of the Week
.
J Am Coll Cardiol
2019
;
74
:
2638
2651
.

180

Tribouilloy
 
C
,
Levy
F
,
Rusinaru
D
,
Gueret
P
,
Petit-Eisenmann
H
,
Baleynaud
S
,
Jobic
Y
,
Adams
C
,
Lelong
B
,
Pasquet
A
,
Chauvel
C
,
Metz
D
,
Quere
JP
,
Monin
JL.
 
Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography
.
J Am Coll Cardiol
2009
;
53
:
1865
1873
.

181

Fougeres
 
E
,
Tribouilloy
C
,
Monchi
M
,
Petit-Eisenmann
H
,
Baleynaud
S
,
Pasquet
A
,
Chauvel
C
,
Metz
D
,
Adams
C
,
Rusinaru
D
,
Gueret
P
,
Monin
JL.
 
Outcomes of pseudo-severe aortic stenosis under conservative treatment
.
Eur Heart J
2012
;
33
:
2426
2433
.

182

Levy
 
F
,
Laurent
M
,
Monin
JL
,
Maillet
JM
,
Pasquet
A
,
Le Tourneau
T
,
Petit-Eisenmann
H
,
Gori
M
,
Jobic
Y
,
Bauer
F
,
Chauvel
C
,
Leguerrier
A
,
Tribouilloy
C.
 
Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study
.
J Am Coll Cardiol
2008
;
51
:
1466
1472
.

183

Sato
 
K
,
Sankaramangalam
K
,
Kandregula
K
,
Bullen
JA
,
Kapadia
SR
,
Krishnaswamy
A
,
Mick
S
,
Rodriguez
LL
,
Grimm
RA
,
Menon
V
,
Desai
MY
,
Svensson
LG
,
Griffin
BP
,
Popovic
ZB.
 
Contemporary outcomes in low-gradient aortic stenosis patients who underwent dobutamine stress echocardiography
.
J Am Heart Assoc
2019
;
8
:
e011168
.

184

Maes
 
F
,
Lerakis
S
,
Barbosa Ribeiro
H
,
Gilard
M
,
Cavalcante
JL
,
Makkar
R
,
Herrmann
HC
,
Windecker
S
,
Enriquez-Sarano
M
,
Cheema
AN
,
Nombela-Franco
L
,
Amat-Santos
I
,
Munoz-Garcia
AJ
,
Garcia Del Blanco
B
,
Zajarias
A
,
Lisko
JC
,
Hayek
S
,
Babaliaros
V
,
Le Ven
F
,
Gleason
TG
,
Chakravarty
T
,
Szeto
W
,
Clavel
MA
,
de Agustin
A
,
Serra
V
,
Schindler
JT
,
Dahou
A
,
Salah-Annabi
M
,
Pelletier-Beaumont
E
,
Cote
M
,
Puri
R
,
Pibarot
P
,
Rodes-Cabau
J.
 
Outcomes from transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy from the TOPAS-TAVI Registry
.
JAMA Cardiol
2019
;
4
:
64
70
.

185

Chadha
 
G
,
Bohbot
Y
,
Rusinaru
D
,
Marechaux
S
,
Tribouilloy
C.
 
Outcome of normal-flow low-gradient severe aortic stenosis with preserved left ventricular ejection fraction: a propensity-matched study
.
J Am Heart Assoc
2019
;
8
:
e012301
.

186

Das
 
P
,
Rimington
H
,
Chambers
J.
 
Exercise testing to stratify risk in aortic stenosis
.
Eur Heart J
2005
;
26
:
1309
1313
.

187

Genereux
 
P
,
Stone
GW
,
O’Gara
PT
,
Marquis-Gravel
G
,
Redfors
B
,
Giustino
G
,
Pibarot
P
,
Bax
JJ
,
Bonow
RO
,
Leon
MB.
 
Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis
.
J Am Coll Cardiol
2016
;
67
:
2263
2288
.

188

Kang
 
DH
,
Park
SJ
,
Lee
SA
,
Lee
S
,
Kim
DH
,
Kim
HK
,
Yun
SC
,
Hong
GR
,
Song
JM
,
Chung
CH
,
Song
JK
,
Lee
JW
,
Park
SW.
 
Early surgery or conservative care for asymptomatic aortic stenosis
.
N Engl J Med
2020
;
382
:
111
119
.

189

Rosenhek
 
R
,
Binder
T
,
Porenta
G
,
Lang
I
,
Christ
G
,
Schemper
M
,
Maurer
G
,
Baumgartner
H.
 
Predictors of outcome in severe, asymptomatic aortic stenosis
.
N Engl J Med
2000
;
343
:
611
617
.

190

Rosenhek
 
R
,
Zilberszac
R
,
Schemper
M
,
Czerny
M
,
Mundigler
G
,
Graf
S
,
Bergler-Klein
J
,
Grimm
M
,
Gabriel
H
,
Maurer
G.
 
Natural history of very severe aortic stenosis
.
Circulation
2010
;
121
:
151
156
.

191

Cioffi
 
G
,
Faggiano
P
,
Vizzardi
E
,
Tarantini
L
,
Cramariuc
D
,
Gerdts
E
,
de Simone
G.
 
Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis
.
Heart
2011
;
97
:
301
307
.

192

Rusinaru
 
D
,
Bohbot
Y
,
Kowalski
C
,
Ringle
A
,
Marechaux
S
,
Tribouilloy
C.
 
Left atrial volume and mortality in patients with aortic stenosis
.
J Am Heart Assoc
2017
;
6
:
e006615
.

193

Dahl
 
JS
,
Videbaek
L
,
Poulsen
MK
,
Rudbaek
TR
,
Pellikka
PA
,
Moller
JE.
 
Global strain in severe aortic valve stenosis: relation to clinical outcome after aortic valve replacement
.
Circ Cardiovasc Imaging
2012
;
5
:
613
620
.

194

Chin
 
CW
,
Shah
AS
,
McAllister
DA
,
Joanna Cowell
S
,
Alam
S
,
Langrish
JP
,
Strachan
FE
,
Hunter
AL
,
Maria Choy
A
,
Lang
CC
,
Walker
S
,
Boon
NA
,
Newby
DE
,
Mills
NL
,
Dweck
MR.
 
High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis
.
Eur Heart J
2014
;
35
:
2312
2321
.

195

Koos
 
R
,
Brandenburg
V
,
Mahnken
AH
,
Muhlenbruch
G
,
Stanzel
S
,
Gunther
RW
,
Floege
J
,
Jahnen-Dechent
W
,
Kelm
M
,
Kuhl
HP.
 
Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients
.
Eur Heart J
2009
;
30
:
2054
2061
.

196

Carroll
 
JD
,
Mack
MJ
,
Vemulapalli
S
,
Herrmann
HC
,
Gleason
TG
,
Hanzel
G
,
Deeb
GM
,
Thourani
VH
,
Cohen
DJ
,
Desai
N
,
Kirtane
AJ
,
Fitzgerald
S
,
Michaels
J
,
Krohn
C
,
Masoudi
FA
,
Brindis
RG
,
Bavaria
JE.
 
STS-ACC TVT Registry of transcatheter aortic valve replacement
.
J Am Coll Cardiol
2020
;
76
:
2492
2516
.

197

Leon
 
MB
,
Smith
CR
,
Mack
M
,
Miller
DC
,
Moses
JW
,
Svensson
LG
,
Tuzcu
EM
,
Webb
JG
,
Fontana
GP
,
Makkar
RR
,
Brown
DL
,
Block
PC
,
Guyton
RA
,
Pichard
AD
,
Bavaria
JE
,
Herrmann
HC
,
Douglas
PS
,
Petersen
JL
,
Akin
JJ
,
Anderson
WN
,
Wang
D
,
Pocock
S
,
PARTNER Trial Investigators
.
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery
.
N Engl J Med
2010
;
363
:
1597
1607
.

198

Deeb
 
GM
,
Reardon
MJ
,
Chetcuti
S
,
Patel
HJ
,
Grossman
PM
,
Yakubov
SJ
,
Kleiman
NS
,
Coselli
JS
,
Gleason
TG
,
Lee
JS
,
Hermiller
JB
Jr.
,
Heiser
J
,
Merhi
W
,
Zorn
GL
3rd
,
Tadros
P
,
Robinson
N
,
Petrossian
G
,
Hughes
GC
,
Harrison
JK
,
Maini
B
,
Mumtaz
M
,
Conte
J
,
Resar
J
,
Aharonian
V
,
Pfeffer
T
,
Oh
JK
,
Qiao
H
,
Adams
DH
,
Popma
JJ
,
CoreValve USCI
.
3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement
.
J Am Coll Cardiol
2016
;
67
:
2565
2574
.

199

Smith
 
CR
,
Leon
MB
,
Mack
MJ
,
Miller
DC
,
Moses
JW
,
Svensson
LG
,
Tuzcu
EM
,
Webb
JG
,
Fontana
GP
,
Makkar
RR
,
Williams
M
,
Dewey
T
,
Kapadia
S
,
Babaliaros
V
,
Thourani
VH
,
Corso
P
,
Pichard
AD
,
Bavaria
JE
,
Herrmann
HC
,
Akin
JJ
,
Anderson
WN
,
Wang
D
,
Pocock
SJ
,
PARTNER Trial Investigators
.
Transcatheter versus surgical aortic-valve replacement in high-risk patients
.
N Engl J Med
2011
;
364
:
2187
2198
.

200

Mack
 
MJ
,
Leon
MB
,
Smith
CR
,
Miller
DC
,
Moses
JW
,
Tuzcu
EM
,
Webb
JG
,
Douglas
PS
,
Anderson
WN
,
Blackstone
EH
,
Kodali
SK
,
Makkar
RR
,
Fontana
GP
,
Kapadia
S
,
Bavaria
J
,
Hahn
RT
,
Thourani
VH
,
Babaliaros
V
,
Pichard
A
,
Herrmann
HC
,
Brown
DL
,
Williams
M
,
Akin
J
,
Davidson
MJ
,
Svensson
LG
,
PARTNER 1 trial Investigators
.
5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial
.
Lancet
2015
;
385
:
2477
2484
.

201

Adams
 
DH
,
Popma
JJ
,
Reardon
MJ
,
Yakubov
SJ
,
Coselli
JS
,
Deeb
GM
,
Gleason
TG
,
Buchbinder
M
,
Hermiller
J
Jr.
,
Kleiman
NS
,
Chetcuti
S
,
Heiser
J
,
Merhi
W
,
Zorn
G
,
Tadros
P
,
Robinson
N
,
Petrossian
G
,
Hughes
GC
,
Harrison
JK
,
Conte
J
,
Maini
B
,
Mumtaz
M
,
Chenoweth
S
,
Oh
JK
,
Investigators USCC
.
Transcatheter aortic-valve replacement with a self-expanding prosthesis
.
N Engl J Med
2014
;
370
:
1790
1798
.

202

Thyregod
 
HG
,
Steinbruchel
DA
,
Ihlemann
N
,
Nissen
H
,
Kjeldsen
BJ
,
Petursson
P
,
Chang
Y
,
Franzen
OW
,
Engstrom
T
,
Clemmensen
P
,
Hansen
PB
,
Andersen
LW
,
Olsen
PS
,
Sondergaard
L.
 
Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial
.
J Am Coll Cardiol
2015
;
65
:
2184
2194
.

203

Leon
 
MB
,
Smith
CR
,
Mack
MJ
,
Makkar
RR
,
Svensson
LG
,
Kodali
SK
,
Thourani
VH
,
Tuzcu
EM
,
Miller
DC
,
Herrmann
HC
,
Doshi
D
,
Cohen
DJ
,
Pichard
AD
,
Kapadia
S
,
Dewey
T
,
Babaliaros
V
,
Szeto
WY
,
Williams
MR
,
Kereiakes
D
,
Zajarias
A
,
Greason
KL
,
Whisenant
BK
,
Hodson
RW
,
Moses
JW
,
Trento
A
,
Brown
DL
,
Fearon
WF
,
Pibarot
P
,
Hahn
RT
,
Jaber
WA
,
Anderson
WN
,
Alu
MC
,
Webb
JG
,
PARTNER 2 Investigators
.
Transcatheter or surgical aortic-valve replacement in intermediate-risk patients
.
N Engl J Med
2016
;
374
:
1609
1620
.

204

Thourani
 
VH
,
Kodali
S
,
Makkar
RR
,
Herrmann
HC
,
Williams
M
,
Babaliaros
V
,
Smalling
R
,
Lim
S
,
Malaisrie
SC
,
Kapadia
S
,
Szeto
WY
,
Greason
KL
,
Kereiakes
D
,
Ailawadi
G
,
Whisenant
BK
,
Devireddy
C
,
Leipsic
J
,
Hahn
RT
,
Pibarot
P
,
Weissman
NJ
,
Jaber
WA
,
Cohen
DJ
,
Suri
R
,
Tuzcu
EM
,
Svensson
LG
,
Webb
JG
,
Moses
JW
,
Mack
MJ
,
Miller
DC
,
Smith
CR
,
Alu
MC
,
Parvataneni
R
,
D’Agostino
RB
Jr.
,
Leon
MB.
 
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
.
Lancet
2016
;
387
:
2218
2225
.

205

Reardon
 
MJ
,
Van Mieghem
NM
,
Popma
JJ
,
Kleiman
NS
,
Sondergaard
L
,
Mumtaz
M
,
Adams
DH
,
Deeb
GM
,
Maini
B
,
Gada
H
,
Chetcuti
S
,
Gleason
T
,
Heiser
J
,
Lange
R
,
Merhi
W
,
Oh
JK
,
Olsen
PS
,
Piazza
N
,
Williams
M
,
Windecker
S
,
Yakubov
SJ
,
Grube
E
,
Makkar
R
,
Lee
JS
,
Conte
J
,
Vang
E
,
Nguyen
H
,
Chang
Y
,
Mugglin
AS
,
Serruys
PW
,
Kappetein
AP
,
SURTAVI Investigators
.
Surgical or transcatheter aortic-valve replacement in intermediate-risk patients
.
N Engl J Med
2017
;
376
:
1321
1331
.

206

Makkar
 
RR
,
Thourani
VH
,
Mack
MJ
,
Kodali
SK
,
Kapadia
S
,
Webb
JG
,
Yoon
SH
,
Trento
A
,
Svensson
LG
,
Herrmann
HC
,
Szeto
WY
,
Miller
DC
,
Satler
L
,
Cohen
DJ
,
Dewey
TM
,
Babaliaros
V
,
Williams
MR
,
Kereiakes
DJ
,
Zajarias
A
,
Greason
KL
,
Whisenant
BK
,
Hodson
RW
,
Brown
DL
,
Fearon
WF
,
Russo
MJ
,
Pibarot
P
,
Hahn
RT
,
Jaber
WA
,
Rogers
E
,
Xu
K
,
Wheeler
J
,
Alu
MC
,
Smith
CR
,
Leon
MB
,
Investigators P
.
Five-year outcomes of transcatheter or surgical aortic-valve replacement
.
N Engl J Med
2020
;
382
:
799
809
.

207

Thyregod
 
HGH
,
Ihlemann
N
,
Jorgensen
TH
,
Nissen
H
,
Kjeldsen
BJ
,
Petursson
P
,
Chang
Y
,
Franzen
OW
,
Engstrom
T
,
Clemmensen
P
,
Hansen
PB
,
Andersen
LW
,
Steinbruchel
DA
,
Olsen
PS
,
Sondergaard
L.
 
Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients
.
Circulation
2019
;
139
:
2714
2723
.

208

Siontis
 
GC
,
Praz
F
,
Pilgrim
T
,
Mavridis
D
,
Verma
S
,
Salanti
G
,
Sondergaard
L
,
Juni
P
,
Windecker
S.
 
Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials
.
Eur Heart J
2016
;
37
:
3503
3512
.

209

Mack
 
MJ
,
Leon
MB
,
Thourani
VH
,
Makkar
R
,
Kodali
SK
,
Russo
M
,
Kapadia
SR
,
Malaisrie
SC
,
Cohen
DJ
,
Pibarot
P
,
Leipsic
J
,
Hahn
RT
,
Blanke
P
,
Williams
MR
,
McCabe
JM
,
Brown
DL
,
Babaliaros
V
,
Goldman
S
,
Szeto
WY
,
Genereux
P
,
Pershad
A
,
Pocock
SJ
,
Alu
MC
,
Webb
JG
,
Smith
CR
,
PARTNER 3 Investigators
.
Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients
.
N Engl J Med
2019
;
380
:
1695
1705
.

210

Popma
 
JJ
,
Deeb
GM
,
Yakubov
SJ
,
Mumtaz
M
,
Gada
H
,
O’Hair
D
,
Bajwa
T
,
Heiser
JC
,
Merhi
W
,
Kleiman
NS
,
Askew
J
,
Sorajja
P
,
Rovin
J
,
Chetcuti
SJ
,
Adams
DH
,
Teirstein
PS
,
Zorn
GL
3rd
,
Forrest
JK
,
Tchetche
D
,
Resar
J
,
Walton
A
,
Piazza
N
,
Ramlawi
B
,
Robinson
N
,
Petrossian
G
,
Gleason
TG
,
Oh
JK
,
Boulware
MJ
,
Qiao
H
,
Mugglin
AS
,
Reardon
MJ
,
Evolut Low Risk Trial Investigators
.
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
.
N Engl J Med
2019
;
380
:
1706
1715
.

211

Siontis
 
GCM
,
Overtchouk
P
,
Cahill
TJ
,
Modine
T
,
Prendergast
B
,
Praz
F
,
Pilgrim
T
,
Petrinic
T
,
Nikolakopoulou
A
,
Salanti
G
,
Sondergaard
L
,
Verma
S
,
Juni
P
,
Windecker
S.
 
Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis
.
Eur Heart J
2019
;
40
:
3143
3153
.

212

Leon
 
MB
,
Mack
MJ
,
Hahn
RT
,
Thourani
VH
,
Makkar
R
,
Kodali
SK
,
Alu
MC
,
Madhavan
MV
,
Chau
KH
,
Russo
M
,
Kapadia
SR
,
Malaisrie
SC
,
Cohen
DJ
,
Blanke
P
,
Leipsic
JA
,
Williams
MR
,
McCabe
JM
,
Brown
DL
,
Babaliaros
V
,
Goldman
S
,
Herrmann
HC
,
Szeto
WY
,
Genereux
P
,
Pershad
A
,
Lu
M
,
Webb
JG
,
Smith
CR
,
Pibarot
P
,
PARTNER 3 Investigators
.
Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk
.
J Am Coll Cardiol
2021
;
77
:
1149
1161
.

213

Greason
 
KL
,
Lahr
BD
,
Stulak
JM
,
Cha
YM
,
Rea
RF
,
Schaff
HV
,
Dearani
JA.
 
Long-term mortality effect of early pacemaker implantation after surgical aortic valve replacement
.
Ann Thorac Surg
2017
;
104
:
1259
1264
.

214

Auffret
 
V
,
Puri
R
,
Urena
M
,
Chamandi
C
,
Rodriguez-Gabella
T
,
Philippon
F
,
Rodes-Cabau
J.
 
Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives
.
Circulation
2017
;
136
:
1049
1069
.

215

Nazif
 
TM
,
Chen
S
,
George
I
,
Dizon
JM
,
Hahn
RT
,
Crowley
A
,
Alu
MC
,
Babaliaros
V
,
Thourani
VH
,
Herrmann
HC
,
Smalling
RW
,
Brown
DL
,
Mack
MJ
,
Kapadia
S
,
Makkar
R
,
Webb
JG
,
Leon
MB
,
Kodali
SK.
 
New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial
.
Eur Heart J
2019
;
40
:
2218
2227
.

216

Tam
 
DY
,
Hughes
A
,
Wijeysundera
HC
,
Fremes
SE.
 
Cost-effectiveness of self-expandable transcatheter aortic valves in intermediate-risk patients
.
Ann Thorac Surg
2018
;
106
:
676
683
.

217

Baron
 
SJ
,
Wang
K
,
House
JA
,
Magnuson
EA
,
Reynolds
MR
,
Makkar
R
,
Herrmann
HC
,
Kodali
S
,
Thourani
VH
,
Kapadia
S
,
Svensson
L
,
Mack
MJ
,
Brown
DL
,
Russo
MJ
,
Smith
CR
,
Webb
J
,
Miller
C
,
Leon
MB
,
Cohen
DJ.
 
Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk
.
Circulation
2019
;
139
:
877
888
.

218

Pilgrim
 
T
,
Windecker
S.
 
Expansion of transcatheter aortic valve implantation: new indications and socio-economic considerations
.
Eur Heart J
2018
;
39
:
2643
2645
.

219

Barbato
 
E
,
Noc
M
,
Baumbach
A
,
Dudek
D
,
Bunc
M
,
Skalidis
E
,
Banning
A
,
Legutko
J
,
Witt
N
,
Pan
M
,
Tilsted
HH
,
Nef
H
,
Tarantini
G
,
Kazakiewicz
D
,
Huculeci
R
,
Cook
S
,
Magdy
A
,
Desmet
W
,
Cayla
G
,
Vinereanu
D
,
Voskuil
M
,
Goktekin
O
,
Vardas
P
,
Timmis
A
,
Haude
M.
 
Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project
.
Eur Heart J
2020
;
41
:
2579
2588
.

220

Johnston
 
DR
,
Soltesz
EG
,
Vakil
N
,
Rajeswaran
J
,
Roselli
EE
,
Sabik
JF
3rd
,
Smedira
NG
,
Svensson
LG
,
Lytle
BW
,
Blackstone
EH.
 
Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants
.
Ann Thorac Surg
2015
;
99
:
1239
1247
.

221

Blackman
 
DJ
,
Saraf
S
,
MacCarthy
PA
,
Myat
A
,
Anderson
SG
,
Malkin
CJ
,
Cunnington
MS
,
Somers
K
,
Brennan
P
,
Manoharan
G
,
Parker
J
,
Aldalati
O
,
Brecker
SJ
,
Dowling
C
,
Hoole
SP
,
Dorman
S
,
Mullen
M
,
Kennon
S
,
Jerrum
M
,
Chandrala
P
,
Roberts
DH
,
Tay
J
,
Doshi
SN
,
Ludman
PF
,
Fairbairn
TA
,
Crowe
J
,
Levy
RD
,
Banning
AP
,
Ruparelia
N
,
Spence
MS
,
Hildick-Smith
D.
 
Long-term durability of transcatheter aortic valve prostheses
.
J Am Coll Cardiol
2019
;
73
:
537
545
.

222

Barbanti
 
M
,
Costa
G
,
Zappulla
P
,
Todaro
D
,
Picci
A
,
Rapisarda
G
,
Di Simone
E
,
Sicuso
R
,
Buccheri
S
,
Gulino
S
,
Pilato
G
,
La Spina
K
,
D’Arrigo
P
,
Valvo
R
,
Indelicato
A
,
Giannazzo
D
,
Imme
S
,
Tamburino
C
,
Patane
M
,
Sgroi
C
,
Giuffrida
A
,
Trovato
D
,
Monte
IP
,
Deste
W
,
Capranzano
P
,
Capodanno
D
,
Tamburino
C.
 
Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement
.
J Am Heart Assoc
2018
;
7
:
e008440
.

223

Didier
 
R
,
Eltchaninoff
H
,
Donzeau-Gouge
P
,
Chevreul
K
,
Fajadet
J
,
Leprince
P
,
Leguerrier
A
,
Lievre
M
,
Prat
A
,
Teiger
E
,
Lefevre
T
,
Tchetche
D
,
Carrie
D
,
Himbert
D
,
Albat
B
,
Cribier
A
,
Sudre
A
,
Blanchard
D
,
Rioufol
G
,
Collet
F
,
Houel
R
,
Dos Santos
P
,
Meneveau
N
,
Ghostine
S
,
Manigold
T
,
Guyon
P
,
Cuisset
T
,
Le Breton
H
,
Delepine
S
,
Favereau
X
,
Souteyrand
G
,
Ohlmann
P
,
Doisy
V
,
Lognone
T
,
Gommeaux
A
,
Claudel
JP
,
Bourlon
F
,
Bertrand
B
,
Iung
B
,
Gilard
M.
 
Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients
.
Circulation
2018
;
138
:
2597
2607
.

224

Deutsch
 
MA
,
Erlebach
M
,
Burri
M
,
Hapfelmeier
A
,
Witt
OG
,
Ziegelmueller
JA
,
Wottke
M
,
Ruge
H
,
Krane
M
,
Piazza
N
,
Bleiziffer
S
,
Lange
R.
 
Beyond the five-year horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices
.
EuroIntervention
2018
;
14
:
41
49
.

225

Pibarot
 
P
,
Ternacle
J
,
Jaber
WA
,
Salaun
E
,
Dahou
A
,
Asch
FM
,
Weissman
NJ
,
Rodriguez
L
,
Xu
K
,
Annabi
MS
,
Guzzetti
E
,
Beaudoin
J
,
Bernier
M
,
Leipsic
J
,
Blanke
P
,
Clavel
MA
,
Rogers
E
,
Alu
MC
,
Douglas
PS
,
Makkar
R
,
Miller
DC
,
Kapadia
SR
,
Mack
MJ
,
Webb
JG
,
Kodali
SK
,
Smith
CR
,
Herrmann
HC
,
Thourani
VH
,
Leon
MB
,
Hahn
RT
,
PARTNER 2 Investigators
.
Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 Trial
.
J Am Coll Cardiol
2020
;
76
:
1830
1843
.

226

Tam
 
DY
,
Vo
TX
,
Wijeysundera
HC
,
Dvir
D
,
Friedrich
JO
,
Fremes
SE.
 
Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis
.
Catheter Cardiovasc Interv
2018
;
92
:
1404
1411
.

227

Deharo
 
P
,
Bisson
A
,
Herbert
J
,
Lacour
T
,
Etienne
CS
,
Porto
A
,
Theron
A
,
Collart
F
,
Bourguignon
T
,
Cuisset
T
,
Fauchier
L.
 
Transcatheter valve-in-valve aortic valve replacement as an alternative to surgical re-replacement
.
J Am Coll Cardiol
2020
;
76
:
489
499
.

228

Gozdek
 
M
,
Raffa
GM
,
Suwalski
P
,
Kolodziejczak
M
,
Anisimowicz
L
,
Kubica
J
,
Navarese
EP
,
Kowalewski
M
,
SIRIO-TAVI group
.
Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis
.
Eur J Cardiothorac Surg
2018
;
53
:
495
504
.

229

Landes
 
U
,
Webb
JG
,
De Backer
O
,
Sondergaard
L
,
Abdel-Wahab
M
,
Crusius
L
,
Kim
WK
,
Hamm
C
,
Buzzatti
N
,
Montorfano
M
,
Ludwig
S
,
Schofer
N
,
Voigtlaender
L
,
Guerrero
M
,
El Sabbagh
A
,
Rodes-Cabau
J
,
Guimaraes
L
,
Kornowski
R
,
Codner
P
,
Okuno
T
,
Pilgrim
T
,
Fiorina
C
,
Colombo
A
,
Mangieri
A
,
Eltchaninoff
H
,
Nombela-Franco
L
,
Van Wiechen
MPH
,
Van Mieghem
NM
,
Tchetche
D
,
Schoels
WH
,
Kullmer
M
,
Tamburino
C
,
Sinning
JM
,
Al-Kassou
B
,
Perlman
GY
,
Danenberg
H
,
Ielasi
A
,
Fraccaro
C
,
Tarantini
G
,
De Marco
F
,
Witberg
G
,
Redwood
SR
,
Lisko
JC
,
Babaliaros
VC
,
Laine
M
,
Nerla
R
,
Castriota
F
,
Finkelstein
A
,
Loewenstein
I
,
Eitan
A
,
Jaffe
R
,
Ruile
P
,
Neumann
FJ
,
Piazza
N
,
Alosaimi
H
,
Sievert
H
,
Sievert
K
,
Russo
M
,
Andreas
M
,
Bunc
M
,
Latib
A
,
Govdfrey
R
,
Hildick-Smith
D
,
Sathananthan
J
,
Hensey
M
,
Alkhodair
A
,
Blanke
P
,
Leipsic
J
,
Wood
DA
,
Nazif
TM
,
Kodali
S
,
Leon
MB
,
Barbanti
M
,
Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction
.
J Am Coll Cardiol
2020
;
75
:
1882
1893
.

230

Buzzatti
 
N
,
Romano
V
,
De Backer
O
,
Soendergaard
L
,
Rosseel
L
,
Maurovich-Horvat
P
,
Karady
J
,
Merkely
B
,
Ruggeri
S
,
Prendergast
B
,
De Bonis
M
,
Colombo
A
,
Montorfano
M
,
Latib
A.
 
Coronary access after repeated transcatheter aortic valve implantation: a glimpse into the future
.
JACC Cardiovasc Imaging
2020
;
13
:
508
515
.

231

Yoon
 
SH
,
Bleiziffer
S
,
De Backer
O
,
Delgado
V
,
Arai
T
,
Ziegelmueller
J
,
Barbanti
M
,
Sharma
R
,
Perlman
GY
,
Khalique
OK
,
Holy
EW
,
Saraf
S
,
Deuschl
F
,
Fujita
B
,
Ruile
P
,
Neumann
FJ
,
Pache
G
,
Takahashi
M
,
Kaneko
H
,
Schmidt
T
,
Ohno
Y
,
Schofer
N
,
Kong
WKF
,
Tay
E
,
Sugiyama
D
,
Kawamori
H
,
Maeno
Y
,
Abramowitz
Y
,
Chakravarty
T
,
Nakamura
M
,
Kuwata
S
,
Yong
G
,
Kao
HL
,
Lee
M
,
Kim
HS
,
Modine
T
,
Wong
SC
,
Bedgoni
F
,
Testa
L
,
Teiger
E
,
Butter
C
,
Ensminger
SM
,
Schaefer
U
,
Dvir
D
,
Blanke
P
,
Leipsic
J
,
Nietlispach
F
,
Abdel-Wahab
M
,
Chevalier
B
,
Tamburino
C
,
Hildick-Smith
D
,
Whisenant
BK
,
Park
SJ
,
Colombo
A
,
Latib
A
,
Kodali
SK
,
Bax
JJ
,
Sondergaard
L
,
Webb
JG
,
Lefevre
T
,
Leon
MB
,
Makkar
R.
 
Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis
.
J Am Coll Cardiol
2017
;
69
:
2579
2589
.

232

Halim
 
SA
,
Edwards
FH
,
Dai
D
,
Li
Z
,
Mack
MJ
,
Holmes
DR
,
Tuzcu
EM
,
Thourani
VH
,
Harrison
JK
,
Brennan
JM.
 
Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
.
Circulation
2020
;
141
:
1071
1079
.

233

Forrest
 
JK
,
Kaple
RK
,
Ramlawi
B
,
Gleason
TG
,
Meduri
CU
,
Yakubov
SJ
,
Jilaihawi
H
,
Liu
F
,
Reardon
MJ.
 
Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves from the STS/ACC TVT Registry
.
JACC Cardiovasc Interv
2020
;
13
:
1749
1759
.

234

Alkhouli
 
M
,
Zack
CJ
,
Sarraf
M
,
Bashir
R
,
Nishimura
RA
,
Eleid
MF
,
Nkomo
VT
,
Sandhu
GS
,
Gulati
R
,
Greason
KL
,
Holmes
DR
,
Rihal
CS.
 
Morbidity and mortality associated with balloon aortic valvuloplasty: a national perspective
.
Circ Cardiovasc Interv
2017
;
10
.

235

Horstkotte
 
D
,
Loogen
F.
 
The natural history of aortic valve stenosis
.
Eur Heart J
1988
;
9 Suppl E
:
57
64
.

236

Lund
 
O.
 
Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis. Reasons for earlier operative intervention
.
Circulation
1990
;
82
:
124
139
.

237

Mangner
 
N
,
Stachel
G
,
Woitek
F
,
Haussig
S
,
Schlotter
F
,
Hollriegel
R
,
Adam
J
,
Lindner
A
,
Mohr
FW
,
Schuler
G
,
Kiefer
P
,
Leontyev
S
,
Borger
MA
,
Thiele
H
,
Holzhey
D
,
Linke
A.
 
Predictors of mortality and symptomatic outcome of patients with low-flow severe aortic stenosis undergoing transcatheter aortic valve replacement
.
J Am Heart Assoc
2018
;
7
:
e007977
.

238

Dahl
 
JS
,
Eleid
MF
,
Michelena
HI
,
Scott
CG
,
Suri
RM
,
Schaff
HV
,
Pellikka
PA.
 
Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement
.
Circ Cardiovasc Imaging
2015
;
8
:
e002917
.

239

Taniguchi
 
T
,
Morimoto
T
,
Shiomi
H
,
Ando
K
,
Kanamori
N
,
Murata
K
,
Kitai
T
,
Kadota
K
,
Izumi
C
,
Nakatsuma
K
,
Sasa
T
,
Watanabe
H
,
Kuwabara
Y
,
Makiyama
T
,
Ono
K
,
Shizuta
S
,
Kato
T
,
Saito
N
,
Minatoya
K
,
Kimura
T
,
CURRENT AS Registry Investigators
.
Prognostic impact of left ventricular ejection fraction in patients with severe aortic stenosis
.
JACC Cardiovasc Interv
2018
;
11
:
145
157
.

240

Bohbot
 
Y
,
de Meester de Ravenstein
C
,
Chadha
G
,
Rusinaru
D
,
Belkhir
K
,
Trouillet
C
,
Pasquet
A
,
Marechaux
S
,
Vanoverschelde
JL
,
Tribouilloy
C.
 
Relationship between left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis
.
JACC Cardiovasc Imaging
2019
;
12
:
38
48
.

241

Capoulade
 
R
,
Le Ven
F
,
Clavel
MA
,
Dumesnil
JG
,
Dahou
A
,
Thebault
C
,
Arsenault
M
,
O’Connor
K
,
Bedard
E
,
Beaudoin
J
,
Senechal
M
,
Bernier
M
,
Pibarot
P.
 
Echocardiographic predictors of outcomes in adults with aortic stenosis
.
Heart
2016
;
102
:
934
942
.

242

Bohbot
 
Y
,
Kowalski
C
,
Rusinaru
D
,
Ringle
A
,
Marechaux
S
,
Tribouilloy
C.
 
Impact of mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction
.
J Am Heart Assoc
2017
;
6
.

243

Otto
 
CM
,
Burwash
IG
,
Legget
ME
,
Munt
BI
,
Fujioka
M
,
Healy
NL
,
Kraft
CD
,
Miyake-Hull
CY
,
Schwaegler
RG.
 
Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome
.
Circulation
1997
;
95
:
2262
2270
.

244

Thourani
 
VH
,
Suri
RM
,
Gunter
RL
,
Sheng
S
,
O’Brien
SM
,
Ailawadi
G
,
Szeto
WY
,
Dewey
TM
,
Guyton
RA
,
Bavaria
JE
,
Babaliaros
V
,
Gammie
JS
,
Svensson
L
,
Williams
M
,
Badhwar
V
,
Mack
MJ.
 
Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients
.
Ann Thorac Surg
2015
;
99
:
55
61
.

245

Gleason
 
TG
,
Reardon
MJ
,
Popma
JJ
,
Deeb
GM
,
Yakubov
SJ
,
Lee
JS
,
Kleiman
NS
,
Chetcuti
S
,
Hermiller
JB
Jr.
,
Heiser
J
,
Merhi
W
,
Zorn
GL
3rd
,
Tadros
P
,
Robinson
N
,
Petrossian
G
,
Hughes
GC
,
Harrison
JK
,
Conte
JV
,
Mumtaz
M
,
Oh
JK
,
Huang
J
,
Adams
DH
,
CoreValve US Pivotal High Risk Trial Clinical Investigators
.
5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients
.
J Am Coll Cardiol
2018
;
72
:
2687
2696
.

246

Rossebo
 
AB
,
Pedersen
TR
,
Boman
K
,
Brudi
P
,
Chambers
JB
,
Egstrup
K
,
Gerdts
E
,
Gohlke-Barwolf
C
,
Holme
I
,
Kesaniemi
YA
,
Malbecq
W
,
Nienaber
CA
,
Ray
S
,
Skjaerpe
T
,
Wachtell
K
,
Willenheimer
R
,
SEAS Investigators
.
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
.
N Engl J Med
2008
;
359
:
1343
1356
.

247

Ponikowski
 
P
,
Voors
AA
,
Anker
SD
,
Bueno
H
,
Cleland
JGF
,
Coats
AJS
,
Falk
V
,
Gonzalez-Juanatey
JR
,
Harjola
VP
,
Jankowska
EA
,
Jessup
M
,
Linde
C
,
Nihoyannopoulos
P
,
Parissis
JT
,
Pieske
B
,
Riley
JP
,
Rosano
GMC
,
Ruilope
LM
,
Ruschitzka
F
,
Rutten
FH
,
van der Meer
P
,
ESC Scientific Document Group
.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
.
Eur Heart J
2016
;
37
:
2129
2200
.

248

Bull
 
S
,
Loudon
M
,
Francis
JM
,
Joseph
J
,
Gerry
S
,
Karamitsos
TD
,
Prendergast
BD
,
Banning
AP
,
Neubauer
S
,
Myerson
SG.
 
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)
.
Eur Heart J Cardiovasc Imaging
2015
;
16
:
834
841
.

249

Ochiai
 
T
,
Saito
S
,
Yamanaka
F
,
Shishido
K
,
Tanaka
Y
,
Yamabe
T
,
Shirai
S
,
Tada
N
,
Araki
M
,
Naganuma
T
,
Watanabe
Y
,
Yamamoto
M
,
Hayashida
K.
 
Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation
.
Heart
2018
;
104
:
644
651
.

250

Dahl
 
JS
,
Videbaek
L
,
Poulsen
MK
,
Pellikka
PA
,
Veien
K
,
Andersen
LI
,
Haghfelt
T
,
Moller
JE.
 
Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis
.
Am J Cardiol
2010
;
106
:
713
719
.

251

Strange
 
G
,
Stewart
S
,
Celermajer
D
,
Prior
D
,
Scalia
GM
,
Marwick
T
,
Ilton
M
,
Joseph
M
,
Codde
J
,
Playford
D
,
National Echocardiography Database of Australia contributing sites. Poor long-term survival in patients with moderate aortic stenosis
.
J Am Coll Cardiol
2019
;
74
:
1851
1863
.

252

van Gils
 
L
,
Clavel
MA
,
Vollema
EM
,
Hahn
RT
,
Spitzer
E
,
Delgado
V
,
Nazif
T
,
De Jaegere
PP
,
Geleijnse
ML
,
Ben-Yehuda
O
,
Bax
JJ
,
Leon
MB
,
Pibarot
P
,
Van Mieghem
NM.
 
Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction
.
J Am Coll Cardiol
2017
;
69
:
2383
2392
.

253

Delesalle
 
G
,
Bohbot
Y
,
Rusinaru
D
,
Delpierre
Q
,
Marechaux
S
,
Tribouilloy
C.
 
Characteristics and prognosis of patients with moderate aortic stenosis and preserved left ventricular ejection fraction
.
J Am Heart Assoc
2019
;
8
:
e011036
.

254

Samad
 
Z
,
Vora
AN
,
Dunning
A
,
Schulte
PJ
,
Shaw
LK
,
Al-Enezi
F
,
Ersboll
M
,
McGarrah
RW
3rd
,
Vavalle
JP
,
Shah
SH
,
Kisslo
J
,
Glower
D
,
Harrison
JK
,
Velazquez
EJ.
 
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction
.
Eur Heart J
2016
;
37
:
2276
2286
.

255

Chaker
 
Z
,
Badhwar
V
,
Alqahtani
F
,
Aljohani
S
,
Zack
CJ
,
Holmes
DR
,
Rihal
CS
,
Alkhouli
M.
 
Sex differences in the utilization and outcomes of surgical aortic valve replacement for severe aortic stenosis
.
J Am Heart Assoc
2017
;
6
.

256

Cote
 
N
,
Clavel
MA.
 
Sex differences in the pathophysiology, diagnosis, and management of aortic stenosis
.
Cardiol Clin
2020
;
38
:
129
138
.

257

Tribouilloy
 
C
,
Bohbot
Y
,
Rusinaru
D
,
Belkhir
K
,
Diouf
M
,
Altes
A
,
Delpierre
Q
,
Serbout
S
,
Kubala
M
,
Levy
F
,
Marechaux
S
,
Enriquez Sarano
M.
 
Excess mortality and undertreatment of women with severe aortic stenosis
.
J Am Heart Assoc
2021
;
10
:
e018816
.

258

Smith
 
WTt
,
Ferguson
TB
Jr.
,
Ryan
T
,
Landolfo
CK
,
Peterson
ED.
 
Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement? A decision analysis approach to the surgical dilemma
.
J Am Coll Cardiol
2004
;
44
:
1241
1247
.

259

Faroux
 
L
,
Campelo-Parada
F
,
Munoz-Garcia
E
,
Nombela-Franco
L
,
Fischer
Q
,
Donaint
P
,
Serra
V
,
Veiga
G
,
Gutierrez
E
,
Vilalta
V
,
Alperi
A
,
Regueiro
A
,
Asmarats
L
,
Ribeiro
HB
,
Matta
A
,
Munoz-Garcia
A
,
Armijo
G
,
Urena
M
,
Metz
D
,
Rodenas-Alesina
E
,
la
de
 
Torre Hernandez JM
,
Fernandez-Nofrerias E, Pascual I, Perez-Fuentes P, Arzamendi D, Campanha-Borges DC, Del Val D, Couture T, Rodes-Cabau J. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR. JACC Cardiovasc Interv
2020
;
13
:
2601
2613
.

260

Sondergaard
 
L
,
Popma
JJ
,
Reardon
MJ
,
Van Mieghem
NM
,
Deeb
GM
,
Kodali
S
,
George
I
,
Williams
MR
,
Yakubov
SJ
,
Kappetein
AP
,
Serruys
PW
,
Grube
E
,
Schiltgen
MB
,
Chang
Y
,
Engstrom
T
,
SURTAVI Trial Investigators
.
Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk: results from the randomized SURTAVI Trial
.
Circulation
2019
;
140
:
1296
1305
.

261

Nombela-Franco
 
L
,
Eltchaninoff
H
,
Zahn
R
,
Testa
L
,
Leon
MB
,
Trillo-Nouche
R
,
D’Onofrio
A
,
Smith
CR
,
Webb
J
,
Bleiziffer
S
,
De Chiara
B
,
Gilard
M
,
Tamburino
C
,
Bedogni
F
,
Barbanti
M
,
Salizzoni
S
,
Garcia del Blanco
B
,
Sabate
M
,
Moreo
A
,
Fernandez
C
,
Ribeiro
HB
,
Amat-Santos
I
,
Urena
M
,
Allende
R
,
Garcia
E
,
Macaya
C
,
Dumont
E
,
Pibarot
P
,
Rodes-Cabau
J.
 
Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis
.
Heart
2015
;
101
:
1395
1405
.

262

D’Ancona
 
G
,
Kische
S
,
Senges
J
,
Ouarrak
T
,
Puls
M
,
Bekeredjian
R
,
Sievert
H
,
Safak
E
,
Ortak
J
,
Oner
A
,
Schillinger
W
,
Ince
H.
 
Combined mitro-aortic pathology: impact of previous aortic valve replacement upon outcomes of MitraClip therapy (from the German transcatheter mitral valve interventions registry)
.
EuroIntervention
2017
;
13
:
475
482
.

263

Witberg
 
G
,
Codner
P
,
Landes
U
,
Barbanti
M
,
Valvo
R
,
De Backer
O
,
Ooms
JF
,
Sievert
K
,
El Sabbagh
A
,
Jimenez-Quevedo
P
,
Brennan
PF
,
Sedaghat
A
,
Masiero
G
,
Werner
P
,
Overtchouk
P
,
Watanabe
Y
,
Montorfano
M
,
Bijjam
VR
,
Hein
M
,
Fiorina
C
,
Arzamendi
D
,
Rodriguez-Gabella
T
,
Fernandez-Vazquez
F
,
Baz
JA
,
Laperche
C
,
Grasso
C
,
Branca
L
,
Estevez-Loureiro
R
,
Benito-Gonzalez
T
,
Amat Santos
IJ
,
Ruile
P
,
Mylotte
D
,
Buzzatti
N
,
Piazza
N
,
Andreas
M
,
Tarantini
G
,
Sinning
JM
,
Spence
MS
,
Nombela-Franco
L
,
Guerrero
M
,
Sievert
H
,
Sondergaard
L
,
Van Mieghem
NM
,
Tchetche
D
,
Webb
JG
,
Kornowski
R.
 
Transcatheter treatment of residual significant mitral regurgitation following TAVR: a multicenter registry
.
JACC Cardiovasc Interv
2020
;
13
:
2782
2791
.

264

Khan
 
F
,
Okuno
T
,
Malebranche
D
,
Lanz
J
,
Praz
F
,
Stortecky
S
,
Windecker
S
,
Pilgrim
T.
 
Transcatheter aortic valve replacement in patients with multivalvular heart disease
.
JACC Cardiovasc Interv
2020
;
13
:
1503
1514
.

265

Baumgartner
 
H
,
Bonhoeffer
P
,
De Groot
NM
,
de Haan
F
,
Deanfield
JE
,
Galie
N
,
Gatzoulis
MA
,
Gohlke-Baerwolf
C
,
Kaemmerer
H
,
Kilner
P
,
Meijboom
F
,
Mulder
BJ
,
Oechslin
E
,
Oliver
JM
,
Serraf
A
,
Szatmari
A
,
Thaulow
E
,
Vouhe
PR
,
Walma
E
,
Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology, Association for European Paediatric Cardiology, ESC Committee for Practice Guidelines
.
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010
).
Eur Heart J
2010
;
31
:
2915
2957
.

266

Dziadzko
 
V
,
Dziadzko
M
,
Medina-Inojosa
JR
,
Benfari
G
,
Michelena
HI
,
Crestanello
JA
,
Maalouf
J
,
Thapa
P
,
Enriquez-Sarano
M.
 
Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome
.
Eur Heart J
2019
;
40
:
2194
2202
.

267

Kingue
 
S
,
Ba
SA
,
Balde
D
,
Diarra
MB
,
Anzouan-Kacou
JB
,
Anisubia
B
,
Damorou
JM
,
Ndobo
P
,
Menanga
A
,
Kane
A
,
Kakou-Guikahue
M
,
Kenfack
M
,
Metogo
B
,
Chelo
D
,
Yangnigni
E
,
Tantchou
C
,
Bertrand
E
,
Monsuez
JJ
,
Working Group on Tropical Cardiology of the Société française de cardiologie. The VALVAFRIC study: a registry of rheumatic heart disease in Western and Central Africa
.
Arch Cardiovasc Dis
2016
;
109
:
321
329
.

268

Zoghbi
 
WA
,
Adams
D
,
Bonow
RO
,
Enriquez-Sarano
M
,
Foster
E
,
Grayburn
PA
,
Hahn
RT
,
Han
Y
,
Hung
J
,
Lang
RM
,
Little
SH
,
Shah
DJ
,
Shernan
S
,
Thavendiranathan
P
,
Thomas
JD
,
Weissman
NJ.
 
Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance
.
J Am Soc Echocardiogr
2017
;
30
:
303
371
.

269

Antoine
 
C
,
Benfari
G
,
Michelena
HI
,
Maalouf
JF
,
Nkomo
VT
,
Thapa
P
,
Enriquez-Sarano
M.
 
Clinical outcome of degenerative mitral regurgitation
.
Circulation
2018
;
138
:
1317
1326
.

270

Samad
 
Z
,
Shaw
LK
,
Phelan
M
,
Glower
DD
,
Ersboll
M
,
Toptine
JH
,
Alexander
JH
,
Kisslo
JA
,
Wang
A
,
Mark
DB
,
Velazquez
EJ.
 
Long-term outcomes of mitral regurgitation by type and severity
.
Am Heart J
2018
;
203
:
39
48
.

271

Carpentier
 
A.
 
Cardiac valve surgery–the “French correction
”.
J Thorac Cardiovasc Surg
1983
;
86
:
323
337
.

272

Boekstegers
 
P
,
Hausleiter
J
,
Baldus
S
,
von Bardeleben
RS
,
Beucher
H
,
Butter
C
,
Franzen
O
,
Hoffmann
R
,
Ince
H
,
Kuck
KH
,
Rudolph
V
,
Schafer
U
,
Schillinger
W
,
Wunderlich
N
,
Germany Society of Cardiology Working Group on Interventional Cardiology Focus Group on Interventional Mitral Valve Therapy
.
Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system
.
Clin Res Cardiol
2014
;
103
:
85
96
.

273

Gavazzoni
 
M
,
Taramasso
M
,
Zuber
M
,
Russo
G
,
Pozzoli
A
,
Miura
M
,
Maisano
F.
 
Conceiving MitraClip as a tool: percutaneous edge-to-edge repair in complex mitral valve anatomies
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
1059
1067
.

274

Cawley
 
PJ
,
Hamilton-Craig
C
,
Owens
DS
,
Krieger
EV
,
Strugnell
WE
,
Mitsumori
L
,
D’Jang
CL
,
Schwaegler
RG
,
Nguyen
KQ
,
Nguyen
B
,
Maki
JH
,
Otto
CM.
 
Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography
.
Circ Cardiovasc Imaging
2013
;
6
:
48
57
.

275

Shanks
 
M
,
Siebelink
HM
,
Delgado
V
,
van de Veire
NR
,
Ng
AC
,
Sieders
A
,
Schuijf
JD
,
Lamb
HJ
,
Ajmone Marsan
N
,
Westenberg
JJ
,
Kroft
LJ
,
de Roos
A
,
Bax
JJ.
 
Quantitative assessment of mitral regurgitation: comparison between three-dimensional transesophageal echocardiography and magnetic resonance imaging
.
Circ Cardiovasc Imaging
2010
;
3
:
694
700
.

276

Uretsky
 
S
,
Gillam
L
,
Lang
R
,
Chaudhry
FA
,
Argulian
E
,
Supariwala
A
,
Gurram
S
,
Jain
K
,
Subero
M
,
Jang
JJ
,
Cohen
R
,
Wolff
SD.
 
Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial
.
J Am Coll Cardiol
2015
;
65
:
1078
1088
.

277

Penicka
 
M
,
Vecera
J
,
Mirica
DC
,
Kotrc
M
,
Kockova
R
,
Van Camp
G.
 
Prognostic implications of magnetic resonance-derived quantification in asymptomatic patients with organic mitral regurgitation: comparison with Doppler echocardiography-derived integrative approach
.
Circulation
2018
;
137
:
1349
1360
.

278

Garg
 
P
,
Swift
AJ
,
Zhong
L
,
Carlhall
CJ
,
Ebbers
T
,
Westenberg
J
,
Hope
MD
,
Bucciarelli-Ducci
C
,
Bax
JJ
,
Myerson
SG.
 
Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging
.
Nat Rev Cardiol
2020
;
17
:
298
312
.

279

Kitkungvan
 
D
,
Nabi
F
,
Kim
RJ
,
Bonow
RO
,
Khan
MA
,
Xu
J
,
Little
SH
,
Quinones
MA
,
Lawrie
GM
,
Zoghbi
WA
,
Shah
DJ.
 
Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse
.
J Am Coll Cardiol
2018
;
72
:
823
834
.

280

Bakkestrom
 
R
,
Banke
A
,
Christensen
NL
,
Pecini
R
,
Irmukhamedov
A
,
Andersen
M
,
Borlaug
BA
,
Moller
JE.
 
Hemodynamic characteristics in significant symptomatic and asymptomatic primary mitral valve regurgitation at rest and during exercise
.
Circ Cardiovasc Imaging
2018
;
11
:
e007171
.

281

Utsunomiya
 
H
,
Hidaka
T
,
Susawa
H
,
Izumi
K
,
Harada
Y
,
Kinoshita
M
,
Itakura
K
,
Masada
K
,
Kihara
Y.
 
Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally symptomatic patients with degenerative mitral regurgitation combined invasive-noninvasive hemodynamic monitoring
.
Circ Cardiovasc Imaging
2018
;
11
:
e007282
.

282

Pizarro
 
R
,
Bazzino
OO
,
Oberti
PF
,
Falconi
M
,
Achilli
F
,
Arias
A
,
Krauss
JG
,
Cagide
AM.
 
Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation
.
J Am Coll Cardiol
2009
;
54
:
1099
1106
.

283

Hiemstra
 
YL
,
Tomsic
A
,
van Wijngaarden
SE
,
Palmen
M
,
Klautz
RJM
,
Bax
JJ
,
Delgado
V
,
Ajmone Marsan
N.
 
Prognostic value of global longitudinal strain and etiology after surgery for primary mitral regurgitation
.
JACC Cardiovasc Imaging
2020
;
13
:
577
585
.

284

Kim
 
HM
,
Cho
GY
,
Hwang
IC
,
Choi
HM
,
Park
JB
,
Yoon
YE
,
Kim
HK.
 
Myocardial strain in prediction of outcomes after surgery for severe mitral regurgitation
.
JACC Cardiovasc Imaging
2018
;
11
:
1235
1244
.

285

Grigioni
 
F
,
Clavel
MA
,
Vanoverschelde
JL
,
Tribouilloy
C
,
Pizarro
R
,
Huebner
M
,
Avierinos
JF
,
Barbieri
A
,
Suri
R
,
Pasquet
A
,
Rusinaru
D
,
Gargiulo
GD
,
Oberti
P
,
Theron
A
,
Bursi
F
,
Michelena
H
,
Lazam
S
,
Szymanski
C
,
Nkomo
VT
,
Schumacher
M
,
Bacchi-Reggiani
L
,
Enriquez-Sarano
M
,
MIDA Investigators
.
The MIDA Mortality Risk Score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation
.
Eur Heart J
2018
;
39
:
1281
1291
.

286

Tribouilloy
 
C
,
Grigioni
F
,
Avierinos
JF
,
Barbieri
A
,
Rusinaru
D
,
Szymanski
C
,
Ferlito
M
,
Tafanelli
L
,
Bursi
F
,
Trojette
F
,
Branzi
A
,
Habib
G
,
Modena
MG
,
Enriquez-Sarano
M
,
MIDA Investigators
.
Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study
.
J Am Coll Cardiol
2009
;
54
:
1961
1968
.

287

Essayagh
 
B
,
Antoine
C
,
Benfari
G
,
Messika-Zeitoun
D
,
Michelena
H
,
Le Tourneau
T
,
Mankad
S
,
Tribouilloy
CM
,
Thapa
P
,
Enriquez-Sarano
M.
 
Prognostic implications of left atrial enlargement in degenerative mitral regurgitation
.
J Am Coll Cardiol
2019
;
74
:
858
870
.

288

Rusinaru
 
D
,
Tribouilloy
C
,
Grigioni
F
,
Avierinos
JF
,
Suri
RM
,
Barbieri
A
,
Szymanski
C
,
Ferlito
M
,
Michelena
H
,
Tafanelli
L
,
Bursi
F
,
Mezghani
S
,
Branzi
A
,
Habib
G
,
Modena
MG
,
Enriquez-Sarano
M
,
Mitral Regurgitation International DAtabase (MIDA) Investigators
.
Left atrial size is a potent predictor of mortality in mitral regurgitation due to flail leaflets: results from a large international multicenter study
.
Circ Cardiovasc Imaging
2011
;
4
:
473
481
.

289

Barbieri
 
A
,
Bursi
F
,
Grigioni
F
,
Tribouilloy
C
,
Avierinos
JF
,
Michelena
HI
,
Rusinaru
D
,
Szymansky
C
,
Russo
A
,
Suri
R
,
Bacchi Reggiani
ML
,
Branzi
A
,
Modena
MG
,
Enriquez-Sarano
M
,
Mitral Regurgitation International DAtabase (MIDA) Investigators
.
Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study
.
Eur Heart J
2011
;
32
:
751
759
.

290

Grigioni
 
F
,
Benfari
G
,
Vanoverschelde
JL
,
Tribouilloy
C
,
Avierinos
JF
,
Bursi
F
,
Suri
RM
,
Guerra
F
,
Pasquet
A
,
Rusinaru
D
,
Marcelli
E
,
Theron
A
,
Barbieri
A
,
Michelena
H
,
Lazam
S
,
Szymanski
C
,
Nkomo
VT
,
Capucci
A
,
Thapa
P
,
Enriquez-Sarano
M
,
MIDA Investigators
.
Long-term implications of atrial fibrillation in patients with degenerative mitral regurgitation
.
J Am Coll Cardiol
2019
;
73
:
264
274
.

291

Szymanski
 
C
,
Magne
J
,
Fournier
A
,
Rusinaru
D
,
Touati
G
,
Tribouilloy
C.
 
Usefulness of preoperative atrial fibrillation to predict outcome and left ventricular dysfunction after valve repair for mitral valve prolapse
.
Am J Cardiol
2015
;
115
:
1448
1453
.

292

Suri
 
RM
,
Vanoverschelde
JL
,
Grigioni
F
,
Schaff
HV
,
Tribouilloy
C
,
Avierinos
JF
,
Barbieri
A
,
Pasquet
A
,
Huebner
M
,
Rusinaru
D
,
Russo
A
,
Michelena
HI
,
Enriquez-Sarano
M.
 
Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets
.
JAMA
2013
;
310
:
609
616
.

293

Jung
 
JC
,
Jang
MJ
,
Hwang
HY.
 
Meta-analysis comparing mitral valve repair versus replacement for degenerative mitral regurgitation across all ages
.
Am J Cardiol
2019
;
123
:
446
453
.

294

Lazam
 
S
,
Vanoverschelde
JL
,
Tribouilloy
C
,
Grigioni
F
,
Suri
RM
,
Avierinos
JF
,
de Meester
C
,
Barbieri
A
,
Rusinaru
D
,
Russo
A
,
Pasquet
A
,
Michelena
HI
,
Huebner
M
,
Maalouf
J
,
Clavel
MA
,
Szymanski
C
,
Enriquez-Sarano
M
,
MIDA Investigators
.
Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry
.
Circulation
2017
;
135
:
410
422
.

295

Chikwe
 
J
,
Toyoda
N
,
Anyanwu
AC
,
Itagaki
S
,
Egorova
NN
,
Boateng
P
,
El-Eshmawi
A
,
Adams
DH.
 
Relation of mitral valve surgery volume to repair rate, durability, and survival
.
J Am Coll Cardiol
2017
;doi: 10.1016/j.jacc.2017.02.026.

296

David
 
TE
,
David
CM
,
Tsang
W
,
Lafreniere-Roula
M
,
Manlhiot
C.
 
Long-term results of mitral valve repair for regurgitation due to leaflet prolapse
.
J Am Coll Cardiol
2019
;
74
:
1044
1053
.

297

Donnellan
 
E
,
Alashi
A
,
Johnston
DR
,
Gillinov
AM
,
Pettersson
GB
,
Svensson
LG
,
Griffin
BP
,
Desai
MY.
 
Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery
.
Circulation
2019
;
140
:
1288
1290
.

298

Vakamudi
 
S
,
Jellis
C
,
Mick
S
,
Wu
Y
,
Gillinov
AM
,
Mihaljevic
T
,
Cosgrove
DM
,
Svensson
L
,
Cho
L.
 
Sex differences in the etiology of surgical mitral valve disease
.
Circulation
2018
;
138
:
1749
1751
.

299

Feldman
 
T
,
Foster
E
,
Glower
DD
,
Kar
S
,
Rinaldi
MJ
,
Fail
PS
,
Smalling
RW
,
Siegel
R
,
Rose
GA
,
Engeron
E
,
Loghin
C
,
Trento
A
,
Skipper
ER
,
Fudge
T
,
Letsou
GV
,
Massaro
JM
,
Mauri
L
,
EVEREST II Investigators
.
Percutaneous repair or surgery for mitral regurgitation
.
N Engl J Med
2011
;
364
:
1395
1406
.

300

Feldman
 
T
,
Kar
S
,
Elmariah
S
,
Smart
SC
,
Trento
A
,
Siegel
RJ
,
Apruzzese
P
,
Fail
P
,
Rinaldi
MJ
,
Smalling
RW
,
Hermiller
JB
,
Heimansohn
D
,
Gray
WA
,
Grayburn
PA
,
Mack
MJ
,
Lim
DS
,
Ailawadi
G
,
Herrmann
HC
,
Acker
MA
,
Silvestry
FE
,
Foster
E
,
Wang
A
,
Glower
DD
,
Mauri
L
,
EVEREST II Investigators
.
Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II
.
J Am Coll Cardiol
2015
;
66
:
2844
2854
.

301

Buzzatti
 
N
,
Van Hemelrijck
M
,
Denti
P
,
Ruggeri
S
,
Schiavi
D
,
Scarfo
IS
,
Reser
D
,
Taramasso
M
,
Weber
A
,
La Canna
G
,
De Bonis
M
,
Maisano
F
,
Alfieri
O.
 
Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis
.
J Thorac Cardiovasc Surg
2019
;
158
:
86
94 e81
.

302

Sorajja
 
P
,
Vemulapalli
S
,
Feldman
T
,
Mack
M
,
Holmes
DR
Jr.
,
Stebbins
A
,
Kar
S
,
Thourani
V
,
Ailawadi
G.
 
Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report
.
J Am Coll Cardiol
2017
;
70
:
2315
2327
.

303

Gammie
 
JS
,
Bartus
K
,
Gackowski
A
,
D’Ambra
MN
,
Szymanski
P
,
Bilewska
A
,
Kusmierczyk
M
,
Kapelak
B
,
Rzucidlo-Resil
J
,
Moat
N
,
Duncan
A
,
Yadev
R
,
Livesey
S
,
Diprose
P
,
Gerosa
G
,
D’Onofrio
A
,
Pitterello
D
,
Denti
P
,
La Canna
G
,
De Bonis
M
,
Alfieri
O
,
Hung
J
,
Kolsut
P.
 
Beating-heart mitral valve repair using a novel ePTFE cordal implantation device: a prospective trial
.
J Am Coll Cardiol
2018
;
71
:
25
36
.

304

Lim
 
DS
,
Kar
S
,
Spargias
K
,
Kipperman
RM
,
O’Neill
WW
,
Ng
MKC
,
Fam
NP
,
Walters
DL
,
Webb
JG
,
Smith
RL
,
Rinaldi
MJ
,
Latib
A
,
Cohen
GN
,
Schafer
U
,
Marcoff
L
,
Vandrangi
P
,
Verta
P
,
Feldman
TE.
 
Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP Study
.
JACC Cardiovasc Interv
2019
;
12
:
1369
1378
.

305

Praz
 
F
,
Braun
D
,
Unterhuber
M
,
Spirito
A
,
Orban
M
,
Brugger
N
,
Brinkmann
I
,
Spring
K
,
Moschovitis
A
,
Nabauer
M
,
Blazek
S
,
Pilgrim
T
,
Thiele
H
,
Lurz
P
,
Hausleiter
J
,
Windecker
S.
 
Edge-to-edge mitral valve repair with extended clip arms: early experience from a multicenter observational study
.
JACC Cardiovasc Interv
2019
;
12
:
1356
1365
.

306

Praz
 
F
,
Spargias
K
,
Chrissoheris
M
,
Bullesfeld
L
,
Nickenig
G
,
Deuschl
F
,
Schueler
R
,
Fam
NP
,
Moss
R
,
Makar
M
,
Boone
R
,
Edwards
J
,
Moschovitis
A
,
Kar
S
,
Webb
J
,
Schafer
U
,
Feldman
T
,
Windecker
S.
 
Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study
.
Lancet
2017
;
390
:
773
780
.

307

Chakravarty
 
T
,
Makar
M
,
Patel
D
,
Oakley
L
,
Yoon
SH
,
Stegic
J
,
Singh
S
,
Skaf
S
,
Nakamura
M
,
Makkar
RR.
 
Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 system
.
JACC Cardiovasc Interv
2020
;
13
:
2402
2414
.

308

Piriou
 
N
,
Al Habash
O
,
Donal
E
,
Senage
T
,
Le Tourneau
T
,
Pattier
S
,
Guyomarch
B
,
Roussel
JC
,
Trochu
JN
,
Vahanian
A
,
Obadia
JF
,
Iung
B
,
Guerin
P.
 
The MITRA-HR study: design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery
.
EuroIntervention
2019
;
15
:
e329
e335
.

309

Zilberszac
 
R
,
Heinze
G
,
Binder
T
,
Laufer
G
,
Gabriel
H
,
Rosenhek
R.
 
Long-term outcome of active surveillance in severe but asymptomatic primary mitral regurgitation
.
JACC Cardiovasc Imaging
2018
;
11
:
1213
1221
.

310

Dejgaard
 
LA
,
Skjolsvik
ET
,
Lie
OH
,
Ribe
M
,
Stokke
MK
,
Hegbom
F
,
Scheirlynck
ES
,
Gjertsen
E
,
Andresen
K
,
Helle-Valle
TM
,
Hopp
E
,
Edvardsen
T
,
Haugaa
KH.
 
The mitral annulus disjunction arrhythmic syndrome
.
J Am Coll Cardiol
2018
;
72
:
1600
1609
.

311

Han
 
HC
,
Ha
FJ
,
Teh
AW
,
Calafiore
P
,
Jones
EF
,
Johns
J
,
Koshy
AN
,
O’Donnell
D
,
Hare
DL
,
Farouque
O
,
Lim
HS.
 
Mitral valve prolapse and sudden cardiac death: a systematic review
.
J Am Heart Assoc
2018
;
7
:
e010584
.

312

Nalliah
 
CJ
,
Mahajan
R
,
Elliott
AD
,
Haqqani
H
,
Lau
DH
,
Vohra
JK
,
Morton
JB
,
Semsarian
C
,
Marwick
T
,
Kalman
JM
,
Sanders
P.
 
Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis
.
Heart
2019
;
105
:
144
151
.

313

Essayagh
 
B
,
Sabbag
A
,
Antoine
C
,
Benfari
G
,
Yang
LT
,
Maalouf
J
,
Asirvatham
S
,
Michelena
H
,
Enriquez-Sarano
M.
 
Presentation and outcome of arrhythmic mitral valve prolapse
.
J Am Coll Cardiol
2020
;
76
:
637
649
.

314

Lancellotti
 
P
,
Pibarot
P
,
Chambers
J
,
Edvardsen
T
,
Delgado
V
,
Dulgheru
R
,
Pepi
M
,
Cosyns
B
,
Dweck
MR
,
Garbi
M
,
Magne
J
,
Nieman
K
,
Rosenhek
R
,
Bernard
A
,
Lowenstein
J
,
Vieira
ML
,
Rabischoffsky
A
,
Vyhmeister
RH
,
Zhou
X
,
Zhang
Y
,
Zamorano
JL
,
Habib
G.
 
Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
2016
;
17
:
589
590
.

315

Yu
 
M
,
Georges
A
,
Tucker
NR
,
Kyryachenko
S
,
Toomer
K
,
Schott
JJ
,
Delling
FN
,
Fernandez-Friera
L
,
Solis
J
,
Ellinor
PT
,
Levine
RA
,
Slaugenhaupt
SA
,
Hagege
AA
,
Dina
C
,
Jeunemaitre
X
,
Milan
DJ
,
Norris
RA
,
Bouatia-Naji
N.
 
Genome-wide association study-driven gene-set analyses, genetic, and functional follow-up suggest GLIS1 as a susceptibility gene for mitral valve prolapse
.
Circ Genom Precis Med
2019
;
12
:
e002497
.

316

Mantovani
 
F
,
Clavel
MA
,
Michelena
HI
,
Suri
RM
,
Schaff
HV
,
Enriquez-Sarano
M.
 
Comprehensive imaging in women with organic mitral regurgitation: implications for clinical outcome
.
JACC Cardiovasc Imaging
2016
;
9
:
388
396
.

317

Asgar
 
AW
,
Mack
MJ
,
Stone
GW.
 
Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations
.
J Am Coll Cardiol
2015
;
65
:
1231
1248
.

318

Bertrand
 
PB
,
Schwammenthal
E
,
Levine
RA
,
Vandervoort
PM.
 
Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications
.
Circulation
2017
;
135
:
297
314
.

319

Deferm
 
S
,
Bertrand
PB
,
Verbrugge
FH
,
Verhaert
D
,
Rega
F
,
Thomas
JD
,
Vandervoort
PM.
 
Atrial functional mitral regurgitation: JACC Review Topic of the Week
.
J Am Coll Cardiol
2019
;
73
:
2465
2476
.

320

Bartko
 
PE
,
Arfsten
H
,
Heitzinger
G
,
Pavo
N
,
Toma
A
,
Strunk
G
,
Hengstenberg
C
,
Hulsmann
M
,
Goliasch
G.
 
A unifying concept for the quantitative assessment of secondary mitral regurgitation
.
J Am Coll Cardiol
2019
;
73
:
2506
2517
.

321

Goliasch
 
G
,
Bartko
PE
,
Pavo
N
,
Neuhold
S
,
Wurm
R
,
Mascherbauer
J
,
Lang
IM
,
Strunk
G
,
Hulsmann
M.
 
Refining the prognostic impact of functional mitral regurgitation in chronic heart failure
.
Eur Heart J
2018
;
39
:
39
46
.

322

Michler
 
RE
,
Smith
PK
,
Parides
MK
,
Ailawadi
G
,
Thourani
V
,
Moskowitz
AJ
,
Acker
MA
,
Hung
JW
,
Chang
HL
,
Perrault
LP
,
Gillinov
AM
,
Argenziano
M
,
Bagiella
E
,
Overbey
JR
,
Moquete
EG
,
Gupta
LN
,
Miller
MA
,
Taddei-Peters
WC
,
Jeffries
N
,
Weisel
RD
,
Rose
EA
,
Gammie
JS
,
DeRose
JJ
Jr
,
Puskas
JD
,
Dagenais
F
,
Burks
SG
,
El-Hamamsy
I
,
Milano
CA
,
Atluri
P
,
Voisine
P
,
O’Gara
PT
,
Gelijns
AC
,
CTSN. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation
.
N Engl J Med
2016
;
374
:
1932
1941
.

323

Obadia
 
JF
,
Messika-Zeitoun
D
,
Leurent
G
,
Iung
B
,
Bonnet
G
,
Piriou
N
,
Lefevre
T
,
Piot
C
,
Rouleau
F
,
Carrie
D
,
Nejjari
M
,
Ohlmann
P
,
Leclercq
F
,
Saint Etienne
C
,
Teiger
E
,
Leroux
L
,
Karam
N
,
Michel
N
,
Gilard
M
,
Donal
E
,
Trochu
JN
,
Cormier
B
,
Armoiry
X
,
Boutitie
F
,
Maucort-Boulch
D
,
Barnel
C
,
Samson
G
,
Guerin
P
,
Vahanian
A
,
Mewton
N
,
MITRA-FR Investigators
.
Percutaneous repair or medical treatment for secondary mitral regurgitation
.
N Engl J Med
2018
;
379
:
2297
2306
.

324

Cavalcante
 
JL
,
Kusunose
K
,
Obuchowski
NA
,
Jellis
C
,
Griffin
BP
,
Flamm
SD
,
Kwon
DH.
 
Prognostic impact of ischemic mitral regurgitation severity and myocardial infarct quantification by cardiovascular magnetic resonance
.
JACC Cardiovasc Imaging
2020
;
13
:
1489
1501
.

325

Kamperidis
 
V
,
Marsan
NA
,
Delgado
V
,
Bax
JJ.
 
Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain
.
Eur Heart J
2016
;
37
:
811
816
.

326

Namazi
 
F
,
van der Bijl
P
,
Hirasawa
K
,
Kamperidis
V
,
van Wijngaarden
SE
,
Mertens
B
,
Leon
MB
,
Hahn
RT
,
Stone
GW
,
Narula
J
,
Ajmone Marsan
N
,
Delgado
V
,
Bax
JJ.
 
Prognostic value of left ventricular global longitudinal strain in patients with secondary mitral regurgitation
.
J Am Coll Cardiol
2020
;
75
:
750
758
.

327

Kang
 
DH
,
Park
SJ
,
Shin
SH
,
Hong
GR
,
Lee
S
,
Kim
MS
,
Yun
SC
,
Song
JM
,
Park
SW
,
Kim
JJ.
 
Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation
.
Circulation
2019
;
139
:
1354
1365
.

328

Grigioni
 
F
,
Enriquez-Sarano
M
,
Zehr
KJ
,
Bailey
KR
,
Tajik
AJ.
 
Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment
.
Circulation
2001
;
103
:
1759
1764
.

329

Acker
 
MA
,
Jessup
M
,
Bolling
SF
,
Oh
J
,
Starling
RC
,
Mann
DL
,
Sabbah
HN
,
Shemin
R
,
Kirklin
J
,
Kubo
SH.
 
Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial
.
J Thorac Cardiovasc Surg
2011
;
142
:
569
574
, 574 e561.

330

Deja
 
MA
,
Grayburn
PA
,
Sun
B
,
Rao
V
,
She
L
,
Krejca
M
,
Jain
AR
,
Leng Chua
Y
,
Daly
R
,
Senni
M
,
Mokrzycki
K
,
Menicanti
L
,
Oh
JK
,
Michler
R
,
Wrobel
K
,
Lamy
A
,
Velazquez
EJ
,
Lee
KL
,
Jones
RH.
 
Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial
.
Circulation
2012
;
125
:
2639
2648
.

331

Petrus
 
AHJ
,
Dekkers
OM
,
Tops
LF
,
Timmer
E
,
Klautz
RJM
,
Braun
J.
 
Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation: long-term analysis of competing outcomes
.
Eur Heart J
2019
;
40
:
2206
2214
.

332

Harmel
 
EK
,
Reichenspurner
H
,
Girdauskas
E.
 
Subannular reconstruction in secondary mitral regurgitation: a meta-analysis
.
Heart
2018
;
104
:
1783
1790
.

333

Acker
 
MA
,
Parides
MK
,
Perrault
LP
,
Moskowitz
AJ
,
Gelijns
AC
,
Voisine
P
,
Smith
PK
,
Hung
JW
,
Blackstone
EH
,
Puskas
JD
,
Argenziano
M
,
Gammie
JS
,
Mack
M
,
Ascheim
DD
,
Bagiella
E
,
Moquete
EG
,
Ferguson
TB
,
Horvath
KA
,
Geller
NL
,
Miller
MA
,
Woo
YJ
,
D’Alessandro
DA
,
Ailawadi
G
,
Dagenais
F
,
Gardner
TJ
,
O’Gara
PT
,
Michler
RE
,
Kron
IL
,
CTSN
.
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation
.
N Engl J Med
2014
;
370
:
23
32
.

334

Mihaljevic
 
T
,
Lam
BK
,
Rajeswaran
J
,
Takagaki
M
,
Lauer
MS
,
Gillinov
AM
,
Blackstone
EH
,
Lytle
BW.
 
Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation
.
J Am Coll Cardiol
2007
;
49
:
2191
2201
.

335

Wu
 
AH
,
Aaronson
KD
,
Bolling
SF
,
Pagani
FD
,
Welch
K
,
Koelling
TM.
 
Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction
.
J Am Coll Cardiol
2005
;
45
:
381
387
.

336

Iung
 
B
,
Armoiry
X
,
Vahanian
A
,
Boutitie
F
,
Mewton
N
,
Trochu
JN
,
Lefevre
T
,
Messika-Zeitoun
D
,
Guerin
P
,
Cormier
B
,
Brochet
E
,
Thibault
H
,
Himbert
D
,
Thivolet
S
,
Leurent
G
,
Bonnet
G
,
Donal
E
,
Piriou
N
,
Piot
C
,
Habib
G
,
Rouleau
F
,
Carrie
D
,
Nejjari
M
,
Ohlmann
P
,
Saint Etienne
C
,
Leroux
L
,
Gilard
M
,
Samson
G
,
Rioufol
G
,
Maucort-Boulch
D
,
Obadia
JF
,
MITRA-FR Investigators
.
Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years
.
Eur J Heart Fail
2019
;
21
:
1619
1627
.

337

Stone
 
GW
,
Lindenfeld
J
,
Abraham
WT
,
Kar
S
,
Lim
DS
,
Mishell
JM
,
Whisenant
B
,
Grayburn
PA
,
Rinaldi
M
,
Kapadia
SR
,
Rajagopal
V
,
Sarembock
IJ
,
Brieke
A
,
Marx
SO
,
Cohen
DJ
,
Weissman
NJ
,
Mack
MJ
,
COAPT Investigators
.
Transcatheter mitral-valve repair in patients with heart failure
.
N Engl J Med
2018
;
379
:
2307
2318
.

338

Mack
 
MJ
,
Lindenfeld
J
,
Abraham
WT
,
Kar
S
,
Lim
DS
,
Mishell
JM
,
Whisenant
BK
,
Grayburn
PA
,
Rinaldi
MJ
,
Kapadia
SR
,
Rajagopal
V
,
Sarembock
IJ
,
Brieke
A
,
Rogers
JH
,
Marx
SO
,
Cohen
DJ
,
Weissman
NJ
,
Stone
GW
,
COAPT Investigators
.
3-Year outcomes of transcatheter mitral valve repair in patients with heart failure
.
J Am Coll Cardiol
2021
;
77
:
1029
1040
.

339

Giustino
 
G
,
Lindenfeld
J
,
Abraham
WT
,
Kar
S
,
Lim
DS
,
Grayburn
PA
,
Kapadia
SR
,
Cohen
DJ
,
Kotinkaduwa
LN
,
Weissman
NJ
,
Mack
MJ
,
Stone
GW.
 
NYHA functional classification and outcomes after transcatheter mitral valve repair in heart failure: the COAPT Trial
.
JACC Cardiovasc Interv
2020
;
13
:
2317
2328
.

340

Malik
 
UI
,
Ambrosy
AP
,
Ku
IA
,
Mishell
JM
,
Kar
S
,
Lim
DS
,
Whisenant
BK
,
Cohen
DJ
,
Arnold
SV
,
Kotinkaduwa
LN
,
Lindenfeld
J
,
Abraham
WT
,
Mack
MJ
,
Stone
GW.
 
Baseline functional capacity and transcatheter mitral valve repair in heart failure with secondary mitral regurgitation
.
JACC Cardiovasc Interv
2020
;
13
:
2331
2341
.

341

Kosmidou
 
I
,
Lindenfeld
J
,
Abraham
WT
,
Kar
S
,
Lim
DS
,
Mishell
JM
,
Whisenant
BK
,
Kipperman
RM
,
Boudoulas
KD
,
Redfors
B
,
Shahim
B
,
Zhang
Z
,
Mack
MJ
,
Stone
GW.
 
Transcatheter mitral valve repair in patients with and without cardiac resynchronization therapy: the COAPT Trial
.
Circ Heart Fail
2020
;
13
:
e007293
.

342

Lerakis
 
S
,
Kini
AS
,
Asch
FM
,
Kar
S
,
Lim
DS
,
Mishell
JM
,
Whisenant
B
,
Grayburn
PA
,
Weissman
NJ
,
Rinaldi
MJ
,
Sharma
SK
,
Kapadia
SR
,
Rajagopal
V
,
Sarembock
IJ
,
Brieke
A
,
Tang
GHL
,
Li
D
,
Crowley
A
,
Lindenfeld
J
,
Abraham
WT
,
Mack
MJ
,
Stone
GW.
 
Outcomes of transcatheter mitral valve repair for secondary mitral regurgitation by severity of left ventricular dysfunction
.
EuroIntervention
2021
;
17
:
e335
e342
.

343

Gertz
 
ZM
,
Herrmann
HC
,
Lim
DS
,
Kar
S
,
Kapadia
SR
,
Reed
GW
,
Puri
R
,
Krishnaswamy
A
,
Gersh
BJ
,
Weissman
NJ
,
Asch
FM
,
Grayburn
PA
,
Kosmidou
I
,
Redfors
B
,
Zhang
Z
,
Abraham
WT
,
Lindenfeld
J
,
Stone
GW
,
Mack
MJ.
 
Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT Trial
.
Circ Cardiovasc Interv
2021
;
14
:e010300.

344

Messika-Zeitoun
 
D
,
Iung
B
,
Armoiry
X
,
Trochu
JN
,
Donal
E
,
Habib
G
,
Brochet
E
,
Thibault
H
,
Piriou
N
,
Cormier
B
,
Tribouilloy
C
,
Guerin
P
,
Lefevre
T
,
Maucort-Boulch
D
,
Vahanian
A
,
Boutitie
F
,
Obadia
JF.
 
Impact of mitral regurgitation severity and left ventricular remodeling on outcome after MitraClip implantation: results from the Mitra-FR Trial
.
JACC Cardiovasc Imaging
2021
;
14
:
742
752
.

345

Grayburn
 
PA
,
Sannino
A
,
Packer
M.
 
Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials
.
JACC Cardiovasc Imaging
2019
;
12
:
353
362
.

346

Mack
 
MJ
,
Abraham
WT
,
Lindenfeld
J
,
Bolling
SF
,
Feldman
TE
,
Grayburn
PA
,
Kapadia
SR
,
McCarthy
PM
,
Lim
DS
,
Udelson
JE
,
Zile
MR
,
Gammie
JS
,
Gillinov
AM
,
Glower
DD
,
Heimansohn
DA
,
Suri
RM
,
Ellis
JT
,
Shu
Y
,
Kar
S
,
Weissman
NJ
,
Stone
GW.
 
Cardiovascular outcomes assessment of the MitraClip in patients with heart failure and secondary mitral regurgitation: design and rationale of the COAPT trial
.
Am Heart J
2018
;
205
:
1
11
.

347

Asch
 
FM
,
Grayburn
PA
,
Siegel
RJ
,
Kar
S
,
Lim
DS
,
Zaroff
JG
,
Mishell
JM
,
Whisenant
B
,
Mack
MJ
,
Lindenfeld
J
,
Abraham
WT
,
Stone
GW
,
Weissman
NJ
,
COAPT Investigators
.
Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation: the COAPT Trial
.
J Am Coll Cardiol
2019
;
74
:
2969
2979
.

348

Coats
 
AJS
,
Anker
SD
,
Baumbach
A
,
Alfieri
O
,
von Bardeleben
RS
,
Bauersachs
J
,
Bax
JJ
,
Boveda
S
,
Celutkiene
J
,
Cleland
JG
,
Dagres
N
,
Deneke
T
,
Farmakis
D
,
Filippatos
G
,
Hausleiter
J
,
Hindricks
G
,
Jankowska
EA
,
Lainscak
M
,
Leclercq
C
,
Lund
LH
,
McDonagh
T
,
Mehra
MR
,
Metra
M
,
Mewton
N
,
Mueller
C
,
Mullens
W
,
Muneretto
C
,
Obadia
JF
,
Ponikowski
P
,
Praz
F
,
Rudolph
V
,
Ruschitzka
F
,
Vahanian
A
,
Windecker
S
,
Zamorano
JL
,
Edvardsen
T
,
Heidbuchel
H
,
Seferovic PM, Prendergast B
.
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
.
Eur Heart J
2021
;
42
:
1254
1269
.

349

Pibarot
 
P
,
Delgado
V
,
Bax
JJ.
 
MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results
.
Eur Heart J Cardiovasc Imaging
2019
;
20
:
620
624
.

350

Praz
 
F
,
Grasso
C
,
Taramasso
M
,
Baumbach
A
,
Piazza
N
,
Tamburino
C
,
Windecker
S
,
Maisano
F
,
Prendergast
B.
 
Mitral regurgitation in heart failure: time for a rethink
.
Eur Heart J
2019
;
40
:
2189
2193
.

351

Adamo
 
M
,
Grasso
C
,
Capodanno
D
,
Rubbio
AP
,
Scandura
S
,
Giannini
C
,
Fiorelli
F
,
Fiorina
C
,
Branca
L
,
Brambilla
N
,
Bedogni
F
,
Petronio
AS
,
Curello
S
,
Tamburino
C.
 
Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: insights from the multicenter GRASP-IT registry
.
Am Heart J
2019
;
217
:
32
41
.

352

Ailawadi
 
G
,
Lim
DS
,
Mack
MJ
,
Trento
A
,
Kar
S
,
Grayburn
PA
,
Glower
DD
,
Wang
A
,
Foster
E
,
Qasim
A
,
Weissman
NJ
,
Ellis
J
,
Crosson
L
,
Fan
F
,
Kron
IL
,
Pearson
PJ
,
Feldman
T
,
EVEREST II Investigators
.
One-year outcomes after MitraClip for functional mitral regurgitation
.
Circulation
2019
;
139
:
37
47
.

353

Iliadis
 
C
,
Metze
C
,
Korber
MI
,
Baldus
S
,
Pfister
R.
 
Impact of COAPT trial exclusion criteria in real-world patients undergoing transcatheter mitral valve repair
.
Int J Cardiol
2020
;
316
:
189
194
.

354

Lindenfeld
 
J
,
Abraham
WT
,
Grayburn
PA
,
Kar
S
,
Asch
FM
,
Lim
DS
,
Nie
H
,
Singhal
P
,
Sundareswaran
KS
,
Weissman
NJ
,
Mack
MJ
,
Stone
GW
,
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Investigators
.
Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT Trial
.
JAMA Cardiol
2021
;
6
:
427
436
.

355

Jung
 
RG
,
Simard
T
,
Kovach
C
,
Flint
K
,
Don
C
,
Di Santo
P
,
Adamo
M
,
Branca
L
,
Valentini
F
,
Benito-Gonzalez
T
,
Fernandez-Vazquez
F
,
Estevez-Loureiro
R
,
Berardini
A
,
Conti
N
,
Rapezzi
C
,
Biagini
E
,
Parlow
S
,
Shorr
R
,
Levi
A
,
Manovel
A
,
Cardenal-Piris
R
,
Diaz Fernandez
J
,
Shuvy
M
,
Haberman
D
,
Sala
A
,
Alkhouli
MA
,
Marini
C
,
Bargagna
M
,
Schiavi
D
,
Denti
P
,
Markovic
S
,
Buzzatti
N
,
Chan
V
,
Hynes
M
,
Mesana
T
,
Labinaz
M
,
Pappalardo
F
,
Taramasso
M
,
Hibbert
B.
 
Transcatheter mitral valve repair in cardiogenic shock and mitral regurgitation: a patient-level, multicenter analysis
.
JACC Cardiovasc Interv
2021
;
14
:
1
11
.

356

Adamo
 
M
,
Fiorelli
F
,
Melica
B
,
D’Ortona
R
,
Lupi
L
,
Giannini
C
,
Silva
G
,
Fiorina
C
,
Branca
L
,
Chiari
E
,
Chizzola
G
,
Spontoni
P
,
Espada Guerreiro
C
,
Curello
S
,
Petronio
AS
,
Metra
M
 
COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation
.
JACC Cardiovasc Interv
2021
;
14
:
15
25
.

357

Iung
 
B
,
Messika-Zeitoun
D
,
Boutitie
F
,
Trochu
JN
,
Armoiry
X
,
Maucort-Boulch
D
,
Obadia
JF
,
Vahanian
A.
 
Characteristics and outcome of COAPT-eligible patients in the MITRA-FR Trial
.
Circulation
2020
;
142
:
2482
2484
.

358

Iung
 
B
,
Vahanian
A.
 
Epidemiology of acquired valvular heart disease
.
Can J Cardiol
2014
;
30
:
962
970
.

359

Abramowitz
 
Y
,
Jilaihawi
H
,
Chakravarty
T
,
Mack
MJ
,
Makkar
RR.
 
Mitral annulus calcification
.
J Am Coll Cardiol
2015
;
66
:
1934
1941
.

360

Desnos
 
C
,
Iung
B
,
Himbert
D
,
Ducrocq
G
,
Urena
M
,
Cormier
B
,
Brochet
E
,
Ou
P
,
Vahanian
A
,
Bouleti
C.
 
Temporal trends on percutaneous mitral commissurotomy: 30 years of experience
.
J Am Heart Assoc
2019
;
8
:
e012031
.

361

Andell
 
P
,
Li
X
,
Martinsson
A
,
Andersson
C
,
Stagmo
M
,
Zoller
B
,
Sundquist
K
,
Smith
JG.
 
Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study
.
Heart
2017
;
103
:
1696
1703
.

362

Baumgartner
 
H
,
Hung
J
,
Bermejo
J
,
Chambers
JB
,
Evangelista
A
,
Griffin
BP
,
Iung
B
,
Otto
CM
,
Pellikka
PA
,
Quinones
M
,
EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice
.
Eur J Echocardiogr
2009
;
10
:
1
25
.

363

Bouleti
 
C
,
Iung
B
,
Laouenan
C
,
Himbert
D
,
Brochet
E
,
Messika-Zeitoun
D
,
Detaint
D
,
Garbarz
E
,
Cormier
B
,
Michel
PL
,
Mentre
F
,
Vahanian
A.
 
Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients
.
Circulation
2012
;
125
:
2119
2127
.

364

Nunes
 
MC
,
Tan
TC
,
Elmariah
S
,
do Lago
R
,
Margey
R
,
Cruz-Gonzalez
I
,
Zheng
H
,
Handschumacher
MD
,
Inglessis
I
,
Palacios
IF
,
Weyman
AE
,
Hung
J.
 
The echo score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty
.
Circulation
2014
;
129
:
886
895
.

365

Wilkins
 
GT
,
Weyman
AE
,
Abascal
VM
,
Block
PC
,
Palacios
IF.
 
Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation
.
Br Heart J
1988
;
60
:
299
308
.

366

Badheka
 
AO
,
Shah
N
,
Ghatak
A
,
Patel
NJ
,
Chothani
A
,
Mehta
K
,
Singh
V
,
Patel
N
,
Grover
P
,
Deshmukh
A
,
Panaich
SS
,
Savani
GT
,
Bhalara
V
,
Arora
S
,
Rathod
A
,
Desai
H
,
Kar
S
,
Alfonso
C
,
Palacios
IF
,
Grines
C
,
Schreiber
T
,
Rihal
CS
,
Makkar
R
,
Cohen
MG
,
O’Neill
W
,
de Marchena
E.
 
Balloon mitral valvuloplasty in the United States: a 13-year perspective
.
Am J Med
2014
;
127
:
1126.e1
1126.e12
.

367

Tomai
 
F
,
Gaspardone
A
,
Versaci
F
,
Ghini
AS
,
Altamura
L
,
De Luca
L
,
Gioffre
G
,
Gioffre
PA.
 
Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis
.
Int J Cardiol
2014
;
177
:
881
885
.

368

Bouleti
 
C
,
Iung
B
,
Himbert
D
,
Messika-Zeitoun
D
,
Brochet
E
,
Garbarz
E
,
Cormier
B
,
Vahanian
A.
 
Relationship between valve calcification and long-term results of percutaneous mitral commissurotomy for rheumatic mitral stenosis
.
Circ Cardiovasc Interv
2014
;
7
:
381
389
.

369

Bouleti
 
C
,
Iung
B
,
Himbert
D
,
Brochet
E
,
Messika-Zeitoun
D
,
Detaint
D
,
Garbarz
E
,
Cormier
B
,
Vahanian
A.
 
Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy
.
Eur Heart J
2013
;
34
:
1923
1930
.

370

Kim
 
JY
,
Kim
SH
,
Myong
JP
,
Kim
YR
,
Kim
TS
,
Kim
JH
,
Jang
SW
,
Oh
YS
,
Lee
MY
,
Rho
TH.
 
Outcomes of direct oral anticoagulants in patients with mitral stenosis
.
J Am Coll Cardiol
2019
;
73
:
1123
1131
.

371

Song
 
H
,
Kang
DH
,
Kim
JH
,
Park
KM
,
Song
JM
,
Choi
KJ
,
Hong
MK
,
Chung
CH
,
Song
JK
,
Lee
JW
,
Park
SW
,
Park
SJ.
 
Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation
.
Circulation
2007
;
116
:
I246
250
.

372

El Sabbagh
 
A
,
Reddy
YNV
,
Barros-Gomes
S
,
Borlaug
BA
,
Miranda
WR
,
Pislaru
SV
,
Nishimura
RA
,
Pellikka
PA.
 
Low-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and outcomes
.
J Am Heart Assoc
2019
;
8
:
e010736
.

373

Kato
 
N
,
Padang
R
,
Scott
CG
,
Guerrero
M
,
Pislaru
SV
,
Pellikka
PA.
 
The natural history of severe calcific mitral stenosis
.
J Am Coll Cardiol
2020
;
75
:
3048
3057
.

374

Nishimura
 
RA
,
Vahanian
A
,
Eleid
MF
,
Mack
MJ.
 
Mitral valve disease–current management and future challenges
.
Lancet
2016
;
387
:
1324
1334
.

375

Barasch
 
E
,
Gottdiener
JS
,
Larsen
EK
,
Chaves
PH
,
Newman
AB
,
Manolio
TA.
 
Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS)
.
Am Heart J
2006
;
151
:
39
47
.

376

Alexis
 
SL
,
Malik
AH
,
El-Eshmawi
A
,
George
I
,
Sengupta
A
,
Kodali
SK
,
Hahn
RT
,
Khalique
OK
,
Zaid
S
,
Guerrero
M
,
Bapat
VN
,
Leon
MB
,
Adams
DH
,
Tang
GHL.
 
Surgical and transcatheter mitral valve replacement in mitral annular calcification: a systematic review
.
J Am Heart Assoc
2021
;
10
:
e018514
.

377

Okuno
 
T
,
Brugger
N
,
Asami
M
,
Heg
D
,
Siontis
GCM
,
Winkel
MG
,
Lanz
J
,
Grani
C
,
Huber
A
,
Stortecky
S
,
George
I
,
Kodali
S
,
Pilgrim
T
,
Windecker
S
,
Khalique
OK
,
Praz
F.
 
Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation
.
J Cardiovasc Comput Tomogr
2021
;
15
:
356
365
.

378

Bertrand
 
PB
,
Churchill
TW
,
Yucel
E
,
Namasivayam
M
,
Bernard
S
,
Nagata
Y
,
He
W
,
Andrews
CT
,
Picard
MH
,
Weyman
AE
,
Levine
RA
,
Hung
J.
 
Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction
.
Eur Heart J
2020
;
41
:
4321
4328
.

379

Urena
 
M
,
Himbert
D
,
Brochet
E
,
Carrasco
JL
,
Iung
B
,
Nataf
P
,
Vahanian
A.
 
Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach
.
JACC Cardiovasc Interv
2017
;
10
:
1905
1919
.

380

Sud
 
K
,
Agarwal
S
,
Parashar
A
,
Raza
MQ
,
Patel
K
,
Min
D
,
Rodriguez
LL
,
Krishnaswamy
A
,
Mick
SL
,
Gillinov
AM
,
Tuzcu
EM
,
Kapadia
SR.
 
Degenerative mitral stenosis: unmet need for percutaneous interventions
.
Circulation
2016
;
133
:
1594
1604
.

381

Guerrero
 
M
,
Urena
M
,
Himbert
D
,
Wang
DD
,
Eleid
M
,
Kodali
S
,
George
I
,
Chakravarty
T
,
Mathur
M
,
Holzhey
D
,
Pershad
A
,
Fang
HK
,
O’Hair
D
,
Jones
N
,
Mahadevan
VS
,
Dumonteil
N
,
Rodes-Cabau
J
,
Piazza
N
,
Ferrari
E
,
Ciaburri
D
,
Nejjari
M
,
DeLago
A
,
Sorajja
P
,
Zahr
F
,
Rajagopal
V
,
Whisenant
B
,
Shah
PB
,
Sinning
JM
,
Witkowski
A
,
Eltchaninoff
H
,
Dvir
D
,
Martin
B
,
Attizzani
GF
,
Gaia
D
,
Nunes
NSV
,
Fassa
AA
,
Kerendi
F
,
Pavlides
G
,
Iyer
V
,
Kaddissi
G
,
Witzke
C
,
Wudel
J
,
Mishkel
G
,
Raybuck
B
,
Wang
C
,
Waksman
R
,
Palacios
I
,
Cribier
A
,
Webb
J
,
Bapat
V
,
Reisman
M
,
Makkar
R
,
Leon
M
,
Rihal
C
,
Vahanian
A
,
O’Neill
W
,
Feldman
T.
 
1-Year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification
.
J Am Coll Cardiol
2018
;
71
:
1841
1853
.

382

Yoon
 
SH
,
Whisenant
BK
,
Bleiziffer
S
,
Delgado
V
,
Dhoble
A
,
Schofer
N
,
Eschenbach
L
,
Bansal
E
,
Murdoch
DJ
,
Ancona
M
,
Schmidt
T
,
Yzeiraj
E
,
Vincent
F
,
Niikura
H
,
Kim
WK
,
Asami
M
,
Unbehaun
A
,
Hirji
S
,
Fujita
B
,
Silaschi
M
,
Tang
GHL
,
Kuwata
S
,
Wong
SC
,
Frangieh
AH
,
Barker
CM
,
Davies
JE
,
Lauten
A
,
Deuschl
F
,
Nombela-Franco
L
,
Rampat
R
,
Nicz
PFG
,
Masson
JB
,
Wijeysundera
HC
,
Sievert
H
,
Blackman
DJ
,
Gutierrez-Ibanes
E
,
Sugiyama
D
,
Chakravarty
T
,
Hildick-Smith
D
,
de Brito
FS
Jr.
,
Jensen
C
,
Jung
C
,
Smalling
RW
,
Arnold
M
,
Redwood
S
,
Kasel
AM
,
Maisano
F
,
Treede
H
,
Ensminger
SM
,
Kar
S
,
Kaneko
T
,
Pilgrim
T
,
Sorajja
P
,
Van Belle
E
,
Prendergast
BD
,
Bapat
V
,
Modine
T
,
Schofer
J
,
Frerker
C
,
Kempfert
J
,
Attizzani
GF
,
Latib
A
,
Schaefer
U
,
Webb
JG
,
Bax
JJ
,
Makkar
RR.
 
Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification
.
Eur Heart J
2019
;
40
:
441
451
.

383

Guerrero
 
M
,
Vemulapalli
S
,
Xiang
Q
,
Wang
DD
,
Eleid
M
,
Cabalka
AK
,
Sandhu
G
,
Salinger
M
,
Russell
H
,
Greenbaum
A
,
Kodali
S
,
George
I
,
Dvir
D
,
Whisenant
B
,
Russo
MJ
,
Pershad
A
,
Fang
K
,
Coylewright
M
,
Shah
P
,
Babaliaros
V
,
Khan
JM
,
Tommaso
C
,
Saucedo
J
,
Kar
S
,
Makkar
R
,
Mack
M
,
Holmes
D
,
Leon
M
,
Bapat
V
,
Thourani
VH
,
Rihal
C
,
O’Neill
W
,
Feldman
T.
 
Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States: data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry
.
Circ Cardiovasc Interv
2020
;
13
:
e008425
.

384

Wang
 
DD
,
Guerrero
M
,
Eng
MH
,
Eleid
MF
,
Meduri
CU
,
Rajagopal
V
,
Yadav
PK
,
Fifer
MA
,
Palacios
IF
,
Rihal
CS
,
Feldman
TE
,
O’Neill
WW.
 
Alcohol septal ablation to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: first-in-man study
.
JACC Cardiovasc Interv
2019
;
12
:
1268
1279
.

385

Khan
 
JM
,
Babaliaros
VC
,
Greenbaum
AB
,
Foerst
JR
,
Yazdani
S
,
McCabe
JM
,
Paone
G
,
Eng
MH
,
Leshnower
BG
,
Gleason
PT
,
Chen
MY
,
Wang
DD
,
Tian
X
,
Stine
AM
,
Rogers
T
,
Lederman
RJ.
 
Anterior leaflet laceration to prevent ventricular outflow tract obstruction during transcatheter mitral valve replacement
.
J Am Coll Cardiol
2019
;
73
:
2521
2534
.

386

El Sabbagh
 
A
,
Eleid
MF
,
Foley
TA
,
Al-Hijji
MA
,
Daly
RC
,
Rihal
CS
,
Said
SM.
 
Direct transatrial implantation of balloon-expandable valve for mitral stenosis with severe annular calcifications: early experience and lessons learned
.
Eur J Cardiothorac Surg
2018
;
53
:
162
169
.

387

Praz
 
F
,
Khalique
OK
,
Lee
R
,
Veeragandham
R
,
Russell
H
,
Guerrero
M
,
Islam
AM
,
Deaton
DW
,
Kaneko
T
,
Kodali
SK
,
Leon
MB
,
Bapat
V
,
Takayama
H
,
Borger
MA
,
George
I.
 
Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification
.
J Thorac Cardiovasc Surg
2018
;
156
:
132
142
.

388

Sorajja
 
P
,
Gossl
M
,
Babaliaros
V
,
Rizik
D
,
Conradi
L
,
Bae
R
,
Burke
RF
,
Schafer
U
,
Lisko
JC
,
Riley
RD
,
Guyton
R
,
Dumonteil
N
,
Berthoumieu
P
,
Tchetche
D
,
Blanke
P
,
Cavalcante
JL
,
Sun
B.
 
Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification
.
J Am Coll Cardiol
2019
;
74
:
1431
1440
.

389

Topilsky
 
Y
,
Maltais
S
,
Medina Inojosa
J
,
Oguz
D
,
Michelena
H
,
Maalouf
J
,
Mahoney
DW
,
Enriquez-Sarano
M.
 
Burden of tricuspid regurgitation in patients diagnosed in the community setting
.
JACC Cardiovasc Imaging
2019
;
12
:
433
442
.

390

Song
 
H
,
Kim
MJ
,
Chung
CH
,
Choo
SJ
,
Song
MG
,
Song
JM
,
Kang
DH
,
Lee
JW
,
Song
JK.
 
Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery
.
Heart
2009
;
95
:
931
936
.

391

Kwak
 
JJ
,
Kim
YJ
,
Kim
MK
,
Kim
HK
,
Park
JS
,
Kim
KH
,
Kim
KB
,
Ahn
H
,
Sohn
DW
,
Oh
BH
,
Park
YB.
 
Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with long-term echocardiographic examinations
.
Am Heart J
2008
;
155
:
732
737
.

392

Ortiz-Leon
 
XA
,
Posada-Martinez
EL
,
Trejo-Paredes
MC
,
Ivey-Miranda
JB
,
Pereira
J
,
Crandall
I
,
DaSilva
P
,
Bouman
E
,
Brooks
A
,
Gerardi
C
,
Ugonabo
I
,
Chen
W
,
Houle
H
,
Akar
JG
,
Lin
BA
,
McNamara
RL
,
Lombo-Lievano
B
,
Arias-Godinez
JA
,
Sugeng
L.
 
Understanding tricuspid valve remodelling in atrial fibrillation using three-dimensional echocardiography
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
747
755
.

393

Kim
 
JB
,
Spevack
DM
,
Tunick
PA
,
Bullinga
JR
,
Kronzon
I
,
Chinitz
LA
,
Reynolds
HR.
 
The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study
.
J Am Soc Echocardiogr
2008
;
21
:
284
287
.

394

Hoke
 
U
,
Auger
D
,
Thijssen
J
,
Wolterbeek
R
,
van der Velde
ET
,
Holman
ER
,
Schalij
MJ
,
Bax
JJ
,
Delgado
V
,
Marsan
NA.
 
Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up
.
Heart
2014
;
100
:
960
968
.

395

Anvardeen
 
K
,
Rao
R
,
Hazra
S
,
Hay
K
,
Dai
H
,
Stoyanov
N
,
Birnie
D
,
Dwivedi
G
,
Chan
KL.
 
Prevalence and significance of tricuspid regurgitation post-endocardial lead placement
.
JACC Cardiovasc Imaging
2019
;
12
:
562
564
.

396

Prihadi
 
EA
,
van der Bijl
P
,
Gursoy
E
,
Abou
R
,
Mara Vollema
E
,
Hahn
RT
,
Stone
GW
,
Leon
MB
,
Ajmone Marsan
N
,
Delgado
V
,
Bax
JJ.
 
Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history
.
Eur Heart J
2018
;
39
:
3574
3581
.

397

Benfari
 
G
,
Antoine
C
,
Miller
WL
,
Thapa
P
,
Topilsky
Y
,
Rossi
A
,
Michelena
HI
,
Pislaru
S
,
Enriquez-Sarano
M.
 
Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction
.
Circulation
2019
;
140
:
196
206
.

398

Dietz
 
MF
,
Prihadi
EA
,
van der Bijl
P
,
Goedemans
L
,
Mertens
BJA
,
Gursoy
E
,
van Genderen
OS
,
Ajmone Marsan
N
,
Delgado
V
,
Bax
JJ.
 
Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation
.
Circulation
2019
;
140
:
836
845
.

399

Muraru
 
D
,
Badano
LP
,
Nagata
Y
,
Surkova
E
,
Nabeshima
Y
,
Genovese
D
,
Otsuji
Y
,
Guida
V
,
Azzolina
D
,
Palermo
C
,
Takeuchi
M.
 
Development and prognostic validation of partition values to grade right ventricular dysfunction severity using 3D echocardiography
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
10
21
.

400

Park
 
JB
,
Lee
SP
,
Lee
JH
,
Yoon
YE
,
Park
EA
,
Kim
HK
,
Lee
W
,
Kim
YJ
,
Cho
GY
,
Sohn
DW.
 
Quantification of right ventricular volume and function using single-beat three-dimensional echocardiography: a validation study with cardiac magnetic resonance
.
J Am Soc Echocardiogr
2016
;
29
:
392
401
.

401

Grothues
 
F
,
Moon
JC
,
Bellenger
NG
,
Smith
GS
,
Klein
HU
,
Pennell
DJ.
 
Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance
.
Am Heart J
2004
;
147
:
218
223
.

402

Song
 
JM
,
Jang
MK
,
Choi
YS
,
Kim
YJ
,
Min
SY
,
Kim
DH
,
Kang
DH
,
Song
JK.
 
The vena contracta in functional tricuspid regurgitation: a real-time three-dimensional color Doppler echocardiography study
.
J Am Soc Echocardiogr
2011
;
24
:
663
670
.

403

de Agustin
 
JA
,
Viliani
D
,
Vieira
C
,
Islas
F
,
Marcos-Alberca
P
,
Gomez de Diego
JJ
,
Nunez-Gil
IJ
,
Almeria
C
,
Rodrigo
JL
,
Luaces
M
,
Garcia-Fernandez
MA
,
Macaya
C
,
Perez de Isla
L.
 
Proximal isovelocity surface area by single-beat three-dimensional color Doppler echocardiography applied for tricuspid regurgitation quantification
.
J Am Soc Echocardiogr
2013
;
26
:
1063
1072
.

404

Chen
 
TE
,
Kwon
SH
,
Enriquez-Sarano
M
,
Wong
BF
,
Mankad
SV.
 
Three-dimensional color Doppler echocardiographic quantification of tricuspid regurgitation orifice area: comparison with conventional two-dimensional measures
.
J Am Soc Echocardiogr
2013
;
26
:
1143
1152
.

405

Dahou
 
A
,
Ong
G
,
Hamid
N
,
Avenatti
E
,
Yao
J
,
Hahn
RT.
 
Quantifying tricuspid regurgitation severity: a comparison of proximal isovelocity surface area and novel quantitative Doppler methods
.
JACC Cardiovasc Imaging
2019
;
12
:
560
562
.

406

Utsunomiya
 
H
,
Harada
Y
,
Susawa
H
,
Takahari
K
,
Ueda
Y
,
Izumi
K
,
Itakura
K
,
Ikenaga
H
,
Hidaka
T
,
Fukuda
Y
,
Shiota
T
,
Kihara
Y.
 
Comprehensive evaluation of tricuspid regurgitation location and severity using vena contracta analysis: a color Doppler three-dimensional transesophageal echocardiographic study
.
J Am Soc Echocardiogr
2019
;
32
:
1526
1537.e2
.

407

Hahn
 
RT
,
Zamorano
JL.
 
The need for a new tricuspid regurgitation grading scheme
.
Eur Heart J Cardiovasc Imaging
2017
;
18
:
1342
1343
.

408

Nickenig
 
G
,
Weber
M
,
Lurz
P
,
von Bardeleben
RS
,
Sitges
M
,
Sorajja
P
,
Hausleiter
J
,
Denti
P
,
Trochu
JN
,
Nabauer
M
,
Dahou
A
,
Hahn
RT.
 
Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study
.
Lancet
2019
;
394
:
2002
2011
.

409

Nickenig
 
G
,
Weber
M
,
Schueler
R
,
Hausleiter
J
,
Nabauer
M
,
von Bardeleben
RS
,
Sotiriou
E
,
Schafer
U
,
Deuschl
F
,
Kuck
KH
,
Kreidel
F
,
Juliard
JM
,
Brochet
E
,
Latib
A
,
Agricola
E
,
Baldus
S
,
Friedrichs
K
,
Vandrangi
P
,
Verta
P
,
Hahn
RT
,
Maisano
F.
 
6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation
.
J Am Coll Cardiol
2019
;
73
:
1905
1915
.

410

Santoro
 
C
,
Marco Del Castillo
A
,
Gonzalez-Gomez
A
,
Monteagudo
JM
,
Hinojar
R
,
Lorente
A
,
Abellas
M
,
Vieitez
JM
,
Garcia Martin
A
,
Casas Rojo
E
,
Ruiz
S
,
Barrios
V
,
Luis Moya
J
,
Jimenez-Nacher
JJ
,
Zamorano Gomez
JL
,
Fernandez-Golfin
C.
 
Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity?
 
Eur Heart J Cardiovasc Imaging
 
2019
;
20
:
1035
1042
.

411

Miura
 
M
,
Alessandrini
H
,
Alkhodair
A
,
Attinger-Toller
A
,
Biasco
L
,
Lurz
P
,
Braun
D
,
Brochet
E
,
Connelly
KA
,
de Bruijn
S
,
Denti
P
,
Deuschl
F
,
Estevez-Loureiro
R
,
Fam
N
,
Frerker
C
,
Gavazzoni
M
,
Hausleiter
J
,
Himbert
D
,
Ho
E
,
Juliard
JM
,
Kaple
R
,
Besler
C
,
Kodali
S
,
Kreidel
F
,
Kuck
KH
,
Latib
A
,
Lauten
A
,
Monivas
V
,
Mehr
M
,
Muntane-Carol
G
,
Nazif
T
,
Nickenig
G
,
Pedrazzini
G
,
Philippon
F
,
Pozzoli
A
,
Praz
F
,
Puri
R
,
Rodes-Cabau
J
,
Schafer
U
,
Schofer
J
,
Sievert
H
,
Tang
GHL
,
Thiele
H
,
Rommel
KP
,
Vahanian
A
,
Von Bardeleben
RS
,
Webb
JG
,
Weber
M
,
Windecker
S
,
Winkel
M
,
Zuber
M
,
Leon
MB
,
Maisano
F
,
Hahn
RT
,
Taramasso
M
,
TriValve Investigators
.
Impact of massive or torrential tricuspid regurgitation in patients undergoing transcatheter tricuspid valve intervention
.
JACC Cardiovasc Interv
2020
;
13
:
1999
2009
.

412

Peri
 
Y
,
Sadeh
B
,
Sherez
C
,
Hochstadt
A
,
Biner
S
,
Aviram
G
,
Ingbir
M
,
Nachmany
I
,
Topaz
G
,
Flint
N
,
Keren
G
,
Topilsky
Y.
 
Quantitative assessment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe and torrential tricuspid regurgitation grade
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
768
776
.

413

Stocker
 
TJ
,
Hertell
H
,
Orban
M
,
Braun
D
,
Rommel
KP
,
Ruf
T
,
Ong
G
,
Nabauer
M
,
Deseive
S
,
Fam
N
,
von Bardeleben
RS
,
Thiele
H
,
Massberg
S
,
Lurz
P
,
Hausleiter
J.
 
Cardiopulmonary hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in chronic heart failure
.
JACC Cardiovasc Interv
2021
;
14
:
29
38
.

414

Nath
 
J
,
Foster
E
,
Heidenreich
PA.
 
Impact of tricuspid regurgitation on long-term survival
.
J Am Coll Cardiol
2004
;
43
:
405
409
.

415

Topilsky
 
Y
,
Nkomo
VT
,
Vatury
O
,
Michelena
HI
,
Letourneau
T
,
Suri
RM
,
Pislaru
S
,
Park
S
,
Mahoney
DW
,
Biner
S
,
Enriquez-Sarano
M.
 
Clinical outcome of isolated tricuspid regurgitation
.
JACC Cardiovasc Imaging
2014
;
7
:
1185
1194
.

416

Chorin
 
E
,
Rozenbaum
Z
,
Topilsky
Y
,
Konigstein
M
,
Ziv-Baran
T
,
Richert
E
,
Keren
G
,
Banai
S.
 
Tricuspid regurgitation and long-term clinical outcomes
.
Eur Heart J Cardiovasc Imaging
2020
;
21
:
157
165
.

417

Topilsky
 
Y
,
Inojosa
JM
,
Benfari
G
,
Vaturi
O
,
Maltais
S
,
Michelena
H
,
Mankad
S
,
Enriquez-Sarano
M.
 
Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction
.
Eur Heart J
2018
;
39
:
3584
3592
.

418

Kadri
 
AN
,
Menon
V
,
Sammour
YM
,
Gajulapalli
RD
,
Meenakshisundaram
C
,
Nusairat
L
,
Mohananey
D
,
Hernandez
AV
,
Navia
J
,
Krishnaswamy
A
,
Griffin
B
,
Rodriguez
L
,
Harb
SC
,
Kapadia
S.
 
Outcomes of patients with severe tricuspid regurgitation and congestive heart failure
.
Heart
2019
;
105
:
1813
1817
.

419

Stuge
 
O
,
Liddicoat
J.
 
Emerging opportunities for cardiac surgeons within structural heart disease
.
J Thorac Cardiovasc Surg
2006
;
132
:
1258
1261
.

420

Kilic
 
A
,
Saha-Chaudhuri
P
,
Rankin
JS
,
Conte
JV.
 
Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database
.
Ann Thorac Surg
2013
;
96
:
1546
1552
.

421

Dreyfus
 
J
,
Ghalem
N
,
Garbarz
E
,
Cimadevilla
C
,
Nataf
P
,
Vahanian
A
,
Caranhac
G
,
Messika-Zeitoun
D.
 
Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French nationwide database)
.
Am J Cardiol
2018
;
122
:
323
326
.

422

Antunes
 
MJ
,
Rodriguez-Palomares
J
,
Prendergast
B
,
De Bonis
M
,
Rosenhek
R
,
Al-Attar
N
,
Barili
F
,
Casselman
F
,
Folliguet
T
,
Iung
B
,
Lancellotti
P
,
Muneretto
C
,
Obadia
JF
,
Pierard
L
,
Suwalski
P
,
Zamorano
P
,
ESC Working Groups of Cardiovascular Surgery and Valvular Heart Disease
.
Management of tricuspid valve regurgitation: position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease
.
Eur J Cardiothorac Surg
2017
;
52
:
1022
1030
.

423

Dreyfus
 
GD
,
Corbi
PJ
,
Chan
KM
,
Bahrami
T.
 
Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair?
 
Ann Thorac Surg
 
2005
;
79
:
127
132
.

424

Van de Veire
 
NR
,
Braun
J
,
Delgado
V
,
Versteegh
MI
,
Dion
RA
,
Klautz
RJ
,
Bax
JJ.
 
Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair
.
J Thorac Cardiovasc Surg
2011
;
141
:
1431
1439
.

425

Chikwe
 
J
,
Itagaki
S
,
Anyanwu
A
,
Adams
DH.
 
Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse
.
J Am Coll Cardiol
2015
;
65
:
1931
1938
.

426

Badhwar
 
V
,
Rankin
JS
,
He
M
,
Jacobs
JP
,
Furnary
AP
,
Fazzalari
FL
,
O’Brien
S
,
Gammie
JS
,
Shahian
DM.
 
Performing concomitant tricuspid valve repair at the time of mitral valve operations is not associated with increased operative mortality
.
Ann Thorac Surg
2017
;
103
:
587
593
.

427

Brescia
 
AA
,
Ward
ST
,
Watt
TMF
,
Rosenbloom
LM
,
Baker
M
,
Khan
S
,
Ziese
E
,
Romano
MA
,
Bolling
SF
,
Michigan Mitral Research Group
.
Outcomes of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation
.
Ann Thorac Surg
2020
;
109
:
1227
1232
.

428

Axtell
 
AL
,
Bhambhani
V
,
Moonsamy
P
,
Healy
EW
,
Picard
MH
,
Sundt
TM
3rd
,
Wasfy
JH.
 
Surgery does not improve survival in patients with isolated severe tricuspid regurgitation
.
J Am Coll Cardiol
2019
;
74
:
715
725
.

429

Zack
 
CJ
,
Fender
EA
,
Chandrashekar
P
,
Reddy
YNV
,
Bennett
CE
,
Stulak
JM
,
Miller
VM
,
Nishimura
RA.
 
National trends and outcomes in isolated tricuspid valve surgery
.
J Am Coll Cardiol
2017
;
70
:
2953
2960
.

430

Dhoble
 
A
,
Zhao
Y
,
Vejpongsa
P
,
Loghin
C
,
Smalling
RW
,
Estrera
A
,
Nguyen
TC.
 
National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery
.
J Cardiovasc Surg (Torino)
2019
;
60
:
119
127
.

431

Alqahtani
 
F
,
Berzingi
CO
,
Aljohani
S
,
Hijazi
M
,
Al-Hallak
A
,
Alkhouli
M.
 
Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation
.
J Am Heart Assoc
2017
;
6
.

432

Dreyfus
 
J
,
Flagiello
M
,
Bazire
B
,
Eggenspieler
F
,
Viau
F
,
Riant
E
,
Mbaki
Y
,
Bohbot
Y
,
Eyharts
D
,
Senage
T
,
Dubrulle
H
,
Nicol
M
,
Doguet
F
,
Nguyen
V
,
Coisne
A
,
Le Tourneau
T
,
Lavie-Badie
Y
,
Tribouilloy
C
,
Donal
E
,
Tomasi
J
,
Habib
G
,
Selton-Suty
C
,
Raffoul
R
,
Iung
B
,
Obadia
JF
,
Messika-Zeitoun
D.
 
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes
.
Eur Heart J
2020
;
41
:
4304
4317
.

433

Hamandi
 
M
,
Smith
RL
,
Ryan
WH
,
Grayburn
PA
,
Vasudevan
A
,
George
TJ
,
DiMaio
JM
,
Hutcheson
KA
,
Brinkman
W
,
Szerlip
M
,
Moore
DO
,
Mack
MJ.
 
Outcomes of isolated tricuspid valve surgery have improved in the modern era
.
Ann Thorac Surg
2019
;
108
:
11
15
.

434

Dietz
 
MF
,
Prihadi
EA
,
van der Bijl
P
,
Ajmone Marsan
N
,
Delgado
V
,
Bax
JJ.
 
Prognostic implications of staging right heart failure in patients with significant secondary tricuspid regurgitation
.
JACC Heart Fail
2020
;
8
:
627
636
.

435

McCarthy
 
PM
,
Bhudia
SK
,
Rajeswaran
J
,
Hoercher
KJ
,
Lytle
BW
,
Cosgrove
DM
,
Blackstone
EH.
 
Tricuspid valve repair: durability and risk factors for failure
.
J Thorac Cardiovasc Surg
2004
;
127
:
674
685
.

436

Chang
 
BC
,
Lim
SH
,
Yi
G
,
Hong
YS
,
Lee
S
,
Yoo
KJ
,
Kang
MS
,
Cho
BK.
 
Long-term clinical results of tricuspid valve replacement
.
Ann Thorac Surg
2006
;
81
:
1317
1323
.

437

Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM, ESC Scientific Document Group
.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
.
Eur Heart J
2021
;doi:10.1093/eurheartj/ehab364.

438

Fam
 
NP
,
Braun
D
,
von Bardeleben
RS
,
Nabauer
M
,
Ruf
T
,
Connelly
KA
,
Ho
E
,
Thiele
H
,
Lurz
P
,
Weber
M
,
Nickenig
G
,
Narang
A
,
Davidson
CJ
,
Hausleiter
J.
 
Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience
.
JACC Cardiovasc Interv
2019
;
12
:
2488
2495
.

439

Lurz
 
P
,
Stephan von Bardeleben
R
,
Weber
M
,
Sitges
M
,
Sorajja
P
,
Hausleiter
J
,
Denti
P
,
Trochu
JN
,
Nabauer
M
,
Tang
GHL
,
Biaggi
P
,
Ying
SW
,
Trusty
PM
,
Dahou
A
,
Hahn
RT
,
Nickenig
G
,
TRILUMINATE Investigators
.
Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation
.
J Am Coll Cardiol
2021
;
77
:
229
239
.

440

Kodali
 
S
,
Hahn
RT
,
Eleid
MF
,
Kipperman
R
,
Smith
R
,
Lim
DS
,
Gray
WA
,
Narang
A
,
Pislaru
SV
,
Koulogiannis
K
,
Grayburn
P
,
Fowler
D
,
Hawthorne
K
,
Dahou
A
,
Deo
SH
,
Vandrangi
P
,
Deuschl
F
,
Mack
MJ
,
Leon
MB
,
Feldman
T
,
Davidson
CJ
,
CLASP TR EFS Investigators
.
Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation
.
J Am Coll Cardiol
2021
;
77
:
345
356
.

441

Nickenig
 
G
,
Weber
M
,
Schuler
R
,
Hausleiter
J
,
Nabauer
M
,
von Bardeleben
RS
,
Sotiriou
E
,
Schafer
U
,
Deuschl
F
,
Alessandrini
H
,
Kreidel
F
,
Juliard
JM
,
Brochet
E
,
Latib
A
,
Montorfano
M
,
Agricola
E
,
Baldus
S
,
Friedrichs
KP
,
Deo
SH
,
Gilmore
SY
,
Feldman
T
,
Hahn
RT
,
Maisano
F.
 
Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study
.
EuroIntervention
2021
;
16
:
e1264
e1271
.

442

Hahn
 
RT
,
Kodali
S
,
Fam
N
,
Bapat
V
,
Bartus
K
,
Rodes-Cabau
J
,
Dagenais
F
,
Estevez-Loureiro
R
,
Forteza
A
,
Kapadia
S
,
Latib
A
,
Maisano
F
,
McCarthy
P
,
Navia
J
,
Ong
G
,
Peterson
M
,
Petrossian
G
,
Pozzoli
A
,
Reinartz
M
,
Ricciardi
MJ
,
Robinson
N
,
Sievert
H
,
Taramasso
M
,
Agarwal
V
,
Bedard
E
,
Tarantini
G
,
Colli
A.
 
Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation
.
JACC Cardiovasc Interv
2020
;
13
:
2482
2493
.

443

Fam
 
NP
,
von Bardeleben
RS
,
Hensey
M
,
Kodali
SK
,
Smith
RL
,
Hausleiter
J
,
Ong
G
,
Boone
R
,
Ruf
T
,
George
I
,
Szerlip
M
,
Nabauer
M
,
Ali
FM
,
Moss
R
,
Bapat
V
,
Schnitzler
K
,
Kreidel
F
,
Ye
J
,
Deva
DP
,
Mack
MJ
,
Grayburn
PA
,
Peterson
MD
,
Leon
MB
,
Hahn
RT
,
Webb
JG.
 
Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience
.
JACC Cardiovasc Interv
2021
;
14
:
501
511
.

444

Lu
 
FL
,
Ma
Y
,
An
Z
,
Cai
CL
,
Li
BL
,
Song
ZG
,
Han
L
,
Wang
J
,
Qiao
F
,
Xu
ZY.
 
First-in-man experience of transcatheter tricuspid valve replacement with lux-valve in high-risk tricuspid regurgitation patients
.
JACC Cardiovasc Interv
2020
;
13
:
1614
1616
.

445

Rommel
 
KP
,
Besler
C
,
Noack
T
,
Blazek
S
,
von Roeder
M
,
Fengler
K
,
Ender
J
,
Gutberlet
M
,
Desch
S
,
Borger
MA
,
Thiele
H
,
Lurz
P.
 
Physiological and clinical consequences of right ventricular volume overload reduction after transcatheter treatment for tricuspid regurgitation
.
JACC Cardiovasc Interv
2019
;
12
:
1423
1434
.

446

Montalto
 
C
,
Sticchi
A
,
Crimi
G
,
Laricchia
A
,
Khokhar
A
,
Giannini
F
,
Ferlini
M
,
Colombo
A
,
Latib
A
,
Mangieri
A.
 
Functional and echocardiographic improvement after transcatheter repair for tricuspid regurgitation: a systematic review and pooled analysis
.
JACC Cardiovasc Interv
2020
;
13
:
2719
2729
.

447

Taramasso
 
M
,
Benfari
G
,
van der Bijl
P
,
Alessandrini
H
,
Attinger-Toller
A
,
Biasco
L
,
Lurz
P
,
Braun
D
,
Brochet
E
,
Connelly
KA
,
de Bruijn
S
,
Denti
P
,
Deuschl
F
,
Estevez-Loureiro
R
,
Fam
N
,
Frerker
C
,
Gavazzoni
M
,
Hausleiter
J
,
Ho
E
,
Juliard
JM
,
Kaple
R
,
Besler
C
,
Kodali
S
,
Kreidel
F
,
Kuck
KH
,
Latib
A
,
Lauten
A
,
Monivas
V
,
Mehr
M
,
Muntane-Carol
G
,
Nazif
T
,
Nickening
G
,
Pedrazzini
G
,
Philippon
F
,
Pozzoli
A
,
Praz
F
,
Puri
R
,
Rodes-Cabau
J
,
Schafer
U
,
Schofer
J
,
Sievert
H
,
Tang
GHL
,
Thiele
H
,
Topilsky
Y
,
Rommel
KP
,
Delgado
V
,
Vahanian
A
,
Von Bardeleben
RS
,
Webb
JG
,
Weber
M
,
Windecker
S
,
Winkel
M
,
Zuber
M
,
Leon
MB
,
Hahn
RT
,
Bax
JJ
,
Enriquez-Sarano
M
,
Maisano
F.
 
Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation
.
J Am Coll Cardiol
2019
;
74
:
2998
3008
.

448

Prihadi
 
EA
,
Delgado
V
,
Hahn
RT
,
Leipsic
J
,
Min
JK
,
Bax
JJ.
 
Imaging needs in novel transcatheter tricuspid valve interventions
.
JACC Cardiovasc Imaging
2018
;
11
:
736
754
.

449

Hahn
 
RT.
 
State-of-the-art review of echocardiographic imaging in the evaluation and treatment of functional tricuspid regurgitation
.
Circ Cardiovasc Imaging
2016
;
9
.

450

Utsunomiya
 
H
,
Itabashi
Y
,
Mihara
H
,
Berdejo
J
,
Kobayashi
S
,
Siegel
RJ
,
Shiota
T.
 
Functional tricuspid regurgitation caused by chronic atrial fibrillation: a real-time 3-dimensional transesophageal echocardiography study
.
Circ Cardiovasc Imaging
2017
;
10
.

451

Filsoufi
 
F
,
Anyanwu
AC
,
Salzberg
SP
,
Frankel
T
,
Cohn
LH
,
Adams
DH.
 
Long-term outcomes of tricuspid valve replacement in the current era
.
Ann Thorac Surg
2005
;
80
:
845
850
.

452

Yeter
 
E
,
Ozlem
K
,
Kilic
H
,
Ramazan
A
,
Acikel
S.
 
Tricuspid balloon valvuloplasty to treat tricuspid stenosis
.
J Heart Valve Dis
2010
;
19
:
159
160
.

453

Unger
 
P
,
Pibarot
P
,
Tribouilloy
C
,
Lancellotti
P
,
Maisano
F
,
Iung
B
,
Pierard
L
,
European Society of Cardiology Council on Valvular Heart Disease. Multiple and mixed valvular heart diseases
.
Circ Cardiovasc Imaging
2018
;
11
:
e007862
.

454

Egbe
 
AC
,
Luis
SA
,
Padang
R
,
Warnes
CA.
 
Outcomes in moderate mixed aortic valve disease: is it time for a paradigm shift?
 
J Am Coll Cardiol
 
2016
;
67
:
2321
2329
.

455

Egbe
 
AC
,
Poterucha
JT
,
Warnes
CA.
 
Mixed aortic valve disease: midterm outcome and predictors of adverse events
.
Eur Heart J
2016
;
37
:
2671
2678
.

456

Zilberszac
 
R
,
Gabriel
H
,
Schemper
M
,
Zahler
D
,
Czerny
M
,
Maurer
G
,
Rosenhek
R.
 
Outcome of combined stenotic and regurgitant aortic valve disease
.
J Am Coll Cardiol
2013
;
61
:
1489
1495
.

457

Unger
 
P
,
Tribouilloy
C.
 
Aortic stenosis with other concomitant valvular disease: aortic regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation
.
Cardiol Clin
2020
;
38
:
33
46
.

458

Philip
 
JL
,
Zens
T
,
Lozonschi
L
,
De Oliveira
NC
,
Osaki
S
,
Kohmoto
T
,
Akhter
SA
,
Tang
PC.
 
Outcomes of surgical aortic valve replacement for mixed aortic valve disease
.
J Thorac Dis
2018
;
10
:
4042
4051
.

459

Chahine
 
J
,
Kadri
AN
,
Gajulapalli
RD
,
Krishnaswamy
A
,
Mick
S
,
Perez
O
,
Lak
H
,
Nair
RM
,
Montane
B
,
Tak
J
,
Tuzcu
EM
,
Griffin
B
,
Svensson
LG
,
Harb
SC
,
Kapadia
SR.
 
Outcomes of transcatheter aortic valve replacement in mixed aortic valve disease
.
JACC Cardiovasc Interv
2019
;
12
:
2299
2306
.

460

Yang
 
LT
,
Enriquez-Sarano
M
,
Scott
CG
,
Padang
R
,
Maalouf
JF
,
Pellikka
PA
,
Michelena
HI.
 
Concomitant mitral regurgitation in patients with chronic aortic regurgitation
.
J Am Coll Cardiol
2020
;
76
:
233
246
.

461

Mehr
 
M
,
Karam
N
,
Taramasso
M
,
Ouarrak
T
,
Schneider
S
,
Lurz
P
,
von Bardeleben
RS
,
Fam
N
,
Pozzoli
A
,
Lubos
E
,
Boekstegers
P
,
Schillinger
W
,
Plicht
B
,
Eggebrecht
H
,
Baldus
S
,
Senges
J
,
Maisano
F
,
Hausleiter
J
,
TriValve, TRAMI Investigators
.
Combined tricuspid and mitral versus isolated mitral valve repair for severe MR and TR: an analysis from the TriValve and TRAMI registries
.
JACC Cardiovasc Interv
2020
;
13
:
543
550
.

462

Goldstone
 
AB
,
Chiu
P
,
Baiocchi
M
,
Lingala
B
,
Patrick
WL
,
Fischbein
MP
,
Woo
YJ.
 
Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement
.
N Engl J Med
2017
;
377
:
1847
1857
.

463

Head
 
SJ
,
Celik
M
,
Kappetein
AP.
 
Mechanical versus bioprosthetic aortic valve replacement
.
Eur Heart J
2017
;
38
:
2183
2191
.

464

Diaz
 
R
,
Hernandez-Vaquero
D
,
Alvarez-Cabo
R
,
Avanzas
P
,
Silva
J
,
Moris
C
,
Pascual
I.
 
Long-term outcomes of mechanical versus biological aortic valve prosthesis: systematic review and meta-analysis
.
J Thorac Cardiovasc Surg
2019
;
158
:
706
714.e18
.

465

David
 
TE
,
Ouzounian
M
,
David
CM
,
Lafreniere-Roula
M
,
Manlhiot
C.
 
Late results of the Ross procedure
.
J Thorac Cardiovasc Surg
2019
;
157
:
201
208
.

466

Malik
 
AH
,
Yandrapalli
S
,
Aronow
WS
,
Panza
JA
,
Cooper
HA.
 
Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves
.
Heart
2019
;
105
:
1432
1436
.

467

Duan
 
L
,
Doctor
JN
,
Adams
JL
,
Romley
JA
,
Nguyen
LA
,
An
J
,
Lee
MS.
 
Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves
.
Am J Cardiol
2021
;
146
:
22
28
.

468

Pasciolla
 
S
,
Zizza
LF
,
Le
T
,
Wright
K.
 
Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements
.
Clin Drug Investig
2020
;
40
:
839
845
.

469

Russo
 
V
,
Carbone
A
,
Attena
E
,
Rago
A
,
Mazzone
C
,
Proietti
R
,
Parisi
V
,
Scotti
A
,
Nigro
G
,
Golino
P
,
D’Onofrio
A.
 
Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves
.
Clin Ther
2019
;
41
:
2549
2557
.

470

Capodanno
 
D
,
Petronio
AS
,
Prendergast
B
,
Eltchaninoff
H
,
Vahanian
A
,
Modine
T
,
Lancellotti
P
,
Sondergaard
L
,
Ludman
PF
,
Tamburino
C
,
Piazza
N
,
Hancock
J
,
Mehilli
J
,
Byrne
RA
,
Baumbach
A
,
Kappetein
AP
,
Windecker
S
,
Bax
J
,
Haude
M.
 
Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS
).
Eur Heart J
2017
;
38
:
3382
3390
.

471

Zoghbi
 
WA
,
Chambers
JB
,
Dumesnil
JG
,
Foster
E
,
Gottdiener
JS
,
Grayburn
PA
,
Khandheria
BK
,
Levine
RA
,
Marx
GR
,
Miller
FA
Jr.
,
Nakatani
S
,
Quinones
MA
,
Rakowski
H
,
Rodriguez
LL
,
Swaminathan
M
,
Waggoner
AD
,
Weissman
NJ
,
Zabalgoitia
M
,
American Society of Echocardiography’s G, Standards C, Task Force on Prosthetic V, American College of Cardiology Cardiovascular Imaging C, Cardiac Imaging Committee of the American Heart A, European Association of E, European Society of C, Japanese Society of E, Canadian Society of E, American College of Cardiology F, American Heart A, European Association of E, European Society of C, Japanese Society of E, Canadian Society of E
.
Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography
.
J Am Soc Echocardiogr
2009
;
22
:
975
1014
.

472

Cannegieter
 
SC
,
Rosendaal
FR
,
Briet
E.
 
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses
.
Circulation
1994
;
89
:
635
641
.

473

Mok
 
CK
,
Boey
J
,
Wang
R
,
Chan
TK
,
Cheung
KL
,
Lee
PK
,
Chow
J
,
Ng
RP
,
Tse
TF.
 
Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial
.
Circulation
1985
;
72
:
1059
1063
.

474

Eikelboom
 
JW
,
Connolly
SJ
,
Brueckmann
M
,
Granger
CB
,
Kappetein
AP
,
Mack
MJ
,
Blatchford
J
,
Devenny
K
,
Friedman
J
,
Guiver
K
,
Harper
R
,
Khder
Y
,
Lobmeyer
MT
,
Maas
H
,
Voigt
JU
,
Simoons
ML
,
Van de Werf
F
,
RE-ALIGN Investigators
.
Dabigatran versus warfarin in patients with mechanical heart valves
.
N Engl J Med
2013
;
369
:
1206
1214
.

475

Iung
 
B
,
Rodes-Cabau
J.
 
The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties
.
Eur Heart J
2014
;
35
:
2942
2949
.

476

Caldeira
 
D
,
David
C
,
Santos
AT
,
Costa
J
,
Pinto
FJ
,
Ferreira
JJ.
 
Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis
.
J Thromb Haemost
2014
;
12
:
650
659
.

477

Laffort
 
P
,
Roudaut
R
,
Roques
X
,
Lafitte
S
,
Deville
C
,
Bonnet
J
,
Baudet
E.
 
Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study
.
J Am Coll Cardiol
2000
;
35
:
739
746
.

478

Sousa-Uva
 
M
,
Head
SJ
,
Milojevic
M
,
Collet
JP
,
Landoni
G
,
Castella
M
,
Dunning
J
,
Gudbjartsson
T
,
Linker
NJ
,
Sandoval
E
,
Thielmann
M
,
Jeppsson
A
,
Landmesser
U.
 
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
.
Eur J Cardiothorac Surg
2018
;
53
:
5
33
.

479

Butchart
 
EG
,
Gohlke-Barwolf
C
,
Antunes
MJ
,
Tornos
P
,
De Caterina
R
,
Cormier
B
,
Prendergast
B
,
Iung
B
,
Bjornstad
H
,
Leport
C
,
Hall
RJ
,
Vahanian
A
,
Working Groups on Valvular Heart Disease; Thrombosis and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology
.
Recommendations for the management of patients after heart valve surgery
.
Eur Heart J
2005
;
26
:
2463
2471
.

480

Torella
 
M
,
Torella
D
,
Chiodini
P
,
Franciulli
M
,
Romano
G
,
De Santo
L
,
De Feo
M
,
Amarelli
C
,
Sasso
FC
,
Salvatore
T
,
Ellison
GM
,
Indolfi
C
,
Cotrufo
M
,
Nappi
G.
 
LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the “LOWERING-IT” Trial
.
Am Heart J
2010
;
160
:
171
178
.

481

Puskas
 
J
,
Gerdisch
M
,
Nichols
D
,
Quinn
R
,
Anderson
C
,
Rhenman
B
,
Fermin
L
,
McGrath
M
,
Kong
B
,
Hughes
C
,
Sethi
G
,
Wait
M
,
Martin
T
,
Graeve
A
,
PROACT Investigators
.
Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial
.
J Thorac Cardiovasc Surg
2014
;
147
:
1202
1210
; discussion 1210-1201.

482

Heneghan
 
C
,
Ward
A
,
Perera
R
,
Self-Monitoring Trialist
C
,
Bankhead
C
,
Fuller
A
,
Stevens
R
,
Bradford
K
,
Tyndel
S
,
Alonso-Coello
P
,
Ansell
J
,
Beyth
R
,
Bernardo
A
,
Christensen
TD
,
Cromheecke
ME
,
Edson
RG
,
Fitzmaurice
D
,
Gadisseur
AP
,
Garcia-Alamino
JM
,
Gardiner
C
,
Hasenkam
JM
,
Jacobson
A
,
Kaatz
S
,
Kamali
F
,
Khan
TI
,
Knight
E
,
Kortke
H
,
Levi
M
,
Matchar
D
,
Menendez-Jandula
B
,
Rakovac
I
,
Schaefer
C
,
Siebenhofer
A
,
Souto
JC
,
Sunderji
R
,
Gin
K
,
Shalansky
K
,
Voller
H
,
Wagner
O
,
Zittermann
A.
 
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
.
Lancet
2012
;
379
:
322
334
.

483

Crowther
 
MA
,
Ageno
W
,
Garcia
D
,
Wang
L
,
Witt
DM
,
Clark
NP
,
Blostein
MD
,
Kahn
SR
,
Vesely
SK
,
Schulman
S
,
Kovacs
MJ
,
Rodger
MA
,
Wells
P
,
Anderson
D
,
Ginsberg
J
,
Selby
R
,
Siragusa
S
,
Silingardi
M
,
Dowd
MB
,
Kearon
C.
 
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial
.
Ann Intern Med
2009
;
150
:
293
300
.

484

Halvorsen
 
S
,
Storey
RF
,
Rocca
B
,
Sibbing
D
,
Ten Berg
J
,
Grove
EL
,
Weiss
TW
,
Collet
JP
,
Andreotti
F
,
Gulba
DC
,
Lip
GYH
,
Husted
S
,
Vilahur
G
,
Morais
J
,
Verheugt
FWA
,
Lanas
A
,
Al-Shahi Salman
R
,
Steg
PG
,
Huber
K
,
ESC Working Group on Thrombosis
.
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
.
Eur Heart J
2017
;
38
:
1455
1462
.

485

Lubetsky
 
A
,
Yonath
H
,
Olchovsky
D
,
Loebstein
R
,
Halkin
H
,
Ezra
D.
 
Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study
.
Arch Intern Med
2003
;
163
:
2469
2473
.

486

Massel
 
DR
,
Little
SH.
 
Antiplatelet and anticoagulation for patients with prosthetic heart valves
.
Cochrane Database Syst Rev
2013
:
CD003464
.

487

Hansen
 
ML
,
Sorensen
R
,
Clausen
MT
,
Fog-Petersen
ML
,
Raunso
J
,
Gadsboll
N
,
Gislason
GH
,
Folke
F
,
Andersen
SS
,
Schramm
TK
,
Abildstrom
SZ
,
Poulsen
HE
,
Kober
L
,
Torp-Pedersen
C.
 
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation
.
Arch Intern Med
2010
;
170
:
1433
1441
.

488

Douketis
 
JD
,
Spyropoulos
AC
,
Kaatz
S
,
Becker
RC
,
Caprini
JA
,
Dunn
AS
,
Garcia
DA
,
Jacobson
A
,
Jaffer
AK
,
Kong
DF
,
Schulman
S
,
Turpie
AG
,
Hasselblad
V
,
Ortel
TL
,
BRIDGE Investigators
.
Perioperative bridging anticoagulation in patients with atrial fibrillation
.
N Engl J Med
2015
;
373
:
823
833
.

489

Kristensen
 
SD
,
Knuuti
J
,
Saraste
A
,
Anker
S
,
Botker
HE
,
Hert
SD
,
Ford
I
,
Gonzalez-Juanatey
JR
,
Gorenek
B
,
Heyndrickx
GR
,
Hoeft
A
,
Huber
K
,
Iung
B
,
Kjeldsen
KP
,
Longrois
D
,
Luscher
TF
,
Pierard
L
,
Pocock
S
,
Price
S
,
Roffi
M
,
Sirnes
PA
,
Sousa-Uva
M
,
Voudris
V
,
Funck-Brentano
C
,
Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA
).
Eur Heart J
2014
;
35
:
2383
2431
.

490

Gellatly
 
RM
,
Leet
A
,
Brown
KE.
 
Fondaparinux: an effective bridging strategy in heparin-induced thrombocytopenia and mechanical circulatory support
.
J Heart Lung Transplant
2014
;
33
:
118
.

491

Brennan
 
JM
,
Edwards
FH
,
Zhao
Y
,
O’Brien
S
,
Booth
ME
,
Dokholyan
RS
,
Douglas
PS
,
Peterson
ED
,
DEcIDE AVR Research Team
.
Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database
.
J Am Coll Cardiol
2012
;
60
:
971
977
.

492

Merie
 
C
,
Kober
L
,
Skov Olsen
P
,
Andersson
C
,
Gislason
G
,
Skov Jensen
J
,
Torp-Pedersen
C.
 
Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding
.
JAMA
2012
;
308
:
2118
2125
.

493

Christersson
 
C
,
James
SK
,
Lindhagen
L
,
Ahlsson
A
,
Friberg
O
,
Jeppsson
A
,
Stahle
E.
 
Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement
.
Heart
2020
;
106
:
838
844
.

494

Rafiq
 
S
,
Steinbruchel
DA
,
Lilleor
NB
,
Moller
CH
,
Lund
JT
,
Thiis
JJ
,
Kober
L
,
Olsen
PS.
 
Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial
.
Thromb Res
2017
;
150
:
104
110
.

495

Maes
 
F
,
Stabile
E
,
Ussia
GP
,
Tamburino
C
,
Pucciarelli
A
,
Masson
JB
,
Marsal
JR
,
Barbanti
M
,
Cote
M
,
Rodes-Cabau
J.
 
Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation
.
Am J Cardiol
2018
;
122
:
310
315
.

496

Brouwer
 
J
,
Nijenhuis
VJ
,
Delewi
R
,
Hermanides
RS
,
Holvoet
W
,
Dubois
CLF
,
Frambach
P
,
De Bruyne
B
,
van Houwelingen
GK
,
Van Der Heyden
JAS
,
Tousek
P
,
van der Kley
F
,
Buysschaert
I
,
Schotborgh
CE
,
Ferdinande
B
,
van der Harst
P
,
Roosen
J
,
Peper
J
,
Thielen
FWF
,
Veenstra
L
,
Chan Pin Yin
D
,
Swaans
MJ
,
Rensing
B
,
van ‘t Hof
AWJ
,
Timmers
L
,
Kelder
JC
,
Stella
PR
,
Baan
J
,
Ten Berg
JM.
 
Aspirin with or without clopidogrel after transcatheter aortic-valve implantation
.
N Engl J Med
2020
;
383
:
1447
1457
.

497

Dangas
 
GD
,
Tijssen
JGP
,
Wohrle
J
,
Sondergaard
L
,
Gilard
M
,
Mollmann
H
,
Makkar
RR
,
Herrmann
HC
,
Giustino
G
,
Baldus
S
,
De Backer
O
,
Guimaraes
AHC
,
Gullestad
L
,
Kini
A
,
von Lewinski
D
,
Mack
M
,
Moreno
R
,
Schafer
U
,
Seeger
J
,
Tchetche
D
,
Thomitzek
K
,
Valgimigli
M
,
Vranckx
P
,
Welsh
RC
,
Wildgoose
P
,
Volkl
AA
,
Zazula
A
,
van Amsterdam
RGM
,
Mehran
R
,
Windecker
S
,
GALILEO Investigators
.
A controlled trial of rivaroxaban after transcatheter aortic-valve replacement
.
N Engl J Med
2020
;
382
:
120
129
.

498

Pagnesi
 
M
,
Moroni
F
,
Beneduce
A
,
Giannini
F
,
Colombo
A
,
Weisz
G
,
Latib
A.
 
Thrombotic risk and antithrombotic strategies after transcatheter mitral valve replacement
.
JACC Cardiovasc Interv
2019
;
12
:
2388
2401
.

499

Guimaraes
 
HP
,
Lopes
RD
,
de Barros
ESPGM
,
Liporace
IL
,
Sampaio
RO
,
Tarasoutchi
F
,
Hoffmann-Filho
CR
,
de Lemos Soares Patriota
R
,
Leiria
TLL
,
Lamprea
D
,
Precoma
DB
,
Atik
FA
,
Silveira
FS
,
Farias
FR
,
Barreto
DO
,
Almeida
AP
,
Zilli
AC
,
de Souza Neto
JD
,
Cavalcante
MA
,
Figueira
F
,
Kojima
FCS
,
Damiani
L
,
Santos
RHN
,
Valeis
N
,
Campos
VB
,
Saraiva
JFK
,
Fonseca
FH
,
Pinto
IM
,
Magalhaes
CC
,
Ferreira
JFM
,
Alexander
JH
,
Pavanello
R
,
Cavalcanti
AB
,
Berwanger
O
,
RIVER Trial Investigators
.
Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve
.
N Engl J Med
2020
;
383
:
2117
2126
.

500

Shim
 
CY
,
Seo
J
,
Kim
YJ
,
Lee
SH
,
De Caterina
R
,
Lee
S
,
Hong
GR
;
Explore the Efficacy and Safety of Edoxaban in Patients after Heart Valve Repair or Bioprosthetic Valve Replacement (ENAVLE) study group
.
Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial
.
J Thorac Cardiovasc Surg
2021
;doi: 10.1016/j.jtcvs.2021.01.127.

501

Nijenhuis
 
VJ
,
Brouwer
J
,
Delewi
R
,
Hermanides
RS
,
Holvoet
W
,
Dubois
CLF
,
Frambach
P
,
De Bruyne
B
,
van Houwelingen
GK
,
Van Der Heyden
JAS
,
Tousek
P
,
van der Kley
F
,
Buysschaert
I
,
Schotborgh
CE
,
Ferdinande
B
,
van der Harst
P
,
Roosen
J
,
Peper
J
,
Thielen
FWF
,
Veenstra
L
,
Chan Pin Yin
D
,
Swaans
MJ
,
Rensing
B
,
van ‘t Hof
AWJ
,
Timmers
L
,
Kelder
JC
,
Stella
PR
,
Baan
J
,
Ten Berg
JM.
 
Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation
.
N Engl J Med
2020
;
382
:
1696
1707
.

502

Jochheim
 
D
,
Barbanti
M
,
Capretti
G
,
Stefanini
GG
,
Hapfelmeier
A
,
Zadrozny
M
,
Baquet
M
,
Fischer
J
,
Theiss
H
,
Todaro
D
,
Chieffo
A
,
Presbitero
P
,
Colombo
A
,
Massberg
S
,
Tamburino
C
,
Mehilli
J.
 
Oral anticoagulant type and outcomes after transcatheter aortic valve replacement
.
JACC Cardiovasc Interv
2019
;
12
:
1566
1576
.

503

van der Wall
 
SJ
,
Olsthoorn
JR
,
Heuts
S
,
Klautz
RJM
,
Tomsic
A
,
Jansen
EK
,
Vonk
ABA
,
Sardari Nia
P
,
Klok
FA
,
Huisman
MV.
 
Antithrombotic therapy after mitral valve repair: VKA or aspirin?
 
J Thromb Thrombolysis
 
2018
;
46
:
473
481
.

504

Spyropoulos
 
AC
,
Turpie
AG
,
Dunn
AS
,
Kaatz
S
,
Douketis
J
,
Jacobson
A
,
Petersen
H
,
REGIMEN Investigators
.
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)
.
Am J Cardiol
2008
;
102
:
883
889
.

505

Dewilde
 
WJ
,
Oirbans
T
,
Verheugt
FW
,
Kelder
JC
,
De Smet
BJ
,
Herrman
JP
,
Adriaenssens
T
,
Vrolix
M
,
Heestermans
AA
,
Vis
MM
,
Tijsen
JG
,
van ‘t Hof
AW
,
ten Berg
JM
,
WOEST Study Investigators
.
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
.
Lancet
2013
;
381
:
1107
1115
.

506

Gibson
 
CM
,
Mehran
R
,
Bode
C
,
Halperin
J
,
Verheugt
FW
,
Wildgoose
P
,
Birmingham
M
,
Ianus
J
,
Burton
P
,
van Eickels
M
,
Korjian
S
,
Daaboul
Y
,
Lip
GY
,
Cohen
M
,
Husted
S
,
Peterson
ED
,
Fox
KA.
 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
.
N Engl J Med
2016
;
375
:
2423
2434
.

507

Lopes
 
RD
,
Heizer
G
,
Aronson
R
,
Vora
AN
,
Massaro
T
,
Mehran
R
,
Goodman
SG
,
Windecker
S
,
Darius
H
,
Li
J
,
Averkov
O
,
Bahit
MC
,
Berwanger
O
,
Budaj
A
,
Hijazi
Z
,
Parkhomenko
A
,
Sinnaeve
P
,
Storey
RF
,
Thiele
H
,
Vinereanu
D
,
Granger
CB
,
Alexander
JH
,
AUGUSTUS Investigators
.
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
.
N Engl J Med
2019
;
380
:
1509
1524
.

508

Fiedler
 
KA
,
Maeng
M
,
Mehilli
J
,
Schulz-Schupke
S
,
Byrne
RA
,
Sibbing
D
,
Hoppmann
P
,
Schneider
S
,
Fusaro
M
,
Ott
I
,
Kristensen
SD
,
Ibrahim
T
,
Massberg
S
,
Schunkert
H
,
Laugwitz
KL
,
Kastrati
A
,
Sarafoff
N.
 
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial
.
J Am Coll Cardiol
2015
;
65
:
1619
1629
.

509

Vranckx
 
P
,
Valgimigli
M
,
Eckardt
L
,
Tijssen
J
,
Lewalter
T
,
Gargiulo
G
,
Batushkin
V
,
Campo
G
,
Lysak
Z
,
Vakaliuk
I
,
Milewski
K
,
Laeis
P
,
Reimitz
PE
,
Smolnik
R
,
Zierhut
W
,
Goette
A.
 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
.
Lancet
2019
;
394
:
1335
1343
.

510

Lamberts
 
M
,
Gislason
GH
,
Lip
GY
,
Lassen
JF
,
Olesen
JB
,
Mikkelsen
AP
,
Sorensen
R
,
Kober
L
,
Torp-Pedersen
C
,
Hansen
ML.
 
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study
.
Circulation
2014
;
129
:
1577
1585
.

511

Yasuda
 
S
,
Kaikita
K
,
Akao
M
,
Ako
J
,
Matoba
T
,
Nakamura
M
,
Miyauchi
K
,
Hagiwara
N
,
Kimura
K
,
Hirayama
A
,
Matsui
K
,
Ogawa
H
,
AFIRE Investigators
.
Antithrombotic therapy for atrial fibrillation with stable coronary disease
.
N Engl J Med
2019
;
381
:
1103
1113
.

512

Collet
 
JP
,
Thiele
H
,
Barbato
E
,
Barthelemy
O
,
Bauersachs
J
,
Bhatt
DL
,
Dendale
P
,
Dorobantu
M
,
Edvardsen
T
,
Folliguet
T
,
Gale
CP
,
Gilard
M
,
Jobs
A
,
Juni
P
,
Lambrinou
E
,
Lewis
BS
,
Mehilli
J
,
Meliga
E
,
Merkely
B
,
Mueller
C
,
Roffi
M
,
Rutten
FH
,
Sibbing
D
,
Siontis
GCM
,
ESC Scientific Document Group
.
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
.
Eur Heart J
2021
;
42
:
1289
1367
.

513

Dewilde
 
WJ
,
Janssen
PW
,
Kelder
JC
,
Verheugt
FW
,
De Smet
BJ
,
Adriaenssens
T
,
Vrolix
M
,
Brueren
GB
,
Van Mieghem
C
,
Cornelis
K
,
Vos
J
,
Breet
NJ
,
ten Berg
JM.
 
Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial
.
EuroIntervention
2015
;
11
:
381
390
.

514

Lip
 
GYH
,
Collet
JP
,
Haude
M
,
Byrne
R
,
Chung
EH
,
Fauchier
L
,
Halvorsen
S
,
Lau
D
,
Lopez-Cabanillas
N
,
Lettino
M
,
Marin
F
,
Obel
I
,
Rubboli
A
,
Storey
RF
,
Valgimigli
M
,
Huber
K
,
ESC Scientific Document Group
.
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
.
Europace
2019
;
21
:
192
193
.

515

Carnicelli
 
AP
,
De Caterina
R
,
Halperin
JL
,
Renda
G
,
Ruff
CT
,
Trevisan
M
,
Nordio
F
,
Mercuri
MF
,
Antman
E
,
Giugliano
RP
,
ENGAGE AF-TIMI 48 Investigators
.
Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves
.
Circulation
2017
;
135
:
1273
1275
.

516

Philippart
 
R
,
Brunet-Bernard
A
,
Clementy
N
,
Bourguignon
T
,
Mirza
A
,
Babuty
D
,
Angoulvant
D
,
Lip
GY
,
Fauchier
L.
 
Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project
.
Eur Heart J
2015
;
36
:
1822
1830
.

517

Philippart
 
R
,
Brunet-Bernard
A
,
Clementy
N
,
Bourguignon
T
,
Mirza
A
,
Angoulvant
D
,
Babuty
D
,
Lip
GY
,
Fauchier
L.
 
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project
.
Thromb Haemost
2016
;
115
:
1056
1063
.

518

Siontis
 
KC
,
Yao
X
,
Gersh
BJ
,
Noseworthy
PA.
 
Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis
.
Circulation
2017
;
135
:
714
716
.

519

Russo
 
A
,
Grigioni
F
,
Avierinos
JF
,
Freeman
WK
,
Suri
R
,
Michelena
H
,
Brown
R
,
Sundt
TM
,
Enriquez-Sarano
M.
 
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications
.
J Am Coll Cardiol
2008
;
51
:
1203
1211
.

520

Butnaru
 
A
,
Shaheen
J
,
Tzivoni
D
,
Tauber
R
,
Bitran
D
,
Silberman
S.
 
Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation
.
Am J Cardiol
2013
;
112
:
1439
1444
.

521

Rodes-Cabau
 
J
,
Masson
JB
,
Welsh
RC
,
Garcia Del Blanco
B
,
Pelletier
M
,
Webb
JG
,
Al-Qoofi
F
,
Genereux
P
,
Maluenda
G
,
Thoenes
M
,
Paradis
JM
,
Chamandi
C
,
Serra
V
,
Dumont
E
,
Cote
M.
 
Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial
.
JACC Cardiovasc Interv
2017
;
10
:
1357
1365
.

522

Dvir
 
D
,
Bourguignon
T
,
Otto
CM
,
Hahn
RT
,
Rosenhek
R
,
Webb
JG
,
Treede
H
,
Sarano
ME
,
Feldman
T
,
Wijeysundera
HC
,
Topilsky
Y
,
Aupart
M
,
Reardon
MJ
,
Mackensen
GB
,
Szeto
WY
,
Kornowski
R
,
Gammie
JS
,
Yoganathan
AP
,
Arbel
Y
,
Borger
MA
,
Simonato
M
,
Reisman
M
,
Makkar
RR
,
Abizaid
A
,
McCabe
JM
,
Dahle
G
,
Aldea
GS
,
Leipsic
J
,
Pibarot
P
,
Moat
NE
,
Mack
MJ
,
Kappetein
AP
,
Leon
MB
,
VIVID Investigators
.
Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves
.
Circulation
2018
;
137
:
388
399
.

523

Tam
 
DY
,
Dharma
C
,
Rocha
RV
,
Ouzounian
M
,
Wijeysundera
HC
,
Austin
PC
,
Chikwe
J
,
Gaudino
M
,
Fremes
SE.
 
Transcatheter ViV versus redo surgical AVR for the management of failed biological prosthesis: early and late outcomes in a propensity-matched cohort
.
JACC Cardiovasc Interv
2020
;
13
:
765
774
.

524

Bleiziffer
 
S
,
Simonato
M
,
Webb
JG
,
Rodes-Cabau
J
,
Pibarot
P
,
Kornowski
R
,
Windecker
S
,
Erlebach
M
,
Duncan
A
,
Seiffert
M
,
Unbehaun
A
,
Frerker
C
,
Conzelmann
L
,
Wijeysundera
H
,
Kim
WK
,
Montorfano
M
,
Latib
A
,
Tchetche
D
,
Allali
A
,
Abdel-Wahab
M
,
Orvin
K
,
Stortecky
S
,
Nissen
H
,
Holzamer
A
,
Urena
M
,
Testa
L
,
Agrifoglio
M
,
Whisenant
B
,
Sathananthan
J
,
Napodano
M
,
Landi
A
,
Fiorina
C
,
Zittermann
A
,
Veulemans
V
,
Sinning
JM
,
Saia
F
,
Brecker
S
,
Presbitero
P
,
De Backer
O
,
Sondergaard
L
,
Bruschi
G
,
Franco
LN
,
Petronio
AS
,
Barbanti
M
,
Cerillo
A
,
Spargias
K
,
Schofer
J
,
Cohen
M
,
Munoz-Garcia
A
,
Finkelstein
A
,
Adam
M
,
Serra
V
,
Teles
RC
,
Champagnac
D
,
Iadanza
A
,
Chodor
P
,
Eggebrecht
H
,
Welsh
R
,
Caixeta
A
,
Salizzoni
S
,
Dager
A
,
Auffret
V
,
Cheema
A
,
Ubben
T
,
Ancona
M
,
Rudolph
T
,
Gummert
J
,
Tseng
E
,
Noble
S
,
Bunc
M
,
Roberts
D
,
Kass
M
,
Gupta
A
,
Leon
MB
,
Dvir
D.
 
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves
.
Eur Heart J
2020
;
41
:
2731
2742
.

525

Hirji
 
SA
,
Percy
ED
,
Zogg
CK
,
Malarczyk
A
,
Harloff
MT
,
Yazdchi
F
,
Kaneko
T.
 
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes
.
Eur Heart J
2020
;
41
:
2747
2755
.

526

Barbanti
 
M
,
Costa
G
,
Picci
A
,
Criscione
E
,
Reddavid
C
,
Valvo
R
,
Todaro
D
,
Deste
W
,
Condorelli
A
,
Scalia
M
,
Licciardello
A
,
Politi
G
,
De Luca
G
,
Strazzieri
O
,
Motta
S
,
Garretto
V
,
Veroux
P
,
Giaquinta
A
,
Giuffrida
A
,
Sgroi
C
,
Leon
MB
,
Webb
JG
,
Tamburino
C.
 
Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS Study
.
JACC Cardiovasc Interv
2020
;
13
:
2542
2555
.

527

De Backer
 
O
,
Landes
U
,
Fuchs
A
,
Yoon
SH
,
Mathiassen
ON
,
Sedaghat
A
,
Kim
WK
,
Pilgrim
T
,
Buzzatti
N
,
Ruile
P
,
El Sabbagh
A
,
Barbanti
M
,
Fiorina
C
,
Nombela-Franco
L
,
Steinvil
A
,
Finkelstein
A
,
Montorfano
M
,
Maurovich-Horvat
P
,
Kofoed
KF
,
Blanke
P
,
Bunc
M
,
Neumann
FJ
,
Latib
A
,
Windecker
S
,
Sinning
JM
,
Norgaard
BL
,
Makkar
R
,
Webb
JG
,
Sondergaard
L.
 
Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography
.
JACC Cardiovasc Interv
2020
;
13
:
2528
2538
.

528

Jawitz
 
OK
,
Gulack
BC
,
Grau-Sepulveda
MV
,
Matsouaka
RA
,
Mack
MJ
,
Holmes
DR
Jr.
,
Carroll
JD
,
Thourani
VH
,
Brennan
JM.
 
Reoperation after transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons Database
.
JACC Cardiovasc Interv
2020
;
13
:
1515
1525
.

529

Dvir
 
D
,
Webb
JG
,
Bleiziffer
S
,
Pasic
M
,
Waksman
R
,
Kodali
S
,
Barbanti
M
,
Latib
A
,
Schaefer
U
,
Rodes-Cabau
J
,
Treede
H
,
Piazza
N
,
Hildick-Smith
D
,
Himbert
D
,
Walther
T
,
Hengstenberg
C
,
Nissen
H
,
Bekeredjian
R
,
Presbitero
P
,
Ferrari
E
,
Segev
A
,
de Weger
A
,
Windecker
S
,
Moat
NE
,
Napodano
M
,
Wilbring
M
,
Cerillo
AG
,
Brecker
S
,
Tchetche
D
,
Lefevre
T
,
De Marco
F
,
Fiorina
C
,
Petronio
AS
,
Teles
RC
,
Testa
L
,
Laborde
JC
,
Leon
MB
,
Kornowski
R
,
Valve-in-Valve International Data Registry Investigators
.
Transcatheter aortic valve implantation in failed bioprosthetic surgical valves
.
JAMA
2014
;
312
:
162
170
.

530

Ye
 
J
,
Cheung
A
,
Yamashita
M
,
Wood
D
,
Peng
D
,
Gao
M
,
Thompson
CR
,
Munt
B
,
Moss
RR
,
Blanke
P
,
Leipsic
J
,
Dvir
D
,
Webb
JG.
 
Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience
.
JACC Cardiovasc Interv
2015
;
8
:
1735
1744
.

531

Simonato
 
M
,
Whisenant
B
,
Ribeiro
HB
,
Webb
JG
,
Kornowski
R
,
Guerrero
M
,
Wijeysundera
H
,
Sondergaard
L
,
De Backer
O
,
Villablanca
P
,
Rihal
C
,
Eleid
M
,
Kempfert
J
,
Unbehaun
A
,
Erlebach
M
,
Casselman
F
,
Adam
M
,
Montorfano
M
,
Ancona
M
,
Saia
F
,
Ubben
T
,
Meincke
F
,
Napodano
M
,
Codner
P
,
Schofer
J
,
Pelletier
M
,
Cheung
A
,
Shuvy
M
,
Palma
JH
,
Gaia
DF
,
Duncan
A
,
Hildick-Smith
D
,
Veulemans
V
,
Sinning
JM
,
Arbel
Y
,
Testa
L
,
de Weger
A
,
Eltchaninoff
H
,
Hemery
T
,
Landes
U
,
Tchetche
D
,
Dumonteil
N
,
Rodes-Cabau
J
,
Kim
WK
,
Spargias
K
,
Kourkoveli
P
,
Ben-Yehuda
O
,
Teles
RC
,
Barbanti
M
,
Fiorina
C
,
Thukkani
A
,
Mackensen
GB
,
Jones
N
,
Presbitero
P
,
Petronio
AS
,
Allali
A
,
Champagnac
D
,
Bleiziffer
S
,
Rudolph
T
,
Iadanza
A
,
Salizzoni
S
,
Agrifoglio
M
,
Nombela-Franco
L
,
Bonaros
N
,
Kass
M
,
Bruschi
G
,
Amabile
N
,
Chhatriwalla
A
,
Messina
A
,
Hirji
SA
,
Andreas
M
,
Welsh
R
,
Schoels
W
,
Hellig
F
,
Windecker
S
,
Stortecky
S
,
Maisano
F
,
Stone
GW
,
Dvir
D.
 
Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry
 
. Circulation
 
2021
;
143
:
104
116
.

532

Sengupta
 
A
,
Yazdchi
F
,
Alexis
SL
,
Percy
E
,
Premkumar
A
,
Hirji
S
,
Bapat
VN
,
Bhatt
DL
,
Kaneko
T
,
Tang
GHL.
 
Reoperative mitral surgery versus transcatheter mitral valve replacement: a systematic review
.
J Am Heart Assoc
2021
;
10
:
e019854
.

533

Urena
 
M
,
Vahanian
A
,
Brochet
E
,
Ducrocq
G
,
Iung
B
,
Himbert
D.
 
Current indications for transcatheter mitral valve replacement using transcatheter aortic valves: valve-in-valve, valve-in-ring, and valve-in-mitral annulus calcification
.
Circulation
2021
;
143
:
178
196
.

534

Little
 
SH
,
Bapat
V
,
Blanke
P
,
Guerrero
M
,
Rajagopal
V
,
Siegel
R.
 
Imaging guidance for transcatheter mitral valve intervention on prosthetic valves, rings, and annular calcification
.
JACC Cardiovasc Imaging
2021
;
14
:
22
40
.

535

Fallon
 
JM
,
DeSimone
JP
,
Brennan
JM
,
O’Brien
S
,
Thibault
DP
,
DiScipio
AW
,
Pibarot
P
,
Jacobs
JP
,
Malenka
DJ.
 
The incidence and consequence of prosthesis-patient mismatch after surgical aortic valve replacement
.
Ann Thorac Surg
2018
;
106
:
14
22
.

536

Flameng
 
W
,
Herregods
MC
,
Vercalsteren
M
,
Herijgers
P
,
Bogaerts
K
,
Meuris
B.
 
Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves
.
Circulation
2010
;
121
:
2123
2129
.

537

Zorn
 
GL
 3rd ,
Little
SH
,
Tadros
P
,
Deeb
GM
,
Gleason
TG
,
Heiser
J
,
Kleiman
NS
,
Oh
JK
,
Popma
JJ
,
Adams
D
,
Huang
J
,
Reardon
MJ.
 
Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of a self-expanding prosthesis
.
J Thorac Cardiovasc Surg
2016
;
151
:
1014
1022
, 1023. e1–3.

538

Head
 
SJ
,
Mokhles
MM
,
Osnabrugge
RL
,
Pibarot
P
,
Mack
MJ
,
Takkenberg
JJ
,
Bogers
AJ
,
Kappetein
AP.
 
The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years
.
Eur Heart J
2012
;
33
:
1518
1529
.

539

Sorajja
 
P
,
Bae
R
,
Lesser
JA
,
Pedersen
WA.
 
Percutaneous repair of paravalvular prosthetic regurgitation: patient selection, techniques and outcomes
.
Heart
2015
;
101
:
665
673
.

540

Ruiz
 
CE
,
Hahn
RT
,
Berrebi
A
,
Borer
JS
,
Cutlip
DE
,
Fontana
G
,
Gerosa
G
,
Ibrahim
R
,
Jelnin
V
,
Jilaihawi
H
,
Jolicoeur
EM
,
Kliger
C
,
Kronzon
I
,
Leipsic
J
,
Maisano
F
,
Millan
X
,
Nataf
P
,
O’Gara
PT
,
Pibarot
P
,
Ramee
SR
,
Rihal
CS
,
Rodes-Cabau
J
,
Sorajja
P
,
Suri
R
,
Swain
JA
,
Turi
ZG
,
Tuzcu
EM
,
Weissman
NJ
,
Zamorano
JL
,
Serruys
PW
,
Leon
MB
,
Paravalvular Leak Academic Research Consortium
.
Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis
.
Eur Heart J
2018
;
39
:
1224
1245
.

541

Chakravarty
 
T
,
Sondergaard
L
,
Friedman
J
,
De Backer
O
,
Berman
D
,
Kofoed
KF
,
Jilaihawi
H
,
Shiota
T
,
Abramowitz
Y
,
Jorgensen
TH
,
Rami
T
,
Israr
S
,
Fontana
G
,
de Knegt
M
,
Fuchs
A
,
Lyden
P
,
Trento
A
,
Bhatt
DL
,
Leon
MB
,
Makkar
RR
,
Resolve, SAVORY Investigators
.
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
.
Lancet
2017
;
389
:
2383
2392
.

542

Karthikeyan
 
G
,
Senguttuvan
NB
,
Joseph
J
,
Devasenapathy
N
,
Bahl
VK
,
Airan
B.
 
Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies
.
Eur Heart J
2013
;
34
:
1557
1566
.

543

Laplace
 
G
,
Lafitte
S
,
Labeque
JN
,
Perron
JM
,
Baudet
E
,
Deville
C
,
Roques
X
,
Roudaut
R.
 
Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients
.
J Am Coll Cardiol
2004
;
43
:
1283
1290
.

544

Petrescu
 
I
,
Egbe
AC
,
Ionescu
F
,
Nkomo
VT
,
Greason
KL
,
Pislaru
C
,
Pellikka
PA
,
Connolly
HM
,
Pislaru
SV.
 
Long-term outcomes of anticoagulation for bioprosthetic valve thrombosis
.
J Am Coll Cardiol
2020
;
75
:
857
866
.

545

Sellers
 
SL
,
Turner
CT
,
Sathananthan
J
,
Cartlidge
TRG
,
Sin
F
,
Bouchareb
R
,
Mooney
J
,
Norgaard
BL
,
Bax
JJ
,
Bernatchez
PN
,
Dweck
MR
,
Granville
DJ
,
Newby
DE
,
Lauck
S
,
Webb
JG
,
Payne
GW
,
Pibarot
P
,
Blanke
P
,
Seidman
MA
,
Leipsic
JA.
 
Transcatheter aortic heart valves: histological analysis providing insight to leaflet thickening and structural valve degeneration
.
JACC Cardiovasc Imaging
2019
;
12
:
135
145
.

546

De Backer
 
O
,
Dangas
GD
,
Jilaihawi
H
,
Leipsic
JA
,
Terkelsen
CJ
,
Makkar
R
,
Kini
AS
,
Veien
KT
,
Abdel-Wahab
M
,
Kim
WK
,
Balan
P
,
Van Mieghem
N
,
Mathiassen
ON
,
Jeger
RV
,
Arnold
M
,
Mehran
R
,
Guimaraes
AHC
,
Norgaard
BL
,
Kofoed
KF
,
Blanke
P
,
Windecker
S
,
Sondergaard
L
,
GALILEO-4D Investigators
.
Reduced leaflet motion after transcatheter aortic-valve replacement
.
N Engl J Med
2020
;
382
:
130
139
.

547

Alkhouli
 
M
,
Rihal
CS
,
Zack
CJ
,
Eleid
MF
,
Maor
E
,
Sarraf
M
,
Cabalka
AK
,
Reeder
GS
,
Hagler
DJ
,
Maalouf
JF
,
Nkomo
VT
,
Schaff
HV
,
Said
SM.
 
Transcatheter and surgical management of mitral paravalvular leak: long-term outcomes
.
JACC Cardiovasc Interv
2017
;
10
:
1946
1956
.

548

Dakik
 
HA
,
Chehab
O
,
Eldirani
M
,
Sbeity
E
,
Karam
C
,
Abou Hassan
O
,
Msheik
M
,
Hassan
H
,
Msheik
A
,
Kaspar
C
,
Makki
M
,
Tamim
H.
 
A new index for pre-operative cardiovascular evaluation
.
J Am Coll Cardiol
2019
;
73
:
3067
3078
.

549

Tashiro
 
T
,
Pislaru
SV
,
Blustin
JM
,
Nkomo
VT
,
Abel
MD
,
Scott
CG
,
Pellikka
PA.
 
Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice
.
Eur Heart J
2014
;
35
:
2372
2381
.

550

Eugene
 
M
,
Urena
M
,
Abtan
J
,
Carrasco
JL
,
Ghodbane
W
,
Nataf
P
,
Vahanian
A
,
Himbert
D.
 
Effectiveness of rescue percutaneous balloon aortic valvuloplasty in patients with severe aortic stenosis and acute heart failure
.
Am J Cardiol
2018
;
121
:
746
750
.

551

Kolte
 
D
,
Khera
S
,
Vemulapalli
S
,
Dai
D
,
Heo
S
,
Goldsweig
AM
,
Aronow
HD
,
Elmariah
S
,
Inglessis
I
,
Palacios
IF
,
Thourani
VH
,
Sharaf
BL
,
Gordon
PC
,
Abbott
JD.
 
Outcomes following urgent/emergent transcatheter aortic valve replacement: insights from the STS/ACC TVT Registry
.
JACC Cardiovasc Interv
2018
;
11
:
1175
1185
.

552

Calleja
 
AM
,
Dommaraju
S
,
Gaddam
R
,
Cha
S
,
Khandheria
BK
,
Chaliki
HP.
 
Cardiac risk in patients aged >75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery
.
Am J Cardiol
2010
;
105
:
1159
1163
.

553

Tarantini
 
G
,
Nai Fovino
L
,
Tellaroli
P
,
Fabris
T
,
Iliceto
S.
 
Asymptomatic severe aortic stenosis and noncardiac surgery
.
Am J Cardiol
2016
;
117
:
486
488
.

554

Regitz-Zagrosek
 
V
,
Roos-Hesselink
JW
,
Bauersachs
J
,
Blomstrom-Lundqvist
C
,
Cifkova
R
,
De Bonis
M
,
Iung
B
,
Johnson
MR
,
Kintscher
U
,
Kranke
P
,
Lang
IM
,
Morais
J
,
Pieper
PG
,
Presbitero
P
,
Price
S
,
Rosano
GMC
,
Seeland
U
,
Simoncini
T
,
Swan
L
,
Warnes
CA
,
ESC Scientific Document Group
. 2018
ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018
;
39
:
3165
3241
.

555

Roos-Hesselink
 
J
,
Baris
L
,
Johnson
M
,
De Backer
J
,
Otto
C
,
Marelli
A
,
Jondeau
G
,
Budts
W
,
Grewal
J
,
Sliwa
K
,
Parsonage
W
,
Maggioni
AP
,
van Hagen
I
,
Vahanian
A
,
Tavazzi
L
,
Elkayam
U
,
Boersma
E
,
Hall
R.
 
Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC)
.
Eur Heart J
2019
;
40
:
3848
3855
.

556

van Hagen
 
IM
,
Thorne
SA
,
Taha
N
,
Youssef
G
,
Elnagar
A
,
Gabriel
H
,
ElRakshy
Y
,
Iung
B
,
Johnson
MR
,
Hall
R
,
Roos-Hesselink
JW
,
ROPAC Investigators and EORP Team
.
Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease
.
Circulation
2018
;
137
:
806
816
.

557

Orwat
 
S
,
Diller
GP
,
van Hagen
IM
,
Schmidt
R
,
Tobler
D
,
Greutmann
M
,
Jonkaitiene
R
,
Elnagar
A
,
Johnson
MR
,
Hall
R
,
Roos-Hesselink
JW
,
Baumgartner
H
,
ROPAC Investigators
.
Risk of pregnancy in moderate and severe aortic stenosis: from the Multinational ROPAC Registry
.
J Am Coll Cardiol
2016
;
68
:
1727
1737
.

558

Meijboom
 
LJ
,
Vos
FE
,
Timmermans
J
,
Boers
GH
,
Zwinderman
AH
,
Mulder
BJ.
 
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study
.
Eur Heart J
2005
;
26
:
914
920
.

559

McKellar
 
SH
,
MacDonald
RJ
,
Michelena
HI
,
Connolly
HM
,
Sundt
TM
3rd.
 
Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events
.
Am J Cardiol
2011
;
107
:
96
99
.

560

Fuchs
 
A
,
Urena
M
,
Chong-Nguyen
C
,
Kikoine
J
,
Brochet
E
,
Abtan
J
,
Fischer
Q
,
Ducrocq
G
,
Vahanian
A
,
Iung
B
,
Himbert
D.
 
Valve-in-valve and valve-in-ring transcatheter mitral valve implantation in young women contemplating pregnancy
.
Circ Cardiovasc Interv
2020
;
13
:
e009579
.

561

van Hagen
 
IM
,
Roos-Hesselink
JW
,
Ruys
TP
,
Merz
WM
,
Goland
S
,
Gabriel
H
,
Lelonek
M
,
Trojnarska
O
,
Al Mahmeed
WA
,
Balint
HO
,
Ashour
Z
,
Baumgartner
H
,
Boersma
E
,
Johnson
MR
,
Hall
R
;
ROPAC Investigators and the EURObservational Research Programme (EORP) Team
.
Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC)
.
Circulation
2015
;
132
:
132
142
.

562

Elassy
 
SM
,
Elmidany
AA
,
Elbawab
HY.
 
Urgent cardiac surgery during pregnancy: a continuous challenge
.
Ann Thorac Surg
2014
;
97
:
1624
1629
.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Supplementary data